NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 338

AN SERVICES US

TOXICOLOGY AND CARCINOGENESIS STUDIES OF ERYTHROMYCIN STEARATE (CAS NO. 643-22-1) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES)

> U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS STUDIES OF ERYTHROMYCIN STEARATE

(CAS NO. 643-22-1)

IN F344/N RATS AND B6C3F1 MICE

(FEED STUDIES)

John Edgar French, Ph.D., Chemical Manager

NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

December 1988

NTP TR 338

NIH Publication No. 89-2594

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

NOTE TO THE READER

This study was performed under the direction of the National Institute of Environmental Health Sciences as a function of the National Toxicology Program. The studies described in this Technical Report have been conducted in compliance with NTP chemical health and safety requirements and must meet or exceed all applicable Federal, state, and local health and safety regulations. Animal care and use were in accordance with the U.S. Public Health Service Policy on Humane Care and Use of Animals. All NTP toxicology and carcinogenesis studies are subjected to a data audit before being presented for public peer review.

Although every effort is made to prepare the Technical Reports as accurately as possible, mistakes may occur. Readers are requested to identify any mistakes so that corrective action may be taken. Further, anyone who is aware of related ongoing or published studies not mentioned in this report is encouraged to make this information known to the NTP. Comments and questions about the National Toxicology Program Technical Reports on Toxicology and Carcinogenesis Studies should be directed to Dr. J.E. Huff, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709 (919-541-3780).

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709.

CONTENTS

ABST	RACT	5
EXPL	ANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY	8
CONT	FRIBUTORS	9
	R REVIEW PANEL	10
SUMN	MARY OF PEER REVIEW COMMENTS	11
I.	INTRODUCTION	13
11.	MATERIALS AND METHODS	19
	PROCUREMENT AND CHARACTERIZATION OF ERYTHROMYCIN STEARATE	20
	PREPARATION AND CHARACTERIZATION OF FORMULATED DIETS	20
	FOURTEEN-DAY STUDIES	25
	THIRTEEN-WEEK STUDIES	25
	TWO-YEAR STUDIES	25
	STUDY DESIGN	25
	SOURCE AND SPECIFICATIONS OF ANIMALS	27
	ANIMAL MAINTENANCE	28
	CLINICAL EXAMINATIONS AND PATHOLOGY	28
	STATISTICAL METHODS	29
III.	RESULTS	31
	RATS	32
	FOURTEEN-DAY STUDIES	32
	THIRTEEN-WEEK STUDIES	32
	TWO-YEAR STUDIES	33
	BODY WEIGHTS, FEED CONSUMPTION, AND CLINICAL SIGNS	33
	SURVIVAL	36
	PATHOLOGY AND STATISTICAL ANALYSES OF RESULTS	36
	MICE	40
	FOURTEEN-DAY STUDIES	40
	THIRTEEN-WEEK STUDIES	40
	TWO-YEAR STUDIES	41
	BODY WEIGHTS, FEED CONSUMPTION, AND CLINICAL SIGNS	41
	SURVIVAL	44
	PATHOLOGY AND STATISTICAL ANALYSES OF RESULTS	44
IV.	DISCUSSION AND CONCLUSIONS	47
v.	REFERENCES	51


PAGE

APPENDIXES

PAGE

APPENDIX A	SUMMARY OF LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	57
APPENDIX B	SUMMARY OF LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	83
APPENDIX C	SUMMARY OF LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	105
APPENDIX D	SUMMARY OF LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	125
APPENDIX E	GENETIC TOXICOLOGY OF ERYTHROMYCIN STEARATE	145
APPENDIX F	SENTINEL ANIMAL PROGRAM	151
APPENDIX G	FEED AND COMPOUND CONSUMPTION BY RATS AND MICE IN THE TWO-YEAR FEED STUDIES OF ERYTHROMYCIN STEARATE	153
APPENDIX H	INGREDIENTS, NUTRIENT COMPOSITION, AND CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION	159
APPENDIX I	AUDIT SUMMARY	165

4



ERYTHROMYCIN STEARATE

CAS No. 643-22-1

 $C_{37}H_{67}NO_{13}$ · $C_{18}H_{36}O_2$ Molecular weight 1,018

Synonyms: erythrocin stearate; erythromycin octadecanoate

Trade names: Abbotcine; Bristamycin; Dowmycin E; Eratrex; Erypar; Ethril; Gallimycin; HSDB 4178; OE 7; Pantomicina; Pfizer-E; SK-Erythromycin; Wyamycin S

ABSTRACT

Toxicology and carcinogenesis studies of erythromycin stearate (USP grade, greater than 96% pure) were conducted by administering the antibiotic in feed to groups of F344/N rats and B6C3F₁ mice of each sex for 14 days, 13 weeks, or 2 years. Erythromycin stearate was studied because of its wide-spread use in humans as a broad-spectrum macrolide antibiotic and because of the lack of adequate long-term studies for carcinogenicity.

Fourteen-Day and Thirteen-Week Studies: In the 14-day studies, none of the rats (at dietary concentrations up to 50,000 ppm) and 2/5 female mice that received 50,000 ppm died before the end of the studies. Final mean body weights of male rats that received 12,500, 25,000, or 50,000 ppm were 10%, 30%, or 36% lower, respectively, than that of controls; final mean body weights of female rats were 10%, 12%, or 32% lower. None of the dosed mouse groups gained weight. The final mean body weight of male mice that received 50,000 ppm was 10% lower than that of controls.

In the 13-week studies, none of the rats or mice (at dietary concentrations up to 20,000 ppm) died before the end of the studies. Final mean body weights of the 20,000-ppm groups of rats were more than 12% lower than that of the controls for males and 7% lower for females. Final mean body weights of mice that received 10,000 or 20,000 ppm were 15% or 19% lower than that of controls for males and 5% or 14% lower for females.

Multinucleated syncytial hepatocytes were observed in 10/10 male rats that received 20,000 ppm but in 0/10 male rats that received 10,000 ppm. No compound-related gross or microscopic pathologic effects were observed in mice.

Based on these results, 2-year studies of erythromycin stearate were conducted by feeding diets containing 0, 5,000, or 10,000 ppm erythromycin stearate to groups of 50 rats of each sex for 103 weeks. Diets containing 0, 2,500, or 5,000 ppm were fed to groups of 50 mice of each sex for 103 weeks.

Body Weight and Survival in the Two-Year Studies: Mean body weights of high dose male rats were comparable to those of controls throughout the studies. Mean body weights of high dose female rats were 5%-10% lower than those of controls. Mean body weights of dosed and control mice were comparable. The average daily feed consumption was similar for dosed and control male and female rats. For mice, estimated daily feed consumption by low and high dose males was similar to that of the controls and by low and high dose females was 92% that of the controls. The average amount of erythromycin stearate consumed per day was approximately 180 or 370 mg/kg for male rats and 210 or 435 mg/kg for female rats; for mice, the average amounts were 270 or 545 mg/kg for males and 250 or 500 mg/kg for females.

No significant differences in survival were observed between any groups of rats or mice of either sex (final survival--male rats: control, 28/50; low dose, 23/50; high dose, 27/50; female rats: 29/50; 30/50; 38/50; male mice: 34/50; 33/50; 40/50; female mice: 38/50; 34/50; 40/50).

Nonneoplastic and Neoplastic Effects in the Two-Year Studies: Granulomas of the liver were observed at increased incidences in high dose rats (male: 1/50; 2/50; 10/50; female: 18/50; 27/50; 43/50). Granulomatous inflammation or granulomas of the spleen were observed in dosed female rats (0/48; 1/49; 3/50). Reticulum cell hyperplasia in the bone marrow occurred at increased incidences in high dose female rats (10/50; 14/50; 25/50).

Squamous cell papillomas of the oral mucosa were observed in 1/50 control, 2/50 low dose, and 3/50 high dose female rats. These tumors were considered to be marginal and not related to exposure. Hyperplasia of the oral mucosa was not observed.

Pheochromocytomas of the adrenal gland in female rats occurred with a positive trend (1/50; 4/49; 5/50). The incidences in the dosed groups are similar to the average historical incidence (9%) of this tumor in untreated control female F344/N rats at the study laboratory. This marginal tumor increase is not considered to be biologically important. No increases in incidences of neoplasms were observed at any site in dosed male rats.

Inflammation in the glandular stomach was observed at increased incidences in dosed male mice (1/49; 4/50; 6/50). Lymphoid hyperplasia in the urinary bladder was observed at increased incidences in dosed female mice (1/50; 9/47; 7/48).

No increases in incidences of neoplasms were observed at any site in dosed male or female mice.

Genetic Toxicology: Erythromycin stearate was not mutagenic in *Salmonella typhimurium* strains TA98, TA100, TA1535, or TA1537 when tested both with or without exogenous metabolic activation. Erythromycin stearate demonstrated equivocal mutagenicity in the mouse L5178Y lymphoma cell assay in the absence of exogenous metabolic activation (S9); erythromycin stearate was not mutagenic in the presence of S9. Treatment of cultured Chinese hamster ovary cells with erythromycin stearate did not produce an increase in the frequency of sister chromatid exchanges or chromosomal aberrations in either the presence or absence of metabolic activation.

Audit: The data, documents, and pathology materials from the 2-year studies of erythromycin stearate have been audited. The audit findings show that the conduct of the studies is documented adequately and support the data and results given in this Technical Report.

Conclusions: Under the conditions of these 2-year studies, there was no evidence of carcinogenic activity* of erythromycin stearate for male or female F344/N rats administered erythromycin stearate in the diet at 5,000 or 10,000 ppm. There was no evidence of carcinogenic activity of erythromycin stearate for male or female $B6C3F_1$ mice administered erythromycin stearate in the diet at 2,500 or 5,000 ppm. Dose-related increases in the incidences of granulomas of the liver were observed in male and female rats. The absence of any biologically important chemical-associated effects in mice suggests that higher doses could have been given to male and female mice.

SUMMARY OF THE TWO-YEAR FEED AND GENETIC TOXICOLOGY STUDIES OF ERYTHROMYCIN STEARATE

Male F344/N Rats	Female F344/N Rats	Male B6C3F ₁ Mice	Female B6C3F ₁ Mice		
Dietary concentrations					
0, 5,000, or 10,000 ppm erythromycin stearate	0, 5,000, or 10,000 ppm erythromycin stearate	0, 2,500, or 5,000 ppm erythromycin stearate	0, 2,500, or 5,000 ppm erythromycin stearate		
Survival rates in the 2-yea					
28/50; 23/50; 27/50	29/50; 30/50; 38/50	34/50; 33/50; 40/50	38/50; 34/50; 40/50		
Nonneoplastic effects Granulomas of the liver reticulum cell hyperplasia of the bone marrow		None	None		
Neoplastic effects None	None	None	None		
Level of evidence of carci No evidence	nogenic activity No evidence	No evidence	No evidence		

Genetic toxicology

Not mutagenic in \tilde{S} . typhimurium strains TA98, TA100, TA1535, or TA1537 with or without activation; equivocally mutagenic in the mouse L5178Y lymphoma assay without activation and not mutagenic in the mouse L5178Y lymphoma assay with activation; did not cause sister chromatid exchanges or chromosomal aberrations in Chinese hamster ovary cells with or without activation.

^{*}Explanation of Levels of Evidence of Carcinogenic Activity is on page 8.

A summary of the Peer Review comments and the public discussion on this Technical Report appears on page 11.

EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection per se is not an indicator of a chemical's carcinogenic potential.

Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans.

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence including: animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results ("Clear Evidence" and "Some Evidence"); one category for uncertain findings ("Equivocal Evidence"); one category for no observable effects ("No Evidence"); and one category for experiments that because of major flaws cannot be evaluated ("Inadequate Study"). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Reports series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following quintet is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to either potency or mechanism.

- Clear Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- Some Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a chemically related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
- Equivocal Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemically related.
- No Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing no chemically related increases in malignant or benign neoplasms.
- Inadequate Study of Carcinogenic Activity is demonstrated by studies that because of major qualitative or quantitative limitations cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. This should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- The adequacy of the experimental design and conduct;
- Occurrence of common versus uncommon neoplasia;
- Progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic lesions;
- Some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to assume that benign neoplasms of those types have the potential to become malignant;
- Combining benign and malignant tumor incidences known or thought to represent stages of progression in the same organ or tissue;
- Latency in tumor induction;
- Multiplicity in site-specific neoplasia;
- Metastases;
- Supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- The presence or absence of dose relationships;
- The statistical significance of the observed tumor increase;
- The concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- Survival-adjusted analyses and false positive or false negative concerns;
- Structure-activity correlations; and
- In some cases, genetic toxicology.

These considerations together with the definitions as written should be used as composite guidelines for selecting one of the five categories. Additionally, the following concepts (as patterned from the International Agency for Research on Cancer Monographs) have been adopted by the NTP to give further clarification of these issues:

The term *chemical carcinogenesis* generally means the induction by chemicals of neoplasms not usually observed, the induction by chemicals of more neoplasms than are generally found, or the earlier induction by chemicals of neoplasms that are commonly observed. Different mechanisms may be involved in these situations. Etymologically, the term *carcinogenesis* means induction of cancer, that is, of malignant neoplasms; however, the commonly accepted meaning is the induction of various types of neoplasms or of a combination of malignant and benign neoplasms. In the Technical Reports, the words *tumor* and *neoplasm* are used interchangeably.

CONTRIBUTORS

The NTP Technical Report on the Toxicology and Carcinogenesis Studies of Erythromycin Stearate is based on the 13-week studies that began in February 1980 and ended in May 1980 and on the 2-year studies that began in December 1980 and ended in December 1982 at Physiological Research Laboratories (Minneapolis, Minnesota).

National Toxicology Program (Evaluated Experiment, Interpreted Results, and Reported Findings)

John Edgar French, Ph.D., Chemical Manager

John Bucher, Ph.D. Scot L. Eustis, D.V.M., Ph.D. Joseph K. Haseman, Ph.D. James Huff, Ph.D.

(Discipline Leaders and Principal Contributors)

Jack Bishop, Ph.D. Douglas W. Bristol, Ph.D. R. Chhabra, Ph.D. C.W. Jameson, Ph.D. E.E. McConnell, D.V.M. G.N. Rao, D.V.M., Ph.D. B.A. Schwetz, D.V.M., Ph.D. M. Vernon, Ph.D. Douglas Walters, Ph.D.

NTP Pathology Working Group (Evaluated Slides and Prepared Pathology Report for Rats on 11/20/86)

John Seely, D.V.M. (Chair) (PATHCO) Roger Brown, D.V.M. (Experimental Pathology Laboratories, Inc.) Michael Elwell, D.V.M., Ph.D. (NTP) Scot L. Eustis, D.V.M., Ph.D. (NTP) Joel Leininger, D.V.M., Ph.D. Physiological Research Laboratories Charles Montgomery, D.V.M. (NTP) James Popp, D.V.M., Ph.D. (Chemical Industry Institute of Toxicology)

(Evaluated Slides and Prepared Pathology Report for Mice on 2/14/85)

Robert Sauer, V.M.D. (Chair) (PATHCO) Gary Boorman, D.V.M., Ph.D. (NTP) Bhola Gupta, Ph.D. (NTP) Allen Hall, D.V.M. (Physiological Research Laboratories) (Observer) LeRoy Hall, D.V.M., Ph.D. (NTP) Gary Riley, Ph.D. (Experimental Pathology Laboratories, Inc.) John Strandberg, D.V.M., Ph.D. Johns Hopkins University

Principal Contributors at Physiological Research Laboratories (Conducted Studies and Evaluated Tissues)

D. Elsberry, Ph.D. M. Cowan, M.S. A. Hall, D.V.M. R. Pieper, M.S. J. Leininger, D.V.M., Ph.D.

Principal Contributors at Experimental Pathology Laboratories, Inc. (Provided Pathology Quality Assurance)

J. Gauchat

R. Brown, D.V.M.

Melvin Hamlin, D.V.M.

Principal Contributors at Carltech Associates, Inc. (Contractor for Technical Report Preparation)

William D. Theriault, Ph.D. Abigail C. Jacobs, Ph.D. John Warner, M.S.

PEER REVIEW PANEL

The members of the Peer Review Panel who evaluated the draft Technical Report on erythromycin stearate on July 14, 1987, are listed below. Panel members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, Panel members have five major responsibilities: (a) to ascertain that all relevant literature data have been adequately cited and interpreted, (b) to determine if the design and conditions of the NTP studies were appropriate, (c) to ensure that the Technical Report presents the experimental results and conclusions fully and clearly, (d) to judge the significance of the experimental results by scientific criteria, and (e) to assess the evaluation of the evidence of carcinogenicity and other observed toxic responses.

National Toxicology Program Board of Scientific Counselors Technical Reports Review Subcommittee

Robert A. Scala, Ph.D. (Chair)

Senior Scientific Advisor, Medicine and Environmental Health Department Research and Environmental Health Division, Exxon Corporation East Millstone, New Jersey

Michael A. Gallo, Ph.D. (Principal Reviewer) Associate Professor, Director of Toxicology Department of Environmental and Community Medicine, UMDNJ - Rutgers Medical School Piscataway, New Jersey Frederica Perera, Dr. P.H.* Division of Environmental Sciences School of Public Health, Columbia University New York, New York

Ad Hoc Subcommittee Panel of Experts

John Ashby, Ph.D. Imperial Chemical Industries, PLC Central Toxicology Laboratory Alderley Park, England

Charles C. Capen, D.V.M., Ph.D. (Principal Reviewer) Department of Veterinary Pathobiology, Ohio State University Columbus, Ohio

Vernon M. Chinchilli, Ph.D. Department of Biostatistics Medical College of Virginia Virginia Commonwealth University Richmond, Virginia

Kim Hooper, Ph.D. Hazard Evaluation System and Information Services Department of Health Services State of California Berkeley, California

Donald H. Hughes, Ph.D.* Scientific Coordinator, Regulatory Services Division, The Procter and Gamble Company Cincinnati, Ohio William Lijinsky, Ph.D.* Director, Chemical Carcinogenesis Frederick Cancer Research Facility Frederick, Maryland

Franklin E. Mirer, Ph.D. Director, Health and Safety Department International Union, United Auto Workers, Detroit, Michigan

James A. Popp, D.V.M., Ph.D. Head, Department of Experimental Pathology and Toxicology Chemical Industry Institute of Toxicology Research Triangle Park, North Carolina

Andrew Sivak, Ph.D. (Principal Reviewer) Vice President, Biomedical Science Arthur D. Little, Inc. Cambridge, Massachusetts

^{*}Unable to attend

SUMMARY OF PEER REVIEW COMMENTS ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF ERYTHROMYCIN STEARATE

On July 14, 1987, the draft Technical Report on the toxicology and carcinogenesis studies of erythromycin stearate received peer review by the National Toxicology Program Board of Scientific Counselors' Technical Reports Review Subcommittee and associated Panel of Experts. The review meeting was held at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

Dr. J.E. French, NIEHS, introduced the studies by reviewing the experimental design, results, and proposed conclusions (no evidence of carcinogenic activity for male or female rats; no evidence of carcinogenic activity for male or female mice).

Dr. Sivak, a principal reviewer, agreed with the conclusions. He asked why the doses for the 2-year studies in mice were only half those given to rats, and he emphasized the importance of explaining the rationale for the dose selection for the long-term studies. Dr. French responded that the dose selections were based solely on the observed body weight depression and that mice showed greater body weight differences than did rats during the 13-week studies.

As a second principal reviewer, Dr. Gallo agreed with the conclusions. He commented on the difficulty in evaluating antibiotics by the usual criteria, such as changes in body weight, as some antibiotics lead to increases in body weight. Dr. Gallo speculated that the granulomas or lymphoid hyperplasia reported in liver, spleen, and bladder might be crystalline deposits of the chemical or its metabolites. Dr. French acknowledged that this could be an alternative explanation for the lesions, but he indicated that none was seen on light microscopy.

As a third principal reviewer, Dr. Capen agreed with the conclusions.

In other discussion, Dr. Ashby commented on the weak positive genotoxic responses to erythromycin stearate in the mammalian cell assay (mouse lymphoma), which may be an artifact resulting from the high doses of the alkaline salt associated with the antibiotic.


Dr. Sivak moved that the Technical Report on erythromycin stearate be accepted with editorial changes discussed and with the conclusions as written for male and female rats and mice, no evidence of carcinogenic activity. Dr. Popp seconded the motion, which was approved unanimously with seven votes.

Erythromycin Stearate, NTP TR 338

12

I. INTRODUCTION

Use, Production, and Exposure Absorption, Metabolism, and Excretion Acute Toxicity Cellular and Subcellular Toxicity Systemic Toxicity Reproductive and Developmental Toxicity Long-Term Toxicity and Carcinogenicity Genetic Toxicology Study Rationale



ERYTHROMYCIN STEARATE

CAS No. 643-22-1

C₃₇H₆₇NO₁₃ · C₁₈H₃₆O₂

Molecular weight 1,018

Synonyms: erythrocin stearate; erythromycin octadecanoate

Trade names: Abbotcine; Bristamycin; Dowmycin E; Eratrex; Erypar; Ethril; Gallimycin; HSDB 4178; OE 7; Pantomicina; Pfizer-E; SK-Erythromycin; Wyamycin S

Use, Production, and Exposure

Erythromycin base and various salts are used extensively in the treatment of gram-positive bacterial infections in humans (Sande and Mandell, 1985). Erythromycin belongs to the chemical class of macrolide antibiotics and was discovered by McGuire and colleagues, according to Sande and Mandell (1985). Erythromycin stearate is one of several derivatives used in different formulations. (Other derivatives include erythromycin estolate, erythromycin ethylsuccinate, and erythromycin lactobionate, or erythromycin gluceptate.) Erythromycin base, prepared by fermentation from Streptomyces erythreus, is reacted with stearic acid in acetone, and the resulting salt is precipitated with water; USP-grade erythromycin stearate is not less than 55% erythromycin base (Remington's, 1975).

Recent production figures for erythromycin base or stearate salt are not available, but commercial production was reported to the International Trade Commission and U.S. Environmental Protection Agency TSCA inventory, indicating that production was greater than 4.5×10^5 g/year (USITC, 1986; NIOSH, 1987). In 1985, an estimated 33 million prescriptions of erythromycin, in all forms, were filled (Baum et al., 1986). The usual oral dose of erythromycin is 1-2 g per day for adults and 30-50 mg/kg per day for children (4 doses, 6 hours apart, between meals) (Sande and Mandell, 1985).

Absorption, Metabolism, and Excretion

In humans, erythromycin base is absorbed from the upper part of the small intestine, with peak concentrations (0.3-0.5 μ g/ml) occurring 4-12 hours after oral administration (Ravagnan et al., 1971; Sande and Mandell, 1985). Various salts of erythromycin have been prepared to improve stability after absorption by different routes. In the gastrointestinal tract, erythromycin base absorption and maximum plasma levels are similar between various salt preparations (Sande and Mandell, 1985). There is a large intersubject and intrasubject variability between route and erythromycin form used (erythromycin base vs. erythromycin stearate) in humans (Welling, 1977; Welling et al., 1978; Mather et al., 1981).

The absorption of erythromycin is affected by the presence or absence of food and the form being administered. Erythromycin is inactivated by gastric juice, and the presence of food delays ultimate absorption (Sande and Mandell, 1985). The form of the derivative and its resistance to acid and/or enzymatic hydrolysis are important variables in absorption and delivery to a target site. In volunteers (age and sex unspecified), ingestion of food delayed the absorption of orally administered erythromycin base, whereas the absorption of the stearate salt was increased in the presence of food (Malmborg, 1979; DiSanto and Chodos, 1981). Other studies in volunteers have reported opposite findings (Rutland et al., 1979; Digranes et al., 1984). In studies that considered both food and water intake (Welling, 1977; Welling et al., 1978), erythromycin stearate absorption was decreased by both food and water intake, independently; in the presence of food and sufficient water intake, erythromycin base and stearate were found to be bioequivalent.

Erythromycin base and erythromycin stearate are inactivated by gastric juices when administered neat and without enteric coatings (Sande and Mandell, 1985). Boggiano and Gleeson (1976) found that under in vitro conditions at a pH of 1.2-3.2, erythromycin stearate dissolved and rapidly lost its biologic activity. Addition of pepsin did not affect the results. Only entericcoated tablets retained biologic activity.

Absorption of erythromycin may be age-dependent. Eriksson et al. (1981) reported that erythromycin, in suspension, was absorbed the least in infants younger than 1 month of age but was well absorbed in fasting children between 6 months and 6 years of age. Erythromycin stearate absorption was not affected by the presence of food in this study.

Antibiotics in general, including erythromycin, are poorly absorbed or not absorbed at all by patients with celiac or Crohn's disease, possibly because of reduced renal clearance (Parsons et al., 1975, 1976a,b, 1977). However, Iliopoulou et al. (1982) found that the excretion rate of erythromycin was similar for controls and for patients with end-stage renal failure who were being treated by dialysis.

According to Sande and Mandell (1985), 2%-5% of the erythromycin administered orally to humans was excreted in a biologically active form in the urine. The amount excreted increased to 12%-15% after intravenous infusion. Ervthromycin is concentrated in the liver and excreted in an active form in the bile. The terminal elimination rate (elimination of 50% of dose, halflife) is 1.6 hours. In pharmacokinetic models based on human exposure, which considered the impact of protein binding and erythromycin affinity for bacterial ribosomes, the half-life was determined to be 1.2 hours (Chun and Seitz, 1977; Wiegand and Chun, 1972). Erythromycin diffuses into intracellular fluids but does not penetrate into brain tissue or cerebrospinal fluid. Erythromycin is stated to penetrate prostatic fluid (resulting in concentrations 40% of those obtained in plasma), traverse the placenta, and attain fetal plasma concentrations of about 5%-20% of those in the maternal circulation (Sande and Mandell, 1985). After oral administration of erythromycin or its stearate to control subjects and to patients with diagnosed infections, erythromycin was detected at therapeutic levels in lung (bronchiolar secretions) (Simon, 1980), saliva (Simon, 1980; Henry et al., 1980), fallopian tubes, peritoneal fluid from the pouch of Douglas (Bergan and Gjonnaess, 1981), vaginal washes (Iliopoulou et al., 1981), and oviduct mucosa (Brihmer, 1986).

Administration of erythromycin or erythromycin stearate to male Sprague Dawley rats (age unspecified) results in the formation of an inactive cytochrome P450-metabolite complex in vivo; a similar complex is formed in vitro after incubation with NADPH and liver microsomes from phenobarbital-induced, but not 3-methylcholanthrene-induced, rats (Larrey et al., 1983). Erythromycin or erythromycin stearate administered to rats induced synthesis of microsomal enzymes and resulted in an inactive erythromycin-P450 complex (Villa et al., 1986). N-demethylation of both erythromycin and aminopyrine was increased. Hydroxylation of aniline was not changed. In dosed rats, O-demethylation of 4-nitroanisole and liver glutathione levels were decreased and pentobarbital sleeping time was increased relative to controls.

Acute Toxicity

The following acute toxicity has been reported for the erythromycin base (strains, age and sex for all species unspecified) (NIOSH, 1983):

Rat Oral $LD_{50} = 9,272 \text{ mg/kg}$ Intravenous $LD_{50} = 209 \text{ mg/kg}$ Subcutaneous $LD_{L0} = 427 \text{ mg/kg}$

 $\begin{array}{l} Mouse\\ Oral \ LD_{50}=3,112\ mg/kg\\ Intraperitoneal \ LD_{50}=463\ mg/kg\\ Intravenous \ LD_{50}=426\ mg/kg\\ Intramuscular \ LD_{50}=394\ mg/kg \end{array}$

Guinea Pig Intraperitoneal $LD_{50} = 413 \text{ mg/kg}$

No data were reported for erythromycin stearate.

Cellular and Subcellular Toxicity

Sande and Mandell (1985) report that erythromycin and other macrolide antibiotics inhibit bacterial protein synthesis by binding to the 50S ribosomal subunits of sensitive bacteria. Erythromycin competes with chloramphenicol for the same binding site. Binding is reversible and can occur only when the 50S subunit is free from transfer-RNA-bearing nascent peptide chains. Gram-positive bacteria concentrate approximately 100 times more erythromycin than do gram-negative bacteria. At alkaline pH, ionization of the erythromycin molecule is decreased, resulting in increased cellular permeability and antimicrobial activity.

In mouse liver explant cultures from 19- to 21day-old C3H mice (sex unspecified), toxicity of erythromycin stearate in vitro paralleled toxicity observed in vivo (Dujovne et al., 1970). Erythromycin estolate is toxic to Chang liver cell cultures, as measured by cell viability (lactate dehydrogenase and β -glucuronidase leakage from cells) (Dujovne et al., 1972). In vitro toxicity correlates with in vivo toxicity.

Systemic Toxicity

Adverse reactions to the administration of erythromycin have included toxicity to the liver (Tolman et al., 1974; Alcalay et al., 1986); these reactions may have resulted from immune hypersensitivity. Inman and Rawson (1983) reviewed the use of erythromycin base and its stearate and estolate salts and tetracycline in 12,208 patients. Sixteen reports of jaundice were associated with presumed liver injury. Three of the 16 patients with jaundice had received erythromycin stearate. Jaundice in the other patients was believed to be due to viral hepatitis, gallstones, or cancer. No association could be made between use of erythromycin stearate and jaundice.

An effect of erythromycin on immune function has been suggested. Cooksley and Powell (1977) reported that a 53-year-old woman developed severe cholestatic hepatitis after administration of erythromycin estolate. Lymphocytes from the patient incubated with erythromycin base, the stearate, or the estolate were blastogenic only in response to the estolate salt. A 60-year-old man with severe respiratory distress was determined to be hypersensitive to erythromycin stearate (Abramov et al., 1978). Erythromycin has been shown to have an immunomodulatory effect. Anderson et al. (1982, 1983, 1984) found that a single oral dose of erythromycin stearate (500 mg) administered to volunteers transiently increased neutrophil chemotaxis and neutrophil antistaphylococcidial activity without affecting phagocytosis and inhibited prostaglandin E₂ release but did not affect mononuclear cell chemotaxis or blast transformation. Administration of erythromycin stearate to mice challenged with Candida albicans resulted in increased mean survival times. Neutrophils from patients with immune defects (abnormal chemotaxis and a history of recurrent infections) who had received erythromycin stearate orally, and neutrophils incubated in vitro with erythromycin stearate, demonstrated normal in vitro chemotaxis to

endotoxin-activated serum factors (Ras and Anderson, 1986). Oral administration of erythromycin to patients with chronic bronchopneumonia or to control subjects increased phagocytosis, superoxide anion free radical formation, and natural killer cell activity 4-6 hours after treatment (Fraschini et al., 1986).

Administration of erythromycin has been associated with changes in bacterial flora in humans, which could result in systemic effects. Administration of erythromycin stearate has been found to alter the flora of the oral cavity, throat, and colon (Heimdahl and Nord, 1982; Heimdahl et al., 1984). Colonization of these sites by erythromycin-resistant aerobic and anaerobic bacteria and yeast occurred after 7 days of treatment. Nord et al. (1985) also found that oral administration of erythromycin stearate decreased the presence of Streptococcus salivarius in the oropharynx, but after treatment was discontinued, normal flora repopulation occurred. In healthy volunteers with no erythromycin-resistant oral streptococci, administration of erythromycin on two separate occasions with a 1-week interval resulted in the presence of erythromycin-resistant bacterial strains that persisted for some time (Harrison et al., 1985).

Reproductive and Developmental Toxicity

Reproductive toxicity has been reported for the erythromycin base but not for erythromycin stearate (rat, 10-15 d pregnant, oral $TD_{L0} = 6$ g/kg; rat, 6-10 d pregnant, subcutaneous = 50 mg/kg; mouse, 8-13 d pregnant, oral = 12 g/kg) (NIOSH, 1983).

Long-Term Toxicity and Carcinogenicity

No long-term toxicity and carcinogenicity data were available in the literature.

Genetic Toxicology

No mutagenicity data for erythromycin stearate other than from NTP experiments were available in the literature; on the basis of the NTP test results, the chemical appears to be a nonmutagen. Erythromycin stearate was not mutagenic in Salmonella typhimurium strains TA98, TA100, TA1535, or TA1537 when tested in a preincubation protocol with or without Aroclor 1254-induced male Sprague Dawley rat or Syrian hamster liver S9 (Mortelmans et al., 1986; Appendix E, Table E1). Erythromycin stearate demonstrated equivocal mutagenicity in the mouse L5178Y lymphoma cell assay because, in the absence of S9, increases in forward mutations were observed only at concentrations at or just below those that caused precipitation (Table E2). No increases in mutations occurred in the presence of Aroclor 1254-induced F344 rat liver S9 at concentrations that did not cause precipitation. The positive responses reported for erythromycin stearate at higher concentrations (above the level that caused precipitation) in the presence of S9 were not considered in judging mutagenicity according to NTP quality control criteria. Treatment of cultured Chinese hamster ovary cells with erythromycin stearate did not produce an increase in the frequency of sister chromatid exchanges or chromosomal aberrations in either the presence or absence of Aroclor 1254-induced male Sprague Dawley rat liver S9 (Tables E3 and E4).

Study Rationale

Erythromycin stearate was nominated by the National Cancer Institute for study because it is the most widely used macrolide antibiotic and because of the lack of adequate carcinogenicity studies. Administration of erythromycin stearate in feed was chosen to obtain exposure by the oral route, the primary route for administration of the drug in humans.

.

II. MATERIALS AND METHODS

PROCUREMENT AND CHARACTERIZATION OF ERYTHROMYCIN STEARATE PREPARATION AND CHARACTERIZATION OF FORMULATED DIETS FOURTEEN-DAY STUDIES THIRTEEN-WEEK STUDIES TWO-YEAR STUDIES Study Design Source and Specifications of Animals

Source and Specifications of Animals Animal Maintenance Clinical Examinations and Pathology Statistical Methods

PROCUREMENT AND CHARACTERIZATION OF ERYTHROMYCIN STEARATE

Certified USP-grade erythromycin stearate was obtained in one lot (lot no. 287 FM) from Upjohn Company (Kalamazoo, Michigan). Purity and identity analyses were conducted at Midwest Research Institute (MRI) (Kansas City, Missouri). MRI reports on analyses performed in support of the erythromycin studies are on file at NIEHS.

Lot no. 287 FM was obtained as a fluffy, colorless powder. Its melting point was determined to be 100°-104° C, although this may be the temperature at which the chemical dissolves in stearic acid. The identity of erythromycin stearate was confirmed by spectroscopy. The infrared spectrum (Figure 1) was consistent with that in the literature (Sadtler Pharmaceutical Spectra). The ultraviolet/visible spectrum and nuclear magnetic resonance spectrum (Figure 2) were consistent with those expected for the structure of erythromycin stearate.


The purity of erythromycin stearate was determined by elemental analysis, water analysis, titration of the amino group, thin-layer chromatography, and high-performance liquid chromatography. Cumulative data indicated that lot no. 287 FM had a minimum purity of approximately 96% as erythromycin stearate. Results of elemental analysis for carbon were low; results for hydrogen and nitrogen agreed with the theoretical values. Water content by Karl Fischer titration was 2.49%. Nonaqueous potentiometric titration of the tertiary amino group with 0.5 N perchloric acid indicated an erythromycin stearate content of 96% corresponding to 69% erythromycin (693 µg erythromycin/mg erythromycin stearate) which exceeds the USP minimum purity of 55% erythromycin. Thinlayer chromatography on silica gel plates with an *n*-butanol: acetic acid: water (3:1:1) solvent system detected a single spot by both iodine and phosphomolybdic acid visualization; a major spot and one minor impurity were detected by an ethyl acetate:methanol (9:1) solvent system. High-performance liquid chromatography on a μ Bondapak C₁₈ column with detection at 230 nm

and a water: methanol solvent system at a flow rate of 1 ml/minute detected four impurities with a total peak area of 15.0% that of the major peak when operated in an isocratic mode (12:88 solvent ratio) and three impurities with a total relative area of 14.9% when used with a solvent program (70%-100% methanol in 8 minutes). Gas chromatography of a silvl ester derivative of the study chemical with a 3% OV-17 column, a nitrogen carrier at a flow rate of 60 ml/minute. and flame ionization detection indicated four impurities, each with a relative area of 1%-10% of the major peak area (exact values were not reported due to the semiguantitative nature of the derivatization procedure). The impurities detected chromatographically were probably other erythromycins (B or C) or isomers of erythromycin.

A stability study, in which stability was monitored by titration of the tertiary amino group with 0.1 N perchloric acid, indicated that erythromycin stearate was stable when stored for 2 weeks at temperatures up to 60° C. Further confirmation of the stability of the bulk chemical during the toxicity studies (storage at 25° C in the dark) was obtained by titration with 0.1 N perchloric acid and gas chromatography of a silyl ester derivative of the sample with an OV-17 or SP-2250 column and flame ionization detection. No degradation of the bulk chemical was observed throughout the studies. The identity of the chemical at the study laboratory was confirmed by infrared spectroscopy.


PREPARATION AND CHARACTERIZATION OF FORMULATED DIETS

The formulated diets were prepared by adding a dry premix of feed and erythromycin stearate to the appropriate amount of feed (Table 1). The mixture was blended for 15 minutes. The homogeneity of diet mixtures formulated at the analytical chemistry and study laboratories was confirmed by extracting feed samples (taken from three points of the blender) with an acetonitrile:water (85:15) solution, preparing silyl derivatives of the extracts, and performing gas chromatographic analysis with an OV-17 column and flame ionization detection. At the analytical chemistry laboratory, values ranged from



WAVELENGTH IN MICRONS

FIGURE 1. INFRARED ABSORPTION SPECTRUM OF ERYTHROMYCIN STEARATE (LOT NO. 287 FM)





Fourteen-Day Studies	Thirteen-Week Studies	Two-Year Studies
Preparation Premix mixed with bulk feed in a Patterson-Kelly 8-qt twin-shell® blender for 5 min with intensifier bar on and 10 min without intensifier bar	Same as 14-d studies	Premix prepared in beaker and mixed with spatula. Bulk mixing done in a 1-ft ³ Patterson-Kelly twin-shell® stainless steel blender for 5 min with intensifier bar on and 10 min without intensifier bar
Maximum Storage Time 14 d	14 d	14 d
Storage Conditions 5° C	≤5° C	5° C

TABLE 1. PREPARATION AND STORAGE OF FORMULATED DIETS IN THE FEED STUDIES OF ERYTHROMYCIN STEARATE

96.1% to 97.8% of the target value at a concentration of 10,000 ppm. At the study laboratory, homogeneous mixing of the formulated feed blends was a problem, as indicated by the results of a homogeneity study which showed a spread of 100%-115% of the target value at a concentration of 20,000 ppm. Further studies at the same analytical laboratory with the same analytical method showed that erythromycin stearate at 10,000 ppm was stable in feed when stored for 2 weeks at 5° C; additional studies detected no notable decrease in concentration of erythromycin stearate in samples stored either in sealed glass bottles in the dark or in feeders kept under normal animal room conditions. Formulated diets were stored at 5° C for no longer than 14 days.

Periodic analyses for erythromycin stearate in feed mixtures were conducted by the study and analytical chemistry laboratories to determine if the formulated diets contained the correct concentrations of erythromycin stearate. Samples were analyzed as described above except that

methanol was used as the extracting solvent and, during the first half of the 2-year studies, extracts were passed through Sep Pac[®] cartridges before silvlation at the study laboratory. Formulated diets were analyzed once, at the beginning of the 13-week studies. The results ranged from 88% to 104% of the target concentration (Table 2). During the 2-year studies, the feed mixtures were analyzed approximately every 1-2 months. Concentrations varied from 14% to 109.6% of the target concentration; the second lowest concentration observed was 90.8% of the target concentration (Table 3). Because 41/42 formulated diets analyzed were within 10% of the target concentrations, it is estimated that the formulated diets were prepared within specifications 98% of the time. Referee analyses were performed periodically by an independent laboratory. Initially, variable agreement was found between laboratories (Table 4). An adjustment in the analytical procedure used by the referee laboratory improved the agreement between laboratories for the last two sets of referee samples.

TABLE 2.	RESULTS OF	ANALYSIS OI	F FORMU	JLATED	DIETS	IN THE	THIRTEEN-WEEK	FEED
		STUDIE	S OF ER	YTHRO	MYCIN	STEARA	TE (a)	

Target Concentration (ppm)	Determined Concentration (ppm) (b)	Determined as a Percent of Target	
1,250	1,290	103	
2,500	2,600	104	
5,000	4,400	88	
10,000	9,400	94	
20,000	19,300	96.5	

(a) Mix date: 1/29/80(b) Results of duplicate analysis

TABLE 3. RESULTS OF ANALYSIS OF FORMULATED DIETS IN THE TWO-YEAR FEED STUDIES OF ERYTHROMYCIN STEARATE (a)

	Concentration of Erythromycin Stearate in Feed for Target Concentration (ppm)					
Date Mixed	2,500	5,000	10,000			
12/03/80	2,400	5,250	(b) 1,400			
12/08/80			(c) 10,300			
12/24/80	2,510	4,780	10,900			
02/05/81	2,510	5,440	10,100			
04/09/81	2,740	5,220	10,300			
	(d) 2,440	(d) 4,640	(d) 10,800			
07/09/81	2,590	5,200	9,900			
08/13/81	2,460	4,910	10,000			
10/08/81	2,340	4,800	9,470			
12/24/81	2,270	4,810	9,700			
01/28/82	2,510	4,760	10,700			
03/11/82	2,490	5,030	10,300			
05/13/82	2,390	5,150	10,400			
06/17/82	2,560	4,670	10,600			
09/02/82	2,340	5,050	9,530			
10/07/82	2,380	4,920	9,390			
ean (ppm)	2.464	4,999	9,478			
andard deviation	121.9	228.0	2,371.7			
pefficient of variation (percent)	4.9	4.6	25.0			
ange (ppm)	2,270-2,740	4,640-5,440	1,400-10,900			
umber of samples	14	14	14			

(a) Results of duplicate analysis

(b) Out of specifications; not used in the studies. If this value is excluded, the mean and standard deviation are 10,099 and 487.8.

(c) Remix; not included in the mean.

(d) Analysis performed by Capsule Laboratories

		Determined Con	ncentration (ppm)
Date Mixed	Target Concentration (ppm)	Study Laboratory (a)	Referee Laboratory (b)
04/09/81	2,500	2,740	(c,d) 3,140
10/08/81	10,000	9,470	(d) 8,100
05/13/82	2,500	2,390	2,360
09/02/82	5,000	5,050	4,990

TABLE 4. RESULTS OF REFEREE ANALYSIS OF FORMULATED DIETS IN THE TWO-YEAR FEEDSTUDIES OF ERYTHROMYCIN STEARATE

(a) Results of duplicate analysis

(b) Results of triplicate analysis

(c) A value of 2,440 ppm was found by Capsule Laboratories. (d) Out of specifications

FOURTEEN-DAY STUDIES

Five- to six-week-old male and female F344/N rats and B6C3F₁ mice were obtained from Harlan Industries and held for approximately 3 weeks before the studies began. Groups of five rats and five mice of each sex were fed diets containing 0, 3,125, 6,250, 12,500, 25,000, or 50,000 ppm erythromycin stearate for 14 consecutive days. Rats and mice were observed twice per day and were weighed once per week. Further details of animal maintenance are given in Table 5.

THIRTEEN-WEEK STUDIES

Thirteen-week studies were conducted to evaluate the cumulative toxic effects of repeated exposure to erythromycin stearate and to determine the concentrations to be used in the 2-year studies.

Four- to five-week-old male and female F344/N rats and 5- to 6-week-old male and female $B6C3F_1$ mice were obtained from Charles River Breeding Laboratories, observed for 16 days, distributed to weight classes, and then assigned to cages according to a table of random numbers. Cages were assigned to dosed and control groups according to another table of random numbers.

Groups of 10 rats and 10 mice of each sex were given diets containing 0, 1,250, 2,500, 5,000, 10,000, or 20,000 ppm erythromycin stearate for 13 weeks. Control diets consisted of NIH 07 Rat and Mouse Ration. Formulated diets, control diets, and water were available ad libitum. Further experimental details are summarized in Table 5.

Animals were checked two times per day; moribund animals were killed. Feed consumption was measured by cage once per week. Individual animal weights were recorded once per week. The following hematologic analyses were conducted on blood from the brachial vessels of the controls and the 20,000-ppm groups: hemoglobin concentration, erythrocyte count, leukocyte count, differential leukocyte count, hematocrit value, nucleated erythrocyte count, and platelet determination.

At the end of the 13-week studies, survivors were killed. A necropsy was performed on all animals except those excessively autolyzed or cannibalized. Tissues and groups examined are listed in Table 5.

TWO-YEAR STUDIES

Study Design

Diets containing 0, 5,000, or 10,000 ppm erythromycin stearate were fed to groups of 50 rats of each sex for 103 weeks. Diets containing 0, 2,500, or 5,000 ppm were fed to groups of 50 mice of each sex for 103 weeks.

TABLE 5. EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE FEED STUDIES OF ERYTHROMYCIN STEARATE

Fourteen-Day Studies	Thirteen-Week Studies	Two-Year Studies
EXPERIMENTAL DESIGN		
Size of Study Groups 5 males and 5 females of each species	10 males and 10 females of each species	50 males and 50 females of each species
Doses 0, 3,125, 6,250, 12,500, 25,000, or 50,000 ppm erythromycin stearate in feed	0, 1,250, 2,500, 5,000, 10,000, or 20,000 ppm erythromycin stearate in feed	Rats0, 5,000, or 10,000 ppm erythromycin stearate in feed; mice 0, 2,500, or 5,000 ppm
Date of First Dose 6/12/79	2/1/80	Rats12/9/80; mice12/23/80
Date of Last Dose 6/25/79	5/2/80	Rats11/29/82; mice12/13/82
Duration of Dosing 14 consecutive d	13 wk	103 wk
Type and Frequency of Observatior Observed 2 × d; weighed on d 1 and 1 × wk thereafter; feed consumption measured 1 × wk	Same as 14-d studies	Observed 2 \times d; weighed initially, 1 \times wk for 13 wk, and 1 \times mo there- after; palpated 1 \times mo at weighing, starting at wk 41; feed consumption estimated 1 \times mo
Necropsy and Histologic Examination Necropsy performed on all animals; 6,250-, 12,500-, and 25,000-ppm groups examined histologically	on Necropsy performed on all animals; histologic exams performed on animals that died before the end of the studies and on all control and high dose animals that had gross lesions; hematologic exam performed on control and high dose groups	Necropsy and histologic examination performed on all animals
ANIMALS AND ANIMAL MAINTE	NANCE	
Strain and Species F344/N rats; B6C3F ₁ mice	F344/N rats; B6C3F $_1$ mice	F344/N rats; B6C3F1 mice
Animal Source Harlan Industries (Indianapolis, IN)	Charles River Breeding Laboratories (Portage, MI [rats], or Kingston, NY [mice])	Charles River Breeding Laboratories (Portage, MI)
Study Laboratory Physiological Research Laboratories	Physiological Research Laboratories	Physiological Research Laboratories
Method of Animal Identification Ratstail mark; miceear punch	Toe clip	Ear notch, toe clip
Time Held Before Study 20 d	16 d	14 d
Age When Placed on Study 8-9 wk	Rats6-7 wk; mice7-8 wk	Same as 13-wk studies
Age When Killed 11 wk	Rats20-21 wk; mice21-22 wk	Rats110-111 wk; mice111-112 wk
Necropsy Dates Rats6/28/79; mice6/27/79	Rats5/5/80-5/8/80; mice5/6/80-5/9/80	Rats12/7/82-12/14/82; mice12/21/82-12/28/82

TABLE 5. EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE FEED STUDIES OF ERYTHROMYCIN STEARATE (Continued)

Fourteen-Day Studies	Thirteen-Week Studies	Two-Year Studies
ANIMAL MAINTENANCE (Continu	ned)	
Method of Animal Distribution Distributed to weight classes, then assigned to cages by a table of random numbers; cages assigned to dosed and control groups by another table of random numbers.	Same as 14-d studies	Same as 14-d studies
Feed Rodent Laboratory Chow 5001® meal (Ralston Purina Co., St. Louis, MO); available ad libitum	NIH 07 Rat and Mouse Ration (Zeigler Bros., Gardners, PA); available ad libitum	Same as 13-wk studies
Bedding Aspen wood chips	Same as 14-d studies	Aspen wood shavings, heat-treated (Minnesota Sawdust and Shavings Co., Anoka, MN)
Water Automatic watering system (Edstrom Industries, Waterford, WI); available ad libitum	Same as 14-d studies	Same as 14-d studies; water softened through sodium zeolite to <1 grain/ gal and then filtered
Cages Polycarbonate (Lab Products, Inc.)	Polycarbonate (Hazleton Systems, Inc., Aberdeen, MD)	Same as 13-wk studies
Cage Filters		Reemay spun-bonded polyester filters (Snow Filtration, Cincinnati, OH)
Animals per Cage 5	5	5
Other Chemicals on Study in the S None	ame Room None	None
Animal Room Environment Temp20.0°-23.3°C; hum33%-46%; light 12 h/d; 120 room air changes/h	Temp17.2°-26.6° C; hum22%-50%; light 12 h/d; 120 room air changes/h	Temp22.2°-26.7° C; hum30%-74%; fluorescent light 12 h/d; 15 room air changes/h

Source and Specifications of Animals

The male and female F344/N rats and B6C3F₁ (C57BL/6N, female \times C3H/HeN MTV⁻, male) mice used in these studies were produced under strict barrier conditions at Charles River Breeding Laboratories under a contract to the Carcinogenesis Program. Breeding stock for the foundation colonies at the production facility originated at the National Institutes of Health Repository. Animals shipped for study were progeny of defined microflora-associated parents that were transferred from isolators to

barrier-maintained rooms. Rats were shipped to the study laboratory at 4-5 weeks of age and mice, at 5-6 weeks of age. The animals were quarantined at the study facility for 2 weeks. Thereafter, a complete necropsy was performed on five animals of each sex and species to assess their health status. The rats were placed on study at 6-7 weeks of age and the mice, at 7-8 weeks of age. The health of the animals was monitored during the course of the studies according to the protocols of the NTP Sentinel Animal Program (Appendix F). A quality control skin grafting program has been in effect since early 1978 to monitor the genetic integrity of the inbred mice used to produce the hybrid $B6C3F_1$ study animal. In mid-1981, data were obtained that showed incompatibility between the NIH C3H reference colony and the C3H colony from a Program supplier. In August 1981, inbred parental lines of mice were further tested for genetic integrity via isozyme and protein electrophoresis profiles that demonstrate phenotype expressions of known genetic loci.

The C57BL/6N mice were homogeneous at all loci tested. Eighty-five percent of the C3H mice monitored were variant at one to three loci, indicating some heterogeneity in the C3H line from this supplier. Nevertheless, the genome of this line is more homogeneous than that of randomly bred stocks.

Male mice from the C3H colony and female mice from the C57BL/6N colony were used as parents for the hybrid B6C3F₁ mice used in these studies. The influence of the potential genetic nonuniformity in the hybrid mice on these results is not known, but results of the studies are not affected because concurrent controls were included in each study.

Animal Maintenance

Rats and mice were housed five per cage; cages were not rotated during the studies. Water and feed were available ad libitum. Further details of animal maintenance are given in Table 5.

Clinical Examinations and Pathology

All animals were observed two times per day, and clinical signs were recorded at least once per month. Body weights were recorded once per week for the first 13 weeks of the study and once per month thereafter. Mean body weights were calculated for each group. Animals found moribund and those surviving to the end of the studies were humanely killed. A necropsy was performed on all animals including those found dead, unless they were excessively autolyzed or cannibalized, missexed, or found missing. Thus, the number of animals from which particular organs or tissues were examined microscopically varies and is not necessarily equal to the number of animals that were placed on study.

During necropsy, all organs and tissues were examined for grossly visible lesions. Tissues were preserved in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Tissues examined microscopically are listed in Table 5.

When the pathology evaluation was completed, the slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were sent to an independent quality assessment laboratory. The individual animal records and tables were compared for accuracy, slides and tissue counts were verified. and histotechnique was evaluated. All tumor diagnoses, all target tissues, and all tissues from a randomly selected 10% of the animals were evaluated by a quality assessment pathologist. The quality assessment report and slides were submitted to the Pathology Working Group (PWG) Chairperson, who reviewed all target tissues and those about which there was a disagreement between the laboratory and quality assessment pathologists.

Representative slides selected by the Chairperson were reviewed by the PWG, which includes the laboratory pathologist, without knowledge of previously rendered diagnoses. When the consensus diagnosis of the PWG differed from that of the laboratory pathologist, the laboratory pathologist was asked to reconsider the original diagnosis. This procedure has been described, in part, by Maronpot and Boorman (1982) and Boorman et al. (1985). The final diagnoses represent a consensus of contractor pathologists and the NTP Pathology Working Group. For subsequent analysis of pathology data, the diagnosed lesions for each tissue type are combined according to the guidelines of McConnell et al. (1986).

Slides/tissues are generally not evaluated in a blind fashion (i.e., without knowledge of dose group) unless the lesions in question are subtle or unless there is an inconsistent diagnosis of lesions by the laboratory pathologist. Nonneoplastic lesions are not examined routinely by the quality assessment pathologist or PWG unless they are considered part of the toxic effect of the chemical.

Statistical Methods

Data Recording: Data on this experiment were recorded in the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive information on the chemicals, animals, experimental design, survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969).

Survival Analyses: The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals were censored from the survival analyses at the time they were found to be missing or dead from other than natural causes; animals dying from natural causes were not censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) life table test for a doserelated trend. When significant survival differences were detected, additional analyses using these procedures were carried out to determine the time point at which significant differences in the survival curves were first detected. All reported P values for the survival analysis are two-sided.

Calculation of Incidence: The incidence of neoplastic or nonneoplastic lesions is given as the ratio of the number of animals bearing such lesions at a specific anatomic site to the number of animals in which that site was examined. In most instances, the denominators include only those animals for which the site was examined histologically. However, when macroscopic examination was required to detect lesions (e.g., skin or mammary tumors) prior to histologic sampling, or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the number of animals on which a necropsy was performed.

Analysis of Tumor Incidence: Three statistical methods are used to analyze tumor incidence data: life table tests, incidental tumor analysis, and Fisher exact/Cochran-Armitage trend analyses. Tests of significance include pairwise comparisons of high dose and low dose groups with controls and tests for overall dose-response trends. For studies in which administration of the test compound has little effect on survival, the results of the three alternative analyses will generally be similar. When differing results are obtained by the three methods, the final interpretation of the data will depend on the extent to which the tumor under consideration is regarded as being the cause of death. Continuity-corrected tests are used in the analysis of tumor incidence, and reported P values are one-sided. The procedures described below also were used to evaluate selected nonneoplastic lesions.

Life Table Analyses--The first method of analysis assumed that all tumors of a given type observed in animals dying before the end of the study were "fatal"; i.e., they either directly or indirectly caused the death of the animal. According to this approach, the proportions of tumorbearing animals in the dosed and control groups were compared at each point in time at which an animal died with a tumor of interest. The denominators of these proportions were the total number of animals at risk in each group. These results, including the data from animals killed at the end of the study, were then combined by the Mantel-Haenszel method (1959) to obtain an overall P value. This method of adjusting for intercurrent mortality is the life table method of Cox (1972) and of Tarone (1975). The underlying variable considered by this analysis is time to death due to tumor. If the tumor is rapidly lethal, then time to death due to tumor closely approximates time to tumor onset. In this case, the life table test also provides a comparison of the time-specific tumor incidences.

Incidental Tumor Analyses--The second method of analysis assumed that all tumors of a given type observed in animals that died before the end of the study were "incidental"; i.e., they were merely observed at necropsy in animals dying of an unrelated cause. According to this approach, the proportions of tumor-bearing animals in dosed and control groups were compared in each of five time intervals: weeks 0-52, weeks 53-78, weeks 79-92, week 93 to the week before the terminal-kill period, and the terminal-kill period. The denominators of these proportions were the number of animals actually examined for tumors during the time interval. The individual time interval comparisons were then combined by the previously described method to obtain a single overall result. (See Haseman, 1984, for the computational details of both methods.) A recently developed method for the analysis of incidental tumors based on logistic regression (Dinse and Lagakos, 1983) was also employed as a supplemental test in some instances. This method has the advantage of not requiring time intervals in the statistical evaluation.

Fisher Exact/Cochran-Armitage Trend Analyses--In addition to survival-adjusted methods, the results of the Fisher exact test for pairwise comparisons and the Cochran-Armitage linear trend test (Armitage, 1971; Gart et al., 1979) are given in the appendixes containing the analyses of tumor incidence. These two tests are based on the overall proportion of tumor-bearing animals and do not adjust for survival differences.

Historical Control Data: Although the concurrent control group is always the first and most appropriate control group used for evaluation, there are certain instances in which historical control data can be helpful in the overall assessment of tumor incidence. Consequently, control tumor incidences from the NTP historical control data base (Haseman et al., 1984, 1985) are included for those tumors appearing to show compound-related effects.

III. RESULTS

RATS

FOURTEEN-DAY STUDIES

THIRTEEN-WEEK STUDIES

TWO-YEAR STUDIES

Body Weights, Feed Consumption, and Clinical Signs Survival Pathology and Statistical Analyses of Results

MICE

FOURTEEN-DAY STUDIES

THIRTEEN-WEEK STUDIES

TWO-YEAR STUDIES

Body Weights, Feed Consumption, and Clinical Signs Survival

Pathology and Statistical Analyses of Results

FOURTEEN-DAY STUDIES

None of the rats died before the end of the studies (Table 6). Feed consumption of rats that received 25,000 or 50,000 ppm was notably lower than that of controls. Final mean body weights of male rats that received 12,500, 25,000, or 50,000 ppm were 10%, 30%, or 36% lower, respectively, than that of controls. Final mean body weights of female rats that received 12,500, 25,000, or 50,000 ppm were 10%, 12%, or 32% lower, respectively, than that of controls. Lethargy and rough coats were observed at 12,500 ppm and above; diarrhea was observed at 50,000 ppm. Two male rats that received 25,000 ppm had hyperemic intestines.

THIRTEEN-WEEK STUDIES

None of the rats died before the end of the studies (Table 7). Final mean body weights of the 20,000-ppm groups were 12% lower than that of the controls for males and 7% lower for females. Feed consumption by dosed and control groups was comparable (except for males at 20,000 ppm). All dosed rats except the 1,250-ppm group of males were lethargic. Males that received 5,000-20,000 ppm and females that received 10,000 or 20,000 ppm had rough coats. Multinucleated syncytial hepatocytes were observed in all males that received 20,000 ppm.

Dose Selection Rationale: Because of lower weight gain at higher concentrations, dietary concentrations of erythromycin stearate selected for rats for the 2-year studies were 5,000 and 10,000 ppm.

TABLE 6. SURVIVAL, MEAN BODY WEIGHTS, AND FEED CONSUMPTION OF RATS IN THEFOURTEEN-DAY FEED STUDIES OF ERYTHROMYCIN STEARATE

			ody Weight		Final Weight Relative Feed Cor			
Concentration		Initial (b)	Final	Change (c)	to Controls		<u>ion (d)</u>	
(ppm)	(a)				(percent)	Week 1	Week 2	
MALE						- <u>.</u>		
0	5/5	110 ± 5	174 ± 12	$+64 \pm 7$		15.1	15.9	
3,125	5/5	103 ± 5	155 ± 11	$+52 \pm 6$	89	13.7	14.8	
6,250	5/5	110 ± 5	169 ± 10	$+59 \pm 5$	97	14.4	15.5	
12,500	5/5	110 ± 8	156 ± 14	$+46 \pm 6$	90	12.1	14.3	
25,000	5/5	108 ± 5	121 ± 8	$+13 \pm 4$	70	7.9	11.1	
50,000	5/5	117 ± 8	111 ± 6	-6 ± 2	64	4.9	6.3	
FEMALE								
0	5/5	92 ± 5	120 ± 7	$+28 \pm 3$		10.9	10.4	
3,125	5/5	101 ± 4	121 ± 4	$+20 \pm 2$	101	12.3	11.0	
6,250	5/5	94 ± 3	112 ± 6	$+18 \pm 3$	93	11.2	10.7	
12,500	5/5	93 ± 6	108 ± 7	$+15 \pm 2$	90	9.1	10.9	
25,000	5/5	99 ± 1	105 ± 2	$+6 \pm 1$	88	6.4	8.5	
50,000	5/5	88 ± 3	82 ± 2	-6 ± 2	68	3.1	4.4	

(a) Number surviving/number initially in group

(b) Initial group mean body weight \pm standard error of the mean

(c) Mean body weight change of the group \pm standard error of the mean

(d) Grams of feed consumed per animal per day; not corrected for scatter.

Concentration	Survival	<u>Mean B</u> Initial (b)	<u>Body Weigh</u> Final	<u>ts (grams)</u> Change (c)	Final Weight Relative to Controls		l Con- tion (d)
(pp m)	(a)				(percent)	Week 4	Week 12
MALE							
0	10/10	135 ± 1	305 ± 5	$+170 \pm 6$		14.5	11.5
1,250	10/10	135 ± 1	305 ± 2	$+170 \pm 2$	100	13.4	11.5
2,500	10/10	127 ± 1	291 ± 10	$+164 \pm 10$	95	13.2	11.1
5,000	10/10	137 ± 1	312 ± 3	$+175 \pm 3$	102	13.9	11.8
10,000	10/10	130 ± 1	285 ± 3	$+155 \pm 3$	93	13.4	11.0
20,000	10/10	138 ± 1	269 ± 2	$+131 \pm 3$	88	12.2	11.3
FEMALE							
0	10/10	101 ± 1	168 ± 2	$+67 \pm 2$		8.2	7.5
1,250	10/10	101 ± 1	168 ± 6	$+67 \pm 6$	100	8.7	8.0
2,500	10/10	105 ± 1	176 ± 2	$+71 \pm 2$	105	8.5	8.2
5,000	10/10	105 ± 2	179 ± 2	$+74 \pm 2$	107	8.5	8.0
10,000	10/10	104 ± 1	164 ± 2	$+60 \pm 1$	98	8.5	7.9
20,000	10/10	104 ± 1	156 ± 2	$+52 \pm 3$	93	7.9	8.0

TABLE 7.	SURVIVAL, MEAN BODY	WEIGHTS, AND	FEED CONSUMPTION OF RATS IN THE
	THIRTEEN-WEEK	FEED STUDIES	OF ERYTHROMYCIN STEARATE

(a) Number surviving/number initially in the group

(b) Initial group mean body weight \pm standard error of the mean

(c) Mean weight change of the group \pm standard error of the mean

(d) Grams of feed consumed per animal per day; not corrected for scatter.

TWO-YEAR STUDIES

Body Weights, Feed Consumption, and Clinical Signs

Mean body weights of high dose male rats were within 6% of those of controls throughout the studies (Table 8 and Figure 3). Mean body weights of high dose female rats were 5%-10% lower than those of controls from week 35 to the end of the studies. Mean body weights of low dose male and female rats were comparable to those of controls throughout the studies. The average daily feed consumption per rat by low dose and high dose rats was 99% and 98% that by controls for males (Appendix G, Table G1) and 103% and 99% for females (Table G2). The average amount of erythromycin stearate consumed per day was approximately 180 or 370 mg/kg by low dose or high dose male rats and 210 or 435 mg/kg by low dose or high dose female rats. No compound-related clinical signs were observed.

Weeks	Control		5,000 ppm			10,000 ppm		
on	Av. Wt.	No. of	Av. Wt.	Wt. (percent	No. of	Av. Wt.	Wt. (percent	No. of
Study	(grams)	Survivors	(grams)	of controls)	Survivors	(grams)	of controls)	Survivors
MALE								
1	168	50	167	99	50	164	98	50
2 3	218 243	50 50	217 242	100 100	50 50	207 232	95 95	50 50
4	267	50	262	98	50	254	95	50
5	279	50	276	99	50	265	95	50
6 7	293 303	50 50	292 305	100 101	50 50	278 289	95 95	50 50
8	312	50	317	102	50	298	96	50
9	326	50	329	101	50	309	95	50
10 11	335 345	50 50	336 347	100 101	50 50	316 326	94 94	50 50
12	358	50	360	101	50	339	95	50
13	369	50	369	100	50	350	95	50
17 21	396 407	50 50	393 406	99 100	50 50	375 390	95 96	50 50
27	432	50	426	99	50	410	95	50
31	442	50	439	99	50	424	96	50
35 40	445 458	50 50	445 458	100 100	50 50	430 443	97 97	50 50
40	458	50	451	99	50	438	96	50
48	468	50	462	99	50	453	97	50
52 57	469 467	50 49	469 471	100 101	50 50	455 455	97 97	50 50
61	470	49	472	100	49	457	97	50
65	464	49	466	100	49	454	98	49
70 75	467	47 45	452 464	97	49	449	96	48
75 79	466 461	43	452	100 98	48 48	448 440	96 95	47 46
83	465	42	453	97	45	445	96	44
87	462	40	449	97	41	436	94	41
91 96	444 438	40 35	445 460	100 105	39 31	425 421	96 96	38 36
100	437	31	427	98	25	416	95	32
103	420	28	410	98	23	410	98	27
FEMALE								
1 2	126	50	127	101	50	124	98	50
3	146 155	50 50	146 156	100 101	50 50	142 151	97 97	50 50
4	166	50	167	101	50	161	97	50
5	168	50	171	102	50	162	96	50
6 7	179 184	50 50	181 183	101 99	50 50	172 176	96 96	50 50
8	189	50	187	99	50	185	98	50
9	193	50	193	100	50	186	96	50
10 11	196 200	50 50	198 201	101 101	50 50	187 191	95 96	50 50
12	202	50	205	101	50	193	96	50
13	205	50	208	101	50	196	96	50
17 21	219 220	50 50	222 227	101 103	50 50	209 212	95 96	50
27	233	49	238	103	50	222	95	50 50
31	238	49	245	103	50	229	96	50
35 40	255 249	49 49	247 256	97 103	50 50	230 234	90	50
40	256	49	261	103	50	234 241	94 94	50 50
48	263	49	273	104	50	250	95	50
52 57	273 289	48	283 292	104	50	257	94	50
57 61	289 293	46 46	292 304	101 104	49 49	266 275	92 94	50 50
65	302	46	313	104	48	283	94	49
70 75	313	46	322	103	47	292	93	47 47
75 79	317 321	46 45	326 327	103 102	46 46	295 294	93 92	47 47
83	323	43	328	102	48	294	92	47
87	326	38	330	101	41	296	91	47 47
91 96	316 330	36 33	328 336	104 102	3 9 37	290 299	92 91	47
100	329	32	328	102	34	300	91	43 41
103	328	29	334	102	30	307	94	37

TABLE 8. MEAN BODY WEIGHTS AND SURVIVAL OF RATS IN THE TWO-YEAR FEED STUDIES OF ERYTHROMYCIN STEARATE




FIGURE 3. GROWTH CURVES FOR RATS FED DIETS CONTAINING ERYTHROMYCIN STEARATE FOR TWO YEARS

Survival

Estimates of the probabilities of survival for male and female rats fed diets containing erythromycin stearate at the concentrations used in these studies and for controls are shown in Table 9 and in the Kaplan and Meier curves in Figure 4. No significant differences in survival were observed between any groups of either sex.

Pathology and Statistical Analyses of Results

This section describes the significant or noteworthy changes in the incidences of rats with neoplastic or nonneoplastic lesions of the oral cavity, adrenal gland, testis, liver, spleen, bone marrow, Zymbal gland, and eye.

Lesions in male rats are summarized in Appendix A. Histopathologic findings on neoplasms are summarized in Table A1. Table A2 gives the survival and tumor status for individual male rats. Table A3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Table A3 (footnotes). Historical incidences of tumors in control male rats are listed in Table A4. Findings on nonneoplastic lesions are summarized in Table A5.

Lesions in female rats are summarized in Appendix B. Histopathologic findings on neoplasms are summarized in Table B1. Table B2 gives the survival and tumor status for individual female rats. Table B3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Table B3 (footnotes). Historical incidences of tumors in control female rats are listed in Table B4. Findings on nonneoplastic lesions are summarized in Table B5.

	Control	5,000 ppm	10,000 ppm
MALE (a)			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	22	27	23
Killed at termination	28	23	27
Survival P values (c)	0.966	0.454	0.900
FEMALE (a)			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	21	20	12
Killed at termination	29	30	38
Survival P values (c)	0.050	0.884	0.055

TABLE 9. SURVIVAL OF RATS IN THE TWO-YEAR FEED STUDIES OF ERYTHROMYCIN STEARATE

(a) Terminal-kill period: week 104

(b) Includes animals killed in a moribund condition

(c) The result of the life table trend test is in the control column, and the results of the life table pairwise comparisons with the controls are in the dosed columns.




FIGURE 4. KAPLAN-MEIER SURVIVAL CURVES FOR RATS FED DIETS CONTAINING ERYTHROMYCIN STEARATE FOR TWO YEARS

Oral Cavity: The incidence of oral cavity squamous cell papillomas was increased in the dosed groups of female rats compared with that in the controls; although the increase was not statistically significant, it is noteworthy, since oral cavity tumors are uncommon in female rats (Table 10).

Adrenal Gland: Pheochromocytomas in female rats occurred with a positive trend; the incidence in the high dose group was significantly greater than that in the controls by the incidental tumor test (Table 11). Results of the incidental tumor test in this study were notably different from results of the life table and Fisher exact tests. Because the results of the incidental tumor test may have been influenced by the choice of time intervals used in the analysis, logistic regression (an alternative procedure for analysis of incidental tumors which does not require selection of time intervals) was carried out as a supplemental test (Dinse and Lagakos, 1983; Dinse and Haseman, 1986). By this approach, neither the trend (P=0.077) nor the high dose incidence (P=0.104) was statistically significant.

TABLE 10.	ANALYSIS OF ORAL CAVITY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED
	STUDY OF ERYTHROMYCIN STEARATE (a)

	Control	5,000 ppm (b)	10,000 ppm (b)
Squamous Cell Papilloma (c)			<u></u>
Overall Rates	1/50 (2%)	2/50 (4%)	3/50 (6%)
Adjusted Rates	3.4%	6.7%	7.4%
Terminal Rates	1/29 (3%)	2/30 (7%)	2/38 (5%)
Week of First Observation	104	104	95
Life Table Tests	P = 0.316	P = 0.512	P = 0.405
Incidental Tumor Tests	P = 0.308	P = 0.512	P = 0.395

(a) The statistical analyses used are discussed in Chapter II (Statistical Methods) and Appendix B, Table B3 (footnotes).
(b) The estimated dose in milligrams per kilograms per day is given in Chapter III (Body Weights, Feed Consumption, and Clinical Signs) and in Appendix G.

(c) Historical incidence of squamous cell tumors at study laboratory: 0/150; historical incidence in NTP studies (mean): 1/1,984 (0.05%)

TABLE 11.	ANALYSIS OF	ADRENAL GLAND	LESIONS IN	FEMALE	RATS IN	THE T	WO-YEAR F	EED
		STUDY OF EF	rythromyci	N STEAR	ATE			

	Control	5,000 ppm	10,000 ppm
Medullary Hyperplasia		····	
Overall Rates	6/50 (12%)	4/49 (8%)	6/50 (12%)
Pheochromocytoma (a)			
Overall Rates	1/50 (2%)	4/49 (8%)	5/50 (10%)
Adjusted Rates	2.3%	11.4%	12.4%
Terminal Rates	0/29 (0%)	2/29 (7%)	4/38 (11%)
Week of First Observation	83	84	91
Life Table Tests	P = 0.146	P = 0.189	P = 0.169
Incidental Tumor Tests	P = 0.025	P = 0.138	P = 0.041

(a) Historical incidence of pheochromocytomas or malignant pheochromocytomas (combined) at study laboratory (mean \pm SD): 13/149 (9% \pm 6%); historical incidence in NTP studies: 98/1,966 (5% \pm 4%)

Testis: Interstitial cell tumors in male rats occurred with a significant positive trend; the incidence in the high dose group was greater than that in the controls (Table 12).

Liver: Granulomas were observed at increased incidences (P < 0.01) in high dose rats (male: control, 1/50; low dose, 2/50; high dose, 10/50; female: 18/50; 27/50; 43/50). The granulomas seen in dosed rats were generally larger than those observed in controls, and they consisted of focal aggregates of macrophages surrounded by varied numbers of lymphocytes.

Spleen: Granulomatous inflammation or granulomas (combined) was observed in dosed female rats (male: none observed; female: control, 0/48; low dose, 1/49; high dose, 3/50). These lesions, which are rarely observed in the spleen of control rats, were similar to the granulomas occurring in the liver.

Bone Marrow: Reticulum cell hyperplasia was observed at increased incidences in dosed female rats (male: control, 2/49; low dose, 3/49; high dose, 4/49; female: 10/50; 14/50; 25/50). This

lesion consisted of small focal aggregates of large polygonal cells with abundant cytoplasm characteristic of macrophages.

Zymbal Gland: Carcinomas in male rats occurred with a significant (P < 0.03) negative trend (male: control, 4/50; low dose, 1/50; high dose, 0/50; female: 0/50; 1/50; 0/50); the incidences in the dosed groups were not significantly lower than that in the controls.

Eye: Mineralization of the crystalline lens was observed at an increased incidence (P < 0.05) in low dose male rats (male: control, 3/50; low dose, 10/50; high dose, 1/50; female: 1/50; 4/50; 1/50). Cataracts were observed at an increased incidence (P < 0.001) in low dose female rats (male: 8/50; 13/50; 9/50; female: 1/50; 19/50; 4/50). At study week 101, the average light intensity was estimated to be 2,054 total footcandles. Low dose male and female rat cages occupied the top two tiers, high dose male and female rat cages occupied the middle two tiers, and control male and female rat cages occupied the bottom two tiers of the rack. Cages were not rotated during the studies.

TABLE 12. ANALYSIS OF TESTICULAR LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

	Control	5,000 ppm	10,000 ppm
Hyperplasia			
Overall Rates	17/50 (34%)	17/50 (34%)	16/50 (32%)
Interstitial Cell Tumor (a)			
Overall Rates	32/50 (64%)	36/50 (72%)	43/50 (86%)
Adjusted Rates	86.2%	91.8%	100.0%
Terminal Rates	23/28 (82%)	20/23 (87%)	27/27 (100%)
Week of First Observation	74	80	76
Life Table Tests	P = 0.024	P = 0.076	P = 0.022
Incidental Tumor Tests	P = 0.003	P = 0.208	P = 0.003
Cochran-Armitage Trend Test	P = 0.008		
Fisher Exact Test		P = 0.260	P = 0.010

(a) Historical incidence at study laboratory (mean \pm SD): 133/150 (89% \pm 6%); historical incidence in NTP studies: 1,681/1,909 (88% \pm 7%)

FOURTEEN-DAY STUDIES

Two of the female mice that received 50,000 ppm died before the end of the studies (Table 13). None of the dosed groups of male or female mice gained weight. Feed consumption by mice that received 25,000 and 50,000 ppm was notably less than that by controls. Lethargy and rough coats were observed at all but the lowest dose. Hydration of the cornea was observed in mice that received 6,250, 12,500, or 25,000 ppm. In mice that received 50,000 ppm, one male had a hyperemic jejunum and cecum, one male had a hemorrhagic spleen, and one female had hemorrhagic intestines.

THIRTEEN-WEEK STUDIES

None of the mice died before the end of the studies (Table 14). Final mean body weights of mice that received 10,000 or 20,000 ppm were 15% or 19% lower than those of controls for males and 5% or 14% lower for females. Estimated feed consumption by dosed groups was comparable to that by the controls. No compound-related clinical signs or microscopic pathologic effects were observed.

Dose Selection Rationale: Because of lower weight gain at higher concentrations, dietary concentrations of erythromycin stearate selected for mice for the 2-year studies were 2,500 and 5,000 ppm.

TABLE 13. SURVIVAL, MEAN BODY WEIGHTS, AND FEED CONSUMPTION OF MICE IN THE FOURTEEN-DAY FEED STUDIES OF ERYTHROMYCIN STEARATE

Concentration	Concentration Survival		<u>Mean Body Weights (grams)</u> tration Survival Initial (b) Final Change (c)		Final Weight Relative to Controls	Feed Con- sumption (d)	
(ppm)	(a)			0	(percent)	Week 1	Week 2
MALE		<u></u>			Φαδαν' απο 4 18 - Β Μαινία αναλικά το Βραγιο Αλλά το Νού το Νού το Νού το Νού αλλα το Νού το Νού το Νού το Τ		
0	5/5	20.5 ± 0.8	21.4 ± 0.9	$+0.9 \pm 1.0$		3.8	3.5
3,125	5/5	22.0 ± 0.7	21.5 ± 0.9	-0.5 ± 0.3	100.5	4.0	3.8
6,250	5/5	21.2 ± 0.5	20.2 ± 0.6	-1.0 ± 0.4	94.4	3.6	3.3
12,500	5/5	23.2 ± 1.2	22.1 ± 1.2	-1.1 ± 0.4	103.3	3.2	3.7
25,000	5/5	22.4 ± 0.5	22.1 ± 0.3	-0.3 ± 0.5	103.3	2.3	2.7
50,000	5/5	20.4 ± 1.0	19.2 ± 1.0	-1.2 ± 0.2	89.7	1.6	2.5
FEMALE							
0	5/5	17.3 ± 0.3	17.5 ± 0.6	$+0.2 \pm 0.4$		3.8	3.3
3,125	5/5	18.1 ± 0.8	18.1 ± 0.5	0.0 ± 0.3	103.4	3.9	3.4
6,250	5/5	18.2 ± 0.5	18.1 ± 0.2	-0.1 ± 0.3	103.4	3.7	3.2
12,500	5/5	17.8 ± 0.4	17.6 ± 0.2	-0.2 ± 0.2	100.6	2.9	3.1
25,000	5/5	18.3 ± 0.8	17.0 ± 0.5	-1.3 ± 0.4	97.1	2.2	2.4
50,000	(e)3/5	17.6 ± 0.4	17.8 ± 1.3	-0.4 ± 1.4	101.7	1.9	2.9

(a) Number surviving/number initially in group

(b) Initial group mean body weight \pm standard error of the mean. Subsequent calculations are based on those animals surviving to the end of the study.

(c) Mean body weight change of the survivors \pm standard error of the mean

(d) Grams of feed consumed per animal per day; not corrected for scatter.

(e) Day of death: 9,10

		Mean	Body Weight	ts (grams)	Final Weight Relativ	e Feed	l Con-
Concentration (ppm)	Survival (a)	Initial (b)	Final	Change (c)	to Controls (percent)		tion (d) Week 12
MALE							
0	10/10	20.9 ± 0.4	31.1 ± 1.2	$+10.2 \pm 1.3$		2.5	3.1
1,250	10/10	21.5 ± 0.5	32.1 ± 1.1	$+10.6 \pm 1.3$	103.2	3.1	3.1
2,500	10/10	22.2 ± 0.5	31.0 ± 0.5	$+8.8 \pm 0.6$	99.7	2.9	3.5
5,000	10/10	21.8 ± 0.1	30.2 ± 0.7	$+8.4 \pm 0.7$	97.1	2.8	3.1
10,000	10/10	21.3 ± 0.4	26.5 ± 0.6	$+5.2 \pm 0.6$	85.2	2.9	3.2
20,000	10/10	21.5 ± 0.2	25.1 ± 0.3	$+3.6\pm0.4$	80.7	3.0	2.8
FEMALE							
0	10/10	17.2 ± 0.2	24.0 ± 0.5	$+6.8 \pm 0.5$		2.1	2.6
1,250	10/10	17.9 ± 0.2	25.5 ± 0.5	$+7.6 \pm 0.4$	106.3	2.4	2.9
2,500	10/10	18.4 ± 0.3	24.5 ± 0.8	$+6.1 \pm 0.5$	102.1	2.6	2.9
5,000	10/10	17.8 ± 0.2	26.0 ± 0.7	$+8.2 \pm 0.6$	108.3	2.4	2.8
10,000	10/10	18.8 ± 0.2	22.7 ± 0.4	$+3.9 \pm 0.4$	94.6	2.4	2.5
20,000	10/10	18.3 ± 0.1	20.7 ± 0.5	$+2.4 \pm 0.5$	86.3	3.2	2.8

TABLE 14. SURVIVAL, MEAN BODY WEIGHTS, AND FEED CONSUMPTION OF MICE IN THE THIRTEEN-WEEK FEED STUDIES OF ERYTHROMYCIN STEARATE

(a) Number surviving/number initially in the group

(b) Initial group mean body weight \pm standard error of the mean

(c) Mean weight change of the group \pm standard error of the mean

(d) Grams of feed consumed per animal per day; not corrected for scatter.

TWO-YEAR STUDIES

Body Weights, Feed Consumption, and Clinical Signs

Mean body weights of dosed and control mice were generally comparable throughout the studies (Table 15 and Figure 5). The average daily feed consumption by low dose and high dose male mice was 103% and 100% that by controls (Appendix G, Table G3) and by low dose and high dose female mice, 92% that by controls (Table G4). The average amount of erythromycin stearate consumed per day was approximately 270 or 545 mg/kg by low or high dose male mice and 250 or 500 mg/kg by low or high dose female mice. No compound-related clinical signs were observed.

Weeks	C	ontrol		2,500 ppm			5,000 ppm	
on	Av. Wt.	No. of	Av. Wt.	Wt. (percent	No. of	Av. Wt.	Wt. (percent	No. of
Study	(grams)	Survivors	(grams)	of controls)	Survivors	(grams)	of controls)	Survivors
MALE								
1	25.5	50	24.6	96	50	24.6	96	50
2 3	26.2 27.7	50 50	25.3 26.9	97 97	50 50	25.3 26.4	97 95	50 50
4	28.1	50	27.6	98	50	27.1	96	49
5	29.0	50	28.3	98	50	27.6	95	49
6	29.9	50	29.2	98 99	50	28.3	95 95	49 49
7 8	30.3 30.9	50 50	30.0 30.5	99	50 50	28.7 29.6	95 96	49
9	31.3	50	31.2	100	50	30.1	96	49
10	31.7	50	31.9	101	50	30.1	95	49
11	32.2	50	32.2	100	50	30.8	96 92	49 49
12 13	34.3 33.0	50 50	32.6 32.9	95 100	50 50	31.5 32.3	92 98	49 49
16	33.4	50	35.1	105	50	33.5	100	49
20	35.4	50	35.8	101	50	34.5	97	49
26	35.1	50	37.0	105	49	35.1	100	49
30 34	36.3 37.2	50 50	36.4 37.5	100 101	49 49	35.4 36.6	98 98	49 49
34	36.9	50	38.0	101	49	36.8	100	49
42	38.4	50	39.0	102	49	38.8	101	49
46	39.5	49	39.6	100	49	39.0	99	49
50	39.7 39.7	49 48	40.0 39.5	101 99	47 47	39.1 39.0	98 98	49 49
55 58	39.4	48	39.3	100	47	39.0	99 99	49
63	40.2	48	40.2	100	47	39.7	99	49
68	39.5	48	40.0	101	47	39.0	99	49
72	39.1	48	39.3	101	46	38.5	98 97	48
77 81	39.1 39.2	47 47	38.4 38.6	98 98	45 44	38.0 37.7	97	46 45
85	38.0	44	37.8	99	41	37.8	99	42
89	37.8	43	39.3	104	39	38.3	101	41
94	37.5	42	38.3	102	38	37.2	99	41
98 103	37.4 37.5	40 34	39.5 38.5	106 103	35 33	37.7 37.3	101 99	40 40
FEMALE								
1	20.0	50	19.4	97	50	19.7	99	50
2 3	20.7 21.7	50 50	20.5 21.1	99 97	50 50	20.5 21.0	99 97	50 50
4	21.9	50	21.4	98	50	21.8	100	50
5	22.6	50	21.9	97	50	22.3	99	50
6	23.1	50	22.7	98	50	23.2	100	50
7 8	23.7 23.9	50 50	23.1 23.5	97 98	50 50	23.4 23.5	99 98	50 50
9	23.9	50	23.9	100	49	23.5	101	50
10	24.7	50	24.3	98	49	24.2	98	50
11	24.8	50 50	25.0	101	49	24.2	98	50
12 13	25.8 26.3	50 50	25.7 26.5	100 101	49 49	25.4 26.2	98 100	50 50
16	27.2	50	27.8	102	49	27.1	100	50
20	29.5	50	28.9	98	49	28.7	97	50
26	30.4	50	30.3	100	49	29.2	96	49
30	31.8	50	32.0	101	48 48	30.9 33.2	97 97	49
34 38	34.3 34.8	50 50	34.0 35.0	99 101	48	33.4	96	49 49
42	35.2	50	36.2	103	48	35.2	100	49
46	37.4	50	37.4	100	48	36.7	98	49
50	38.1	50 50	38.3	101	48	37.9	99 100	49
55 58	37.7 38.6	50 50	37.8 37.0	100 96	48 48	37.6 37.4	100 97	49 49
63	39.7	50	38.5	97	47	39.1	98	49
68	40.1	50	38.9	97	47	39.6	99	49
72	39.7 29.1	50	38.6	97	47	40.2	101	49
77 81	39.1 39.9	49 48	38.5 38.9	98 97	46 46	39.1 39.8	100 100	48 48
85	39.9	48	39.5	99	46	40.3	101	47
89	39.3	48	39.0	99	46	39.9	102	47
94	39.5	45	39.2	99	40	40.2	102	46
98 103	39.5 40.4	42 38	39.9 39.6	101 98	38 34	40.9 40.5	104 100	44 41
			~~.~		~ 7		100	

TABLE 15. MEAN BODY WEIGHTS AND SURVIVAL OF MICE IN THE TWO-YEAR FEED STUDIESOF ERYTHROMYCIN STEARATE




FIGURE 5. GROWTH CURVES FOR MICE FED DIETS CONTAINING ERYTHROMYCIN STEARATE FOR TWO YEARS

Survival

Estimates of the probabilities of survival for male and female mice fed diets containing erythromycin stearate at the concentrations used in these studies and for controls are shown in Table 16 and in the Kaplan and Meier curves in Figure 6. No significant differences in survival were observed between any groups of either sex.

Pathology and Statistical Analyses of Results

This section describes changes in the incidences of mice with nonneoplastic lesions of the glandular stomach and urinary bladder.

Lesions in male mice are summarized in Appendix C. Histopathologic findings on neoplasms are summarized in Table C1. Table C2 gives the survival and tumor status for individual male mice. Table C3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are

discussed in Chapter II (Statistical Methods) and Table C3 (footnotes). Findings on nonneoplastic lesions are summarized in Table C4.

Lesions in female mice are summarized in Appendix D. Histopathologic findings on neoplasms are summarized in Table D1. Table D2 gives the survival and tumor status for individual female mice. Table D3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Table D3 (footnotes). Findings on nonneoplastic lesions are summarized in Table D4.

Glandular Stomach: Inflammation was observed at increased incidences in dosed male mice (male: control, 1/49; low dose, 4/50; high dose, 6/50; female: 3/49; 4/49; 0/50).

Urinary Bladder: Lymphoid hyperplasia was observed at increased incidences in dosed female mice (male: control, 3/50; low dose, 4/50; high dose, 8/50; female: 1/50; 9/47; 7/48).

	Control	2,500 ppm	5,000 ppm
MALE (a)			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	16	17	10
Killed at termination	34	32	40
Died during termination period	0	1	0
Survival P values (c)	0.316	0.831	0.328
FEMALE (a)			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	12	15	10
Accidentally killed	0	1	0
Killed at termination	38	34	40
Survival P values (c)	0.728	0.539	0.789

TABLE 16. SURVIVAL OF MICE IN THE TWO-YEAR FEED STUDIES OF ERYTHROMYCIN STEARATE

(a) Terminal-kill period: week 104

(b) Includes animals killed in a moribund condition

(c) The result of the life table trend test is in the control column, and the results of the life table pairwise comparisons with the controls are in the dosed columns.




FIGURE 6. KAPLAN-MEIER SURVIVAL CURVES FOR MICE FED DIETS CONTAINING ERYTHROMYCIN STEARATE FOR TWO YEARS

Erythromycin Stearate, NTP TR 338

.

IV. DISCUSSION AND CONCLUSIONS

Toxicology and carcinogenesis studies of erythromycin stearate were conducted by administering erythromycin stearate (USP grade, greater than 96% pure) in feed to groups of F344/N rats and B6C3F₁ mice for 14 days, 13 weeks, or 2 years. Erythromycin stearate was studied and evaluated because of its widespread use in humans as a broad-spectrum macrolide antibiotic and because of the absence of reported long-term studies for carcinogenicity.

Diets containing up to 50,000 ppm erythromycin stearate (5% of the diet) were given to animals in the 14-day studies; all the rats and male mice survived, but 2/5 female mice receiving 50,000 ppm died. Marked dose-related decreases in weight gain correlated with proportional decreases in feed consumption except in female mice. This seems unusual, since the reported acute oral (gavage) toxicity of erythromycin base is greater for mice than for rats (age, sex, and strain unspecified; NIOSH, 1983). Clinical observations and gross pathologic lesions were indicative of gastrointestinal distress, most likely associated with killing of intestinal bacteria. Histopathologic examinations were not performed in the 14-day studies, and no information is available on target organ toxicity at these dose levels for these studies.

In the 13-week studies, none of the rats or mice receiving dietary concentrations up to 20,000 ppm died before the end of the studies. Final mean body weights of the 20,000-ppm groups of rats and mice were lower than those of the controls, with a proportionately greater reduction in males. The estimated feed consumption rates were similar to control values.

The liver (multinucleated syncytial hepatocytes) was the only organ affected in male rats. No compound-related gross or microscopic pathologic effects were observed in mice. Erythromycin is known to concentrate in the liver and to be excreted in the bile (Sande and Mandell, 1985). In vitro and in vivo studies and case reports in humans suggest that erythromycin is toxic to the liver (Dujovne et al., 1970, 1972; Tolman et al., 1974; Alcalay et al., 1986).

Based on these results, primarily the effects on final body weights, the 2-year studies of erythromycin stearate were conducted by administering erythromycin stearate in the diet at 0, 5,000, or 10,000 ppm to groups of 50 rats of each sex for 103 weeks. Diets containing 0, 2,500, or 5,000 ppm erythromycin stearate were fed to groups of 50 mice of each sex for 103 weeks.

Lower relative mean body weights were observed throughout the studies for high dose rats: females were more affected than were males after week 35, indicating an effect due to administration of erythromycin stearate. The similarity between mean body weights of dosed and control male and female mice suggests that greater dietary concentrations might have been given. The amount of erythromycin stearate consumed, calculated on the basis of estimated feed consumption by group-housed animals, was similar for all four studies: approximately 200-250 mg/kg per day in the low dose groups and 400-500 mg/kg per day in the high dose groups. By contrast, the usual oral therapeutic dosage of 1-2 g per day for a 70-kg human is approximately 15-30 mg/kg per day. No differences in survival were observed between any groups of rats or mice.

Granulomas of the liver in male and female rats and reticulum cell hyperplasia in the bone marrow of female rats are considered to be related to the administration of erythromycin stearate and indicate that the doses used were sufficient to elicit a biologic effect. These lesions may be exacerbated by the potential immunomodulatory effects (increased leukocyte migration) of erythromycin (Anderson et al., 1982, 1983, 1984; Ras and Anderson, 1986; Fraschini et al., 1986). Small granulomas occur in the liver of control rats and generally occur more frequently in females than in males. Although the cause of these spontaneous granulomas is unknown, they may be caused by the absorption of bacteria or bacterial products from the intestine. Estrogens are known to cause some immunosuppression (Luster et al., 1984; Dieter et al., 1987), which may explain the sex difference. In addition, the liver concentrates erythromycin (Sande and Mandell, 1985); crystallization of erythromycin may exacerbate this condition.

No neoplastic lesions were considered to be related to the consumption of erythromycin stearate by male or female rats or mice. Squamous cell papillomas of the oral mucosa were observed in 1/50 control, 2/50 low dose, and 3/50 high dose female rats. Although these lesions are uncommon in the historical control data base, they are not considered to be related to the administration of erythromycin stearate because the increased incidences in the dosed groups are not statistically different from that in the concurrent control group, one papilloma was seen in each group of control rats, and the biologic importance of these lesions is not clear at this time. Hyperplasia of the oral mucosa was not observed in female rats.

Pheochromocytomas of the adrenal gland in female rats occurred with a positive trend (control, 1/50; low dose, 4/49; high dose, 5/50); the increased incidences were considered to be marginal and were discounted because complementary increases in hyperplasia did not occur (6/50; 4/49; 6/50), the increases were marginal, the lesion is relatively common, and the incidences are similar to the mean historical incidence at this laboratory. Thus, these lesions are not considered to be biologically important.

Male rats showed a dose-related increase in the incidence of interstitial cell tumors of the testis (control, 32/50; low dose, 36/50; high dose, 43/50), but this is a commonly occurring tumor that is observed in almost all older animals. In this particular study, the control incidence was somewhat low relative to that in previous studies (133/150, 89%, at this laboratory; 1,681/1,909, 88%, throughout the Program; Appendix A, Table A4a). This marginal increase is not considered to be biologically important.

Several confounding factors in interpreting these studies are known. Initial killing of intestinal bacteria and reduction in the flora by erythromycin is followed by repopulation by erythromycin-resistant strains and acclimation (natural repopulation of gut flora) (Heimdahl et al., 1984; Nord et al., 1985; Harrison et al., 1985), which may have occurred in the 2-year and 13-week studies but probably not in the 14day studies. Systemic effects, including gastrointestinal distress, which result from the killing of intestinal flora and the release of bacterial endotoxins may confuse determination of the direct effects of erythromycin mammalian toxicity at the relatively high doses used in these studies.

Another complicating factor is administration of erythromycin stearate salt in the diet. Erythromycin base is known to be inactivated by gastric juice (Boggiano and Gleeson, 1976; Sande and Mandell, 1985), and various derivatives have been prepared to resist decomposition (Sande and Mandell, 1985). Erythromycin stearate is a reasonable choice, although the literature is conflicting on whether administration with or without food affects the amount and rate of erythromycin base absorption (Welling, 1977; Welling et al., 1978; Malmborg, 1979; Rutland et al., 1979; DiSanto and Chodos, 1981; Digranes et al., 1984). To accurately estimate the dose actually delivered, data would be required on the changes in the bacterial flora, absorption rate, disposition, and excretion rates under study conditions. These data are not available.

The experimental and tabulated data for the NTP Technical Report on erythromycin stearate were examined for accuracy, consistency, completeness, and compliance with Good Laboratory Practice regulations. As summarized in Appendix I, the audit revealed no major problems with the conduct of the studies or with collection and documentation of the experimental data. No discrepancies were found that influenced the final interpretation of the results of these studies. Conclusions: Under the conditions of these 2year studies, there was no evidence of carcinogenic activity* of erythromycin stearate for male or female F344/N rats administered erythromycin stearate in the diet at 5,000 or 10,000 ppm. There was no evidence of carcinogenic activity of erythromycin stearate for male or female B6C3F₁ mice administered erythromycin stearate in the diet at 2,500 or 5,000 ppm. Doserelated increases in the incidences of granulomas of the liver were observed in male and female rats. The absence of any biologically important chemical-associated effects in mice suggests that higher doses could have been given to male and female mice.

^{*}Explanation of Levels of Evidence of Carcinogenic Activity is on page 8.

A summary of the Peer Review comments and the public discussion on this Technical Report appears on page 11.

V. REFERENCES

V. REFERENCES

1. Abramov, L.A.; Yust, I.C.; Fierstater, E.M.; Vardinon, N.E. (1978) Acute respiratory distress caused by erythromycin hypersensitivity. Arch. Intern. Med. 138:1156-1158.

2. Alcalay, J.; Halevy, S.; Theodor, E.; Sandbank, M. (1986) Asymptomatic liver injury due to erythromycin stearate. Drug Intell. Clin. Pharm. 20:601-602.

3. Anderson, R.; Van Rensburg, C.E.J.; Eftychis, H.; Joone, G.; van Rensburg, A.J. (1982) Further studies on erythromycin effects on cellular immune functions *in vitro* and *in vivo*. Enhancement of neutrophil motility by erythromycin combined with ascorbate or thiamine. J. Antimicrob. Chemother. 10:409-417.

4. Anderson, R.; Fernandes, A.C.; Theron, A.; Joone, G. (1983) In vitro and in vivo studies of the nonspecific immunopotentiating properties of erythromycin. 13th Proc. Int. Congr. Chemother. 10:516-518.

5. Anderson, R.; Fernandes, A.C.; Eftychis, H.E. (1984) Studies on the effects of ingestion of a single 500 mg oral dose of erythromycin stearate on leucocyte motility and transformation and on release *in vitro* of prostaglandin E_2 by stimulated leucocytes. J. Antimicrob. Chemother. 14:41-50.

6. Armitage, P. (1971) Statistical Methods in Medical Research. New York: John Wiley & Sons, Inc., pp. 362-365.

7. Baum, C.; Kennedy, D.L.; Knapp, D.E.; Faich, G.A. (1986) Drug Utilization in the U.S.--1985 Seventh Annual Review, Office of Epidemiology and Biostatistics, National Center for Drugs and Biologics, Food and Drug Administration, Rockville, MD.

8. Berenblum, I., Ed. (1969) Carcinogenicity Testing: A Report of the Panel on Carcinogenicity of the Cancer Research Commission of UICC, Vol. 2. Geneva: International Union Against Cancer.

9. Bergan, T.; Gjonnaess, H. (1981) Penetration of erythromycin to female pelvic organs. Curr. Ther. Res. 30:597-604. 10. Boggiano, B.G.; Gleeson, M. (1976) Gastric acid inactivation of erythromycin stearate in solid dosage forms. J. Pharm. Sci. 65:497-502.

11. Boorman, G.A.; Montgomery, C.A., Jr.; Eustis, S.L.; Wolfe, M.J.; McConnell, E.E.; Hardisty, J.F. (1985) Quality assurance in pathology for rodent carcinogenicity studies. Milman, H.; Weisburger, E., Eds.: Handbook of Carcinogen Testing. Park Ridge, NJ: Noyes Publications, pp. 345-357.

12. Brihmer, C. (1986) Levels of erythromycin in human oviduct mucosa and serum. IRCS Med. Sci. 14:1114-1115.

13. Chun, A.H.C.; Seitz, J.A. (1977) Pharmacokinetics and biological availability of erythromycin. Infection 5(Suppl. 1):14-22.

14. Clive, D.; Johnson, K.O.; Spector, J.F.S.; Batson, A.G.; Brown, M.M.M. (1979) Validation and characterization of the $L5178Y/TK^{+/-}$ mouse lymphoma mutagen assay system. Mutat. Res. 59:61-108.

15. Cooksley, W.G.E.; Powell, L.W. (1977) Erythromycin jaundice: Diagnosis by an in vitro challenge test. Aust. N.Z. J. Med. 7:291-293.

16. Cox, D.R. (1972) Regression models and life tables. J. R. Stat. Soc. B34:187-220.

17. Dieter, M.; French, J.; Boorman, G.; Luster, M. (1987) Metabolic characterization of mouse bone marow cells responsive to estrogenic inhibition: Hexose monophosphate shunt enzyme activity in enriched populations of mature cells and progenitor cells. J. Leukocyte Biol. 41:212-219.

18. Digranes, A.; Josefsson, K.; Schreiner, A. (1984) Influence of food on the absorption of erythromycin from enteric-coated pellets and stearate tablets. Curr. Ther. Res. 35:313-320.

19. Dinse, G.E.; Haseman, J.K. (1986) Logistic regression analysis of incidental-tumor data from animal carcinogenicity experiments. Fundam. Appl. Toxicol. 6:44-52.

20. Dinse, G.E.; Lagakos, S.W. (1983) Regression analysis of tumour prevalence data. J. R. Stat. Soc. Ser. C (Applied Statistics) 32:236-248.

21. DiSanto, A.R.; Chodos, D.J. (1981) Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate. Antimicrob. Agents Chemother. 20:190-196.

22. Dujovne, C.A.; Lavelle, G.; Weiss, P.; Bianchine, J.R.; Lasagna, L. (1970) Toxicity of hepatotoxic drugs on mouse liver tissue culture. Arch. Int. Pharmacodyn. Ther. 186:84-93.

23. Dujovne, C.A.; Shoeman, D.; Bianchine, J.; Lasagna, L. (1972) Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J. Lab. Clin. Med. 79:832-844.

24. Eriksson, M.; Bolme, P.; Blennow, M. (1981) Absorption of erythromycin from pediatric suspension in infants and children. Scand. J. Infect. Dis. 13:211-215.

25. Fraschini, F.; Scaglione, F.; Ferrara, F.; Marelli, O.; Braga, P.C.; Teodori, F. (1986) Evaluation of the immunostimulating activity of erythromycin in man. Chemotherapy 32:286-290.

26. Galloway, S.M.; Bloom, A.D.; Resnick, M.; Margolin, B.H.; Nakamura, F.; Archer, P.; Zeiger, E. (1985) Development of a standard protocol for in vitro cytogenetic testing with Chinese hamster ovary cells: Comparison of results for 22 compounds in two laboratories. Environ. Mutagen. 7:1-51.

27. Gart, J.J.; Chu, K.C.; Tarone, R.E. (1979) Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. J. Natl. Cancer Inst. 62:957-974.

28. Harrison, G.A.; Stross, W.P.; Rubin, M.P.; Davies, R.M.; Speller, D.C. (1985) Resistance in oral streptococci after repeated three-dose erythromycin prophylaxis. J. Antimicrob. Chemother. 15:471-479. 29. Haseman, J.K. (1984) Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies. Environ. Health Perspect. 58:385-392.

30. Haseman, J.K.; Huff, J.; Boorman, G.A. (1984) Use of historical control data in carcinogenicity studies in rodents. Toxicol. Pathol. 12:126-135.

31. Haseman, J.K.; Huff, J.; Rao, G.N.; Arnold, J.; Boorman, G.A.; McConnell, E.E. (1985) Neoplasms observed in untreated and corn oil gavage control groups of F344/N rats and (C57BL/6N \times C3H/HeN)F₁ (B6C3F₁) mice. J. Natl. Cancer Inst. 75:975-984.

32. Haworth, S.; Lawlor, T.; Mortelmans, K.; Speck, W.; Zeiger, E. (1983) Salmonella mutagenicity test results for 250 chemicals. Environ. Mutagen. Suppl. 1:3-142.

33. Heimdahl, A.; Nord, C.E. (1982) Impact of erythromycin on the normal human flora and colonization of the oral cavity, throat, and colon. 12th Proc. Int. Congr. Chemother. 2:914-916.

34. Heimdahl, A.; Nord, C.E.; Borthen, L. (1984) Impact of phenoxymethylpenicillin, erythromycin, clindamycin and doxycycline on *Strepto*coccus salivarius in the oropharynx. J. Antimicrob. Chemother. 13:505-509.

35. Henry, J.; Garland, M.; Turner, P.; Esmieu, F. (1980) Plasma and salivary concentrations of erythromycin after administration of three different formulations. Postgrad. Med. J. 55:707-710.

36. Iliopoulou, A.; Thin, R.N.; Turner, P. (1981) Fluorimetric and microbiological assays of erythromycin concentrations in plasma and vaginal washings. Br. J. Vener. Dis. 57:263-267.

37. Iliopoulou, A.; Downey, K.; Chaput de Saintonge, D.M.; Turner, P. (1982) Should erythromycin dose be altered in haemodialysis patients? Eur. J. Clin. Pharmacol. 23:435-440.

V. REFERENCES

38. Inman, W.H.W.; Rawson, N.S.B. (1983) Erythromycin estolate and jaundice. Br. Med. J. 286:1954-1955.

39. Kaplan, E.L.; Meier, P. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481.

40. Larrey, D.; Tinel, M.; Pessayre, D. (1983) Formation of inactive cytochrome P-450 Fe(II)metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem. Pharmacol. 32:1487-1493.

41. Linhart, M.S.; Cooper, J.; Martin, R.L.; Page, N.; Peters, J. (1974) Carcinogenesis Bioassay Data System. Comput. Biomed. Res. 7:230-248.

42. Luster, M.; Boorman, G.; Korach, K.; Dieter, M.; Hong, L. (1984) Mechanisms of estrogen-induced myelotoxicity: Evidence for thymic regulation. Int. J. Immunopharmacol. 6:287-294.

43. Malmborg, A.-S. (1979) Effect of food on absorption of erythromycin: A study of two derivatives, the stearate and the base. J. Antimicrob. Chemother. 5:591-599.

44. Mantel, N.; Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22:719-748.

45. Maronpot, R.R.; Boorman, G.A. (1982) Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. Toxicol. Pathol. 10:71-80.

46. Mather, L.E.; Austin, K.L.; Philpot, C.R.; McDonald, P.J. (1981) Absorption and bioavailability of oral erythromycin. Br. J. Clin. Pharmacol. 12:131-140.

47. McConnell, E.E.; Solleveld, H.A.; Swenberg, J.A.; Boorman, G.A. (1986) Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J. Natl. Cancer Inst. 76:283-289. 48. Mortelmans, K.; Haworth, S.; Lawlor, T.; Speck, W.; Tainer, B.; Zeiger, E. (1986) Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals. Environ. Mutagen. 8(Suppl. 7):1-119.

49. Myhr, B.; Bowers, L.; Caspary, W.J. (1985) Assays for the induction of gene mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells in culture. Prog. Mutat. Res. 5:555-568.

50. National Cancer Institute (NCI) (1976) Guidelines for Carcinogen Bioassay in Small Rodents. NCI Technical Report No. 1. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health. 65 p.

51. National Institute for Occupational Safety and Health (NIOSH) (1983) Registry of Toxic Effects of Chemical Substances 1981-1982, Vol. 2, p. 211.

52. National Institute for Occupational Safety and Health (NIOSH) (1987) Registry of Toxic Effects of Chemical Substances--1985-6, Vol. 3, p. 2200.

53. National Institutes of Health (NIH) (1978) Open Formula Rat and Mouse Ration (NIH-07). Specification NIH-11-1335. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.

54. Nord, C.E.; Heimdahl, A.; Borthen, L.; Soederholm, J. (1985) Impact of phenoxymethylpenicillin, erythromycin, clindamycin, and doxycycline on Streptococcus salivarius in the oropharynx. Recent Adv. Streptococci Streptococcal Dis., Proc. Lancefield Int. Symp. Streptococci Streptococcal, pp. 320-321.

55. Parsons, R.L.; Hossack, G.; Paddock, G. (1975) The absorption of antibiotics in adult patients with coeliac disease. J. Antimicrob. Chemother. 1:39-50.

56. Parsons, R.L.; Jusko, W.J.; Young, J.M. (1976a) Pharmacokinetics of antibiotic absorption in coeliac disease. J. Antimicrob. Chemother. 2:214-215.

57. Parsons, R.L.; Paddock, G.; Kaye, C.M. (1976b) Drug absorption in malabsorption syndromes. Excerpta Med. Int. Congr. Ser. 383:193-202.

58. Parsons, R.L.; Paddock, M.; Hossack, A. (1977) Particular aspects of the pharmacokinetics of erythromycin. Infection 5(Suppl. 1):23-28.

59. Ras, G.J.; Anderson, R. (1986) An *in-vitro* study of oral therapeutic doses of co-trimoxazole and erythromycin stearate on abnormal polymorphonuclear leukocyte migration. J. Antimicrob. Chemother. 17:185-193.

60. Ravagnan, L.; Ravagnan, G.; Garaci, E. (1971) Serum and tissue levels of erythromycin after oral administration. Antibiotica 9:34-38.

61. Remington's Pharmaceutical Sciences (1975) 15th ed. Easton, PA: Mack Publishing Co.

62. Rutland, J.; Berend, N.; Marlin, G.E. (1979) The influence of food on the bioavailability of new formulations of erythromycin stearate and base. Br. J. Clin. Pharmacol. 8:343-347.

63. Sadtler Pharmaceutical Spectra, IR No. R264. Philadelphia: Sadtler Research Laboratories.

64. Sande, M.A.; Mandell, G.L. (1985) Antimicrobial agents: Tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. Gilman, A.G., Goodman, L.S.; Rall, T.W.; Murad, F., Eds.: The Pharmacological Basis of Therapeutics, 8th ed. New York: Macmillan Publishing Company, pp. 1184-1188. 65. Simon, C. (1980) Pharmacokinetics of erythromycin in healthy adults and in adults with respiratory infections. Curr. Med. Res. Opin. 6(Suppl. 8):17-22.

66. Tarone, R.E. (1975) Tests for trend in life table analysis. Biometrika 62:679-682.

67. Tolman, K.G.; Sannella, J.J.; Freston, J.W. (1974) Chemical structure of erythromycin and hepatotoxicity. Ann. Intern. Med. 81:58-60.

68. U.S. International Trade Commission (USITC) (1986) Synthetic Organic Chemicals, United States Production and Sales 1985. USITC Publication No. 1892, Washington, DC: Government Printing Office.

69. Villa, P.; Corti, F.; Guaitani, A.; Bartosek, I.; Casacci, F.; De Marchi, F.; Pacei, E. (1986) Effects of a new fluorinated macrolide (P-0501A) and other erythromycins on drug metabolizing enzymes in rat liver. J. Antibiot. (Tokyo) 39:463-468.

70. Welling, P.G. (1977) How food and fluid affect drug absorption: Results of initial studies. Postgrad. Med. 62:73-75.

71. Welling, P.G.; Huang, H.; Hewitt, P.F.; Lyons, L.L. (1978) Bioavailability of erythromycin stearate: Influence of food and fluid volume. J. Pharm. Sci. 67:764-766.

72. Wiegand, R.G.; Chun, A.H.C. (1972) Serum protein binding of erythromycin and erythromycin 2'-propionate ester. J. Pharm. Sci. 61:425-428.

Erythromycin Stearate, NTP TR 338

APPENDIX A

SUMMARY OF LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

		PAGE
TABLE A1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	59
TABLE A2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	62
TABLE A3	ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	70
TABLE A4a	HISTORICAL INCIDENCE OF TESTICULAR INTERSTITIAL CELL TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT	74
TABLE A4b	HISTORICAL INCIDENCE OF ZYMBAL GLAND TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT	75
TABLE A5	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	76

TABLE A1.	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR
	FEED STUDY OF ERYTHROMYCIN STEARATE

τ	Intreat	ed Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY	50		50	····	50	
ANIMALS NECROPSIED	50		50		50	
ANIMALS EXAMINED HISTOPATHOLOGICALL	Y 50		50		50	
INTEGUMENTARY SYSTEM						
*Skin	(50)		(50)		(50)	
Basal cell tumor			1	(2%)		
Sebaceous adenoma		(2%)		(0~)		
Keratoacanthoma *Subcutaneous tissue		(2%)		(2%)		(2%)
Subcutaneous tissue Sarcoma, NOS	(50)		(50)		(50)	(2%)
Fibroma	1	(2%)	3	(6%)		(2%) (4%)
Fibrosarcoma		(2%)		(2%)	4	(4/0)
Neurilemoma, malignant	-		-	(=,	1	(2%)
RESPIRATORY SYSTEM						
#Trachea	(50)		(49)		(48)	
Fibrosarcoma, metastatic				(2%)	(10)	
#Lung	(50)		(50)		(50)	
Alveolar/bronchiolar adenoma		(2%)	1	(2%)	1	(2%)
Alveolar/bronchiolar carcinoma	2	(4%)			1	(2%)
Neurilemoma, metastatic					1	(2%)
HEMATOPOIETIC SYSTEM						
*Multiple organs	(50)		(50)		(50)	
Leukemia, mononuclear cell		(58%)		(54%)		(66%)
#Spleen	(46)		(49)		(50)	
Leukemia, mononuclear cell			2	(4%)	1	(2%)
CIRCULATORY SYSTEM			<u> </u>	· · · · · · · · · · · · · · · · · · ·		
*Sternum	(50)		(50)		(50)	
Hemangiosarcoma				(2%)		
*Artery	(50)		(50)		(50)	
Fibrosarcoma, metastatic			1	(2%)		
DIGESTIVE SYSTEM						
*Palate	(50)	(00)	(50)		(50)	
Squamous cell papilloma Ribrogarcoma, motostatio	T	(2%)	•	(90)		
Fibrosarcoma, metastatíc *Tongue	(50)		(50)	(2%)	(50)	
Squamous cell papilloma	(50)		(00)			(2%)
#Salivary gland	(49)		(48)		(50)	(270)
Neurilemoma, malignant	(10)			(2%)	(00)	
#Submaxillary gland	(49)		(48)		(50)	
Neurilemoma, metastatic						(2%)
#Liver	(50)		(50)		(50)	
Neoplastic nodule		(2%)		(2%)		(6%)
#Colon	(49)	(901)	(48)		(49)	
Mucinous adenocarcinoma		(2%)				
URINARY SYSTEM						
#Kidney	(50)		(50)	(90)	(50)	
Tubular cell adenoma			1	(2%)		

	Untreat	ed Control	Low	Dose	High	Dose
ENDOCRINE SYSTEM						
#Anterior pituitary	(49)		(47)		(47)	
Carcinoma, NOS		(2%)	()		····	
Adenoma, NOS		(29%)	14	(30%)	11	(23%)
#Adrenal	(50)	()	(50)		(50)	(10/0)
Cortical adenoma	(,		(,			(2%)
Cortical carcinoma			1	(2%)		(2%)
#Adrenal medulla	(50)		(50)	(1,0)	(50)	
Pheochromocytoma		(38%)		(26%)		(34%)
Pheochromocytoma, malignant		(12%)		(2%)		(4%)
#Thyroid	(50)		(48)		(50)	
Follicular cell adenoma				(2%)	(/	
Follicular cell carcinoma				(2%)	1	(2%)
C-cell adenoma	6	(12%)		(19%)		(10%)
C-cell carcinoma	U			(4%)		(2%)
#Pancreatic islets	(48)		(49)		(49)	/
Islet cell adenoma		(4%)		(4%)		(6%)
Islet cell carcinoma		(2%)		(2%)		(2%)
REPRODUCTIVE SYSTEM						
*Mammary gland	(50)		(50)		(50)	
Adenoma, NOS			(00)			(2%)
Adenocarcinoma, NOS			1	(2%)	1	(— / V /
*Preputial gland	(50)		(50)		(50)	
Carcinoma, NOS		(2%)		(2%)	(00)	
Adenoma, NOS	•			(4%)		
#Testis	(50)		(50)	. =	(50)	
Interstitial cell tumor		(64%)		(72%)		(86%)
NERVOUS SYSTEM None						· · · ·
SPECIAL SENSE ORGANS	<u></u>		- + 2 <u>-</u>		<u> </u>	
*Eyelid	(50)		(50)		(50)	
Fibrosarcoma					1	(2%)
*Zymbal gland	(50)		(50)		(50)	
Carcinoma, NOS	4	(8%)	1	(2%)		
Keratoacanthoma				(2%)		
MUSCULOSKELETAL SYSTEM						
*Lumbar vertebra	(50)		(50)		(50)	
Sarcoma, NOS	(24)			(2%)	(20)	
*Femur	(50)		(50)	/	(50)	
Osteosarcoma				(2%)	(
						<u> </u>
SUDY CAVELLES	(50)		(50)		(50)	
	(00)		(00)			(2%)
*Mesentery					-	
Lipoma			1	(2%)		
*Mesentery Lipoma Mesothelioma, NOS	(50)			(2%)	(50)	
*Mesentery Lipoma	(50)		(50)	(2%) (4%)	(50)	

TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Untreated Control	Low Dose	High Dose
ALL OTHER SYSTEMS			
*Multiple organs	(50)	(50)	(50)
Carcinoma, NOS, metastatic	1 (2%)		
Sarcoma, NOS		1 (2%)	
Mesothelioma, NOS	1 (2%)		
Mesothelioma, malignant			1 (2%)
Neurilemoma, malignant			1 (2%)
ANIMAL DISPOSITION SUMMARY			
Animals initially in study	50	50	50
Natural death	3	3	1
Moribund sacrifice	19	24	22
Terminal sacrifice	28	23	27
TUMOR SUMMARY			
Total animals with primary tumors**	49	49	49
Total primary tumors	126	133	138
Total animals with benign tumors	45	46	47
Total benign tumors	78	85	87
Total animals with malignant tumors	39	38	37
Total malignant tumors	46	44	48
Total animals with secondary tumors##	1	1	1
Total secondary tumors	1	3	2
Total animals with tumors uncertain			
benign or malignant	2	4	3
Total uncertain tumors	2	4	3

TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically.
** Primary tumors: all tumors except secondary tumors
Number of animals examined microscopically at this site
Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ

												•			-	00									
ANIMAL NUMBER	1 1 7	$1\\3\\6$	1 0 9	1 1 6	1 1 1	1 0 3	1 4 6	1 5 0	1 4 4	1 4 1	1 0 5	$\begin{array}{c}1\\2\\7\end{array}$	1 3 3	$\frac{1}{2}$	1 3 7	1 4 0	$ \begin{array}{c} 1 \\ 3 \\ 1 \end{array} $	1 0 6	1 1 5	1 3 5	1 3 8	1 3 4	1 0 1	$ \begin{array}{c} 1 \\ 0 \\ 2 \end{array} $	1 0 4
WEEKS ON STUDY	0 5 6	0 6 7	0 7 0	0 7 4	0 7 5	0 7 9	0 7 9	0 8 0	0 8 5	0 8 6	0 9 4	0 9 4	0 9 4	0 9 6	0 9 6	0 9 6	0 9 8	0 9 9	0 9 9	$\begin{array}{c}1\\0\\2\end{array}$	1 0 2	1 0 3	$ \begin{array}{c} 1 \\ 0 \\ 4 \end{array} $	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Skin Sebaceous adenoma Keratoacanthoma Subcutaneous tissue Fibroma Fibrosarcoma	++	+	+	+	+	+	+	+ + X	+ +	++	+	+	++	* * +	+ +	+	+ +	+	+	+	+ +	+ X +	+	+	++
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Trachea	+++++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X +	+	+	+
HEMATOPOIETIC SYSTEM Bone marrow Spieen Lymph nodes Thymus	++++++	+++++	+ + + -	+ + + +	+ + + +	+ + + +	+ + + +	++++	++++++	++++-	++++++	++++++	+ + + +	+ + + +	+ + + +	+++	+++++	+ + + +	+ + + -	+++++	+ + + +	+++++	+ + + +	+ + + +	+ + +
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland Liver Neoplastic nodule Bile duct Pancreas Esophagus Stomach Small intestine Large intestine Mucinous adenocarcinoma	N ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++	N ++ +++++	Z + + + + + + + + + + + + + + + + + + +	N + + + + + + + + + + + + + + + + + + +	N ++ ++++++	N + + + + + + + + + + + + + + + + + + +	X ++ +++++	Z ++ ++++++	N ++ +++++++	NX + + + + + + + + -	N ++ ++++++	N ++ +++++	N ++ +++++	X ++ +++++	X ++ + + + + + + + + + + + + + + + + +	N + + + + + + + + + X	N ++ +++++	N ++ ++++++	N ++ ++++++	X ++ ++++++	Z ++ ++++++	N ++ +++++	N ++X++++++	N ++ ++++++	N ++ +++++++
URINARY SYSTEM Kidney Urinary bladder	++++	+++	+++	+++	+++	+++	+++	++++	++++	+++	++++	++++	++++	+++	++++	++++	 + +	++++	++	++++	++++	+++	+++++	++++	++++
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS Adrenal Pheochromocytoma Pheochromocytoma, malignant Thyroid C-ceil adenoma Parathyroid Pancreatic islets Islet cell adenoma Islet cell adenoma Islet cell carcinoma	+ X + +	+ + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + +	+ * * + + +	+ X + X + +	+ + X + +	+ X + + + + +	+ + + + +	+ X + + + + + + + + + + + + + + + + + +	+ + X + X + + + +	+ X + + +	+ X + + +	+ + X + +	+ X + +	+ + * * *	+ + x + + + + x	+ + + + + + + + + + + + + + + + + + + +	+ X + + +	- + + - + + + + + + + + + + + + + + + +	+ + X + +	+ + + + + + + + + + + + + + + + + + + +	+ + X + +	+ + X + + +	+ + X + +
REPRODUCTIVE SYSTEM Mammary gland Testis Interstitial cell tumor Prostate Preputial/clitoral gland Carcinoma, NOS	+ + + N	+ + + N	+ + + + X	N + X + N	N + + N	4 + +	Z+ ++	z++ +z	+ + + X + N	+ + + + N	+ + + X + N	+ + + N	+ + + N	+ + + X + N	+ + X N	+ + X + N	+ + X+	+ + X + N	Z+ +Z	+ + X + N	z++ +z	+ + + X + N	+ + X + N	+ + + + N	+ + X + N
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Zymbal gland Carcinoma, NOS	N	N	*	N	N	*	N	N	N	N	N	N	N	N	N	N	N	* x	N	N	*	N	N	N	N
ALL OTHER SYSTEMS Multiple organs, NOS Carcinoma, NOS, metastatic Mesothelioma, NOS Leukemia, mononuclear cell	N	N	N X	N X	N X	N	N	N	N	N	N X	N	N	N X	N X	N	N X X	N	N X	N	N	N X	N X	N X	

TABLE A2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE: UNTREATED CONTROL

+: Tissue examined microscopically
 -: Required tissue not examined microscopically
 X: Tumor incidence
 Necropsy, no autolysis, no microscopic examination
 S: Animal missexed

: No tissue information submitted C: Necropsy, no histology due to protocol A: Autolysis M: Animal missing B: No necropsy performed

TABLE A2.	. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS: U	UNTREATED CONTROL
	(Continued)	

ANIMAL NUMBER	$\begin{array}{c}1\\0\\7\end{array}$	1 0 8	$1 \\ 1 \\ 0$	$\begin{array}{c}1\\1\\2\end{array}$	1 1 3	1 1 4	1 1 8	1 1 9	$\begin{array}{c} 1 \\ 2 \\ 0 \end{array}$	$\begin{array}{c}1\\2\\1\end{array}$	$\frac{1}{2}$	1 2 4	$\frac{1}{2}$ 5		$\frac{1}{2}$	$\frac{1}{2}$ 9	1 3 0	1 3 2	1 3 9	$\begin{array}{c}1\\4\\2\end{array}$	1 4 3	1 4 5	1 4 7	1 4 8	1 4 9	
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL: TISSUES TUMORS
INTEGUMENTARY SYSTEM Skin Keratoacanthoma Sebaceous adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*50 1 1
Subcutaneous tissue Fibroma Fibrosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	* X	*50 1 1
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	* x	+	+	50 1 2
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
HEMATOPOIETIC SYSTEM Bone marrow Spleen	+	++++	++++	-+	+++++++++++++++++++++++++++++++++++++++	+++++	++++	+	+	++++	+	+++	+++	+++	+++	+++	++++	+++	+ +	++++	++++	++	+++	+++	++++	49 46
Lymph nodes Thymus	+ +	+++++	+ +	-	+ +	+ +	+ -	+ -	+ +	+ +	+ +	+	+	++	+	+ +	+	+ +	+ +	+	+	+++	+	+++	+	48 36
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50
Salivary gland Liver Neoplastic nodule	+ +	+ +	+ +	+ +	+ +	+• +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	+ +	+ +	+ +	+ +	49 50
Bile duct Pancreas	+++	+ +	+ +	+++	+ +	+ +	++++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	++++	+ +	+ +	+ +	+ +	+ +	+++	+++	+ +	50 48
Esophagus Stomach	+++	+ +	+ +	++++	+++	+++	++++	+ +	++++	+++	++++	+ +	++++	+ +	+ +	+ +	++++	+++++++++++++++++++++++++++++++++++++++	+++	+++	+++	+ +	+++	+++	+++	50 50
Small intestine Large intestine Mucinous adenocarcinoma	++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	50 49 1
URINARY SYSTEM Kidney Urinary bladder	+++++++++++++++++++++++++++++++++++++++	+++	++++	++++	++++	++++	++++	+++	++++	++++	++++	+++	+ +	++++	+++	+ + +	+ +	++++	+ + +	+++	+++	+ + +	++++	+++++	++++	50 50
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 1
Adenoma, NOS Adrenal Pheochromocytoma Pheochromocytoma, malignant	+	* x	* X	x x	* X	х +	+	х +	*	* X	+	X +	+	x + X	*	*	* X X	x + x	x + X	+	+	+	+	+	x + X	14 50 19 6
Thyroid C-cell adenoma	+	+	+	+	+	+	+	+	+	x x	* X	+	+	+	+	+	+	+	+	+	+	*	+	+	*	50 6
Parathyroid Pancreatic islets Islet cell adenoma Islet cell carcinoma	++	+	+	+	+	+	+	+	+++	+ +	+ +	+	+	+	+	+ +	+ +	+ +	+ + X	+	+	+ +	++	+	- + X	37 48 2 1
REPRODUCTIVE SYSTEM Mammary gland Testis	+++	++++	+ +	+++	+ +	+++	+++	+++	+	+++	++++	N +	+++	+++	++++	++	++	++	N +	+++	+++	+++	+++	+++	+++	*50
Interstitial cell tumor Prostate Preputial/clitoral gland Carcinoma, NOS	+ N	+ N	X + N	X + N	X + N	+ N	X + N	X + N	X + N	X + N	X + N	X + N	X + N	X + N	X + N X	X + N	X + N	X + N	+ N	X + N	X + N	X + N	X + N	X + N	X + N	32 49 *50 1
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	_	+	+	+	+	+	+	+	48
SPECIAL SENSE ORGANS Zymbal gland Carcinoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 4
ALL OTHER SYSTEMS Multiple organs, NOS Carcinoma, NOS, metastatic	N	N	N	N	N	N	N	N	N	N	N	N	N	Ν	N	N	N	N	N	N	N	N	N	N	N	*50
Mesothelioma, NOS Leukemia, mononuclear cell	x	x	x	x	х		x	x	х		x	x	x	x		x		x			x	x	х		x	$1 \\ 29$

* Animals necropsied

TABLE A2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS IN THE TWO-YEAR FEEDSTUDY OF ERYTHROMYCIN STEARATE: LOW DOSE

ANIMAL NUMBER	0 0 9	0 1 2	0 4 1	0 0 1	0 4 4	0 0 5	0 1 7	0 3 8	0 2 5	0 5 0	0 1 3	0 2 7	0 0 4	0 2 3	0 3 1	0 4 7	$\begin{array}{c} 0 \\ 0 \\ 2 \end{array}$	0 0 8	0 2 8	0 2 9	0 4 5	0 0 6	$\begin{array}{c} 0 \\ 1 \\ 6 \end{array}$	0 2 4	0 3 6
WEEKS ON STUDY	0 6 0	0 7 4	0 8 0	0 8 1	0 8 1	0 8 3	0 8 3	0 8 4	0 8 5	0 8 8	0 8 9	0 9 2	0 9 4	0 9 4	0 9 4	0 9 5	0 9 6	0 9 6	0 9 6	0 9 7	0 9 7	0 9 9	0 9 9	0 9 9	0 9 9
INTEGUMENTARY SYSTEM Skin																									
Basal cell tumor Keratoacanthoma		Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	+	+	+	+	×	x	+	+	+	+	+	+
Subcutaneous tissue Fibroma Fibrosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	*
RESPIRATORY SYSTEM Lungs and bronchi	+																								
Alveolar/bronchiolar adenoma Trachea		- -	- -	- -	-	+	- -	+	+ +	- -	Ť	Ť	- -	+ +	- -	+	- -	+	- -	т _	-	+	- -	x	+
Fibrosarcoma, metastatic		т	Ŧ	7	-	Ŧ	Ŧ	Ŧ	т	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	x	Ŧ	+	Ŧ	Ŧ	Ŧ	-	+	+	+	Ŧ
HEMATOPOIETIC SYSTEM Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+		+	+	+	+
Spleen Leukemia, mononuclear cell	+	÷	+	÷	÷	÷	+	÷	÷	+	÷	÷	÷	÷	÷	÷	÷	÷	÷	÷	+	÷	÷	÷	+
Lymph nodes Thymus	++	+ +	+ +	+ +	+ -	+ +	+ +	+++++	+ +	+ +	+ +	+	+ -	_	+	+ +	+ +	+ +	+ -	+ +	+ +	+ +	+ +	+ +	+ +
CIRCULATORY SYSTEM																							•		
Heart Blood vessels Fibrosarcoma, metastatic	N N	n N	'n	n N	n N	+ N	n N	+ N	+ N	+ N	+ N	n N	+ N	+ N	+ N X	+ N	+ N	+ N	+ N	+ N	'n	N	+ N	+ N	n N
DIGESTIVE SYSTEM Oral cavity	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Fibrosarcoma, metastatic Salivary gland				-	14	14			-	14	14	14	-	-	X		14	1.	14		-11	14	1		
Neurilemoma, malignant Liver		т 1	- -	Ţ	+	- -	T.	+ -	Ť	т ,	т 1	Ť	т 1.	-	_		т	Ţ	Ţ	- -	-	Ţ	- -	Ţ	+
Neoplastic nodule Bile duct		т	Ť	+	Ţ	- -	т				Ť	Ţ	Ť	т	- -	Ţ	Ť	Ţ	Ţ	Ţ	+	т	- -	+	
Pancreas	+	+	++	+	+ +	+	+	+	+ +	+	+ +	+	+	+ +	+	+	+	+	+	÷	+	+	+	+	+ +
Esophagus Stomach	+++++	+++	++	+++	++++	++	++++	+++	+++	+++	+++	+ +	+++	+++	++++	+ +	+++++++++++++++++++++++++++++++++++++++	++	+ +	+++	++	+++	+	++	+++
Small intestine	+	÷	+	+	+	+	+	+	÷	+	÷	÷	÷	÷	+	+	÷	+	+	÷	+	÷	+	÷	÷
Large intestine	+	+	+	+	+	+	+	+	-	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
URINARY SYSTEM Kidney	+	+	+	+	+	+	+	+	+		Ŧ	+	+	+	+	+		+	+	+	+				
Tubular cell adenoma		•			,	,	x	1		'			,	,			'		'		,	,		r	
Urinary bladder	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ENDOCRINE SYSTEM Pituitary	+	+	4	+				<u>т</u>	.		-	+	_L	+		+		+	+	+	_	1	-		+
Adenoma, NOS	T	x	Ŧ	Ŧ	x	Ŧ	т	т	Ŧ	Ŧ	Ŧ	x	Ŧ	Ŧ	-	т	_	т	X	x	-	Ŧ	x	Ŧ	Ŧ
Adrenal Cortical carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma									х				х				х							X	X
Pheochromocytoma, malignant Thyroid	+	+	+	+	+	+	+	+	+	+	+	+	_	+	+	+	+	+	+	+	+	+	+	+	+
Follicular cell adenoma Follicular cell carcinoma																								x	
C-cell adenoma C-cell carcinoma				х					X			х		X X				X							
Parathyroid	-+	+	-	+	-	+	+	+	+	+	+ +	+	-	÷	+	+	+	+	+	-	-	+	+	+	++
Pancreatic islets Islet cell adenoma	+	+	+	+	+	+	Ŧ	+	Ŧ.	+		-	÷	+	+	+	+	+	+	+	+	+	+	+	+
Islet cell carcinoma	1										X														

0 3 5	0 4 6	0 0 3	0 0 7	0 1 0	0 1 1	0 1 4	0 1 5	0 1 8	0 1 9	0 2 0	0 2 1	$\begin{array}{c} 0 \\ 2 \\ 2 \end{array}$	0 2 6	0 3 0	0 3 2:	0 3 3	0 3 4	0 3 7	0 3 9	0 4 0	0 4 2	0 4 3	0 4 8	0 4 9	
1 0 0	1 0 2	1 0 4	1 0 4	1 0 4	1 0 4	$\begin{array}{c}1\\0\\4\end{array}$	1 0 4	1 0 4	$\begin{array}{c}1\\0\\4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0: 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL: TISSUES TUMORS
+	+ + X	+	++	++	++	+ +	++	+	+	N N	+	+ + X	+	+	+	++	+ +	+ +	+	++	+ +	+	+ +	+	*50 1 *50 3 1
+	++	+ +	++	+ +	+ +	+ +	+ +	+++	+ +	+	++	++	+	+++	++	++	+ +	+ +	++	++	+++	+ +	+ +	+ +	50 1 49 1
++++	+++	+ + + +	+++++-	++++++	++++-	+ + + +	+ + + +	+ + + + +	+ + + +	+++++	++++	++++++	+ ~~ + +	+ + + +	+ + + +	+ + X + +	++++++	+ + +	++++++	+ + + +	++++-	+ + + X + +	+ + + +	+ + + +	49 49 2 48 39
+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	48 *50 1
N + + + + + + + + + + + + + + + + + + +	X + + ++++++++++++++++++++++++++++++++	N + + ++++++	N + + ++++++	N + + ++++++	N + + + + + + + + + + + + + + + + + + +	N + + X + + + + + + + + + + + + + + + +	N + + +++++	N + + + + + + + + + + + + + + + + + + +	N + + ++++++	N + + ++++++	N + + ++++++	N + + + + + + + + + + + + + + + + + + +	N + + +++++	N + + ++++++	N + X + + + + + + + + + + + + + + + + +	N + + + + + + + + + + + + + + + + + + +	N + + + + + + + + + + + + + + + + + + +	N + + ++++++	Z + + +++++	N + + ++++++	N + + ++++++	Z + + +++++	N + + ++++++	N + + +++++	*50 1 48 1 50 1 50 50 50 50 50 48
+	+ +	+ +	+ +	++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	++	+ +	+ +	+ +	+	+ +	+ +	+ +	+++	+	++	+ +	50 1 49
+++++++++++++++++++++++++++++++++++++++	+ x + x +	+++++	+ + X + X +	+ + + + + + + X	+ + + + +	+ + + + X +	+ + + x +	+ x + x +	+ + +	* + x +	+ + + +	+ + +	+ + + +	+ + +	+ + X +	+ + +	+ + + + *	+ x + + x + + x + + x	+ + X +	+ + X +	+ x + x + +	+ + X +	+ + X +	+ + + x -	$ \begin{array}{c} 47 \\ 14 \\ 50 \\ 1 \\ 13 \\ 1 \\ 48 \\ 1 \\ 9 \\ 2 \\ 36 \\ 49 \\ \end{array} $
	5 1000 + + + + + + + + + + + + + + + + +	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	5 6 3 7 0 1 4 1 1 1 1 1 1 1 1 0 2 4 4 4 4 4 4 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + <td>5 6 3 7 0 1 4 5 1 0</td> <td>5 6 3 7 0 1 4 5 8 1</td> <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td>	5 6 3 7 0 1 4 5 1 0	5 6 3 7 0 1 4 5 8 1	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$										

TABLE A2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS: LOW DOSE (Continued)

ANIMAL NUMBER	0 0 9	$ \begin{array}{c} 0 \\ 1 \\ 2 \end{array} $	0 4 1	0 0 1	0 4 4	0 0 5	0 1 7	0 3 8	0 2 5	0 5 0	0 1 3	0 2 7	0 0 4	0 2 3	0 3 1	0 4 7	0 0 2	0 0 8	0 2 8	0 2 9	0 4 5	0 0 6	0 1 6	$\begin{array}{c} 0 \\ 2 \\ 4 \end{array}$	0 3 6
WEEKS ON STUDY	0 6 0	0 7 4	0 8 0	0 8 1	0 8 1	0 8 3	0 8 3	0 8 4	0 8 5	0 8 8	0 8 9	0 9 2	0 9 4	0 9 4	0 9 4	0 9 5	0 9 6	0 9 6	0 9 6	0 9 7	0 9 7	0 9 9	0 9 9	0 9 9	0 9 9
REPRODUCTIVE SYSTEM Mammary gland Adenocarcinoma, NOS	+	+	+	+	+	+	+	+	N	+	: +	+	+	+	+	+	+	+	+	+	+	N	+	+	+
Testis Interstitial cell tumor Prostate Preputial/citorai gland Carcinoma, NOS Adenoma, NOS	+ + N	+ + N	+ X + N	+ X + N	+ + Z	+ X + N	+ X + N	+ + N	+ X + N	+ + N	+ X + N	+ + N	+ X + N	+ X + N X	+ X + N	+ + N	+ X + N	+ X + N	+ + N	+ + N	+ X + N N	+ X + N X + N	+ + N	+ X + N	+ X + N
NERVOUS SYSTEM Brain	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Zymbal gland Carcinoma, NOS Keratoacanthoma	 N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	+	N	N	N	N	* X	+ X	N
MUSCULOSKELETAL SYSTEM Bone Sarcoma, NOS Hemangiosarcoma Osteosarcoma	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N
BODY CAVITIES Tunica vaginalis Mesothelioma, NOS Mesentery	- + +	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ X N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ X N	+ N	+ N
Mesothelioma, NOS ALL OTHER SYSTEMS Multiple organs, NOS	-	N	N	N	N	N	N	N	N		N		N	N	N	N	 N	N	N	N	N	N	N	N	N
Sarcoma, NOS Leukemia, mononuclear cell			X	x		x	x	x	x	x	•	•	x	.,	.,	x	x	x	x	x	x	x	x	x	-

TABLE A2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS: LOW DOSE (Continued)

TABLE A2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS: LOW DOSE (Continued)

ANIMAL NUMBER	0 3 5	0 4 6	0 0 3	0 0 7	0 1 0	0 1 1	0 1 4	0 1 5	0 1 8	0 1 9	0 2 0	0 2 1	$ \begin{array}{c} 0 \\ 2 \\ 2 \end{array} $	0 2 6	0 3 0	0 3 2	0 3 3	0 3 4	0 3 7	0 3 9	0 4 0	0 4 2	0 4 3	0 4 8	0 4 9	TOTAL
WEEKS ON STUDY	1 0 0	$1 \\ 0 \\ 2$	1 0 4	1 0 4	1 0 4	1 0 4	$\begin{array}{c}1\\0\\4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	$1\\0\\4$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL: TISSUES TUMORS
REPRODUCTIVE SYSTEM Mammary gland Adenocarcinoma, NOS Testis Interstitial cell tumor Prostate Preputal/clitoral gland Carcinoma, NOS Adenoma, NOS	N + X + N	+ + + N	+ + X + N	+ + X + N	+ + X + N	+ + X + N	+ X + X + N	+ + X + N	+ + X + N	+ + X + N	+ + X + N X	+ + X + N	+ + + N	+ + + N	+ + X + N	N + X + N	+ + X + N	+ + X + N	+ + + N	+ + X + N	+ + + X + N	N + X + N	+ + X+ N	+ + X + N	+ + X + N	*50 1 50 36 50 *50 1 2
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
SPECIAL SENSE ORGANS Zymbal gland Carcinoma, NOS Keratoacanthoma	+	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 1 1
MUSCULOSKELETAL SYSTEM Bone Sarcoma, NOS Hemangiosarcoma Osteosarcoma	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N	*50 1 1 1
BODY CAVITIES Tunica vaginalis Mesothelioma, NOS Mesentery Mesothelioma, NOS	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N X	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	*50 2 *50 1
ALL OTHER SYSTEMS Multiple organs, NOS Sarcoma, NOS Leukemia, mononuclear cell	N X	N X	N	N X	N X	N X	N	N	N	N	N	N	N X	N	N	N	N	N X	N X	N	N	N	N	N X	N	*50 1 27

* Animals necropsied

Erythromycin Stearate, NTP TR 338

SIGDIO					0 10			0.	ĽF				н	G 11		05									
ANIMAL NUMBER	0 5 6	0 7 5	0 8 7	0 8 9	0 7 7	0 5 4	0 9 5	0 6 3	0 6 6	0 7 0	0 6 7	0 8 6	0 6 2	0 5 7	0 5 9	0 6 9	0 7 1	0 8 8	0 5 3	0 8 0	0 9 4	0 5 1	0 7 3	0 5 2	0 5 5
WEEKS ON STUDY	0 6 2	0 7 0	0 7 1	0 7 6	0 7 9	0 8 2	0 8 5	0 8 6	0 8 6	0 8 7	0 8 9	0 9 0	0 9 4	0 9 5	0 9 7	0 9 7	0 9 9	0 9 9	1 0 1	1 0 1	1 0 1	1 0 2	1 0 3	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Skin	+	+	+	+	+	+	+	+	 +	+	+	+	+	+	+	 +	+	+	+	+	+	+	+	+	+
Keratoacanthoma Subcutaneous tissue Sarcoma, NOS Fibroma Neurilemoma, malignant	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X X	+	+	+	+	X +	+
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Neurilemoma, metastatic	+	+	+	+ x	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Trachea	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
HEMATOPOIETIC SYSTEM Bone marrow Spleen Leukemia, mononuclear cell Lymph nodes Thymus	++++	+++++	++ ++	++ ++ ++	+ + + +	+++	++++	+ + + +	+++++	+ + + +	+ + +	+++	+++++++++++++++++++++++++++++++++++++++	+ + + +	++++	· + ++	+++++	+ + + -	+++	+++-	+++++	+ + + +	++++++	+++++	+ + + +
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +
Neurilemoma, metastatic Liver Neoplastic nodule Bile duct	+++	+ +	+ +	x + +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +
Pancreas Esophagus Stomach Small intestine Large intestine	++++	+++++	+ - + + +	+ + + + +	+++++	+ + + + +	+ + + + +	+ + + + + + + +	+ + + +	+ + + + 1	+++++	+ + + + +	+ + + +	+ + + +	+ + + + +	+++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + +	+ + + + +
URINARY SYSTEM Kidney Urinary bladder	++++	++	+++	+++	 + +	+++	++	+ +	+	++++	++++	+++	++++	++++	+++	 + +	++++	++++	+++	+++	+++	+++	+++++	++++	+ +
ENDOCRINE SYSTEM Pituitary Adenoma, NOS Adrenal Cortical adenoma	+ X +	+	+ +	++	* * +	* * +	+ +	+ +	+ X +	+ +	+++	+ +	++	+ +	+ +	++	* * +	- +	+ +	- +	-+	+ +	+++	++	* *
Cortical carcinoma Pheochromocytoma Pheochromocytoma, malignant											x		x		x			x	x			x		x	x
Thyroid Follicular cell carcinoma C-cell adenoma C-cell carcinoma	+	+	+	+	+	+	+	+ X	+	+	x	+	+	+	+	+	+	+	+	+	+	+ X	+	+ X	+ X
Parathyroid Pancreatic islets Islet cell adenoma Islet cell carcinoma	+	+	+	+	+ +	+ +	+ +	+ +	+ + X	+	+ +	+	+	+ +	+	+ +	+ +	+++	+ +	+ +	+ +	+	+ +	+ +	+
REPRODUCTIVE SYSTEM Mammary gland Adenoma, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Testis Interstitial cell tumor Prostate	+ +	+	++	* *	+	+	+ x +	++	+ X +	* *	+ X +	* *	+ X +	* +	* *	* +	+	* *	* * +	* *	* +	+ X +	+ X +	* *	* *
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Eye appendages Fibrosarcoma	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
BODY CAVITIES Tunica vaginalis Mesothelioma, malignant Mesontery Lipoma	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ X N	+ N	+ N
ALL OTHER SYSTEMS Multiple organs, NOS Mesothelioma, malignant Neurilemoma, malignant Leukemia, mononuclear cell	N	N	N X	N				N X					N X	х									N X	N	N

TABLE A2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS IN THE TWO-YEAR FEEDSTUDY OF ERYTHROMYCIN STEARATE: HIGH DOSE

											ueu															
ANIMAL NUMBER	0 5 8	0 6 0	0 6 1	0 6 4	0 6 5	0 6 8	0 7 2	0 7 4	0 7 6	0 7 8	0 7 9	0 8 1	0 8 2	0 8 3	0 8 4	0 8 5	0 9 0	0 9 1	0 9 2	0 9 3	0 9 6	0 9 7	0 9 8	0 9 9	1 0 0	
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL: TISSUES TUMORS
INTEGUMENTARY SYSTEM							• • • •																		- -	
Skin Keratoacanthoma Subcutaneous tissue Sarcoma, NOS Fibroma Neurilemoma, malignant	+	+ +	+ +	+ +	+	+ +	+ +	+	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	*50 1 *50 1 2 1
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Neurilemoma, metastatic Trachea	+	+	+	+	+	+	+	+ X	+	* X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 1 1 48
	+	+	_	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
HEMATOPOIETIC SYSTEM Bone marrow Spleen Laukemia, mononuclear cell Lymph nodes Thymus	+++++++++++++++++++++++++++++++++++++++	++++	+ + + +	+ + +	+ + + -	+ + +	+ + + +	+ + - +	+ + +	+ + - +	+ + + +	+ + +	+ + + -	+ + - +	+ + + +	+ + + +	+ + X + -	+ + + +	+ + + +	+ + + +	+ + +	+++++	+ + + +	+ + +	+ + +	49 50 1 46 37
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland Neurilemoma, metastatic	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N X +	N +	N +	N +	*50 1 50 1
Liver Neoplastic nodule Bile duct Pancreas	++++	++++	+ X + +	+++	+ + +	++++	++++	++++	+ + + +	++++	+++	+ + +	++++	++++	++++	+++	++++	+ X + +	++++	++++	+++	+++	++++	+ + -	++++	50 3 50 49
Esophagus Stomach Small intestine Large intestine	+ + +	+ + + +	+ + + +	+++++	+ + +	+++++	+ + + +	+++++	+ + + +	+ + +	+ + + +	+ + + +	+ + +	+ + +	++++	+ + + +	+ + +	+ + +	+ + + +	+++++	+ + + +	+ + +	+ + +	+ + +	+ + + +	49 50 49 49
URINARY SYSTEM Kidney Urinary bladder	++++	+++	+++++	++++	++++	+ +	+ +	+ +	+ +	+ +	++++	+ +	+ +	+ +	+++++++++++++++++++++++++++++++++++++++	+++	++++	+++	+++	++++	++++	++++	+++++	++++	++++	50 49
ENDOCRINE SYSTEM Pituitary Adenna, NOS Adrenal Cortical adenoma Cortical adenoma	++	+ x + x	+ +	+ +	+ +	+ +	+ X +	+ +	+	++	+ +	+ +	+ +	+ +	+ +	* X +	+ +	+ +	+ +	++	+ +	+ + X	* * +	* * +	+++	47 11 50 1 1
Cortical carcinoma Pheochromocytoma Pheochromocytoma, malignant	x	•			x		x	x			X X			+			x		X	X		X		x +		17 2 50
Thyroid Follicular cell carcinoma C-cell adenoma C-cell carcinoma	+	x	+	+	+	+	+	+	+	+	+	+	+	x	+	+	+	+	+	Ŧ	+	+	+	+	+	1 5 1
Parathyroid Pancreatic islets Islet cell adenoma Islet cell carcinoma	+	++	+ * X	+ +	+ +	+ + X	+ + X	+ +	+	+ +	+ +	+	+	+ +	+	+ +	+ +	+	+ +	+ +	+	+	÷	+	+ +	37 49 3 1
REPRODUCTIVE SYSTEM Mammary gland Adenoma, NOS Testis	+	+++	* X +	N +	+++	+	+++	N +	+++	++	+	+++	N +	+++	+	+ +	+ +	+++	+ +	+++	N +	++	+ +	+ +	++++	*50 1 50
Interstitial cell tumor Prostate	Х +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	X +	43 50
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
SPECIAL SENSE ORGANS Eye appendages Fibrosarcoma	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 1
BODY CAVITIES Tunica vaginalis Mesothelioma, malignant Mesentery Lipoma	+ N	+ N	+ N	+ N	+ N	+ N X	+ N	+ X N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	*50 2 *50 1						
ALL OTHER SYSTEMS Multiple organs, NOS Mesothelioma, malignant Neurilemoma, malignant	N	N	N	Ν	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 1 1

TABLE A2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS: HIGH DOSE (Continued)

* Animals necropsied

	Control	5,000 ppm	10,000 ppm
Subcutaneous Tissue: Fibroma			
Overall Rates (a)	1/50 (2%)	3/50 (6%)	2/50 (4%)
Adjusted Rates (b)	3.6%	11.5%	6.7%
Terminal Rates (c)	1/28 (4%)	1/23 (4%)	1/27 (4%)
Week of First Observation	104	99	101
Life Table Tests (d)	P = 0.396	P = 0.242	P = 0.495
Incidental Tumor Tests (d)	P = 0.375	P = 0.310	P = 0.481
Cochran-Armitage Trend Test (d)	P = 0.399		
Fisher Exact Test (d)		P = 0.309	P = 0.500
Subcutaneous Tissue: Fibroma or Fibros	arcoma		
Overall Rates (a)	2/50 (4%)	4/50 (8%)	(e) 2/50 (4%)
Adjusted Rates (b)	5.8%	13.8%	6.7%
Terminal Rates (c)	1/28 (4%)	1/23(4%)	1/27 (4%)
Week of First Observation	80	94	101
Life Table Tests (d)	P = 0.577	P = 0.288	P = 0.692N
Incidental Tumor Tests (d)	P = 0.588	P = 0.411	P = 0.666N
Cochran-Armitage Trend Test (d)	P = 0.588	1 -0.411	1 - 0.00011
Fisher Exact Test (d)	1 - 0.000	P = 0.339	P = 0.691
Lung: Alveolar/Bronchiolar Adenoma or	Carcinoma		
Overall Rates (a)	3/50 (6%)	1/50 (2%)	2/50 (4%)
Adjusted Rates (b)	10.3%	3.4%	7.4%
Terminal Rates (c)	2/28(7%)	0/23 (0%)	2/27 (7%)
Week of First Observation	103	99	104
Life Table Tests (d)	P = 0.413N	P = 0.376N	P = 0.516N
Incidental Tumor Tests (d)	P = 0.420N	P = 0.300N	P = 0.521N
Cochran-Armitage Trend Test (d)	P = 0.399N	1 -0.00011	1 = 0:02111
Fisher Exact Test (d)	r - 0.39919	P = 0.309 N	P = 0.500 N
Hematopoietic System: Mononuclear Cel	l Leukemia		
Overall Rates (a)	29/50 (58%)	29/50 (58%)	34/50 (68%)
Adjusted Rates (b)	79.9%	67.0%	73.5%
Terminal Rates (c)	21/28 (75%)	9/23 (39%)	15/27 (56%)
Week of First Observation	74	81	71
Life Table Tests (d)	P = 0.234	P = 0.323	P = 0.237
Incidental Tumor Tests (d)	P = 0.234 P = 0.192	P = 0.523 P = 0.529N	P = 0.237 P = 0.212
		r -0.02514	1 -0.212
Cochran-Armitage Trend Test (d) Fisher Exact Test (d)	P = 0.178	P = 0.580 N	P = 0.204
Liver: Neoplastic Nodule	1/50 (90)	1/50 (00)	2/50 (60)
Overall Rates (a)	1/50 (2%)	1/50 (2%)	3/50 (6%)
Adjusted Rates (b)	3.6%	4.3%	11.1%
Terminal Rates (c)	1/28 (4%)	1/23 (4%)	3/27 (11%)
Week of First Observation	104	104 D 0 719	104 D 0 000
Life Table Tests (d)	P = 0.196	P = 0.718	P = 0.290
Incidental Tumor Tests (d)	P = 0.196	P = 0.718	P = 0.290
Cochran-Armitage Trend Test (d)	P = 0.202		
Fisher Exact Test (d)		P=0.753	P = 0.309
Anterior Pituitary Gland: Adenoma			
Overall Rates (a)	14/49 (29%)	14/47 (30%)	11/47 (23%)
Adjusted Rates (b)	37.1%	43.6%	30.9%
Terminal Rates (c)	7/28(25%)	7/23 (30%)	6/27 (22%)
Week of First Observation	56	74	62
Life Table Tests (d)	P = 0.319N	P = 0.442	P = 0.350 N
Incidental Tumor Tests (d)	P = 0.324N	P = 0.540	P = 0.330N
Cochran-Armitage Trend Test (d)	P = 0.327 N		
Fisher Exact Test (d)		P = 0.537	P = 0.366N

TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

	Control	5,000 ppm	10,000 ppm
Anterior Pituitary Gland: Adenoma or Ca	arcinoma		<u> </u>
Overall Rates (a)	15/49 (31%)	14/47 (30%)	11/47 (23%)
Adjusted Rates (b)	38.6%	43.6%	30.9%
Terminal Rates (c)	7/28 (25%)	7/23 (30%)	6/27 (22%)
Week of First Observation	56	74	62
Life Table Tests (d)	P = 0.251 N		P = 0.277N
		P = 0.523	
Incidental Tumor Tests (d)	P = 0.238N	P = 0.519N	P = 0.236N
Cochran-Armitage Trend Test (d) Fisher Exact Test (d)	P = 0.252N	P = 0.554N	P = 0.287 N
drenal Gland: Pheochromocytoma			
Overall Rates (a)	19/50 (38%)	13/50 (26%)	17/50 (34%)
Adjusted Rates (b)	58.2%	42.7%	50.3%
Terminal Rates (c)	15/28 (54%)	7/23 (30%)	11/27 (41%)
Week of First Observation	75	85	89
Life Table Tests (d)	P = 0.416N	P = 0.307N	P = 0.459N
Incidental Tumor Tests (d)	P = 0.421N	P = 0.209N	P = 0.474N
Cochran-Armitage Trend Test (d)	P = 0.375N	1 = 0.20011	1 - 0.1111
Fisher Exact Test (d)	1 -0.01011	P = 0.142N	P = 0.418N
		1 - 0.1421	1 -0.4101
drenal Gland: Malignant Pheochromocy			
Overall Rates (a)	6/50 (12%)	1/50 (2%)	2/50 (4%)
Adjusted Rates (b)	17.4%	4.3%	7.4%
Terminal Rates (c)	3/28 (11%)	1/23 (4%)	2/27(7%)
Week of First Observation	79	104	104
Life Table Tests (d)	P = 0.081 N	P = 0.085 N	P = 0.147N
Incidental Tumor Tests (d)	P = 0.061 N	P = 0.041 N	P = 0.110N
Cochran-Armitage Trend Test (d)	P = 0.070 N		
Fisher Exact Test (d)		P = 0.056N	P = 0.135N
drenal Gland: Pheochromocytoma or M	alignant Pheochromocy	ytoma	
Overall Rates (a)	23/50 (46%)	14/50 (28%)	18/50 (36%)
Adjusted Rates (b)	64.3%	46.3%	53.4%
Terminal Rates (c)	16/28 (57%)	8/23 (35%)	12/27 (44%)
Week of First Observation	75	85	89
Life Table Tests (d)	P = 0.220N	P = 0.155N	P = 0.253N
Incidental Tumor Tests (d)	P = 0.191N	P = 0.062N	P = 0.222N
Cochran-Armitage Trend Test (d)	P = 0.175N	1 = 0.00210	1 - 0.42210
Fisher Exact Test (d)	1-0,1(01)	P=0.049N	P = 0.208N
hyroid Gland: C-Cell Adenoma			
Overall Rates (a)	6/50 (12%)	9/48 (19%)	5/50 (10%)
Adjusted Rates (b)	18.7%	27.4%	16.3%
Terminal Rates (c)		$\frac{27.4\%}{4/23(17\%)}$	3/27 (11%)
	4/28 (14%)		
Week of First Observation	94 B-0.466N	81 D=0.917	89 D-0 595 N
Life Table Tests (d)	P = 0.466N	P = 0.217	P = 0.525N
Incidental Tumor Tests (d)	P = 0.413N	P = 0.324	P = 0.503N
Cochran-Armitage Trend Test (d)	P = 0.442N	D 4 5 5 5	D A FA A TA A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A
		P=0.259	P = 0.500N
Fisher Exact Test (d)			
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci			A 1 A A A A A A A A A A A A A A A A A A
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci Overall Rates (a)	6/50 (12%)	10/48 (21%)	6/50 (12%)
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci Overall Rates (a) Adjusted Rates (b)	6/50 (12%) 18.7%	31.2%	18.3%
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci Overall Rates (a) Adjusted Rates (b) Terminal Rates (c)	6/50 (12%) 18.7% 4/28 (14%)	31.2% 5/23 (22%)	18.3% 3/27 (11%)
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation	6/50 (12%) 18.7% 4/28 (14%) 94	31.2% 5/23 (22%) 81	18.3% 3/27 (11%) 86
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci Overall Rates (a) Adjusted Rates (b) Terminal Rates (c)	6/50 (12%) 18.7% 4/28 (14%)	31.2% 5/23 (22%)	18.3% 3/27 (11%) 86 P=0.597
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation Life Table Tests (d) Incidental Tumor Tests (d)	6/50 (12%) 18.7% 4/28 (14%) 94	31.2% 5/23 (22%) 81	18.3% 3/27 (11%) 86
Fisher Exact Test (d) hyroid Gland: C-Cell Adenoma or Carci Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation Life Table Tests (d)	6/50 (12%) 18.7% 4/28 (14%) 94 P=0.533	31.2% 5/23 (22%) 81 P=0.146	18.3% 3/27 (11%) 86 P=0.597

TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Control	5,000 ppm	10,000 ppm
Pancreatic Islets: Islet Cell Adenoma	······		
Overall Rates (a)	2/48 (4%)	2/49 (4%)	3/49 (6%)
Adjusted Rates (b)	7.4%	8.7%	9.8%
Terminal Rates (c)	2/27 (7%)	2/23 (9%)	2/26 (8%)
Week of First Observation	104	104	86
Life Table Tests (d)	P = 0.396	P = 0.638	P = 0.491
Incidental Tumor Tests (d)	P = 0.417	P = 0.638	P = 0.529
Cochran-Armitage Trend Test (d)	P = 0.415		
Fisher Exact Test (d)		P = 0.684N	P = 0.510
ancreatic Islets: Islet Cell Adenoma or Ca	arcinoma		
Overall Rates (a)	3/48 (6%)	3/49 (6%)	4/49 (8%)
Adjusted Rates (b)	10.1%	11.0%	13.6%
Terminal Rates (c)	2/27 (7%)	2/23(9%)	3/26 (12%)
Week of First Observation	98	89	86
Life Table Tests (d)	P = 0.411	P = 0.599	P = 0.489
Incidental Tumor Tests (d)	P = 0.449	P = 0.645N	P = 0.485 P = 0.521
Cochran-Armitage Trend Test (d)	P = 0.431	1 -0.04014	1 -0.021
Fisher Exact Test (d)	r = 0.401	P = 0.651 N	P = 0.512
reputial Gland: Adenoma or Carcinoma			
Overall Rates (a)	1/50 (2%)	3/50 (60-)	0/50 (00/)
	3.6%	3/50(6%)	0/50 (0%)
Adjusted Rates (b)		10.1%	0.0%
Terminal Rates (c) Weak of First Observation	1/28 (4%)	1/23 (4%)	0/27 (0%)
Week of First Observation	104 D. 0.000N	94	
Life Table Tests (d)	P = 0.389N	P = 0.258	P = 0.507N
Incidental Tumor Tests (d)	P = 0.396N	P = 0.310	P = 0.507 N
Cochran-Armitage Trend Test (d)	P = 0.378N		
Fisher Exact Test (d)		P = 0.309	P = 0.500N
estis: Interstitial Cell Tumor			
Overall Rates (a)	32/50 (64%)	36/50 (72%)	43/50 (86%)
Adjusted Rates (b)	86.2%	91.8%	100.0%
Terminal Rates (c)	23/28 (82%)	20/23 (87%)	27/27 (100%)
Week of First Observation	74	80	76
Life Table Tests (d)	P = 0.024	P = 0.076	P = 0.022
Incidental Tumor Tests (d)	P = 0.003	P = 0.208	P = 0.003
Cochran-Armitage Trend Test (d)	P = 0.008	1 0.200	1 0.000
Fisher Exact Test (d)	1 -0.000	P = 0.260	P = 0.010
ymbal Gland: Carcinoma			
Overall Rates (a)	4/50 (8%)	1/50 (2%)	0/50 (0%)
Adjusted Rates (b)	10.2%	3.4%	0.0%
Terminal Rates (c)	0/28 (0%)	0/23 (0%)	0/27 (0%)
Week of First Observation	70	99	0.21 (0.0)
Life Table Tests (d)	P = 0.029N	P = 0.211N	P = 0.068 N
Incidental Tumor Tests (d)	P = 0.024N P = 0.024N	P = 0.211N P = 0.144N	P = 0.060 N P = 0.061 N
Cochran-Armitage Trend Test (d)	P = 0.024 N P = 0.026 N	I - U.1441N	r -0.00114
Fisher Exact Test (d)	r - 0.02014	P = 0.181 N	P = 0.059N
Il Sitas Masatholiama			
ll Sites: Mesothelioma	1/50 (000)	0150 (00)	0/50 (02)
Overall Rates (a)	1/50 (2%)	3/50 (6%)	3/50 (6%)
Adjusted Rates (b)	2.9%	9.9%	9.7%
Terminal Rates (c)	0/28 (0%)	1/23 (4%)	1/27 (4%)
Week of First Observation	98	88	95
Life Table Tests (d)	P = 0.244	P = 0.269	P = 0.302
Incidental Tumor Tests (d)	P = 0.231	P = 0.390	P = 0.276
	P = 0.238		
Cochran-Armitage Trend Test (d)	r = 0.230		

TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Control	5,000 ppm	10,000 ppm
All Sites: Benign Tumors			
Overall Rates (a)	45/50 (90%)	46/50 (92%)	47/50 (94%)
Adjusted Rates (b)	97.8%	100.0%	100.0%
Terminal Rates (c)	27/28 (96%)	23/23 (100%)	27/27 (100%)
Week of First Observation	56	74	62
Life Table Tests (d)	P = 0.359	P = 0.174	P = 0.383
Incidental Tumor Tests (d)	P = 0.273	P = 0.525	P = 0.351
Cochran-Armitage Trend Test (d)	P = 0.290		
Fisher Exact Test (d)		P = 0.500	P = 0.357
All Sites: Malignant Tumors			
Overall Rates (a)	39/50 (78%)	38/50 (76%)	37/50 (74%)
Adjusted Rates (b)	88.4%	79.1%	77.1%
Terminal Rates (c)	23/28 (82%)	13/23 (57%)	16/27 (59%)
Week of First Observation	70	74	71
Life Table Tests (d)	P = 0.443N	P = 0.359	P = 0.471 N
Incidental Tumor Tests (d)	P = 0.308N	P = 0.334N	P = 0.349 N
Cochran-Armitage Trend Test (d)	P = 0.363N		
Fisher Exact Test (d)		P = 0.500 N	P = 0.408N
All Sites: All Tumors			
Overall Rates (a)	49/50 (98%)	49/50 (98%)	49/50 (98%)
Adjusted Rates (b)	100.0%	100.0%	100.0%
Terminal Rates (c)	28/28 (100%)	23/23 (100%)	27/27 (100%)
Week of First Observation	56	74	62
Life Table Tests (d)	P = 0.482	P = 0.222	P = 0.510
Incidental Tumor Tests (d)	P = 0.565N	P = 0.549 N	P = 0.723N
Cochran-Armitage Trend Test (d)	P = 0.640		
Fisher Exact Test (d)		P = 0.752	P = 0.752

TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY **OF ERYTHROMYCIN STEARATE (Continued)**

 $(a) \, Number \, of tumor-bearing animals/number \, of animals examined \, at the site$

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N). (e) A sarcoma, NOS, was observed in a rat with a fibroma.

TABLE A4a. HISTORICAL INCIDENCE OF TESTICULAR INTERSTITIAL CELL TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)

Study	Incidence in Controls	
Historical Incidence at Physiological Researc	ch Laboratories	
Ephedrine sulfate	45/50	
Phenylephrine hydrochloride	47/50	
Oxytetracycline hydrochloride	41/50	
TOTAL	133/150 (88.7%)	
SD(b)	6.11%	
Range(c)		
High	47/50	
Low	41/50	
Overall Historical Incidence		
TOTAL	1,681/1,909 (88.1%)	
SD (b)	7.32%	
Range (c)		
High	49/50	
Low	34/50	

(a) Data as of August 7, 1986, for studies of at least 104 weeks; no malignant tumors have been observed.
(b) Standard deviation
(c) Range and SD are presented for groups of 35 or more animals.

TABLE A4b. HISTORICAL INCIDENCE OF ZYMBAL GLAND TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)

Study	Incidence in Controls	
Historical Incidence at Physiological Researc	h Laboratories	
Ephedrine sulfate	0/50	
Phenylephrine hydrochloride	1/50	
Oxytetracycline hydrochloride	0/50	
TOTAL	1/150 (0.7%)	
SD (b)	1.15%	
Range (c)		
High	1/50	
Low	0/50	
Overall Historical Incidence		
TOTAL	(d) 15/1,937 (0.8%)	
SD (b)	1.27%	
Range (c)		
High	(e) 3/50	
Low	0/50	

(a) Data as of August 7, 1986, for studies of at least 104 weeks
(b) Standard deviation
(c) Range and SD are presented for groups of 35 or more animals.
(d) Includes five carcinomas, NOS, nine squamous cell carcinomas, and one ceruminous carcinoma; no benign tumors have been observed.

(e) Second highest: 1/50

	Untreat	ed Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY	50	<u> </u>	50		50	
ANIMALS NECROPSIED	50		50		50	
ANIMALS EXAMINED HISTOPATHOLOGICALI			50		50	
NTEGUMENTARY SYSTEM			1 			
*Skin	(50)		(50)		(50)	
Epidermal inclusion cyst	2	(4%)	1	(2%)	1	(2%)
Ulceration, diffuse			1	(2%)		
Inflammation, suppurative		(2%)				
Ulcer, acute		(2%)				
Inflammation, chronic focal		(2%)				
Hyperkeratosis	-	(10%)				
Acanthosis	1	(2%)				
RESPIRATORY SYSTEM						
#Tracheal submucosa	(50)		(49)		(48)	
Cyst, NOS	2	(4%)		(4%)		(2%)
Lymphocytic inflammatory infiltrate	1	(2%)	2	(4%)		
#Lung	(50)		(50)		(50)	
Congestion, NOS	2	(4%)		(2%)	1	(2%)
Edema, interstitial				(4%)		
Hemorrhage				(2%)		
Lymphocytic inflammatory infiltrate		(2%)	1	(2%)		(0~)
Inflammation, interstitial		(2%)			1	(2%)
Inflammation, chronic focal Granuloma, NOS		(2%)				
Inflammation, granulomatous focal	1	(2%)	1	(2%)		
Hyperplasia, adenomatous	1	(2%)		(2%)	1	(2%)
Hyperplasia, mesothelial	I	(270)	1	(270)		(2%)
#Lung/alveoli	(50)		(50)		(50)	(2,0)
Histiocytosis		(2%)	(00)			(4%)
HEMATOPOIETIC SYSTEM						
#Bone marrow	(49)		(49)		(49)	
Hyperemia	1	(2%)				
Atrophy, focal					1	(2%)
Atrophy, diffuse					2	(4%)
Myelofibrosis				(2%)	-	(4%)
Hyperplasia, hematopoietic		(63%)		(57%)		(55%)
Hyperplasia, reticulum cell	_	(4%)	3	(6%)		(8%)
Mastocytosis		(4%)	(10)			(2%)
#Spleen	(46)	(40)	(49)	(0.01)	(50)	
Congestion, NOS	2	(4%)	4	(8%)		(901)
Scar Hemosiderosis		(2%) (11%)	,	(2%)		(8%) (4%)
Hyperplasia, lymphoid		(2%)	1	(270)	2	(4170)
Hematopoiesis	T	(270)	1	(2%)		
#Splenic red pulp	(46)		(49)	2.27	(50)	
Fibrosis, focal		(4%)		(2%)		(2%)
Fibrosis, diffuse	-		•	·- ·-·		(2%)
#Lymph node	(48)		(48)		(46)	
Dilatation/sinus		(8%)				
Cyst, NOS		(8%)	1	(2%)	1	(2%)
Congestion, NOS	2	(4%)			1	(2%)
Edema, NOS		(2%)				(2%)
Hemorrhage		(2%)	3	(6%)	1	(2%)
Inflammation, acute	1	(2%)				
Fibrosis			1	(2%)		
Histiocytosis			-	(4%)		

	Untreat	ted Control	Low	Dose	High	Dose
IEMATOPOIETIC SYSTEM			<u></u>	<u></u> , ,		
#Lymph node (Continued)	(48)		(48)		(46)	
Plasmacytosis		(4%)	(40)		(40)	
Hyperplasia, lymphoid		(1)	1	(2%)	1	(2%)
Mastocytosis	1	(2%)	-	(= /0 /	-	/ /
#Mandibular lymph node	(48)	(2,0)	(48)		(46)	
Cyst, NOS		(4%)	,			(2%)
Hemorrhage, chronic	-	()				(2%)
Inflammation, chronic necrotizing						(2%)
Plasmacytosis	3	(6%)	1	(2%)	-	
#Mesenteric lymph node	(48)	(0,6)	(48)	(2,0)	(46)	
Multiple cysts		(2%)	(40)		(40)	
Hyperplasia, lymphoid		(2)0)			1	(2%)
#Peyer's patch	(50)		(50)		(49)	(270)
Hyperplasia, lymphoid	(00)		(00)			(2%)
#Duodenum	(50)		(50)		(49)	(210)
Plasmacytosis		(2%)	(00)		(43)	
Hyperplasia, lymphoid	1	(270)	1	(2%)		
#Thymus	(36)		(39)	(270)	(97)	
	(30)		(39)		(37)	(3%)
Cystic ducts	4	(90)	•	(EQ)	-	
Hemorrhage	1	(3%)		(5%)	1	(3%)
Inflammation, acute			1	(3%)		(0 ~)
Fibrosis, focal						(3%)
Hypertrophy, NOS						(5%)
Hyperplasia, epithelial					2	(5%)
IRCULATORY SYSTEM		<u> </u>	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		
#Brain	(48)		(50)		(50)	
Thrombosis, NOS	(40)			(901)	(50)	
*Tail	(50)			(2%)	(50)	
	(50)		(50)	(0.77)	(50)	
Thrombosis, NOS	(50)			(2%)	(50)	
#Lung	(50)	(0)77.)	(50)	(0~)	(50)	
Thrombosis, NOS		(2%)		(2%)		
#Heart/atrium	(50)	(0~)	(48)		(50)	
Mineralization		(2%)				
	9	(4%)	3	(6%)	1	(2%)
Thrombosis, NOS			-			
#Left ventricle	(50)		(48)		(50)	
#Left ventricle Dilatation, NOS	(50) 1	(2%)	(48)			
#Left ventricle Dilatation, NOS #Myocardium	(50)	(2%)	-		(50)	
#Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative	(50) 1 (50)		(48) (48)		(50) 1	(2%)
#Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS	(50) 1 (50) 49	(2%) (98%)	(48) (48) 45	(94%)	(50) 1 40	(2%) (80%)
#Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve	(50) 1 (50)		(48) (48)	(94%)	(50) 1 40 (50)	(80%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS 	(50) 1 (50) 49 (50)	(98%)	(48) (48) 45 (48)		(50) 1 40 (50) 1	(80%) (2%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid 	(50) 1 (50) 49 (50) 5		(48) (48) 45 (48) 3	(94%) (6%)	(50) 1 40 (50) 1 5	(80%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve 	(50) 1 (50) 49 (50) 5 (50)	(98%) (10%)	(48) (48) 45 (48)		(50) 1 40 (50) 1	(80%) (2%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid 	(50) 1 (50) 49 (50) 5 (50) 1	(98%)	(48) (48) 45 (48) 3 (48)		(50) 1 40 (50) 1 5 (50)	(80%) (2%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery 	(50) 1 (50) 49 (50) 5 (50) 1 (50)	(98 %) (10%) (2%)	(48) (48) 45 (48) 3		(50) 1 40 (50) 1 5 (50) (50)	(80%) (2%) (10%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous 	(50) 1 (50) 49 (50) 5 (50) 1 (50)	(98%) (10%)	(48) (48) (48) (48) (48) (50)		(50) 1 40 (50) 1 5 (50) (50)	(80%) (2%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery 	(50) 1 (50) 49 (50) 5 (50) 1 (50)	(98 %) (10%) (2%)	(48) (48) 45 (48) 3 (48)		(50) 1 40 (50) 1 5 (50) (50)	(80%) (2%) (10%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous 	(50) 1 (50) 49 (50) 5 (50) 1 (50) 4	(98 %) (10%) (2%)	(48) (48) (48) (48) (48) (50)		$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ $	(80%) (2%) (10%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery 	(50) 1 (50) 49 (50) 5 (50) 1 (50) 4	(98 %) (10%) (2%)	 (48) (48) 45 (48) 3 (48) (50) (50) 		$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ 1 \\ 1$	(80%) (2%) (10%) (8%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery Arteriosclerosis, NOS 	(50) 1 (50) 49 (50) 5 (50) 4 (50)	(98 %) (10%) (2%)	 (48) (48) 45 (48) 3 (48) (50) (50) (50) 	(6%)	$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ $	(80%) (2%) (10%) (8%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery Arteriosclerosis, NOS *Pulmonary artery 	(50) 1 (50) 49 (50) 5 (50) 4 (50)	(98 %) (10%) (2%)	(48) (48) (48) (48) (48) (50) (50) (50) (50) 1	(6%)	$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ 1 \\ 1$	(80%) (2%) (10%) (8%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery Arteriosclerosis, NOS *Pulmonary artery Thrombosis, NOS Edema, NOS 	(50) 1 (50) 49 (50) 5 (50) 1 (50) 4 (50) (50)	(98 %) (10%) (2%) (8%)	(48) (48) (48) (48) (48) (50) (50) (50) (50) 1	(6%)	$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ 1 \\ 1$	(80%) (2%) (10%) (8%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery Arteriosclerosis, NOS *Pulmonary artery Thrombosis, NOS Edema, NOS Arteriolosclerosis 	(50) 1 (50) 49 (50) 5 (50) 1 (50) 4 (50) (50)	(98 %) (10%) (2%)	 (48) (48) (48) (48) (48) (50) (50) (50) 1 1 	(6%) (2%) (2%)	$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ 1 \\ (50) \\ (50$	(80%) (2%) (10%) (8%) (2%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery Arteriosclerosis, NOS *Pulmonary artery Thrombosis, NOS Edema, NOS Arteriolosclerosis Hypertrophy, NOS 	(50) 1 (50) 49 (50) 5 (50) 1 (50) 4 (50) (50) 1	(98 %) (10%) (2%) (8%)	 (48) (48) (48) (48) (50) (50) (50) 1 1 2 	(6%)	$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ 1 \\ (50) \\ 2 \\ 2$	(80%) (2%) (10%) (8%)
 #Left ventricle Dilatation, NOS #Myocardium Inflammation, acute suppurative Degeneration, NOS #Mitral valve Thrombosis, NOS Degeneration, mucoid #Aortic valve Degeneration, mucoid *Artery Metaplasia, cartilaginous *Coronary artery Arteriosclerosis, NOS *Pulmonary artery Thrombosis, NOS Edema, NOS Arteriolosclerosis 	(50) 1 (50) 49 (50) 5 (50) 1 (50) (50) 1 (50)	(98 %) (10%) (2%) (8%)	(48) (48) (48) (48) (50) (50) (50) (50) 1 1 1 2 (50)	(6%) (2%) (2%)	$(50) \\ 1 \\ 40 \\ (50) \\ 1 \\ 5 \\ (50) \\ (50) \\ 4 \\ (50) \\ 1 \\ (50) \\ (50$	(80%) (2%) (10%) (8%) (2%)

	Untrea	ted Control	Low	Dose	High	n Dose
CIRCULATORY SYSTEM (Continued)						
#Kidney/capsule	(50)		(50)		(50)	
Thrombosis, NOS		(2%)				
#Adrenal	(50)		(50)		(50)	
Thrombosis, NOS	1	(2%)				
DIGESTIVE SYSTEM						
*Palate	(50)		(50)		(50)	
Hyperplasia, epithelial			-	(2%)		
*Tongue	(50)		(50)		(50)	
Hyperplasia, epithelial #Salivary gland		(2%)	(49)		(50)	
Cystic ducts	(49)		(48)	(4%)	(50)	
Inflammation, chronic			2	(4.70)	1	(2%)
Necrosis, focal						(2%)
Nuclear enlargement	1	(2%)				(4%)
Atrophy, focal		(14%)	3	(6%)		(2%)
Hyperplasia, focal		(4%)				
#Submaxillary gland	(49)		(48)		(50)	
Atrophy, pressure						(2%)
#Liver	(50)		(50)		(50)	
Accessory structure		(2%)	-	(0)()		
Congestion, chronic		(4%)	1	(2%)		
Lymphocytic inflammatory infiltrate Inflammation, acute focal	2	(4%)				(90)
Inflammation, acute necrotizing	9	(4%)			1	(2%)
Inflammation, chronic focal		(4%)			1	(2%)
Granuloma, NOS		(2%)	2	(4%)		(2%)
Degeneration, cystic		(18%)		(20%)		(16%)
Necrosis, NOS		(2%)		(2010)	0	(10/0)
Atrophy, focal		(2%)				
Angiectasis					1	(2%)
#Liver/centrilobular	(50)		(50)		(50)	
Congestion, NOS				(2%)		
Degeneration, NOS				(2%)		
#Liver/periportal	(50)		(50)		(50)	
Inflammation, acute/chronic		(2%)	(
#Liver/hepatocytes	(50)	(100)	(50)	(4.4.00)	(50)	(0~)
Cytoplasmic vacuolization Focal cellular change		(10%) (54%)		(14%)		(6%)
Hyperplasia, focal	27	(54%)		(38%) (2%)		(54%) (4%)
Regenerative nodule	8	(16%)		(2%) (10%)		(4%) (28%)
#Bile duct	(50)		(50)	(10,0)	(50)	
Cyst, NOS	(00)			(2%)	(00)	
Hyperplasia, NOS	48	(96%)		(94%)	50	(100%)
#Pancreas	(48)		(49)		(49)	
Cyst, NOS				(4%)		
Cystic ducts			1	(2%)		
Inflammation, acute		(2%)		(150)		
Atrophy, focal		(40%)		(45%)		(45%)
Atrophy, diffuse	1	(2%)	1	(2%)		(10%)
Hypertrophy, focal Hyperplasia, focal	1	(90)	0	(AG_{i})		(2%)
#Glandular stomach	(50)	(2%)	(50)	(4%)	(50)	(4%)
Cyst, NOS		(46%)		(66%)		(44%)
Edema, NOS	20			(2%)	24	17770/
Ulcer, NOS				(2%)		
Erosion			-	. =	1	(2%)
Fibrosis, focal						(2%)
Hyperplasia, focal			3	(6%)		(2%)
Hyperplasia, diffuse					1	(2%)

	Untreat	ed Control	Low	Dose	High	Dose
DIGESTIVE SYSTEM (Continued)						···· · · ·
#Forestomach	(50)		(50)		(50)	
Cyst, NOS	(00)			(2%)	(00)	
Edema, NOS	2	(4%)		(4%)	1	(2%)
Ulcer, NOS		(2%)		(2%)	1	(210)
Inflammation, acute focal	1	(2)0)		(2%)		
Inflammation, acute diffuse				(4%)		
Ulcer, perforated	1	(2%)	-	(1)07		
Infection, bacterial	•	(270)			1	(2%)
Hyperplasia, epithelial	9	(4%)	1	(2%)		(2%)
Hyperkeratosis	2	(4/0/	1	(2.07		(2%)
#Duodenum	(50)		(50)		(49)	(1,0)
Lymphocytic inflammatory infiltrate		(2%)	(007		(10)	
#Jejunum	(50)		(50)		(49)	
Ulcer, chronic		(2%)	(00)		(10)	
JRINARY SYSTEM #Kidney	(50)		(50)		(50)	
Lymphocytic inflammatory infiltrate		(2%)	(00)		(,	
Pyelonephritis, acute	-	(2,0)	1	(2%)		
Inflammation, acute suppurative			-	(=)	1	(2%)
Pyelonephritis, chronic			1	(2%)	-	(=,
Scar				(2%)		
Nephropathy	49	(98%)		(98%)	49	(98%)
#Kidney/cortex	(50)		(50)		(50)	
Cyst, NOS			2	(4%)	2	(4%)
#Kidney/pelvis	(50)		(50)		(50)	
Hyperplasia, epithelial				(2%)		
#Urinary bladder	(50)		(49)		(49)	
Calculus, gross observation only				(2%)		
Edema, NOS	1	(2%)			1	(2%)
Inflammation, acute diffuse		(=,	1	(2%)		()
Inflammation, acute hemorrhagic				(2%)		
Degeneration, NOS			-	(2,0)	t	(2%)
Hyperplasia, epithelial	1	(2%)			-	(2,0)
NDOCRINE SYSTEM						
#Pituitary	(49)		(47)		(47)	
Hemorrhage					1	(2%)
<pre>#Pituitary intermedia</pre>	(49)		(47)		(47)	
Cyst, NOS	1	(2%)			2	(4%)
#Anterior pituitary	(49)		(47)		(47)	
Cyst, NOS	7	(14%)	3	(6%)	5	(11%)
Necrosis, hemorrhagic			1	(2%)		
Pigmentation, NOS	1	(2%)				
Hyperplasia, focal		(41%)		(32%)		(40%)
Hyperplasia, cystic	1	(2%)	2	(4%)	2	(4%)
Angiectasis				(2%)		
#Pituitary posterior	(49)		(47)		(47)	
Cyst, NOS			1	(2%)		
Inflammation, chronic						(2%)
Gliosis			1	(2%)		(2%)
#Adrenal/capsule	(50)		(50)		(50)	
Hyperplasia, focal					0	(4%)

	Untrea	ted Control	Low	Dose	High	Dose
ENDOCRINE SYSTEM (Continued)		· · · · · · · · · · · · · · · · · · ·				
#Adrenal cortex	(50)		(50)		(50)	
Multiple cysts			,			(2%)
Hemorrhage	1	(2%)				(2%)
Necrosis, focal		(2%)	2	(4%)	_	
Cytoplasmic vacuolization	9	(18%)	3	(6%)	6	(12%)
Atrophy, pressure	1	(2%)				
Hypertrophy, focal	8	(16%)	6	(12%)	5	(10%)
Hyperplasia, focal	20	(40%)	24	(48%)	25	(50%)
Angiectasis	2	(4%)				
#Adrenal medulla	(50)		(50)		(50)	
Hemorrhagic cyst				(2%)		
Hyperplasia, focal		(14%)	16	(32%)	6	(12%)
Angiectasis		(2%)				
#Thyroid	(50)		(48)		(50)	
Ultimobranchial cyst		(2%)				
Follicular cyst, NOS		(2%)	1	(2%)		
Atrophy, diffuse		(2%)		/ ·		
Hyperplasia, C-cell	9	(18%)	-	(10%)	13	(26%)
Hyperplasia, follicular cell			-	(2%)		
#Parathyroid	(37)		(36)		(37)	
Hyperplasia, focal	1	(3%)	1	(3%)		
REPRODUCTIVE SYSTEM						
*Mammary gland	(50)		(50)		(50)	
Galactocele	(00)		(00)			(2%)
Hemorrhagic cyst			1	(2%)	•	(= /0)
Inflammation, focal	1	(2%)		(2%)		
Fibrosis	-		-	. =	1	(2%)
Hyperplasia, NOS	5	(10%)	7	(14%)		(2%)
Hyperplasia, cystic		(24%)		(14%)		(12%)
*Prepuce	(50)		(50)		(50)	
Ulcer, NOS	1	(2%)				
*Preputial gland	(50)		(50)		(50)	
Inflammation, suppurative	1	(2%)				
Inflammation, acute/chronic	1	(2%)				
Inflammation, chronic		(4%)				
Atrophy, focal		(2%)				
Atrophy, diffuse		(18%)		(8%)		(12%)
#Prostate	(49)		(50)		(50)	
Mineralization	1	(2%)				
Cyst, NOS						(2%)
Inflammation, suppurative	-	(19)	~	(19)	1	(2%)
Inflammation, acute focal		(4%)		(4%)		
Inflammation, chronic focal		(57%)		(46%)		(50%)
Inflammation, chronic diffuse		(18%)	7	(14%)	6	(12%)
Atrophy, diffuse		(2%)				
Hyperplasia, focal	1	(2%)			-	(0~~ ·
Hyperplasia, cystic	/E0\		(50)			(2%)
*Seminal vesicle	(50)	(000)	(50)	(00)	(50)	(10~)
Atrophy, diffuse		(20%)	3	(6%)	8	(16%)
Hyperplasia, diffuse #Testic		(4%)	(50)		(FO)	
#Testis	(50)		(50)	(971)	(50)	(90)
Mineralization			1	(2%)		(2%)
Edema, NOS				(90)	1	(2%)
Inflammation, acute		(9.4.01)		(2%)	<u>^</u>	(10~)
Degeneration, NOS	12	(24%)	12	(24%)		(16%)
Necrosis, coagulative				(001)	1	(2%)
Infarct, acute Hyperplasia, interstitial cell	1 17	(210-)		(2%)	10	(000)
Hyperplasia, interstitial cell	17	(34%)	1.1	(34%)	16	(32%)

	Untreat	ted Control	Low	Dose	High	Dose
NERVOUS SYSTEM						
#Lateral ventricle	(48)		(50)		(50)	
Dilatation, NOS			2	(4%)		
#Third ventricle	(48)		(50)		(50)	
Dilatation, NOS				(2%)		
#Fourth ventricle	(48)		(50)		(50)	
Dilatation, NOS	(10)		(***)			(2%)
#Brain	(48)		(50)	(2%)	(50)	
Hemorrhage Inflammation, focal		(2%) (2%)	1	(2%)	1	(2%)
Necrosis, hemorrhagic	1	(270)	1	(2%)		
#Brain stem	(48)		(50)	(2)0)	(50)	
Hemorrhage	(40)		(00)			(2%)
Atrophy, pressure	1	(2%)			1	(2,70)
*Spinal cord	(50)	(270)	(50)		(50)	
Hemorrhage	(30)		(00)			(2%)
Degeneration, NOS			1	(2%)	•	. =,
SPECIAL SENSE ORGANS						
*Eye	(50)		(50)		(50)	
Inflammation, chronic				(4%)		
*Eye/anterior chamber	(50)		(50)		(50)	
Inflammation, acute				(2%)		
*Eyeball, tunica fibrosa	(50)	(1 01)	(50)		(50)	
Mineralization		(4%)				
*Eye/cornea	(50)		(50)		(50)	
Scar				(2%)		
*Eye/choroid	(50)	(00)	(50)	(40)	(50)	
Inflammation, chronic		(2%)		(4%)	150	
*Eye/iris	(50)	(AOL)	(50)	(90)	(50)	
Inflammation, NOS Synachia, postarior		(4%) (2%)		(2%) (4%)	0	(4%)
Synechia, posterior *Eye/retina	(50)	(470)	(50)	(+170)	(50)	(1 70)
Inflammation, chronic	(80)			(2%)	(50)	
Degeneration, NOS	1	(2%)		(2%)	1	(2%)
*Eye/crystalline lens	(50)		(50)		(50)	(2,0)
Mineralization		(6%)		(20%)		(2%)
Cataract		(16%)		(26%)		(18%)
MUSCULOSKELETAL SYSTEM None						<u></u>
BODY CAVITIES						
*Peritoneum	(50)		(50)		(50)	
Inflammation, acute/chronic		(2%)				
Inflammation, chronic		(2%)				
*Pleura	(50)		(50)		(50)	
Inflammation, chronic						(2%)
*Pleural mesothelium	(50)	(90)	(50)		(50)	
Granulation tissue	1	(2%)			-	00
Hypertrophy, NOS	/ F A \		(50)			(2%)
*Mesentery	(50)	(00)	(50)		(50)	
Diverticulum		(2%)	0	(00)	•	(00)
Necrosis, fat	6	(12%)	3	(6%)	3	(6%)

	Untreated Control	Low Dose	High Dose
ALL OTHER SYSTEMS			
*Multiple organs	(50)	(50)	(50)
Bacterial septicemia			1 (2%)
Diaphragm			
Ĥernia, NOS			1
Adipose tissue			
Hyperemia	1		

* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically. # Number of animals examined microscopically at this site

APPENDIX B

SUMMARY OF LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

		PAGE
TABLE B1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	85
TABLE B2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	88
TABLE B3	ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	94
TABLE B4a	HISTORICAL INCIDENCE OF ORAL CAVITY SQUAMOUS CELL TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT	98
TABLE B4b	HISTORICAL INCIDENCE OF ADRENAL GLAND TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT	98
TABLE B5	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	99

Erythromycin Stearate, NTP TR 338

84

τ	Intreat	ed Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY	50		50		50	
ANIMALS NECROPSIED	50		50		50	
ANIMALS EXAMINED HISTOPATHOLOGICALL	Y 50		50		50	
NTEGUMENTARY SYSTEM						
*Skin	(50)		(50)		(50)	
Keratoacanthoma	(50)			(2%)	(50)	
*Subcutaneous tissue	(50)		(50)	(2%)	(50)	
Sarcoma, NOS Fibroma	1	(2%)		(2%)		
Fibrosarcoma	*	(2,0)	-		2	(4%)
Lipoma	1	(2%)				
RESPIRATORY SYSTEM						
#Lung	(49)		(49)		(49)	
Alveolar/bronchiolar adenoma			1	(2%)		
HEMATOPOIETIC SYSTEM						
*Multiple organs	(50)	(900)	(50)	(990)	(50)	(1901)
Leukemia, mononuclear cell		(28%)	(49)	(38%)	(50)	(18%)
#Spleen	(48)		(49)			(2%)
Leukemia, mononuclear cell #Mandibular lymph node	(45)		(45)		(49)	
Fibrosarcoma, metastatic	(40)		(40)			(2%)
#Liver	(50)		(50)		(50)	
Kupffer cell sarcoma				(2%)		
#Thymus	(42)		(35)		(41)	
Thymoma, malignant					1	(2%)
CIRCULATORY SYSTEM			(70)		(50)	
#Heart	(50)	(90)	(50)		(50)	
Neurilemoma, malignant	(50)	(2%)	(50)		(50)	
*Pulmonary vein Carcinoma, NOS, metastatic		(2%)	(00)		(00)	
DIGESTIVE SYSTEM						
*Palate	(50)		(50)		(50)	
Squamous cell papilloma				(4%)		(2%)
*Tongue	(50)	(90)	(50)		(50)	(2%)
Squamous cell papilloma		(2%)	(50)		(50)	(270)
*Gum of mandible Squamous cell papilloma	(50)		(00)		1	(2%)
#Salivary gland	(48)		(49)		(49)	
Neurilemoma, malignant				(2%)		
#Liver	(50)		(50)		(50)	
Neoplastic nodule				(2%)		(4%)
#Small intestine	(49)		(50)	(201)	(50)	
Leiomyosarcoma			1	(2%)		
URINARY SYSTEM	. 10		150		(50)	
#Kidney	(49)	(90)	(50)	(2%)	(50)	
Tubular cell adenoma Tubular cell adenocarcinoma	1	(2%)	1	(270)	1	(2%)
						,
#Urinary bladder	(47)		(48)		(48)	

TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEARFEED STUDY OF ERYTHROMYCIN STEARATE

	Untreat	ed Control	Low	Dose	High	Dose
ENDOCRINE SYSTEM						
#Anterior pituitary	(49)		(50)		(50)	
Carcinoma, NOS		(8%)		(4%)		(4%)
Adenoma, NOS		(37%)		(36%)		(32%)
#Adrenal cortex	(50)	(01/0)	(49)	(00%)	(50)	(02 /0)
Carcinoma, NOS	(00)			(2%)	(50)	
Adenoma, NOS	1	(2%)		(6%)		
#Adrenal medulla	(50)	(270)	(49)	(0%)	(50)	
Pheochromocytoma		(2%)		(8%)		(10%)
#Thyroid	(50)	(270)	(50)	(070)	(50)	(10%)
C-cell adenoma		(18%)		(16%)		(6%)
C-cell carcinoma	5	(10%)		(10%)		(3%)
#Parathyroid	(35)			(4%)		(490)
Adenoma, NOS	(33)		(31) 1	(3%)	(34)	
REPRODUCTIVE SYSTEM	,					·
*Mammary gland	(50)		(50)		(50)	
Adenoma, NOS		(2%)	(00)		(00)	
Adenocarcinoma, NOS		(4%)				
Fibroadenoma		(26%)	19	(26%)	15	(30%)
*Clitoral gland	(50)	(4070)	(50)	(20%)		(00%)
Carcinoma, NOS		(2%)		(40)	(50)	
				(4%)	0	(00)
Adenoma, NOS		(10%)		(6%)		(6%)
#Uterus	(50)		(49)	(00)	(50)	
Sarcoma, NOS				(2%)		
Endometrial stromal polyp		(20%)	5	(10%)	14	(28%)
Endometrial stromal sarcoma		(6%)				
#Ovary	(49)		(49)		(50)	
Granulosa cell tumor	2	(4%)				
NERVOUS SYSTEM				<u> </u>		
#Brain	(50)		(49)		(50)	
Carcinoma, NOS, invasive	1	(2%)				
Astrocytoma	3	(6%)				
Oligodendroglioma			2	(4%)		
Meningioma					1	(2%)
#Brain stem	(50)		(49)		(50)	
Carcinoma, NOS, invasive	(=)	(6%)		(2%)		
SPECIAL SENSE ORGANS	<u></u>	<u></u>	<u> </u>	<u></u>	· · · · · · · · · · · · · · · · · · ·	
*Zymbal gland	(50)		(50)		(50)	
Carcinoma, NOS			1	(2%)		
MUSCULOSKELETAL SYSTEM None						
BODY CAVITIES	<u>t=</u>	<u> </u>		<u></u>		
*Mesentery	(50)		(50)		(50)	
Sarcoma, NOS	1	(2%)				
ALL OTHER SYSTEMS						
*Multiple organs Sarcoma, NOS, metastatic	(50)		(50)	(2%)	(50)	

TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Untreated Control	Low Dose	High Dose
ANIMAL DISPOSITION SUMMARY	····		
Animals initially in study	50	50	50
Natural death	2	5	2
Moribund sacrifice	19	15	10
Terminal sacrifice	29	30	38
rumor summary			<u></u>
Total animals with primary tumors**	49	48	42
Total primary tumors	93	96	81
Total animals with benign tumors	38	37	38
Total benign tumors	62	61	60
Total animals with malignant tumors	27	30	17
Total malignant tumors	29	34	19
Total animals with secondary tumors##	5	2	1
Total secondary tumors	5	2	1
Total animals with tumors uncertain			
benign or malignant	2	1	2
Total uncertain tumors	2	1	2

TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically.
** Primary tumors: all tumors except secondary tumors
Number of animals examined microscopically at this site
Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ

TABLE B2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR FEEDSTUDY OF ERYTHROMYCIN STEARATE: UNTREATED CONTROL

ANIMAL NUMBER	$\begin{array}{c}1\\2\\5\end{array}$	1 4 6	1 1 5	1 1 0	1 2 9	$\begin{array}{c}1\\3\\2\end{array}$	$\begin{array}{c}1\\3\\7\end{array}$	1 0 5	1 0 6	$\frac{1}{2}$	1 4 3	1 4 9	$\frac{1}{2}$	$1\\3\\4$	1 4 0	$\begin{array}{c}1\\0\\2\end{array}$	1 2 6	1 4 4	$\begin{array}{c}1\\2\\4\end{array}$	1 0 9	$\begin{array}{c}1\\1\\3\end{array}$	1 0 1	$\begin{array}{c}1\\0\\3\end{array}$	1 0 4	1 0 7
WEEKS ON STUDY	0 2 6	0 4 9	0 5 5	0 5 7	0 7 8	0 8 2	0 8 3	0 8 4	0 8 4	0 8 4	0 8 5	0 8 6	0 8 9	0 8 9	0 9 2	0 9 4	0 9 6	0 9 9	1 0 1	$\begin{array}{c}1\\0\\2\end{array}$	$egin{array}{c} 1 \\ 0 \\ 2 \end{array}$	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibroma Lipoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+
RESPIRATORY SYSTEM Lungs and bronch: Trachea	++++	+ +	+ +	+ +	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	++	+++	++	+ +	++	+ +	+ +
HEMATOPOIETIC SYSTEM Bone marrow Spleen Lymph nodes Thymus	++++-++	+ + + +	+ + + +	++++++	+ + + +	+ + - +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + + -	++++	+ + +	+++++++	+ + + +	++++++	++++	+++++	+ + + +	+++++	+++-	+++++	+ + + +
CIRCULATORY SYSTEM Heart Neurlemoma, malıgnant Blood vessels Carcınoma, NOS, metastatıc	+ X N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N X	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland Liver Bile duct	N + + +	N + + + +	N + + +	N + + +	N + + +	N + + +	N + + + +	N + + + +	N + + + +	N + + +	N + + +	N + + +	N + + +	N + + +	N + + + +	N + + + +	N + + + +	N +++++	N + + +	N + + +	N + + +	N ++++	N + + +	N + + +	N + + +
Pancreas Esophagus Stomach Small intestine Large intestine	+++++++	+++++	+ + + +	+++++	+++++++	+ - + + +	++++++	++++++	+ + + + +	++++++	++++++	+ + + + +	+++++	++++++	+++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	++++++	++++++++	++++++	+++++++	++-++	-+++++	++++	++++++
URINARY SYSTEM Kıdney Tubular cell adenoma Urınary bladder	++	+ +	+ +	+ +	+	+ +	 +	+ +	+ +	+ ~	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ X +	+ +	+ +	+ +
ENDOCRINE SYSTEM Priutary Carcinoma, NOS Adenoma, NOS Adrenal Adenoma, NOS	-+	+	++	+ X +	+ X +	+	+ +	+ X +	+	+	+	* * +	+	++	+	+ +	* X +	+	+ X +	+ X +	+ X +	+	+	+ X +	+
Pheochromocytoma Thyroid C-cell adenoma Parathyroid	+	+ +	+ +	+~~	+ -	+ -	X + +	+ +	+	+ +	+ +	+ +	+ X +	+ +	+ +	+ +	+ +	* *	+ X +	+ +	+	+ +	+ +	+ +	+ +
REPRODUCTIVE SYSTEM Mammary gland Adenoma, NOS	+	+	+	+	+	+	+	+	+	+	N	+	N	+	+	+	+	+	+ X	+	+	+	+	+	+
Adenocarcinoma, NOS Fibroadenoma Preputial/clitoral gland Carcinoma, NOS	N	N	X N	N	N	N	N	N	N	N	N X	N	N	N	X N	X N	N	N	X N	X N	N	N	N	N	X N
Adenoma, NOS Uterus Endometral stromal polyp Endometral stromal sarcoma	+	+	+	+	*	+	* x	+	+	+ X	+	+	+ X	+	+	+	+	+	+	+	+	*	X +	+	+
Ovary Granulosa cell tumor	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*	+	+	+	+	+	*	+	+	+
NERVOUS SYSTEM Brain Carcinoma, NOS, invasive Astrocytoma	+	+	+	+	+ X	+ X	+	+ X	÷	+	+	* X	+	+	+	+	* x	+	+	+	+	+	+	+	+
BODY CAVITIES Mesentery Sarcoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N
ALL OTHER SYSTEMS Multiple organs, NOS Leukemia, mononuclear cell	N	N X	N	N	N	N	N	N	N X	N	N	N	N	N X	N X	N	N	N X	N X	N	N	N X	N	N	N X

Tissue examined microscopically
 Required tissue not examined microscopically
 X: Tumor incidence
 Necropsy, no autolysis, no microscopic examination
 S: Animal missexed

No tissue information submitted C Necropsy, no histology due to protocol A: Autolysis M Animal missing B: No necropsy performed

								• -				· ·														
ANIMAL NUMBER	1 0 8	1 1 1	$\begin{array}{c}1\\1\\2\end{array}$	1 1 4	1 1 6	1 1 7	1 1 8	1 1 9	1 2 0	$\begin{array}{c}1\\2\\1\end{array}$	$\frac{1}{2}$	$\frac{1}{2}$ 7	1 3 0	1 3 1	1 3 3	1 3 5	1 3 6	1 3 8	1 3 9	1 4 1	1 4 2	1 4 5	$\frac{1}{4}$	1 4 8	1 5 0	TOTAL
WEEKS ON STUDY	104	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL: TISSUES TUMORS
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibroma Lipoma	+	+	+	+	+	+	+	+	+	+	+	+	* X	+	+	+	+	÷	+	+	+	+	+	+	+	*50 1 1
RESPIRATORY SYSTEM Lungs and bronchi Trachea	++	+ +	+ +	+++++	+ +	+ +	+ +	+ +	+ +	+++	++	+++	+++	+ +	++	+ +	+ +	+ +	+ +	++++	++++	+ +	+ +	+ +		49 50
HEMATOPOIETIC SYSTEM Bone marrow Spieen Lymph nodes Thymus	++++	+ + +	+++++	+++++	+++++++++++++++++++++++++++++++++++++++	++++++	+ + + +	+ + + +	++++++	+ + -	++++	+ + + +	+++++	+++++++++++++++++++++++++++++++++++++++	++++	+ + + +	+ + - +	+++++	+ + + +	+++++++	++++++	+ + + +	++++-	+ - + -	+++++	50 48 45 42
CIRCULATORY SYSTEM Heart Neurilemoma, malignant Blood vessels Carcinoma, NOS, metastatic	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	+ N	50 1 *50 1
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland Liver Bile duct Pancreas Esophagus Stomach Small intestine Large intestine	N ++++++++++++++++++++++++++++++++++++	N + + + + + + + + + + + + + + + + + + +	N ++++++++	N + + + + + + + + + + + + + + + + + + +	Z +++++++++	N + + + + + + + + + + + + + + + + + + +	Z + + + + + + + + + + + + + + + + + + +	Z ++++++++	Z +++++++++++++++	Z ++++++++++++++++++++++++++++++++++++	Z ++++++++	Z ++++++++	Z ++++++++	XX + + + + + + + + + + + + + + + + + +	Z ++++++++++	Z ++++++++	Z +++++++++	Z + + + + + + + + + + + + + + + + + + +	Z ++++++++	N + + + + + + + + + + + + + + + + + + +	Z +++++++++	Z ++++++++	Z +++++++++	Z ++++++++	N ++++++++	*50 1 48 50 50 49 49 49 49 49
URINARY SYSTEM Kidney Tubular cell adenoma Urinary bladder	+	+++	++	+++	+ +	++++	++	++	++	+ +	++	+++	++	+++	++	++	++	++	+++	+ +	+++	+++	++	+++	+++	49 1 47
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS Adrenal Adroma, NOS Pheochromocytoma Thyroid C-cell adenoma Parathyroid	+ X + +	++++++	+ X + X + + +	+ X + +	+ X + +	+ + +	+ X + X +	+ X + +	+ X + +	+ + +	+ + + + X	+ + +	+ + +	+ + +	++++	+ + *	+ + + +	+ X + + +	+ X + + X +	+ + + +	+ X + X +	+ + *	+ X + +	+ X + +	+ + + +	49 4 18 50 1 1 50 9 35
REPRODUCTIVE SYSTEM Mammary gland Adenoma, NOS Adenocarcinoma, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+ X	+	+	+	+	*50 1 2
Fibroadenoma Preputial/clitoral gland Carcinoma, NOS Adenoma, NOS Uterus	N +	X N	N +	N +	N +	X N	N +	N +	N +	N +	N +	N X	N +	N +	X N X + X	N +	N +	X N	X N X	X N +	N +	X N	N +	N +	N X	13 *50 1 5 50
Endometrial stromal polyp Endometrial stromal sarcoma Ovary Granulosa cell tumor	+	+	+	+	* +	+	+	+	+ X +	, +	+	+	, +	+	х +	+	+	+	х́ +	х +	x +	<u>x</u>	х́ +	÷	+	10 3 49 2
NERVOUS SYSTEM Brain Carcinoma, NOS, invasive Astrocytoma	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	50 4 3
BODY CAVITIES Mesentery Sarcoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 1
ALL OTHER SYSTEMS Multiple organs, NOS Leukemia, mononuclear ceil	N	N	N X	N	N	N X	N	N	N	N X	N	N	N X	N	N	N	N	N	N	N	N	N X	N	N X	N	*50

TABLE B2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS: UNTREATED CONTROL (Continued)

* Animals necropsied

TABLE B2. INDIVIDUAL	ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR FEED
	STUDY OF ERYTHROMYCIN STEARATE: LOW DOSE

ANIMAL NUMBER	0 4 2	0 0 9	0 1 5	0 3 8	0 4 4	0 4 7	0 3 0		0 2 5	0 1 4	0 4 6	0 3 7	0 2 4	0 0 1	$ \begin{array}{c} 0 \\ 3 \\ 2 \end{array} $	0 1 6	0 4 8	$0\\2\\3$	0 4 1	0 3 4	0 0 2	0 0 3	0 0 4	0 0 5	0 0 6
WEEKS ON STUDY	0 5 3	0 6 3	0 7 0	0 7 1	0 8 0	0 8 2	0 8 3	0 8 4	0 8 7	0 8 8	0 8 9	0 9 2	0 9 6	0 9 7	0 9 8	1 0 0	1 0 0	1 0 1	$\frac{1}{0}{2}$	1 0 3	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM	-																								
Skin Keratoacanthoma Subcutaneous tissue Sarcoma, NOS Fibroma	-	+	+	+ +	+	+ +	+ + X	+ +	+	N N	+	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Trachea	+	++++	+ +	++++	+++	+ +	+++	+++	++	+	+++	++	+++	+ +	+ +	++	++	++++	+++	+	+ +	+++	++	+++	++++
HEMATOPOIETIC SYSTEM Bone marrow Spleen Lymph nodes Thymus	- + + +	+++++	+++-+	+ + + +	+ + + +	++++-	++++	+++++	+ + +	++++	++++++	++++++	+ + + +	+ + + +	++++-	+ + + +	+++++	++++++	+++++	+ + + -	+++++	+++++	++++	++++	+++++
CIRCULATORY SYSTEM Heart	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland Neurilemoma, malignant	N +	N +	N +	N +	N -	N +	N +	N +	N +	N +	N +	N +	N X +	N +	N +	N +	N +								
Liver Neoplastic nodule Kupffer cell sarcoma Bile duct	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pancreas Esophagus Stomach Smail intestine	+++++++++++++++++++++++++++++++++++++++	+++++	+++++	+ + + + +	+ + + + +	+ + + + +	+ + + +	+++++	+ + + + +	+ + + + +	+++++	+++++	+ + + +	+ + + + +	+++++++	+++++	++++++	+ + + + +	+++++	+ + + + +	+++++	+ + + + +	+ + + + +	+ + + + +	+ + + +
Leiomyosarcoma Large intestine	+	+	+	÷	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
URINARY SYSTEM Kidney Tubular cell adenoma Urinary bladder	+ +	+ +	+	+	+ +	+ +	+ +	+ +	++	+ +	+ +	++	+ +	+	+ +	+++	+	+ +	+ +	+	+ +	+++	+	+++	+ +
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS	•+	+	+	+	+	+	+	+	+	* X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma, NOS Adrenal Carcinoma, NOS Adenoma, NOS	+	х +	+	+	+	+	+	+	+	+	÷	X +	x + x	х +	+	+	÷	х +	+	+	+	+	+	+	X +
Pheochromocytoma Thyroid C-cell adenoma _C-cell carcinoma	+	+	+	+	+	+	Ŧ	X +	+	+	+	X +	+	$\stackrel{+}{x}$	+	+	+	+	+	+	+	* X	+	+	+
Parathyroid Adenoma, NOS	-	+	+	-	+	+	~	+	+	-	+	+	+	+	+	+	+	+	-	+	-	+	+	+	-
REPRODUCTIVE SYSTEM Mammary gland Fibroadenoma Preputial/clitoral gland Carcinoma, NOS	+ N	+ N	+ N	+ N	+ X N	+ N	* X N	+ X N	+ X N	+ N	+ X N	+ N	+ N	+ X N	+ N	+ N	+ N	+ N							
Adenoma, NOS Uterus Sarcoma, NOS Endometrial stromal polyp	+	+	* X	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+ X	+ X	+	+	+	Х +	+
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+
NERVOUS SYSTEM Brain Carcinoma, NOS, invasive Oligodendroglioma	+ x	+	+	+	+	+	+	+	+	* X	+	-	+	+	+	+	+	+ X	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Zymbai gland Carcinoma, NOS	N	N	N	N	N	N	N	* X	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
ALL OTHER SYSTEMS Multiple organs, NOS Sarcoma, NOS, metastatic Leukemia, mononuclear cell	N	N	N X		N X		N	N	N X	N		N X	N X	N	N X	N	N X	N	N X		N	N	N	N	N

								(U	on		acu															
ANIMAL NUMBER	0 0 8	0 1 0	0 1 1	$ \begin{array}{c} 0 \\ 1 \\ 2 \end{array} $	0 1 3	0 1 7	0 1 8	0 1 9	0 2 0	0 2 1	$\begin{array}{c} 0 \\ 2 \\ 2 \end{array}$	0 2 6	0 2 7	0 2 8	0 2 9	0 3 1	0 3 3	0 3 5	0 3 6	0 3 9	0 4 0	0 4 3	0 4 5	0 4 9	0 5 0	
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL: TISSUES TUMORS
INTEGUMENTARY SYSTEM																			 .							
Skin Keratoacanthoma Subcutaneous tissue Sarcoma, NOS Fibroma	++	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ X +	+ +	+	+ +	+ + X	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +	*50 1 *50 1 1
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Trachea	+++	+ +	+++	+ +	+ +	+++	+	+++	++	+++	+++	+ +	* *	+ +	+ +	+++	+	+++	++++	-+	+++	+++	+++	+++	+++	49 1 50
HEMATOPOIETIC SYSTEM Bone marrow Spieen Lymph nodes Thymus	++++++	+++++	++++++	++++-	++	+++++	++++++	++++++	+ + + +	++++	+++++	++++++	++++	+++1	+++++++	+++-	+++++	+++++	+ +	+ + + +	+++-+++++++++++++++++++++++++++++++++++	+ + + +	++++-	+++++	++++++	50 49 45 35
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland Neurilemoma, malignant	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N X +	N +	N +	N +	N +	N +	N +	N + X	N +	N +	N +	N +	*50 2 49 1
Liver Neoplastic nodule Kupffer cell sarcoma Bile duct Fancreas	++++	+++	++++	+++++	+ + +	+++	++++	++++	++++	++++	++++	++++	+++	+ X + +	++++	++++	++++	++++	++++	+++	++++	++	++++++	++++	+++++	50 1 1 50 49
Esophagus Stomach Small intestine Leiomyosarcoma Large intestine	+++++++++++++++++++++++++++++++++++++++	+++	++++++	+ + +	+ + X +	++++++	+ + +	+ + +	++++++	++++++	++++++	++++	+++++++	++++++++	++++++	++++++	+++++++++++++++++++++++++++++++++++++++	++++++	+ + +	+++++	++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + +	+ + +	50 50 50 1 47
URINARY SYSTEM Kidney Tubular cell adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	50
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS Adenoma, NOS Adrenal	++	+ X +	+ X +	+ X +	+	+	++	+ X +	++	+ X +	+	+ X +	+	+ X +	+	+	+ X +	+ X +	+ X + X	+ x +	+	++	+ X +	+	+ X +	50 2 18 49
Carcinoma, NOS Adenoma, NOS Pheochromocytoma Thyroid C-cell adenoma	+	X +	X +	+	+	+ X	+	+	X X + X	+ X	+	+ X	+	+	+	+	+	+ X	х +	+	+	+	+	+ X	+	1 3 4 50 8 2
C-cell carcinoma Parathyroid Adenoma, NOS	-	+	<u>x</u>	-	-	-	-	+	+	+	-	+	-	-	÷	x + X	-	÷	+	+	+	+	-	+	-	$\begin{vmatrix} 2\\ 31\\ 1 \end{vmatrix}$
REPRODUCTIVE SYSTEM Mammary gland Fibroadenoma Preputial/clitoral gland Carcinoma, NOS Adenoma, NOS	+ N X	+ X N	+ N	+ N X	+ N	+ N	+ N	+ N	+ N	+ X N	+ N	+ X N	+ N X	+ N	+ N	+ N	+ N	+ X N	+ X N	+ N	+ X N X	+ X N	+ N	+ N	+ N	*50 13 *50 2 3
Uterus Sarcoma, NOS Endometrial stromal polyp	+	+	+	+	+	+	+	+	+	+	+ X	+	÷	+ X	+ X	+	+	+	+	+	+	+	+	+	+	49 1 5
Ovary NERVOUS SYSTEM Brain Carringma NOS invasive	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Carcinoma, NOS, invasive Oligodendroglioma SPECIAL SENSE ORGANS																										2
Zymbal gland Carcinoma, NOS ALL OTHER SYSTEMS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 1
ALL OTHER SYSTEMS Multiple organs, NOS Sarcoma, NOS, metastatic Leukemia, mononuclear cell	N	N X	Ν	N X	N	N	N	N	N	N	N	N	Ν	N X	N	N X	Ν	-	N X	Ν	N	N X	N	N	N X	*50 1 19

TABLE B2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS: LOW DOSE (Continued)

* Animals necropsied

	01 2							~ -								~~-	_								
ANIMAL NUMBER	0 7 4	0 6 6	0 9 2	0 7 7	0 6 9	0 6 1	0 7 5		0 9 8	0 5 7	0 6 0	0 9 3	0 5 1	0 5 2	0 5 3	0 5 4	0 5 5	056	0 5 8	0 5 9	0 6 2	0 6 3	0 6 4	0 6 5	0 6 7
WEEKS ON STUDY	0 6 2	0 6 8	0 6 8	0 9 1	0 9 2	0 9 4	0 9 5	0 9 8	0 9 9	1 0 3	1 0 3	1 0 3	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	$\begin{array}{c}1\\0\\4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibrosarcoma	+	+	+	+	+	÷	+	+	+	+ X	+	+	+	+	* X	+	+	+	+	+	+	+	+	+	+
RESPIRATORY SYSTEM Lungs and bronchi Trachea	+++	+ +	+++	+ +	+ +	+ +	+++	+ +	+ +	+++++	+++	+++	+ +	+ +	++++	+ +	+++	++++	++++	+++	++++	+++	+++		+ +
HEMATOPOIETIC SYSTEM Bone marrow Spleen Leukemia, mononuclear cell	+++	+++	+ +	+ +	+ + X	+++	++++	+ +	++++	+ +	++++	+++	+++	++++	++++	+++	+ +	+++	+++						
Jymph nodes Fibrosarcoma, metastatic Thymus Thymoma, malignant	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ X +	+ +	+ +	+ -	+ -	+ +	+	+	+ +	+ +	+ +	+ +	+ -	+ +	+ +	+ +
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland	N +	N +	N +	N +	N +	N +	N X +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +						
Liver Neoplastic nodule Bile duct Pancreas	+++++++++++++++++++++++++++++++++++++++	+ + +	+ + +	+ + +	+ + +	+ + +	++++	+ + +	+ + +	+ + +	+ + +	++++	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+++++	+ + +	+ + +	+ + +	+ + +	+ + +	++++
Esophagus Stomach Small intestine Large intestine	+++++++++++++++++++++++++++++++++++++++	+ + +	 + + +	+++++	+ + + +	+ + + +	+ + + +	+ + +	+ + +	+ + + +	+++++	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+++++	+ + + +	+++++	+++++	+ + + +	+++++	+ + + +	+ + + +
U RINARY SYSTEM Kidney Tubular cell adenocarcinoma Urinary bladder Transitional cell papilloma	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ + +	++	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	* *	++	++	++	+ +	++	++	++
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS Adenoma, NOS	+	+ X	+	+ X	+	+	+	+ X	* X	+ X	+	+ X	+ X	+	+ X	+	+	+	+	+	+	+	+ x	+ x	+
Adrenai Pheochromocytoma Thyroid C-cell adenoma C-cell carcinoma	+	+ +	+	+ X +	+ +	+	+	+ +	+ +	+ +	+	+ +	+ X +	+ +	+ +	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +	+ x +	+ + X
Parathyroid REPRODUCTIVE SYSTEM		-	+	-	+	+	+	+	+	+		-	-	+	+	-	+	-	-	+	+	-	+	х -	+
Mammary gland Fibroadenoma Preputial/clitoral gland Adenoma, NOS	x N	+ N	+ X N	X N	* X N	* X N	+ N	x N	+ N	+ N	X N	+ N	+ N	+ N	+ N	+ N	+ X N X	+ N	x N	+ N	+ X N	+ N	+ N	+ N	+ N
Uterus Endometrial stromal polyp Ovary	+	+ +	+ +	+ +	+ X +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	x + X +	+ +	* x +	+ +	+ +	+ +	+ +	+ +	+ +
NERVOUS SYSTEM Brain Meningioma	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ALL OTHER SYSTEMS Multiple organs, NOS Leukemia, mononuclear cell	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	N	N

TABLE B2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE: HIGH DOSE

TABLE B2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS: HIGH DOSE (Continued)

ANIMAL NUMBER	0 6 8	0 7 0	0 7 1	0 7 2	0 7 3	0 7 6	0 7 8	0 7 9	0 8 0	0 8 1	0 8 3	0 8 4	0 8 5	0 8 6	0 8 7	0 8 8	0 8 9	0 9 0	0 9 1	0 9 4	0 9 5	0 9 6	0 9 7	0 9 9	1 0 0	
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL: TISSUES TUMORS
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibrosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*50 2
RESPIRATORY SYSTEM Lungs and bronchi Trachea	+++	++++	+ +	+++	+ +	+ +	+++	+ +	++++	+ +	++++	+++	++++	++++	+ +	+ +	+++	+ +	+++	+ +	+ +	+++	++++	++	+ +	49 50
HEMATOPOIETIC SYSTEM Bone marrow Spleen Leukemia, mononuclear ceil	++++	++++	+ +	+ +	+ +	++++	+ +	+ +	++++	+ +	++++	+ +	+++++	++++	+ +	+ +	+++++	+ +	++++	++	++++	+ +	++++	++++	+ +	50 50 1
Lymph nodes Fibrosarcoma, metastatic Thymus Thymoma, malignant	+	+ +	+ +	+ +	+ +	+ + X	+ -	+ -	+ +	+ +	+ +	+ +	+ +	+ -	+	+ +	+	+ +	+ +	+	+ +	+ +	+ +	+ +	+ +	49 1 41 1
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
DIGESTIVE SYSTEM Oral cavity Squamous cell papilloma Salivary gland	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N +	N X +	N +	N +	N +	N _	N +	N X +	N +	N +	N +	*50 3 49
Liver Neoplastic nodule Bile duct Pancreas	+++++++++++++++++++++++++++++++++++++++	++++	+ + +	+ + +	+ + +	+++++	+ + +	+ + +	+ + +	+ + +	+++++	+ + +	+ + +	+ X + +	+ + +	+ + +	+ + +	+ + +	+ + +	* + +	+++++	+ + +	+ + +	+ + +	+ + +	50 2 50 50
Esophagus Stomach Small intestine Large intestine	+++++++	+++++	+ + + +	+ + + +	+ + + +	+ + +	+ + + +	+ + + +	-+ ++ +	+ + + +	++++++	+++++	+ + + +	+ + + +	+++++	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	++++++	+++++	+ + + +	+ + + +	48 50 50 50
URINARY SYSTEM Kidney Tubular cell adenocarcinoma Urinary bladder Transitional cell papilloma	+++	+ -	+ +	+ + X	+ + +	++	+++	+ +	+ +	+ +	++	++	+ +	+ +	+ +	+ +	+ +	+ +	++	+	+	+ +	+ +	++	+++	50 1 48 1
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS Adenoma, NOS Adrenal Pheochromocytoma Thyroid C-cell adenoma C-cell carcinoma Parathyroid	+ X + X +	+ + X + X +	+ + X +	+ + +	+ X + +	+++++	+++++	+ + + +	+ + + +	+ + + +	+++++	+ X + +	++++++	+ + +	+ X + +	* * + +	++++	+++++	+ X + +	++++++	+ X + +	+ + X -	+ + +	+ X + +	+ + + +	50 2 16 50 5 50 3 2 34
REPRODUCTIVE SYSTEM Mammary gland Fibroadenoma Preputial/clitoral gland Adenoma, NOS Uterus	+ X + X	+ N +	+ N +	+ X N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ N +	+ X N +	+ X N +	+ N +	+ X N +	+ X N +	+ N +	+ N X +	+ N +	*50 15 *50 3 50
Endometrial stromal polyp Ovary NERVOUS SYSTEM Brain	+	+	* +	+	+	× + +	+	+	+	× + +	+	+	× + +	+	× + +	* + +	× + +	* +	+	X +	+	+	+	+ +	* + +	14 50 50
Meningioma ALL OTHER SYSTEMS Multiple organs, NOS Leukemia, mononuclear cell	N X	N	N X	N	N X	N X	N	N X	N	N	N	N	N	N X	N	N	N	N	N	N X	X N X	N	N	N	N	1 *50 9

* Animals necropsied

	Control	5,000 ppm	10,000 ppm
Hematopoietic System: Mononuclear Cell	Leukemia	<u> </u>	
Overall Rates (a)	14/50 (28%)	19/50 (38%)	10/50 (20%)
Adjusted Rates (b)	38.4%	45.1%	24.7%
Terminal Rates (c)	8/29 (28%)	8/30 (27%)	8/38 (21%)
Week of First Observation	49	71	92
Life Table Tests (d)	P = 0.081N	P = 0.271	P = 0.091 N
Incidental Tumor Tests (d)	P = 0.363N	P = 0.165	P = 0.335N
Cochran-Armitage Trend Test (d)	P = 0.219N	1 = 0.105	F = 0.33514
Fisher Exact Test (d)	P = 0.219 N	D-0109	P = 0.242N
risher Exact Test(d)		P = 0.198	P = 0.242 N
ral Cavity: Squamous Cell Papilloma			
Overall Rates (a)	1/50(2%)	2/50 (4%)	3/50 (6%)
Adjusted Rates (b)	3.4%	6.7%	7.4%
Terminal Rates (c)	1/29 (3%)	2/30(7%)	2/38(5%)
Week of First Observation	104	104	95
Life Table Tests (d)	P = 0.316	P = 0.512	P = 0.405
Incidental Tumor Tests (d)	P = 0.308	P = 0.512	P = 0.395
Cochran-Armitage Trend Test (d)	P = 0.222		
Fisher Exact Test (d)		P = 0.500	P = 0.309
nterior Pituitary Gland: Adenoma			
Overall Rates (a)	18/49 (37%)	18/50 (36%)	16/50 (32%)
Adjusted Rates (b)	52.1%	50.3%	36.7%
Terminal Rates (c)	13/29 (45%)	13/30 (43%)	11/38 (29%)
Week of First Observation	57	63	68
Life Table Tests (d)	P = 0.118N	P = 0.523N	P = 0.145 N
Incidental Tumor Tests (d)	P = 0.163 N	P = 0.447 N	P = 0.191 N
Cochran-Armitage Trend Test (d)	P = 0.348N		
Fisher Exact Test (d)		P = 0.553 N	P = 0.388N
Anterior Pituitary Gland: Carcinoma	4/40 (00)	9/50 (10)	9/50 (401)
Overall Rates (a)	4/49 (8%)	2/50(4%)	2/50 (4%)
Adjusted Rates (b)	10.8%	5.7%	4.9%
Terminal Rates (c)	1/29 (3%)	1/30 (3%)	1/38 (3%)
Week of First Observation	84	88	99
Life Table Tests (d)	P = 0.182N	P = 0.317N	P = 0.249 N
Incidental Tumor Tests (d)	P = 0.373N	P = 0.360N	P = 0.484N
Cochran-Armitage Trend Test (d)	P = 0.244N		
Fisher Exact Test (d)		P = 0.329 N	P = 0.329N
nterior Pituitary Gland: Adenoma or Ca	rainama		
Overall Rates (a)	22/49 (45%)	20/50 (40%)	18/50 (36%)
Adjusted Rates (b)	58.5%	54.4%	40.5%
Terminal Rates (c)	14/29 (48%)	14/30 (47%)	12/38 (32%)
Week of First Observation	57	63	68
Life Table Tests (d)		P = 0.364N	P = 0.072N
Incidental Tumor Tests (d)	P = 0.056N P = 0.116N	P = 0.304 N P = 0.307 N	P = 0.072 N P = 0.140 N
	P = 0.116N	P = 0.307 N	F = 0.1401
Cochran-Armitage Trend Test (d)	P = 0.212N	$\mathbf{D} = 0.29$ CN	P = 0.243 N
Fisher Exact Test (d)		P = 0.386 N	P = 0.243 N
drenal Gland: Adenoma			
Overall Rates (a)	1/50 (2%)	3/49 (6%)	0/50(0%)
Adjusted Rates (b)	3.4%	9.3%	0.0%
Terminal Rates (c)	1/29 (3%)	2/29(7%)	0/38 (0%)
Week of First Observation	104	96	0.00.00
	P-0 200N	P=0.316	P=0 AAGN
Life Table Tests (d)	P = 0.300N P = 0.305N	P = 0.316 P = 0.332	P = 0.446N P = 0.446N
	P = 0.300N P = 0.305N P = 0.379N	P = 0.316 P = 0.332	P = 0.446N P = 0.446N

TABLE B3. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDYOF ERYTHROMYCIN STEARATE

	Control	5,000 ppm	10,000 ppm
Adrenal Gland: Adenoma or Carcinoma	<u> </u>		
Overall Rates (a)	1/50 (2%)	4/49 (8%)	0/50 (0%)
Adjusted Rates (b)	3.4%	12.7%	0.0%
Terminal Rates (c)	1/29 (3%)	3/29 (10%)	0/38 (0%)
Week of First Observation	104	96	
Life Table Tests (d)	P = 0.301N	P = 0.187	P = 0.446N
Incidental Tumor Tests (d)	P = 0.305N	P = 0.198	P = 0.446N
Cochran-Armitage Trend Test (d)	P = 0.3031N P = 0.391N	F = 0.198	r -0.44014
Fisher Exact Test (d)	P=0.391N	P = 0.175	P = 0.500 N
drenal Gland: Pheochromocytoma			
Overall Rates (a)	1/50 (2%)	4/49 (8%)	5/50 (10%)
Adjusted Rates (b)	2.3%	11.4%	12.4%
Terminal Rates (c)	0/29 (0%)	2/29 (7%)	4/38 (11%)
Week of First Observation	83	84	91
Life Table Tests (d)	P = 0.146	P = 0.189	P = 0.169
Incidental Tumor Tests (d)	P = 0.025	P = 0.138	P = 0.041
Cochran-Armitage Trend Test (d)	P = 0.081		
Fisher Exact Test (d)		P = 0.175	P = 0.102
hyroid Gland: C-Cell Adenoma			
Overall Rates (a)	9/50 (18%)	8/50 (16%)	3/50 (6%)
Adjusted Rates (b)	27.5%	25.4%	7.9%
Terminal Rates (c)	6/29 (21%)	7/30 (23%)	3/38 (8%)
Week of First Observation	89	97 D. A.CON	104 D = 0.022N
Life Table Tests (d)	P = 0.017N	P = 0.463N	P = 0.023N
Incidental Tumor Tests (d)	P = 0.023 N	P = 0.442N	P = 0.037 N
Cochran-Armitage Trend Test (d)	P = 0.053 N		
Fisher Exact Test (d)		P = 0.500 N	P = 0.061 N
hyroid Gland: C-Cell Adenoma or Carcino			
Overall Rates (a)	9/50 (18%)	10/50 (20%)	5/50 (10%)
Adjusted Rates (b)	27.5%	31.9%	13.2%
Terminal Rates (c)	6/29 (21%)	9/30 (30%)	5/38 (13%)
Week of First Observation	89	97	104
Life Table Tests (d)	P = 0.062N	P = 0.539	P = 0.083N
Incidental Tumor Tests (d)	P = 0.079N	P = 0.559	P = 0.122N
		r — 0.009	r -0.1221
Cochran-Armitage Trend Test (d)	P = 0.170 N		D-0 104M
Fisher Exact Test (d)		P = 0.500	P = 0.194N
lammary Gland: Fibroadenoma	19/50/0000	10/50 (000)	1 5 (50 / 00 / 0
Overall Rates (a)	13/50 (26%)	13/50 (26%)	15/50 (30%)
Adjusted Rates (b)	37.2%	36.1%	32.4%
Terminal Rates (c)	8/29 (28%)	8/30 (27%)	8/38 (21%)
Week of First Observation	55	80	62
Life Table Tests (d)	P = 0.422N	P = 0.537 N	P = 0.465N
Incidental Tumor Tests (d)	P = 0.463	P = 0.482N	P = 0.464
Cochran-Armitage Trend Test (d)	P = 0.368		
	1 -0.000	D-0 500N	P = 0.412
Fisher Exact Test (d)		P = 0.590 N	r — 0.414
ammary Gland: Adenoma or Adenocarcine		0/50 (0/2)	
Overall Rates (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)
Adjusted Rates (b)	9.8%	0.0%	0.0%
Terminal Rates (c)	2/29(7%)	0/30 (0%)	0/38(0%)
Week of First Observation	101		
Life Table Tests (d)	P = 0.026 N	P = 0.117 N	P = 0.081 N
Incidental Tumor Tests (d)	P = 0.026N	P = 0.102N	P = 0.085N
Cochran-Armitage Trend Test (d)	P = 0.020 N P = 0.037 N		
	1-0.00711	D = 0.191 M	P = 0.121 N
Fisher Exact Test (d)		P = 0.121 N	P = 0.121 N

TABLE B3. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Control	5,000 ppm	10,000 ppm
	· · · · · · · · · · · · · · · · · · ·		··
Overall Rates (a)	5/50 (10%)	3/50 (6%)	3/50 (6%)
Adjusted Rates (b)	17.2%	10.0%	7.9%
Terminal Rates (c)	5/29(17%)	3/30 (10%)	
Week of First Observation			3/38 (8%)
	104	104	104
Life Table Tests (d)	P = 0.165N	P = 0.334N	P = 0.217N
Incidental Tumor Tests (d)	P = 0.165N	P = 0.334N	P = 0.217 N
Cochran-Armitage Trend Test (d)	P = 0.283 N		
Fisher Exact Test (d)		P = 0.357 N	P = 0.357 N
litoral Gland: Adenoma or Carcinoma			
Overall Rates (a)	6/50 (12%)	5/50(10%)	3/50 (6%)
Adjusted Rates (b)	19.3%	16.7%	7.9%
Terminal Rates (c)	5/29 (17%)	5/30 (17%)	3/38 (8%)
Week of First Observation	85	104	104
Life Table Tests (d)	P = 0.098N	P = 0.475N	P = 0.133N
Incidental Tumor Tests (d)	P = 0.124N	P = 0.475 R P = 0.492 N	P = 0.133 N P = 0.191 N
Cochran-Armitage Trend Test (d)	P = 0.124N P = 0.195N	1 -0.43211	1 -0.1911N
Fisher Exact Test (d)	r=0.1951N	P = 0.500 N	P = 0.243 N
(terus: Endometrial Stromal Polyp Overall Rates (a)	10/50 (20%)	5/40 (100)	11/50 (990)
		5/49 (10%)	14/50 (28%)
Adjusted Rates (b)	30.8%	15.6%	35.6%
Terminal Rates (c)	8/29 (28%)	3/30 (10%)	13/38 (34%)
Week of First Observation	78	102	92
Life Table Tests (d)	P = 0.406	P = 0.121 N	P = 0.499
Incidental Tumor Tests (d)	P = 0.306	P = 0.112N	P = 0.354
Cochran-Armitage Trend Test (d)	P = 0.188		
Fisher Exact Test (d)		P = 0.140 N	P = 0.241
Iterus: Endometrial Stromal Sarcoma			
Overall Rates (a)	3/50 (6%)	0/49 (0%)	0/50 (0%)
Adjusted Rates (b)	8.2%	0.0%	0.0%
Terminal Rates (c)			
	1/29 (3%)	0/30 (0%)	0/38(0%)
Week of First Observation	84		
Life Table Tests (d)	P = 0.029 N	P = 0.119N	P = 0.092N
Incidental Tumor Tests (d)	P = 0.073 N	P = 0.144N	P = 0.285 N
Cochran-Armitage Trend Test (d)	P = 0.038N		
Fisher Exact Test (d)		P = 0.125N	P = 0.121 N
terus: Sarcoma or Endometrial Stromal S	arcoma		
Overall Rates (a)	3/50 (6%)	1/49 (2%)	0/50 (0%)
Adjusted Rates (b)	8.2%	2.1%	0.0%
Terminal Rates (c)	1/29 (3%)	0/30 (0%)	0/38 (0%)
Week of First Observation	84	70	
Life Table Tests (d)			D = 0.000 M
	P = 0.050N P = 0.100N	P = 0.297N	P = 0.092N
Incidental Tumor Tests (d)	P = 0.109N	P = 0.316N	P = 0.285N
Cochran-Armitage Trend Test (d)	P = 0.061 N	.	
Fisher Exact Test (d)		P = 0.316N	P = 0.121 N
rain: Astrocytoma			
	3/50 (6%)	0/49(0%)	0/50 (0%)
Overall Rates (a)			0.0%
	7.6%	0.0%	
Overall Rates (a) Adjusted Rates (b)	7.6%	0.0% 0/30 (0%)	
Overall Rates (a) Adjusted Rates (b) Terminal Rates (c)	7.6% 1/29(3%)	0.0% 0/30(0%)	0/38(0%)
Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation	7.6% 1/29(3%) 78	0/30(0%)	0/38(0%)
Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation Life Table Tests (d)	7.6% 1/29(3%) 78 P=0.033N	0/30(0%) P=0.122N	0/38(0%) P=0.105N
Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation Life Table Tests (d) Incidental Tumor Tests (d)	7.6% 1/29 (3%) 78 P = 0.033 N P = 0.050 N	0/30(0%)	0/38 (0%)
Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation Life Table Tests (d)	7.6% 1/29(3%) 78 P=0.033N	0/30(0%) P=0.122N	0/38(0%) P=0.105N

TABLE B3. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Control	5,000 ppm	10,000 ppm
Brain: Astrocytoma or Oligodendroglioma			
Overall Rates (a)	3/50 (6%)	2/49 (4%)	0/50 (0%)
Adjusted Rates (b)	7.6%	5.0%	0.0%
Terminal Rates (c)	1/29 (3%)	0/30 (0%)	0/38 (0%)
Week of First Observation	78	53	
Life Table Tests (d)	P = 0.070N	P = 0.491N	P = 0.105 N
Incidental Tumor Tests (d)	P = 0.093 N	P = 0.450N	P = 0.178N
Cochran-Armitage Trend Test (d)	P = 0.083 N		
Fisher Exact Test (d)		P = 0.510N	P = 0.121 N
All Sites: Benign Tumors			
Overall Rates (a)	38/50 (76%)	37/50 (74%)	38/50 (76%)
Adjusted Rates (b)	94.9%	90.1%	77.5%
Terminal Rates (c)	27/29 (93%)	26/30 (87%)	27/38(71%)
Week of First Observation	55	63	62
Life Table Tests (d)	P = 0.050 N	P = 0.390N	P = 0.067 N
Incidental Tumor Tests (d)	P = 0.118N	P = 0.246N	P = 0.157 N
Cochran-Armitage Trend Test (d)	P = 0.546 N		
Fisher Exact Test (d)		P = 0.500 N	P = 0.592
Il Sites: Malignant Tumors			
Overall Rates (a)	27/50 (54%)	30/50 (60%)	17/50 (34%)
Adjusted Rates (b)	60.1%	63.2%	40.2%
Terminal Rates (c)	12/29 (41%)	13/30 (43%)	13/38 (34%)
Week of First Observation	26	53	92
Life Table Tests (d)	P = 0.008N	P = 0.448	P = 0.008N
Incidental Tumor Tests (d)	P = 0.173 N	P = 0.215	P = 0.183N
Cochran-Armitage Trend Test (d)	P = 0.029 N		
Fisher Exact Test (d)		P = 0.343	P = 0.035N
All Sites: All Tumors			
Overall Rates (a)	49/50 (98%)	48/50 (96%)	42/50 (84%)
Adjusted Rates (b)	98.0%	96.0%	84.0%
Terminal Rates (c)	28/29 (97%)	28/30 (93%)	30/38 (79%)
Week of First Observation	26	53	62
Life Table Tests (d)	P = 0.003 N	P = 0.388N	P = 0.004 N
Incidental Tumor Tests (d)	P = 0.017 N	P = 0.512N	P = 0.043 N
Cochran-Armitage Trend Test (d)	P = 0.006 N		
Fisher Exact Test (d)		P = 0.500N	P = 0.016N

TABLE B3. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

TABLE B4a. HISTORICAL INCIDENCE OF ORAL CAVITY SQUAMOUS CELL TUMORS IN FEMALEF344/N RATS F344/N RATS RECEIVING NO TREATMENT (a)

I	Incidence in Controls				
Historical Incidence at Physiological Research Laboratories	0/150				
Overall Historical Incidence	(b) 1/1,984 (0.05%)				

(a) Data as of August 7, 1986, for studies of at least 104 weeks(b) Squamous cell carcinoma of the tongue observed in the rotenone study

TABLE B4b. HISTORICAL INCIDENCE OF ADRENAL GLAND TUMORS IN FEMALE F344/N RATSRECEIVING NO TREATMENT (a)

	Inci	Incidence in Controls				
Study	Pheochromocytoma	Pheochromocytoma or Malignant Pheochromocytoma				
Historical Incidence at Physiologica	al Research Laboratories					
Ephedrine sulfate	1/49	1/49				
Phenylephrine hydrochloride	6/50	6/50				
Oxytetracycline hydrochloride	6/50	6/50				
TOTAL	13/149 (8.7%)	13/149 (8.7%)				
SD (b)	5.75%	5.75%				
Range (c)						
High	6/50	6/50				
Low	1/49	1/49				
Overall Historical Incidence						
TOTAL	92/1,966 (4.7%)	98/1,966 (5.0%)				
SD (b)	3.69%	3.57%				
Range (c)						
High	8/50	8/50				
Low	0/50	0/50				

(a) Data as of August 7, 1986, for studies of at least 104 weeks

(b) Standard deviation(c) Range and SD are presented for groups of 35 or more animals.

	Untrea	ted Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY	50	<u>_</u>	50	<u> </u>	50	
ANIMALS NECROPSIED	50		50		50	
ANIMALS EXAMINED HISTOPATHOLOGICALI	LY 50		50		50	
NTEGUMENTARY SYSTEM				<u> </u>	••	
*Skin	(50)		(50)		(50)	
Inflammation, NOS					1	(2%)
Inflammation, focal		(2%)				
Hyperkeratosis Polypoid hyperplasia	1	(2%)			1	(2%)
	<u></u>	·	- .			·
RESPIRATORY SYSTEM	(50)		(50)		(50)	
#Nasal cavity	(50)		(50)		(50)	(90)
Inflammation, acute focal #Tracheal submucosa	(50)		(EO)			(2%)
Cyst, NOS		(9%)	(50)	(19.)	(50)	(90)
Lymphocytic inflammatory infiltrate	1	(2%)	Z	(4%)	1	(2%) (2%)
#Lung	(49)		(49)		(49)	(470)
Atelectasis		(4%)	(40)		(43)	
Congestion, NOS	2		2	(4%)		
Edema, NOS			-		1	(2%)
Hemorrhage	1	(2%)	4	(8%)		(2%)
Lymphocytic inflammatory infiltrate	4	(8%)			4	(8%)
Inflammation, interstitial					1	(2%)
Inflammation, acute focal			1	(2%)		
Inflammation, chronic focal		(00)	•	(1~)	2	(4%)
Hyperplasia, adenomatous	1	(2%)	2	(4%)		
IEMATOPOIETIC SYSTEM						
#Bone marrow	(50)		(50)		(50)	
Cyst, NOS		(0~)			1	(2%)
Atrophy, focal	1	(2%)	0	(40)	0	(401)
Myelofibrosis Hyperplasia, hematopoietic	25	(50%)		(4%) (42%)		(4%) (26%)
Hyperplasia, reticulum cell		(20%)		(42%) (28%)		(50%)
#Spleen	(48)	(2070)	(49)	(20 n)	(50)	
Inflammation, granulomatous	(()			(2%)
Granuloma, NOS			1	(2%)		(4%)
Scar					2	(4%)
Infarct, NOS	1	(2%)				
Hemosiderosis	7	(15%)	5	(10%)	9	(18%)
Hematopoiesis		(6%)				
#Splenic capsule	(48)		(49)	(907)	(50)	
Lymphocytic inflammatory infiltrate				(2%)		
Inflammation, chronic #Lymph node	(45)		(45)	(2%)	(49)	
#Lymph node Dilatation/sinus		(2%)		(4%)	(49)	
Hemorrhage		(4%)		(4%) (7%)	3	(6%)
Inflammation, granulomatous	2	(*/0)	5			(2%)
Hemosiderosis	2	(4%)			1	. =,
Histiocytosis	-	/ . /	1	(2%)		
#Mandibular lymph node	(45)		(45)		(49)	
Dilatation/sinus				(9%)		
Cyst, NOS					3	(6%)
Pigmentation, NOS						(2%)
Histiocytosis		(2%)	2	(4%)		
Hyperplasia, lymphoid	9	(4%)			2	(4%)

	Untreat	ed Control	Low	Dose	High	Dose
HEMATOPOIETIC SYSTEM (Continued)						
#Mesenteric lymph node	(45)		(45)		(49)	
Dilatation/sinus	(,		,			(2%)
Inflammation, chronic			1	(2%)		
Histiocytosis			1	(2%)		
#Thymus	(42)		(35)		(41)	
Dilatation/sinus	-	(2%)				
Cyst, NOS		(2%)			1	(2%)
Hypertrophy, NOS		(2%)				
Hyperplasia, epithelial		(2%)	3	(9%)	1	(2%)
Hyperplasia, lymphoid	2	(5%)				
CIRCULATORY SYSTEM						
#Spleen	(48)		(49)		(50)	
Arteriosclerosis, NOS			1	(2%)		
#Lung	(49)		(49)		(49)	
Thrombus, fibrin				(2%)		
#Heart	(50)		(50)		(50)	
Atrophy, diffuse						(2%)
#Heart/atrium	(50)		(50)		(50)	(0.07)
Degeneration, NOS	(FA)		(E0)			(2%)
#Myocardium	(50)		(50)	$(A \sigma)$	(50)	
Fibrosis, focal	47	(94%)		(4%)	4.77	(0.407)
Degeneration, NOS #Mitral valve		(94%)		(88%)		(94%)
<i>#</i> Mitral valve Degeneration, mucoid	(50)	(2%)	(50)	(2%)	(50)	(4%)
*Artery	(50)	(270)	(50)	(2%)	(50)	(41%)
Inflammation, chronic focal		(2%)	(00)		(30)	
Degeneration, mucoid	1	(270)			1	(2%)
Metaplasia, cartilaginous	1	(2%)	1	(2%)		(4%)
*Aorta	(50)	(2.10)	(50)	(2.01	(50)	(4/0)
Metaplasia, cartilaginous		(2%)	(00)		(00)	
*Pulmonary artery	(50)	(2,0)	(50)		(50)	
Edema, NOS	(00)		(,	(2%)	(00)	
#Hepatic sinusoid	(50)		(50)	(=,0)	(50)	
Dilatation, NOS		(2%)	(00)		(00)	
DIGESTIVE SYSTEM						
#Salivary gland	(48)		(49)		(49)	
Cystic ducts		(2%)	()		(12)	
Inflammation, focal		(2%)	1	(2%)	· 2	(4%)
Inflammation, suppurative					1	(2%)
Basophilic cyto change		(2%)				
Atrophy, focal	4	(8%)		(6%)	5	(10%)
Atrophy, diffuse			1	(2%)		
Hyperplasia, focal						(4%)
#Liver	(50)		(50)		(50)	
Accessory structure		(10%)		(10%)	10	(20%)
Congestion, NOS	1	(2%)		(2%)		
Inflammation, acute focal		(0.0 %)		(4%)		1000
Granuloma, NOS		(36%)	27	(54%)	43	(86%)
Degeneration, cystic		(2%)			-	(00)
Angiectasis		(2%)	150			(2%)
#Liver/centrilobular	(50)		(50)	$(9\mathbf{a})$	(50)	
Necrosis, NOS	(=0)			(2%)	(50)	
#Liver/periportal Lymphocytic inflammatory infiltrate	(50)	(2%)	(50)	(2%)	(50)	(2%)
Atrophy, NOS			1	(270)	1	2701
Auopity, NOO	1	(2%)				

	Untrea	ted Control	Low	Dose	High	Dose
DIGESTIVE SYSTEM (Continued)						
#Liver/hepatocytes	(50)		(50)		(50)	
Necrosis, central	(00)			(2%)	(00)	
Cytoplasmic vacuolization	3	(6%)		(10%)	2	(4%)
Focal cellular change	-	(84%)		(76%)		(72%)
Regenerative nodule		(4%)		(8%)		(4%)
#Bile duct	(50)		(50)	(0.0)	(50)	(470)
Hyperplasia, NOS		(68%)	(-)	(72%)		(76%)
#Pancreas				(1270)		(10%)
	(49)		(49)	(19)	(50)	
Cystic ducts			Z	(4%)	0	(10)
Lymphocytic inflammatory infiltrate				(0~)		(4%)
Inflammation, interstitial		(00)	1	(2%)	1	(2%)
Inflammation, chronic focal	1	(2%)				
Fibrosis, focal			1	(2%)		
Cytoplasmic vacuolization						(2%)
Atrophy, focal	22	(45%)		(37%)		(32%)
Atrophy, diffuse				(4%)		(2%)
#Glandular stomach	(49)		(50)		(50)	
Cyst, NOS		(43%)	23	(46%)	24	(48%)
Edema, NOS		(2%)				
Erosion	1	(2%)				
#Stomach wall	(49)		(50)		(50)	
Inflammation, chronic					1	(2%)
#Forestomach	(49)		(50)		(50)	
Edema, NOS	3	(6%)	2	(4%)		
Ulcer, NOS	1	(2%)				
Hyperplasia, epithelial			2	(4%)	1	(2%)
Hyperkeratosis			1	(2%)	2	(4%)
#Duodenum	(49)		(50)		(50)	(= / = /
Lymphocytic inflammatory infiltrate						(2%)
#Colon	(49)		(47)		(50)	(=,
Lymphocytic inflammatory infiltrate	1	(2%)				
JRINARY SYSTEM	(10)					
#Kidney	(49)		(50)		(50)	
Hydronephrosis				(2%)		
Congestion, NOS			1	(2%)	1	(2%)
Lymphocytic inflammatory infiltrate			1	(2%)		
Inflammation, interstitial			1	(2%)		
Scar					1	(2%)
Nephropathy	37	(76%)	36	(72%)		(54%)
#Kidney/tubule	(49)		(50)	·	(50)	
Degeneration, NOS	· · ·	(12%)		(16%)		(16%)
Hyperplasia, epithelial	0	··=··/		(2%)	0	
#Kidney/pelvis	(49)		(50)	/	(50)	
Mineralization		(2%)	(00)			
	(47)		(48)		(48)	
#Urinary bladder	(147)	(2%)	(40)		(40)	
#Urinary bladder Edema NOS	1				1	(2%)
Edema, NOS	1					
Edema, NOS Lymphocytic inflammatory infiltrate					1	(270)
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic		(2%)		(971)		
Edema, NOS Lymphocytic inflammatory infiltrate			1	(2%)		(2%)
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic			1	(2%)		
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic Hyperplasia, epithelial			(50)	(2%)		
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic Hyperplasia, epithelial CNDOCRINE SYSTEM	(49)			(2%)	1	
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic Hyperplasia, epithelial CNDOCRINE SYSTEM #Pituitary intermedia	(49)	(2%)		(2%)	1	
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic Hyperplasia, epithelial ENDOCRINE SYSTEM #Pituitary intermedia Cyst, NOS #Anterior pituitary	(49) (49) (49)	(2%)	(50)	(2%)	(50)	
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic Hyperplasia, epithelial ENDOCRINE SYSTEM #Pituitary intermedia Cyst, NOS #Anterior pituitary Cyst, NOS	(49) (49) (49)	(2%)	(50) (50) 34	(68%)	(50)	(2%)
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic Hyperplasia, epithelial 	(49) (49) (49) 28	(2%) (2%) (57%)	(50) (50) 34		(50)	(2%)
Edema, NOS Lymphocytic inflammatory infiltrate Inflammation, hemorrhagic Hyperplasia, epithelial CNDOCRINE SYSTEM #Pituitary intermedia Cyst, NOS #Anterior pituitary Cyst, NOS	(49) (49) (49) 28 1	(2%)	(50) (50) 34 1	(68%)	(50) (50) 35	(2%)

ENDOCRINE SYSTEM (Continued) #Adrenal/capsule (50) Hyperplasia, focal (50) Ectopia (50) Congestion, NOS Hemorrhage (50) Necrosis, focal (10%) Hypertrophy, focal (19) Angiectasis (50) Ectopia (6%) #Adrenal medulla (50) Ectopia (50) Ectopia (50) Whyperplasia, focal (12%) Hyperplasia, focal (50) Ultimobranchial cyst (24%) Hyperplasia, Cocal (12%) Hyperplasia, Gocal (12%) Hyperplasia, folicular cell (12%) Hyperplasia, Cocal (12%) #Thyroid (50) Ultimobranchial cyst (24%) Hyperplasia, Collicular cell (12%) #Thyroid follicle (50) Ultimobranchial cyst (49) Atrophy, NOS (10%) Inflammation, chronic focal (10%) Inflammation, chronic suppurative (10%) Fibrosis (21%) *Endometrial cavity (50) Dilatation, NOS (21%) *Uterus (50) Dilatation, NOS (21%) #Uterus (50) Dilatation, NOS (21%) #Uterus (50) Dilatation, NOS (21%) #Uterus/endometrium (50) Cyst, NOS (10%) Lymphocytic inflammatory infiltrate	(49) (49) $1 (2%)$ $1 (2%)$ $1 (2%)$ $3 (6%)$ $14 (29%)$ $24 (49%)$ $4 (8%)$ (49) $1 (2%)$ $4 (8%)$ (49) (50) $24 (48%)$	(50) 1 6 20 28 1 (50) 1 5	(2%)
#Adrenal/capsule (50) Hyperplasia, focal (50) Ectopia (50) Congestion, NOS 1 Hemorrhage 1 Necrosis, focal 1 (2%) (2%) Cytoplasmic vacuolization 5 Hypertrophy, focal 19 Hypertrophy, focal 19 Magiectasis 3 Margiectasis 3 Mecrosis, focal 6 Hyperplasia, focal 1 Hyperplasia, focal 2 #Thyroid (50) Ultimobranchial cyst 2 #Thyroid follicle (50) Ultimobranchial cyst (49) Atrophy, NOS 1 Hyperplasia, cystic 27 #Mammary gland (50) Inflammation, chronic focal 1 Inflammation, chronic suppurative 1 Hyperplasia, cystic 27 <t< th=""><th>(49) 1 (2%) 1 (2%) 1 (2%) 3 (6%) 14 (29%) 24 (49%) 4 (8%) (49) 1 (2%) 4 (8%) (50)</th><th>1 (50) 1 6 20 28 1 (50) 1 5</th><th>(2%) (2%) (12%) (40%) (56%)</th></t<>	(49) 1 (2%) 1 (2%) 1 (2%) 3 (6%) 14 (29%) 24 (49%) 4 (8%) (49) 1 (2%) 4 (8%) (50)	1 (50) 1 6 20 28 1 (50) 1 5	(2%) (2%) (12%) (40%) (56%)
#Adrenal cortex (50) Ectopia Congestion, NOS Hemorrhage 1 (2%) Necrosis, focal 1 (2%) Cytoplasmic vacuolization 5 (10%) Hypertrophy, focal 19 (38%) Hyperplasia, focal 30 (60%) Angiectasis 3 (6%) #Adrenal medulla (50) Ectopia (50) Necrosis, focal (50) Hyperplasia, focal 6 (12%) Hyperplasia, focal (50) Ultimobranchial cyst 2 (4%) Hyperplasia, C-cell 21 (42%) Hyperplasia, folicular cell 1 (2%) #Thyroid (50) Ultimobranchial cyst #Pancreatic islets #Pancreatic islets (49) Atrophy, NOS 1 (2%) Hyperplasia, cystic 27 (54%) *Mammary gland (50) Goldation, chronic focal 1 (2%) Inflammation, chronic suppurative 1 (2%) Hyperplasia, cystic 27 (54%) *Mammary duct (50) Dilatation, NOS 2 (4%) *Endome	(49) 1 (2%) 1 (2%) 1 (2%) 3 (6%) 14 (29%) 24 (49%) 4 (8%) (49) 1 (2%) 4 (8%) (50)	1 (50) 1 6 20 28 1 (50) 1 5	(2%) (2%) (12%) (40%) (56%)
#Adrenal cortex (50) Ectopia (50) Congestion, NOS 1 Hemorrhage 1 Necrosis, focal 1 (2ytoplasmic vacuolization 5 Hypertrophy, focal 19 Hypertplasia, focal 30 Angiectasis 3 Necrosis, focal (50) Ectopia (50) Necrosis, focal (50) Hyperplasia, focal (50) Ultimobranchial cyst 2 #Thyroid (50) Ultimobranchial cyst 2 #Pancreatic islets (49) Atrophy, NOS 1 Hyperplasia, cystic 27 *Pancreatic islets (49) Atrophy, NOS 1 Hyperplasia, cystic 27 *Mammary duct (50) Inflammation, chronic focal 1 Inflammation, chronic suppurative 1 Hyperplasia, cystic 27 *Mamary duct (50) Dilatation, NOS 1 *Endometrial cavity (50)	$ \begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	(50) 1 6 20 28 1 (50) 1 5	(2%) (12%) (40%) (56%)
Congestion, NOS Hemorrhage1(2%)Necrosis, focal1(2%)Cytoplasmic vacuolization5(10%)Hypertrophy, focal19(38%)Hyperplasia, focal30(60%)Angiectasis3(6%)#Adrenal medulla(50)EctopiaNecrosis, focal1(2%)Hyperplasia, focal6(12%)Hyperplasia, focal6(12%)Hyperplasia, focal(50)(44%)Hyperplasia, C-cell21(42%)Hyperplasia, follicular cell1(2%)#Thyroid follicle(50)(50)Ultimobranchial cyst(49)Atrophy, NOS1(2%)Hypertrophy, NOS1(2%)Hyperplasia, cystic27(54%)*Mammary gland(50)(10%)Inflammation, chronic focal1(2%)Inflammation, chronic suppurative1(2%)Fibrosis2(4%)**Endometrial cavity(50)0)Dilatation, NOS3(6%)#Uterus(50)1(2%)Inflammation, chronic suppurative1(2%)Inflammation, chronic suppurative1(2%)Inflammation, chronic suppurative1(2%)Inflammation, NOS3(6%)#Uterus(50)0)2Dilatation, NOS3(6%)#Uterus/endometrium(50)0)Dilatation, NOS2(4%) <tr< td=""><td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td><td>6 20 28 1 (50) 1 5</br></td><td>(12%) (40%) (56%)</td></tr<>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	6 20 28 	(12%) (40%) (56%)
Hemorrhage1(2%)Necrosis, focal1(2%)Cytoplasmic vacuolization5(10%)Hypertrophy, focal19(38%)Hypertplasia, focal30(60%)Angiectasis3(6%)#Adrenal medulla(50)Ectopia(50)Necrosis, focal6Hyperplasia, focal6Hyperplasia, focal6Hyperplasia, focal1(2%)4Hyperplasia, focal1(2%)1Hyperplasia, focal1(2%)1Hyperplasia, follicular cell1#Thyroid follicle(50)Ultimobranchial cyst(49)#Thyroid follicle(50)Ultimobranchial cyst(49)Atrophy, NOS1Hyperplasia, cystic27*Mammary gland(50)Inflammation, chronic focal1Inflammation, chronic focal1Inflammation, chronic suppurative1Hyperplasia, cystic27*Mammary duct(50)Inflammation, chronic suppurative1Fibrosis2*Clitoral gland(50)Cystic ducts1Inflammation, suppurative1Inflammation, suppurative1Inflammation, chronic suppurative1Inflammation, suppurative1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Inflammation, NOS3#Uterus	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	6 20 28 1 (50) 1 5	(12%) (40%) (56%)
Hemorrhage1(2%)Necrosis, focal1(2%)Cytoplasmic vacuolization5(10%)Hypertrophy, focal19(38%)Hyperplasia, focal30(60%)Angiectasis3(6%)#Adrenal medulla(50)Ectopia(50)Necrosis, focal6Hyperplasia, focal6Hyperplasia, focal6Hyperplasia, focal1(2%)4Hyperplasia, focal1(2%)1Hyperplasia, focal1(2%)1Hyperplasia, Gollicular cell1#Thyroid follicle(50)Ultimobranchial cyst(49)#Thyroid follicle(50)Ultimobranchial cyst(49)#Atrophy, NOS1Hyperplasia, cystic27#Mammary gland(50)Galactocele5Hyperplasia, cystic27*Mammary duct(50)Inflammation, chronic focal1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Pibrosis2*Clitoral gland(50)Cystic ducts1Inflammation, suppurative1Inflammation, suppurative1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Inflammation, NOS3#Uterus <td< td=""><td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td><td>6 20 28 1 (50) 1 5</td><td>(12%) (40%) (56%)</td></td<>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	6 20 28 1 (50) 1 5	(12%) (40%) (56%)
Necrosis, focal1(2%)Cytoplasmic vacuolization5(10%)Hypertrophy, focal19(38%)Hyperplasia, a focal30(60%)Angiectasis3(6%)Angiectasis3(6%)#Adrenal medulla(50)Ectopia6(12%)Hyperplasia, focal6(12%)Hyperplasia, focal6(12%)Hyperplasia, focal6(12%)Hyperplasia, focal1(2%)#Thyroid(50)(142%)Hyperplasia, C-cell21(42%)Hyperplasia, C-cell1(2%)#Thyroid follicle(50)(50)Ultimobranchial cyst##Pancreatic islets(49)Atrophy, NOS1(2%)EPRODUCTIVE SYSTEM5*Mammary gland(50)Galactocele5Hyperplasia, cystic27*Mammary duct(50)Inflammation, chronic focal1Inflammation, chronic suppurative1Hyperplasia, cystic2*Clitoral gland(50)Cystic ducts1Inflammation, suppurative1Inflammation, chronic suppurative1Inflam	3 (6%) 14 (29%) 24 (49%) 4 (8%) (49) 1 (2%) 4 (8%) (50)	6 20 28 1 (50) 1 5	(12%) (40%) (56%)
Cytoplasmic vacuolization5 (10%)Hypertophy, focal19 (38%)Hyperplasia, focal30 (60%)Angiectasis3 (6%)#Adrenal medulla(50)Ectopia(50)Necrosis, focal(50)Hyperplasia, focal6 (12%)Hyperplasia, diffuse2 (4%)#Thyroid(50)Ultimobranchial cyst2 (4%)Hyperplasia, follicular cell1 (2%)#Thyroid follicle(50)Ultimobranchial cyst(49)#Pancreatic islets(49)Atrophy, NOS1 (2%)Hypertophy, NOS1 (2%)EPRODUCTIVE SYSTEM(50)Galactocele5 (10%)Inflammation, chronic focal1 (2%)Inflammation, chronic diffuse1 (2%)Hyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, nons3 (6%)Hemosiderosis1 (2%)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	3 (6%) 14 (29%) 24 (49%) 4 (8%) (49) 1 (2%) 4 (8%) (50)	20 28 1 (50) 1 5	(40%) (56%)
Hypertrophy, focal19 (38%)Hyperplasia, focal30 (60%)Angiectasis3 (6%)#Adrenal medulla(50)Ectopia(50)Necrosis, focal(50)Hyperplasia, focal6 (12%)Hyperplasia, focal2 (4%)Hyperplasia, C-cell21 (42%)Hyperplasia, C-cell1 (2%)#Thyroid(50)Ultimobranchial cyst(49)#Thyroid follicle(50)Ultimobranchial cyst(49)#Thyroid follicle(50)Ultimobranchial cyst(49)#Pancreatic islets(49)Atrophy, NOS1 (2%)EPRODUCTIVE SYSTEM(50)*Mammary gland(50)Galactocele5 (10%)Inflammation, chronic focal1 (2%)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Eldometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, NOS3 (6%)Hemosiderosis1 (2%)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Dilatation, NOS1 (2%)Decidual alteration, NOS1 (2%)	14 (29%) 24 (49%) 4 (8%) (49) 1 (2%) 4 (8%) (50)	20 28 1 (50) 1 5	(40%) (56%)
Hyperplasia, focal30 (60%)Angiectasis3 (6%)#Adrenal medulla(50)Ectopia(50)Necrosis, focal(50)Hyperplasia, focal6 (12%)Hyperplasia, focal(50)Ultimobranchial cyst2 (4%)Hyperplasia, C-cell21 (42%)Hyperplasia, follicular cell1 (2%)#Thyroid follicle(50)Ultimobranchial cyst(49)#Thyroid follicle(50)Ultimobranchial cyst(49)#Pancreatic islets(49)Atrophy, NOS1 (2%)Hyperplasia, cystic27 (54%)*Mammary gland(50)Galactocele5 (10%)Inflammation, chronic focal1 (2%)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Dilatation, NOS2 (4%)#Uterus(50)Dilatation, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	24 (49%) 4 (8%) (49) 1 (2%) 4 (8%) (50)	28 1 (50) 1 5	(56%)
Angiectasis3(6%)#Adrenal medulla(50)Ectopia(50)Necrosis, focal(12%)Hyperplasia, focal6Hyperplasia, diffuse(50)"Thyroid(50)Ultimobranchial cyst2Hyperplasia, C-cell1(2%)4Hyperplasia, follicular cell1(2%)#Thyroid follicle"Thyroid follicle(50)Ultimobranchial cyst(49)Atrophy, NOS1Hypertrophy, NOS1Hypertrophy, NOS1EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5Hyperplasia, cystic27Hyperplasia, cystic27*Mammary duct(50)Inflammation, chronic focal1Inflammation, chronic suppurative1Hyperplasia, cystic2*Endometrial cavity(50)Dilatation, NOS1*Clitoral gland(50)Cystic ducts1Inflammation, chronic suppurative1Inflammation, suppurative1Inflammation, chronic suppurative1Inflammation, suppurative1Inflammation, NOS3#Uterus(50)Dilatation, NOS3Hemosiderosis1Decidual alteration, NOS2Wetrus(50)Dilatation, NOS2Uterus/endometrium(50)Cyst, NOS1(2%)Decidual altera	4 (8%) (49) 1 (2%) 4 (8%) (50)	1 (50) 1 5	
#Adrenal medulla(50)EctopiaNecrosis, focalHyperplasia, focal6 (12%)Hyperplasia, diffuse2 (4%)#Thyroid(50)Ultimobranchial cyst2 (4%)Hyperplasia, C-cell21 (42%)Hyperplasia, follicular cell1 (2%)#Thyroid follicle(50)Ultimobranchial cyst(49)Atrophy, NOS1 (2%)Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM5 (10%)Inflammation, chronic focal1 (1%)Inflammation, chronic diffuse1 (2%)Hyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative1 (2%)Inflammation, nOS2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Mation, NOS3 (6%)#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Dilatation, NOS2 (4%)	(49) 1 (2%) 4 (8%) (50)	(50) 1 5	
Ectopia Necrosis, focal Hyperplasia, focal Hyperplasia, focal Myperplasia, diffuse6 (12%) (12%)#Thyroid Ultimobranchial cyst(50) 2 (4%) Hyperplasia, follicular cell1 (2%)#Thyroid follicle Ultimobranchial cyst(50) 2 (4%)#Thyroid follicle Ultimobranchial cyst(49) Atrophy, NOS#Pancreatic islets Atrophy, NOS(49)Hypertrophy, NOS Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM *Mammary gland Inflammation, chronic focal Inflammation, chronic focal Inflammation, chronic suppurative Fibrosis2 (4%)*Mammary duct Fibrosis(50) 2 (4%)*Endometrial cavity Dilatation, NOS(50) 3 (6%)*Clitoral gland Inflammation, chronic suppurative Inflammation, chronic suppurative Inflammation, suppurative Inflammation, chronic suppurative Inflammation, chronic suppurative Inflammation, suppurative Inflammation, NOS1 (2%)*Clitoral gland Cystic ducts(50) 3 (6%) 4 (2%)#Uterus Inflammation, NOS3 (6%) 4 (2%)#Uterus Inflammation, NOS3 (6%) 4 (2%)#Uterus Inflammation, NOS3 (6%) 4 (2%)#Uterus Inflammation, NOS3 (6%) 4 (2%)#Uterus/endometrium Cyst, NOS1 (2%)	1 (2%) 4 (8%) (50)	1	
Necrosis, focalHyperplasia, focal6 (12%)Hyperplasia, diffuse(50)Ultimobranchial cyst2 (4%)Hyperplasia, C-cell21 (42%)Hyperplasia, follicular cell1 (2%)#Thyroid follicle(50)Ultimobranchial cyst(49)Atrophy, NOS1 (2%)Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM5 (10%)*Mammary gland(50)Galactocele5 (10%)Inflammation, chronic focal1 (2%)Inflammation, chronic diffuse1 (2%)Hyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)	4 (8%) (50)	5	(2%)
Hyperplasia, focal6(12%)Hyperplasia, diffuse#Thyroid(50)Ultimobranchial cyst2(4%)Hyperplasia, C-cell21(42%)Hyperplasia, follicular cell1(2%)#Thyroid follicle(50)Ultimobranchial cyst#Pancreatic islets(49)Atrophy, NOSHypertrophy, NOS1(2%)EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5(10%)Inflammation, chronic focal1(2%)Inflammation, chronic diffuse1(2%)Hyperplasia, cystic27(54%)*Mammary duct(50)1(2%)Inflammation, chronic suppurative1(2%)Fibrosis2(4%)*Endometrial cavity(50)Dilatation, NOS1(2%)1#Uterus(50)3(6%)Hemosiderosis1(2%)3Dilatation, NOS3(6%)4%)#Uterus/endometrium(50)3(6%)Hemosiderosis1(2%)3Decidual alteration, NOS2(4%)	4 (8%) (50)	-	(2/0)
Hyperplasia, diffuse(50)#Thyroid(50)Ultimobranchial cyst2 (4%)Hyperplasia, C-cell21 (42%)Hyperplasia, follicular cell1 (2%)#Thyroid follicle(50)Ultimobranchial cyst4#Pancreatic islets(49)Atrophy, NOS1 (2%)Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5 (10%)Inflammation, chronic focalInflammation, chronic focalInflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS3 (6%)#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Dilatation, NOS2 (4%)	(50)	-	(10%)
#Thyroid(50)Ultimobranchial cyst2Hyperplasia, C-cell21(42%)1Hyperplasia, follicular cell1(2%)1#Thyroid follicle(50)Ultimobranchial cyst##Pancreatic islets(49)Atrophy, NOS1Hypertrophy, NOS1Hypertrophy, NOS1Hypertrophy, NOS1EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5Inflammation, chronic focal1Inflammation, chronic diffuse1Hyperplasia, cystic27*Mammary duct(50)Inflammation, chronic suppurative1Fibrosis2*Endometrial cavity(50)Dilatation, NOS1*Clitoral gland(50)Cystic ducts1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Inflammation, NOS3*Uterus(50)Dilatation, NOS3#Uterus(50)Dilatation, NOS2#Uterus/endometrium(50)Dicidual alteration, NOS2#Uterus/endometrium(50)Cyst, NOS1(2%)			(10%) (2%)
Ultimobranchial cyst2 (4%)Hyperplasia, C-cell21 (42%)Hyperplasia, follicular cell1 (2%)#Thyroid follicle(50)Ultimobranchial cyst(49)Atrophy, NOS1 (2%)Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM(50)*Mammary gland(50)Galactocele5 (10%)Inflammation, chronic focal1 (2%)Inflammation, chronic diffuse1 (2%)Hyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Distation, NOS2 (4%)		(50)	(470)
Hyperplasia, C-cell21 (42%)Hyperplasia, follicular cell1 (2%)#Thyroid follicle(50)Ultimobranchial cyst(49)#Pancreatic islets(49)Atrophy, NOS1 (2%)Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM*Mammary glandGalactocele5 (10%)Inflammation, chronic focalInflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Dilatation, NOS2 (4%)#Uterus(50)Dilatation, NOS2 (4%)#Uterus(50)Dilatation, NOS2 (4%)#Uterus/endometrium(50)Decidual alteration, NOS2 (4%)	24 (48%)	(00)	
Hyperplasia, follicular cell1(2%)#Thyroid follicle(50)Ultimobranchial cyst#Pancreatic islets(49)Atrophy, NOS1(2%)Hypertrophy, NOS1(2%)EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5(10%)Inflammation, chronic focal1(2%)*Mammary duct(50)1(2%)Inflammation, chronic diffuse1(2%)Hyperplasia, cystic27(54%)*Mammary duct(50)1(2%)Inflammation, chronic suppurative1(2%)Fibrosis2(4%)*Endometrial cavity(50)Dilatation, NOS1(2%)1Inflammation, chronic suppurative1(2%)Inflammation, suppurative1(2%)Inflammation, chronic suppurative1(2%)Inflammation, NOS3(6%)Hemosiderosis1(2%)Dilatation, NOS2(4%)#Uterus(50)1Dilatation, NOS2(4%)#Uterus/endometrium(50)Decidual alteration, NOS2(4%)#Uterus/endometrium(50)1Cyst, NOS1(2%)	24 (4070)	99	(46%)
#Thyroid follicle (50) Ultimobranchial cyst (49) #Pancreatic islets (49) Atrophy, NOS 1 Hypertrophy, NOS 1 Hypertrophy, NOS 1 EPRODUCTIVE SYSTEM (50) Galactocele 5 Inflammation, chronic focal 1 Inflammation, chronic diffuse (50) Hyperplasia, cystic 27 *Mammary duct (50) Inflammation, chronic suppurative 1 Hyperplasia (50) Inflammation, chronic suppurative 1 Hyperblasia (50) Inflammation, chronic suppurative 1 Fibrosis 2 *Endometrial cavity (50) Dilatation, NOS 1 *Clitoral gland (50) Cystic ducts 1 (2%) Inflammation, suppurative 1 Inflammation, NOS 3 (6%) Hemosiderosis 1 (2%) Dilatation, NOS 2 (4%) #Uterus/endometrium (50) 2		23	(40%)
Ultimobranchial cyst#Pancreatic islets(49)Atrophy, NOS1 (2%)Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5 (10%)Inflammation, chronic focalInflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic1 (2%)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)#Uterus(50)Dilatation, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	(50)	(50)	
#Pancreatic islets(49)Atrophy, NOS1Hypertrophy, NOS1Hypertrophy, NOS1*Mammary gland(50)Galactocele5Inflammation, chronic focalInflammation, chronic diffuseHyperplasia, cystic27*Mammary duct(50)Inflammation, chronic diffuseHyperplasia, cystic27*Mammary duct(50)Inflammation, chronic1(2%)Fibrosis2*Endometrial cavity(50)Dilatation, NOS1*Clitoral gland(50)Cystic ducts1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Inflammation, suppurative1Inflammation, NOS3#Uterus(50)Dilatation, NOS3#Uterus(50)Decidual alteration, NOS2#Uterus/endometrium(50)Cyst, NOS1(2%)	(50) 1 (2%)	(50)	
Atrophy, NOS Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM *Mammary gland(50) GalactoceleInflammation, chronic focal Inflammation, chronic diffuse Hyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic diffuse Hyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative Fibrosis1 (2%)Filammation, chronic suppurative Dilatation, NOS1 (2%)*Clitoral gland Cystic ducts(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative Inflammation, chronic suppurative Inflammation, suppurative Inflammation, chronic suppurative Inflammation, NOS3 (6%)#Uterus Decidual alteration, NOS 2 (4%)2 (4%)#Uterus/endometrium Cyst, NOS1 (2%)	· · · · · · ·	(50)	
Hypertrophy, NOS1 (2%)EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5 (10%)Inflammation, chronic focalInflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Inflammation, suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)#Uterus(50)Dilatation, NOS2 (4%)#Uterus(50)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	(49) 1 (2%)	(50)	
EPRODUCTIVE SYSTEM*Mammary gland(50)Galactocele5Inflammation, chronic focal1Inflammation, chronic diffuse4Hyperplasia, cystic27*Mammary duct(50)Inflammation, chronic suppurative1(2%)1Fibrosis2*Endometrial cavity(50)Dilatation, NOS1*Clitoral gland(50)Cystic ducts1Inflammation, chronic suppurative1Inflammation, suppurative1Inflammation, suppurative1Inflammation, suppurative1Inflammation, NOS3*Uterus(50)Dilatation, NOS3#Uterus(50)Dilatation, NOS3#Uterus(50)Dilatation, NOS2#Uterus/endometrium(50)Cyst, NOS1(2%)	= (+,+,+,		
*Mammary gland(50)Galactocele5Inflammation, chronic focalInflammation, chronic diffuseHyperplasia, cystic27*Mammary duct(50)Inflammation, chronic1(2%)Inflammation, chronic suppurative1Fibrosis2*Endometrial cavity(50)Dilatation, NOS*Clitoral gland(50)Cystic ducts1Inflammation, chronic suppurative1Inflammation, suppurative1Inflammation, chronic suppurative1Inflammation, suppurative1Inflammation, Suppurative1Inflammation, NOS3#Uterus(50)Dilatation, NOS3#Uterus(50)Decidual alteration, NOS2#Uterus/endometrium(50)Cyst, NOS1(2%)2	3 (6%)		
Inflammation, chronic focal Inflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic1 (2%)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS1 (2%)Inflammation, suppurative1 (2%)Inflammation, suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	(50)	(50)	
Inflammation, chronic diffuseHyperplasia, cystic27 (54%)*Mammary duct(50)Inflammation, chronic1 (2%)Inflammation, chronic suppurative1 (2%)Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS1 (2%)Inflammation, suppurative1 (2%)Inflammation, suppurative1 (2%)Inflammation, suppurative1 (2%)Inflammation, suppurative1 (2%)Inflammation, chronic suppurative1 (2%)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	5 (10%)	2	(4%)
Hyperplasia, cystic27(54%)*Mammary duct(50)Inflammation, chronic1(2%)Inflammation, chronic suppurative1(2%)Fibrosis2(4%)*Endometrial cavity(50)Dilatation, NOS**Clitoral gland(50)Cystic ducts1(2%)Inflammation, suppurative1(2%)Inflammation, chronic suppurative1(2%)Muterus(50)50)Dilatation, NOS3(6%)Hemosiderosis1(2%)Decidual alteration, NOS2(4%)#Uterus/endometrium(50)2Cyst, NOS1(2%)		4	(8%)
*Mammary duct (50) Inflammation, chronic 1 (2%) Inflammation, chronic suppurative 1 (2%) Fibrosis 2 (4%) *Endometrial cavity (50) 0 Dilatation, NOS * * *Clitoral gland (50) (50) Cystic ducts 1 (2%) Inflammation, suppurative 1 (2%) Atrophy, diffuse * * #Uterus (50) 3 (6%) Hemosiderosis 1 (2%) 2 (4%) #Uterus/endometrium (50) 2 (4%) #Uterus/endometrium (50) 2 (4%)		1	(2%)
*Mammary duct(50)Inflammation, chronic1Inflammation, chronic suppurative1Fibrosis2Fibrosis2*Endometrial cavity(50)Dilatation, NOS**Clitoral gland(50)Cystic ducts1Inflammation, suppurative1Inflammation, chronic suppurative1Inflammation, chronic suppurative1Matters(50)Dilatation, NOS3#Uterus(50)Dilatation, NOS3Hemosiderosis1Decidual alteration, NOS2#Uterus/endometrium(50)Cyst, NOS1(2%)	32 (64%)	21	(42%)
Inflammation, chronic1(2%)Inflammation, chronic suppurative1(2%)Fibrosis2(4%)*Endometrial cavity(50)Dilatation, NOS1(2%)*Clitoral gland(50)Cystic ducts1(2%)Inflammation, suppurative1(2%)Inflammation, chronic suppurative1(2%)Dilatation, NOS3(6%)#Uterus(50)1Dilatation, NOS3(6%)Hemosiderosis1(2%)Decidual alteration, NOS2(4%)#Uterus/endometrium(50)2Cyst, NOS1(2%)	(50)	(50)	
Inflammation, chronic suppurative1(2%)Fibrosis2(4%)*Endometrial cavity(50)Dilatation, NOS(50)*Clitoral gland(50)Cystic ducts1(2%)Inflammation, suppurative1(2%)Inflammation, chronic suppurative1(2%)Atrophy, diffuse50)1(2%)Dilatation, NOS3(6%)1Hemosiderosis1(2%)2Decidual alteration, NOS2(4%)#Uterus/endometrium(50)2Cyst, NOS1(2%)	1 (2%)	,	
Fibrosis2 (4%)*Endometrial cavity(50)Dilatation, NOS*Clitoral gland*Clitoral gland(50)Cystic ducts1 (2%)Inflammation, suppurative1 (2%)Atrophy, diffuse*Uterus#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)			
*Endometrial cavity (50) Dilatation, NOS (50) *Clitoral gland (50) Cystic ducts 1 (2%) Inflammation, suppurative 1 (2%) Inflammation, chronic suppurative 1 (2%) Atrophy, diffuse (50) 0 #Uterus (50) 3 (6%) Hemosiderosis 1 (2%) 2 Decidual alteration, NOS 2 (4%) #Uterus/endometrium (50) 2 (4%)			
Dilatation, NOS(50)*Clitoral gland(50)Cystic ducts1 (2%)Inflammation, suppurative1 (2%)Atrophy, diffuse(50)#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	(50)	(50)	
*Clitoral gland (50) Cystic ducts 1 (2%) Inflammation, suppurative 1 (2%) Atrophy, diffuse 1 (2%) #Uterus (50) Dilatation, NOS 3 (6%) Hemosiderosis 1 (2%) Decidual alteration, NOS 2 (4%) #Uterus/endometrium (50) Cyst, NOS 1 (2%)	(00)		(2%)
Cystic ducts1(2%)Inflammation, suppurative1(2%)Inflammation, chronic suppurative1(2%)Atrophy, diffuse(50)1#Uterus(50)1Dilatation, NOS3(6%)Hemosiderosis1(2%)Decidual alteration, NOS2(4%)#Uterus/endometrium(50)1Cyst, NOS1(2%)	(50)	(50)	·~ ·~)
Inflammation, suppurative1(2%)Inflammation, chronic suppurative1(2%)Atrophy, diffuse(50)#Uterus(50)Dilatation, NOS3(6%)Hemosiderosis1(2%)Decidual alteration, NOS2(4%)#Uterus/endometrium(50)Cyst, NOS1(2%)	1 (2%)	(00)	
Inflammation, chronic suppurative1(2%)Atrophy, diffuse(50)#Uterus(50)Dilatation, NOS3(6%)Hemosiderosis1(2%)Decidual alteration, NOS2(4%)#Uterus/endometrium(50)Cyst, NOS1(2%)		1	(2%)
Atrophy, diffuse(50)#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)		1	(= 10)
#Uterus(50)Dilatation, NOS3 (6%)Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)		1	(2%)
Dilatation, NOS3(6%)Hemosiderosis1(2%)Decidual alteration, NOS2(4%)#Uterus/endometrium(50)Cyst, NOS1(2%)	- (=/0)	(50)	(270)
Hemosiderosis1 (2%)Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)			(10%)
Decidual alteration, NOS2 (4%)#Uterus/endometrium(50)Cyst, NOS1 (2%)	(49)	0	(1070)
#Uterus/endometrium (50) Cyst, NOS 1 (2%)			
Cyst, NOS 1 (2%)	(49)	(50)	
	(49) 4 (8%)	(50)	(90)
Lymphocytic initammatory inflitrate	(49) 4 (8%) (49)		(2%)
	(49) 4 (8%)	1	(2%)
Inflammation, acute diffuse 1 (2%)	(49) 4 (8%) (49)		
Inflammation, chronic 1 (2%)	(49) 4 (8%) (49)		
Inflammation, chronic suppurative 1 (2%)	(49) 4 (8%) (49)		(10~)
Hyperplasia, cystic 1 (2%)	(49) 4 (8%) (49) 1 (2%)		(12%)
#Endometrial gland (50)	(49) 4 (8%) (49) 1 (2%) 3 (6%)		(0.00)
Dilatation, NOS 1 (2%)	(49) 4 (8%) (49) 1 (2%) 3 (6%) (49)	(50)	
#Fallopian tube (50) Cyst, NOS	(49) 4 (8%) (49) 1 (2%) 3 (6%)	(50)	(8%)

	Untreat	ted Control	Low	Dose	High	Dose
REPRODUCTIVE SYSTEM (Continued)		·····				<u> </u>
#Ovary	(49)		(49)		(50)	
Cyst, NOS		(4%)		(10%)		(6%)
Follicular cyst, NOS		(4%)		(12%)		(12%)
Parovarian cyst		(4%)		(2%)		(4%)
Lymphocytic inflammatory infiltrate		(=);	-	(= /*/		(2%)
Necrosis, focal						(2%)
Atrophy, diffuse	1	(2%)				(2%)
NERVOUS SYSTEM	<u> </u>	<u>, , , , , , , , , , , , , , , , , , , </u>				
#Brain/meninges	(50)		(49)		(50)	
Hemorrhage	,			(4%)		
Metaplasia, osseous	1	(2%)	-			
#Lateral ventricle	(50)		(49)		(50)	
Dilatation, NOS				(2%)		(4%)
Hemorrhage			-			(2%)
#Third ventricle	(50)		(49)		(50)	
Dilatation, NOS	(00)		(40)			(4%)
Hemorrhage			1	(2%)	2	(= 10)
#Fourth ventricle	(50)		(49)	(2,0)	(50)	
Dilatation, NOS	(00)			(2%)	(00)	
#Brain	(50)		(49)	(270)	(50)	
Spongiosis	,	(2%)		(8%)		(6%)
Hemorrhage		(2%)		(2%)		(2%)
Inflammation, granulomatous		(2%)	·+	(20)	1	(470)
Gliosis		(2%)			1	(2%)
Degeneration, myelin	1	(2,10)				(2%) (2%)
Atrophy, pressure	1	(2%)				(2%) (4%)
#Brain stem	(50)		(49)		(50)	(= 10)
Atrophy, pressure		(12%)		(12%)		(6%)
#Medulla oblongata	(50)	(1470)	(49)	(1270)	(50)	(0,0)
Inflammation, focal		(2%)	(43)		(00)	
SPECIAL SENSE ORGANS				<u> </u>		
*Eye	(50)		(50)		(50)	
Inflammation, chronic diffuse			4	(8%)	1	(2%)
*Eye/iris	(50)		(50)		(50)	
Inflammation, acute				(2%)		
Synechia, anterior				(2%)		
Synechia, posterior				(10%)		(2%)
*Eye/crystalline lens	(50)		(50)		(50)	_
Mineralization		(2%)		(8%)		(2%)
Cataract		(2%)		(38%)		(8%)
*Harderian gland	(50)		(50)		(50)	
Inflammation, chronic focal			1	(2%)		
Atrophy, NOS	1	(2%)				
IUSCULOSKELETAL SYSTEM						
*Femur	(50)		(50)		(50)	
Dyschondroplasia	1	(2%)				
*Skeletal muscle	(50)		(50)		(50)	
Inflammation, chronic		(2%)				(2%)

	Untreated Control	Low Dose	High Dose
BODY CAVITIES			
*Mesentery	(50)	(50)	(50)
Lymphocytic inflammatory infiltrate	1 (2%)	1 (2%)	
Necrosis, fat	6 (12%)	3 (6%)	8 (16%)
ALL OTHER SYSTEMS		<u></u>	
*Multiple organs	(50)	(50)	(50)
Degeneration, NOS			1 (2%)
Hyperplasia, cystic		1 (2%)	

None

* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically. # Number of animals examined microscopically at this site

APPENDIX C

SUMMARY OF LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

		PAGE
TABLE C1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	106
TABLE C2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	108
TABLE C3	ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	114
TABLE C4	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	118

105

TABLE C1.	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR
	FEED STUDY OF ERYTHROMYCIN STEARATE

U	ntreat	ed Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY					50	
ANIMALS NECROPSIED	50		50		50	
ANIMALS EXAMINED HISTOPATHOLOGICALLY			50		50	
INTEGUMENTARY SYSTEM			····			
*Skin	(50)		(50)		(50)	
Squamous cell carcinoma	1	(2%)				
*Subcutaneous tissue	(50)		(50)		(50)	
Sarcoma, NOS		(2%)				
Fibroma		(6%)		(6%)		(12%)
Fibrosarcoma	12	(24%)		(14%)	5	(10%)
Lipoma		(90)	1	(2%)		
Neurofibrosarcoma Neurilemoma	1	(2%)	1	(2%)	1	(2%)
RESPIRATORY SYSTEM				<u>.</u>		
#Lung	(50)		(50)		(50)	
Hepatocellular carcinoma, metastatic	(007		(00)			(2%)
Alveolar/bronchiolar adenoma	4	(8%)	2	(4%)		(2%)
Alveolar/bronchiolar carcinoma		(4%)		(6%)	-	
HEMATOPOIETIC SYSTEM	*****				· · · · · · · · · · · · · · · · · · ·	<u>.</u>
*Multiple organs	(50)		(50)		(50)	
Malignant lymphoma, undifferentiated type		(2%)	(007		(00)	
Malignant lymphoma, histiocytic type	1					
Malignant lymphoma, mixed type	-	(8%)	1	(2%)	3	(6%)
#Spleen	(50)		(49)	()	(50)	(0,0)
Malignant lymphoma, undifferentiated type			1	(2%)		
Malignant lymphoma, mixed type	2	(4%)	1	(2%)	1	(2%)
#Lung	(50)		(50)		(50)	
Malignant lymphoma, histiocytic type	1	(2%)				
CIRCULATORY SYSTEM						<u></u>
*Subcutaneous tissue	(50)		(50)		(50)	
Hemangiosarcoma		(2%)				
#Spleen	(50)		(49)		(50)	
Hemangiosarcoma						(2%)
#Myocardium	(50)	(90)	(50)		(50)	
Hemangiosarcoma #Liver	(50)	(2%)	(50)		(50)	
#Liver Hemangioma		(2%)		(2%)	(50)	
Hemangiosarcoma		(2 %) (4 %)		(2%)	2	(4%)
DIGESTIVE SYSTEM						
#Salivary gland	(50)		(50)		(50)	
Fibrosarcoma, metastatic	(00)			(2%)	(50)	
#Liver	(50)		(50)	(=,0)	(50)	
Hepatocellular adenoma		(16%)		(12%)		(14%)
Hepatocellular carcinoma		(16%)		(6%)		(10%)
Lipoma			-			(2%)
#Duodenum	(48)		(45)		(48)	
Carcinoma, NOS					1	(2%)
URINARY SYSTEM None						

	Untreated Control	Low Dose	High Dose
ENDOCRINE SYSTEM	<u>a //// //// //// //// //// _ //// _ //// / //////</u>	<u></u>	
#Pituitary intermedia	(50)	(50)	(50)
Adenoma, NOS		1 (2%)	
#Adrenal	(49)	(48)	(48)
Cortical adenoma	(49)	(2%)	(48)
#Adrenal/capsule Adenoma, NOS	(49)	(40)	(48)
#Adrenal medulla	(49)	(48)	(48)
Pheochromocytoma	3 (6%)	1 (2%)	2 (4%)
Pheochromocytoma, malignant	1 (2%)		
#Thyroid	(49)	(49)	(50)
Follicular cell adenoma		1 (2%)	
REPRODUCTIVE SYSTEM None			
NERVOUS SYSTEM None	·····		
			·
SPECIAL SENSE ORGANS	(50)	(50)	(50)
*Harderian gland Carcinoma, NOS	(50)	(50) 1 (2%)	(50) 1 (2%)
Adenoma, NOS	2 (4%)	1 (2%)	1 (2,0)
MUSCULOSKELETAL SYSTEM None			<u> </u>
BODY CAVITIES	······································		
*Pleura Alveolar/bronchiolar carcinoma, metastatic	(50)	(50) 1 (2%)	(50)
Alveolar/bronchiolar carcinoma, metastatic		1 (2%)	
ALL OTHER SYSTEMS Diaphragm			
Alveolar/bronchiolar carcinoma, metastatic		1	
ANIMAL DISPOSITION SUMMARY			
Animals initially in study	50	50	$50 \\ 2$
Natural death Moribund sacrifice	5 11	8 10	2 8
Terminal sacrifice	34	32	40
TUMOR SUMMARY			
Total animals with primary tumors**	37	26	29
	60 16	38 15	41 19
Total primary tumors			
Total animals with benign tumors Total benign tumors	21	19	22
Total animals with benign tumors Total benign tumors Total animals with malignant tumors	21 30	15	17
Total animals with benign tumors Total benign tumors	21	19 15 19 2	

TABLE C1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

* Number of animals receiving complete necropsy examinations; all gross lesions including masses examined microscopically.
** Primary tumors: all tumors except secondary tumors
Number of animals examined microscopically at this site
Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ
† Multiple occurrence of morphology in the same organ; tissue is counted once only.

STUDY OF ERY						STI	un	KA		:: U		IR.	EA					RU							
ANIMAL NUMBER	1 5 0	1 0 6	1 0 2	1 1 1	1 1 9	$\begin{array}{c} 1\\ 2\\ 1\end{array}$	1 0 1	1 0 3	$\frac{1}{2}$	1 4 6	$\frac{1}{2}$ 9	1 4 4	1 0 4	$\frac{1}{2}$ 6	$\frac{1}{3}$ 2	$\begin{array}{c}1\\4\\2\end{array}$	$ \begin{array}{c} 1 \\ 0 \\ 5 \end{array} $	1 0 7	1 0 8	1 0 9	1 1 0	$\frac{1}{3}$	1 1 4	1 1 5	1 1 6
WEEKS ON STUDY	0 4 3	0 5 4	0 7! 3	0 8 1	0 8 1	0 8 4	0 8 8	0 9 3	0 9 5	0 9 7	0 9 9	1 0 0	1 0 1	1 0 1	1 0 3	1 0 3	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Squamous cell carcinoma Subottaneous tissue Sarcoma, NOS Fibroma Fibrosarcoma Hemanguosarcoma Neurofibrosarcoma	+	+	+	+ X	+ X	+ x	+	+ X	÷ X	+	+ X	+ X	+	+ X	+	+	+	+ X	+	+	+	+	+	+	+
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma	+	+	+	+	+	+	+	+	+	+ x	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar carcinoma Malignant lymphoma, histiocytic type Trachea	+	+	+	+	_	+	+	+	X X +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
HEMATOPOIETIC SYSTEM Bone marrow Spieen	+++	+++	+++	+++	++++	+++	+++	+ +	+ +	++++	++	+ +	+ +	+ +	+++	+ +	+ +	+ +	+ +	+ +	+ +	+++	+++	+++	+++
Malignant lymphoma, mixed type Lymph nodes Thymus	+ -	+ +	+ +	+ +	+	+ +	+ +	+ +	+ -	+++	+ +	+ -	+ -	+ -	+	+	+ +	+ +	+ +	+ +	+ +	+ +	+ -	+++++	+ -
CIRCULATORY SYSTEM Heart Hemangiosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Salivary gland Liver Hepatocellular adenoma Hepatocellular carcinoma Hemangioma	+++	+ +	+ + X	+ + X	+ +	+ +	+ + X X	+ +	+ + X	+ +	+ + X	+ +	+ + X X	++++	+ + X	+ +	+ +	+ +	+ + X	+ +	+++	+ + X	+ +	+ + X	+++
Hemangiosarcoma Bile duct Gallbladder & common bile duct Pancreas Esophagus Stomach Small intestine	+ N + + + +	+++++	X + + + + + +	+ + + + + +	++	+++++	++++	+ + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+ + + + + + -	+++++	++++++	+ + + + + + +	+ + + + + +	+ + + + + + -	+ + + + + + + + + + + + + + + + + + + +	++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+ + + + + +	+++++	++++++	+ + + + + + + + + + + + + + + + + + + +
Large intestine URINARY SYSTEM Kidney Urinary bladder	+	+	++++	+	+ + +	+ + +	- + +	+	+	+	+ + +	+	+	+	+	+	+	+ + + +	+++++	+ + +	+ + +	+ + +	+ + +	+ + + +	+ + +
ENDOCRINE SYSTEM Pituitary Adrenal Pheochromocytoma	+++	+++	+++	+++	+ +	++	+ +	+++	+	++++	+ +	+++	+ + X	+++	+++	+++	++	+++	++++	+++	+ + X	++++	++++	+++	+
Pheochromocytoma, malignant Thyroid Parathyroid	++++	+ -	+ +	+ +	-	+ +	+ +	+ -	+ +	+ +	+ -	+ +	+ +	+ +	+++	+ -	+ +	+ +	X + +	+ +	+	+ -	+ -	+ -	+ -
REPRODUCTIVE SYSTEM Mammary gland Testis Prostate	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + + +	N + +	N + +	N + +
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Harderian gland Adenoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, undifferentiated type Malignant lymphoma, histiocytic type Malignant lymphoma, mixed type	N	N	N	N	N	N	N	N	N X	N X	N	N	N	N	N	N X	N	N	N	N	N	N	N X	N	N

TABLE C2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR FEEDSTUDY OF ERYTHROMYCIN STEARATE: UNTREATED CONTROL

+: Tissue examined microscopically
 -: Required tissue not examined microscopically
 X: Tumor incidence
 N: Necropsy, no autolysis, no microscopic examination
 S: Animal missexed

: No tissue information submitted C: Necropsy, no histology due to protocol A: Autolysis M: Animal missing B: No necropsy performed

ANIMAL NUMBER	1 1 7	1 1 8	$\begin{array}{c}1\\2\\0\end{array}$	$\frac{1}{2}$	1 2 3	$\begin{array}{c}1\\2\\4\end{array}$	$\frac{1}{2}{5}$	$\frac{1}{2}$	$\frac{1}{2}$	1 3 0	1 3 1	1 3 3	1 3 4	1 3 5	1 3 6	1 3 7	1 3 8	1 3 9	1 4 0	1 4 1	1 4 3	1 4 5	1 4 7	1 4 8	1 4 9	TOTAL:
WEEKS ON STUDY	1 0 4	1 0 4	$1\\0\\4$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	$\begin{array}{c}1\\0\\4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TISSUES TUMORS
INTEGUMENTARY SYSTEM				-									-													
Skin Squamous cell carcinoma Subcutaneous tissue Sarcoma, NOS Fibroma Fibrosarcoma	+ + X	+ + X	+ + X	+ +	+ +	+ +	+ + X	+	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ X +	+ +	+ + X X	+ +	+ +	*50 1 *50 1 3 12
Hemangiosarcoma Neurofibrosarcoma									x																	1
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma	+	+ X	+	÷	+	+	+	+	+	+	+	+	+	* x	+	+	+	+	+	*	+	, x	+	+	+	50 4 2
Malignant lymphoma, histiocytic type Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 49
HEMATOPOIETIC SYSTEM Bone marrow Spleen	+++++	+++	++++	++++	+++	+++	+++	++++	+ +	+++	++++	++++	+++	+++	+++	+ +	+++	+ + +	+++	+ + X	++++	+++++++++++++++++++++++++++++++++++++++	++++	++++	+++++	50 50
Malignant lymphoma, mixed type Lymph nodes Thymus	+++++++++++++++++++++++++++++++++++++++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	+ +	+ +	+ -	+ +	X + +	+ +	+ +	+ +	+ +	X + +	+ +	+ +	+ +	- +	+ +	2 48 39
CIRCULATORY SYSTEM Heart Hemangiosarcoma	+	+	+	* x	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
DIGESTIVE SYSTEM Salivary gland Liver Hepatocellular adenoma Hepatocellular carcinoma	++++	+ +	+ + X	+ +	+++	+ +	+ + X	++	+ +	+ +	+++	+++	+ +	+ +	+ +	+ +	+ + X	+++	+ + X	+ + X	+++	++++	+ +	+ +	++++	50 50 8 8
Hemangiosa Hemangiosarcoma Bile duct Gallbladder & common bile duct	+++++	+ +	+ +	X + +	+ +	+++	+ +	+++	+++	+++	+++	+ +	++	++++	+ +	+++	++++	+ +	+++	+++	+ N	+ +	++++	+++	+++++	1 2 50 *50
Pancreas Esophagus Stomach Small intestine	+ + + + +	+ + + +	+ + +	+ + +	+ + + +	++++	+ + + +	+ + +	+ + +	++++	+ + + +	+ + + +	+ + + +	+++++	+ - + +	++++	++++	++++	++++++	+ + + +	+++++	+ + + +	+++++	+++++	+ + + +	49 48 49 48
Large intestine	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
URINARY SYSTEM Kidney Urinary bladder	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	50 50
ENDOCRINE SYSTEM Pituitary Adrenal Pheochromocytoma	++++	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	50 49 3
Pheochromocytoma, malignant Thyroid Parathyroid	+++	+ -	+	+ +	+ +	+ -	+ +	+ +	+ -	+ -	+ +	+ +	+	+ -	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	49 32
REPRODUCTIVE SYSTEM Mammary gland Testis Prostate	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	*50 50 50
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
SPECIAL SENSE ORGANS Harderian gland Adenoma, NOS	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 2
ALL OTHER SYSTEMS Multiple organs, NOS Mal. lymphoma, undifferentiated type Malignant lymphoma, histiocytic type Malignant lymphoma, mixed type	N	N	N	N	N	N	N	N	N	N	N X	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	*50 1 1 4

TABLE C2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE: UNTREATED CONTROL (Continued)

* Animals necropsied

TABLE C2.	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR FEED)
	STUDY OF ERYTHROMYCIN STEARATE: LOW DOSE	

ANIMÄL NUMBER	0 2 0	0 4 3	0 0 9	0 () 6)	0 0 3	0 1 0	0 1 3	0 1 4	0 1 5	0 3 2	0 3 5	0 4 1	0 2 4	0 1 2	0 0 7	${0 \\ 2 \\ 2 \\ 2 }$	0 1 8	0 0 1	$\begin{array}{c} 0 \\ 0 \\ 2 \end{array}$	0 0 4	0 0 5	0 0 8	0 1 1	0 1 6	0 1 7
WEEKS ON STUDY	0 2 7	0 4 7	0 4 9	0 7 1	0 7 3	0 7 9	0 8 4	0 8 4	0 8 4	0 8 5	0 8 5	0 9 0	0 9 4	0 9 6	0 9 9	0 9 9	1 0 0	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibroma Fibroma Lipoma Neurilemoma	+	+	+	+ X	+	+	+	+	+	+ 2X	+ X	+	+ X	+ X	+ X	+ X	+	+	+	+	+	+	+	*	+
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Trachea	+	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X +	+	+	+	+	++	++
HEMATOPOIETIC SYSTEM Bone marrow Spleen Malignant lymphoma, undifferentiated type Malignant lymphoma, mixed type Lymph nodes	++++	++++++	++++++	+ + X +	++++++	++++++	+ -	+++++++	+++++	+++	++++++	++++++	+ + +	+ + +	+++++	+++++++++++++++++++++++++++++++++++++++	+ + +	++++++	+ + +	+++++++++++++++++++++++++++++++++++++++	++++++	+ + +	++++++	++++++	+++++
Thymus CIRCULATORY SYSTEM	+	-	+	+	+	+	-	+	-	-	+	-	_	+	-	-		+	+	+	+	+	+	+	+
Heart DIGESTIVE SYSTEM	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivary gland Fibrosarcoma, metastatic Liver Hepatocellular adenoma Hepatocellular carcinoma	+	+	+	+	+	+	+	+	+	* +	+	+ + X	+	+	+	+ + X	+	+	+	+ X	+	+	+ * X	+	+
Hemangioma Hemangiosarcoma Bile duct Gallbladder & common bile duct Pancreas Esophagus Stomach Stomach Small intestine Large intestine	+ + + + + + 1	+ N + + + - +	+ + + + +	+ + + + + + + +	+ X + + + + +	+ Z + + + +	++-++	++++++	+ + + + + +	++++++++	+ + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + +	X + + + + + + + -	+ + + + + +	++++++	++++++	++++++	++++++	++++++	++++++	+ + + + + +
URINARY SYSTEM Kidney Urinary bladder	++++	+++	+++	+++	+ +	+ +	+++	++	+++	++++	+++	+++	+++	+++	+++	+++	++++++	+ +	+++	++++	+++	++++	+ +	+++	++++
ENDOCRINE SYSTEM Pituitary Adenoma, NOS Adrenal Cortical adenoma Pheochromocytoma Thyroid Follicular cell adenoma Parathyroid	++++	++++++	+++++	++++++	+ - + +	++++	++++++	+ + + +	+++++	++++++	++++++	+++++	+++++	++++	+++++++	++	+++++++	+ + + +	+++++	+ - + -	+++++	+ + + + +	++++++	+++++	+ + +
REPRODUCTIVE SYSTEM Mammary gland Testis Prostate	N + +	N -+	N + +	N + +	N + +	N + +	N	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Harderian gland Carcinoma, NOS Adenoma, NOS	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
BODY CAVITIES Pleura Alveolar/bronchiolar carcinoma, metastatic	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, mixed type Diaphragm, NOS Alveolar/bronchiolar carcinoma, metastatic	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N

@: Multiple occurrence of morphology

ANIMAL NUMBER	0 1 9	0 2 1	0 2 3	0 2 5	0 2 6	0 2 7	0 2 8	0 2 9	0 3 0	0 3 1	0 3 3	0 3 4	0 3 6	0 3 7	0 3 8	0 3 9	0 4 0	0 4 2	0 4 4	0 4 5	0 4 6	0 4 7	0 4 8	0 4 9	0 5 0	TOTAL:
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TISSUES
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibroma Fibrosarcoma Lipoma Neurilemoma	+	+	+	+ x	+	+	+	+	+	+	* x	*	+	+	+	+	+ x	+	+	+	+	+	+	+	+	*50 3 7 1 1
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Trachea	+	+	+	+	* x +	+ X +	+	+	++	+	+ x +	+	+	+	+	+	+	+	+	+	+	++	+	+	+ X +	50 2 3 50
HEMATOPOIETIC SYSTEM Bone marrow Spleen Mai. lymphoma, undifferentiated type Maiignant lymphoma, mixed type Lymph nodes	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + +	+ + X +	++++++	+ + +	+ + +	+++++	+ + +	+ + +	+++++++++++++++++++++++++++++++++++++++	+++++	++++	+++++	+++++	+++++	++++	++++	+++++	+++++	++++	++	+++++	50 49 1 1 48
Thymus CIRCULATORY SYSTEM Heart		+	+		+	-+		+	+	+ +	+ +	+	+ +	+ +	++	+	+	+	+	+	+	+	+	+ +	+	36 50
DIGESTIVE SYSTEM Salivary gland Fibrosarcoma, metastatic Liver Hepatocellular adenoma Hepatocellular carcinoma Hemangiosarcoma Hemangiosarcoma	+ + X X	+ * X	+ +	++	+ +	+ +	+ +	+ +	+++	+ +	++	++	++	+ +	+ +	++	+ +	+ +	+ + X	+ +	+ + X	+ +	++	+ +	+ + X	50 1 50 6 3 1 1
Bile duct Gallbladder & common bile duct Fancreas Esophagus Stomach Small intestine Large intestine	· + + + + + + +	+ + + + + +	++++++	+ + + + + + +	+ + + + + + +	+++++++	+++++++	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + + + +	+++++++	+ + + + + + +	+++++++	+++++++++++++++++++++++++++++++++++++++	++++++	+ + + + + +	+ + + + + + +	+ Z + + + + + +	++++++	+ + + + + + + +	++++++	+++++++++++++++++++++++++++++++++++++++	++++++	++++++	50 *50 49 50 50 45 47
URINARY SYSTEM Kidney Urinary bladder	+++	+ +	+ +	+ +	+ +	+ +	+ +	+++	++	+++	+ +	+ +	+ +	+ +	+ +	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	50 50
ENDOCRINE SYSTEM Pituitary Adenoma, NOS Adrenal Cortical adenoma Pheochromocytoma Thyroid Follicular cell adenoma Parathyroid	+++++++	+ + X + +	+ + +	+ + + +	++++	+++	+++++	++++++	+++++	+++++	+ + +	+ + +	+++++	+ + +	+ + +	++++++	+ + *	+ + +	+++	+ + +	+++	+++	+++	+ + + +	+ + X +	50 1 48 1 1 49 1 35
REPRODUCTIVE SYSTEM Mammary gland Testis Prostate	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	Z + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	*50 48 49
NERVOUS SYSTEM Brain	+	+	+	· +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
SPECIAL SENSE ORGANS Harderian gland Carcinoma, NOS Adenoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	*50 1 1
BODY CAVITIES Pleura Alveolar/bronchiolar carcinoma, meta	N	N	N	I N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	*50 1
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, mixed type Diaphragm, NOS Alveolar/bronchiolar carcinoma, meta	N	N	N	IN	I N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	*50 1 1

TABLE C2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE: LOW DOSE (Continued)

* Animals necropsied

ANIMAL NUMBER	0 6 9	0 7 8	0 7 1	0 6 0	0 9 9	0 9 1	0 5 2	0 6 8	0 9 2	0 7 5	0 5 1	0 5 3	0 5 4	0 5 5	0 5 6	0 5 7	0 5 8	0 5 9	0 6 1	0 6 2	0 6 3	0 6 4	0 6 5	0 6 6	0 6 7
WEEKS ON STUDY	0 0 4	0 7 1	0 7 3	0 7 5	0 8 0	0 8 2	0 8 3	0 8 5	0 8 8	0 9 6	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibroma Fibrosarcoma Neurilemoma	+	+	+ X	+	+	+ X	*	+	+ X	N X	+	* X	+	+	+	+	+	+	+	+ X	+	+	+	+	+
RESPIRATORY SYSTEM Lungs and bronchi Hepatocellular carcinoma, metastatic Alveolar/bronchiolar adenoma Trachea	+	+	+ X +	+ +	+	+	+	* * +	+	++	+	++	++	++	++	+	+	++	+	++	++	+ X +	++	+	+ X +
HEMATOPOIETIC SYSTEM Bone marrow Spleen Hemangiosarcoma Molioraturablema minod hum	+++	+ +	+ +	+ +	+ +	++++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+++	+++	+++	+ +	+ +	+ +	+	+ +	+++	+++	++	+ +
Malignant lymphoma, mixed type Lymph nodes Thymus	-	+ +	+ +	_	+ -	-	+ +	+ +	+ +	+ +	+ +	+ +	 +	+ +	+ +	+ +	+ -	+ +	+ +	+ +	+ +	+ -	+ +	+ +	+ +
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Salivary giand Liver Hepatocellular adenoma Hepatocellular carcinoma Lipoma	++++	+ +	+++	++++	+ + X X	+ +	+ + X	+ + X	+++	+ +	+++	+ + x	++++	++++	+ +	+ +	+++	+ +	+ + X	+ + X	++++	+ +	+ + x	+ + X	+ +
Hemangiosarcoma Bile duct Gailbladder & common bile duct Pancreas Esophagus Stomach Small intestine Carcinoma, NOS Large intestine	+ Z + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++ +	+++++++++++++++++++++++++++++++++++++++	+ Z + + +	+++++++++++++++++++++++++++++++++++++++	+++++ +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+ + + + + +	+ + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++ ++++++++++++++++++++++++++++++++++++	+ N + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++
URINARY SYSTEM Kidney Urinary bladder	++++	++++	+ +	+ +	+ +	+++	++++	+++	+++	++++	++++	++++	++++	+ +	+ +	+ +	+ +	+ + +	++++	+ +	+ +	++++	++++	++++	++++
ENDOCRINE SYSTEM Pituitary Adrenal Adenoma, NOS Pheochromocytoma Thyroid	+ - + +	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++++++++++++++++++++++++++++++++++	+ - +	+++++++++++++++++++++++++++++++++++++++	+++++	++++++	+ + +	+++++	+++++	+++++	++++++	+++++++++++++++++++++++++++++++++++++++	++++++	+++++++++++++++++++++++++++++++++++++++	++++++	+ + +	+ + +	+++++	+++++++++++++++++++++++++++++++++++++++	+++++	+++++	+++++	++++++
Parathyroid REPRODUCTIVE SYSTEM Mammary gland Testis Prostate	- N + +	- N + +	+ N + +	+ N + +	- N + +	+ N + +	- N + +	- N + +	+ N + +	- N + +	+ N + +	+ N + +	+ N + +	+ N + +	+ N + +	- N + +	+ N + +	- N + +	- N + +	- N + +	+ N + +	+ N + +	- N + +	+ N + +	- N + +
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Harderian gland Carcinoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, mixed type	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N

TABLE C2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR FEEDSTUDY OF ERYTHROMYCIN STEARATE: HIGH DOSE

ANIMAL NUMBER	0 7 0	0 7 2	0 7 3	0 7 4	0 7 6	0 7 7	0 7 9	0 8 0	0 8 1	0 8 2	0 8 3	0 8 4	0 8 5	0 8 6	0 8 7	0 8 8	0 8 9	0 9 0	0 9 3	0 9 4	0 9 5	0 9 6	0 9 7	0 9 8	1 0 0	TOTAL
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TISSUES								
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibroma Fibrosarcoma Neunlemoma	+ X	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+ X	* X	* X	+	*50 6 5 1
RESPIRATORY SYSTEM Lungs and bronchi Hepatocellular carcinoma, metastatic Alveolar/bronchiolar adenoma Trachea	+ X +	++	+	++	+	+	+	+	+	+	+	++	+	++	+	++	+	+	+	+	++	+	+	++	++	50 1 4 48
HEMATOPOIETIC SYSTEM Bone marrow Spleen Hemangiosarcoma Malignant lymphoma, mixed type	+++	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ + X	++++	+ +	+ +	+ +	+++++	+ +	+ +	+++	+ +	+ + +	+ +	++++	+ +	+ +	++++	+ +	50 50 1
Lymph nodes Thymus	++++	+	+ +	+ +	+ +	 +	+ +	+	+ +	+ +	+ +	+ +	+ +	+ -	+	+ +	+ +	+ +	+ -	+	+ +	+ +	+ -	+ -	+ +	42 39
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
DIGESTIVE SYSTEM Salvary gland Liver Hepatocellular adenoma Hepatocellular carcinoma Lipoma	+++	+++	+ + X	+ +	+ +	++++++	+ +	+ +	++++	+ +	++++	++++	+ +	++++	+ + X	+ +	+ +	++++	+ +	+ +	+ +	+ + X	+ +	++++	+ + X	50 50 7 5 1
Hemangiosarcoma Bile duct Gallbladder & common bile duct Pancreas Esophagus	++++++	++++++	+ + +	+ + +	+ + +	+++++++	++++++	+ + +	+ + +	X + + + + +	+ N + + +	+++++	+++++	+ + +	++++++	++++++	+ + +	+ + +	++++++	+ + +	X + + + +	+++++	+ + +	+ + +	+ + +	2 50 *50 49 48
Stomach Small intestine Carcinoma, NOS Large intestine	+++++++++++++++++++++++++++++++++++++++	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + X +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	50 48 1 50
URINARY SYSTEM Kidney Urinary bladder	++++	++++	+++	+++	++++	+++++	+++	++++	++++	+ +	++++	+ +	+ +	+++	++++	++++	++++	++++	+++++++++++++++++++++++++++++++++++++++	+++	+++++	++++++	++++	++++	++++	50 50
ENDOCRINE SYSTEM Pituitary Adrenal Adrenoma, NOS	+++	+ +	+++++	+ +	+ +	++++	+ +	+ + X	+ +	+++	++++	+ +	+ +	+++	+ +	+ +	+ +	+ +	+++	+ +	++++	+ +	++++	+++	+ +	50 48 1
Pheochromocytoma Thyroid Parathyroid	+++	+ +	+ +	+ +	+ +	X + -	+ +	+ +	+ -	+ +	+ +	+ +	+ 	+ 	+ ~	+ +	+ +	+ +	X + +	+ +	+ -	+ 	+ +	+ +	+ +	2 50 31
REPRODUCTIVE SYSTEM Mammary gland Testis Prostate	N + +	N + +	+ + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	N + +	*50 50 50
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
SPECIAL SENSE ORGANS Harderian gland Carcinoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	*50
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, mixed type	N X	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N X	N X	N	N	N	N	N	N	*50

113

TABLE C2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE: HIGH DOSE (Continued)

* Animals necropsied

	Control	2,500 ppm	5,000 ppm
Subcutaneous Tissue: Fibroma			
Overall Rates (a)	3/50 (6%)	3/50 (6%)	6/50 (12%)
Adjusted Rates (b)	8.1%	9.1%	14.5%
Terminal Rates (c)	2/34(6%)	3/33 (9%)	5/40 (13%)
Week of First Observation	95	104	83
Life Table Tests (d)			
	P = 0.240	P = 0.641	P = 0.308
Incidental Tumor Tests (d)	P = 0.185	P = 0.606	P = 0.223
Cochran-Armitage Trend Test (d)	P = 0.178		5
Fisher Exact Test (d)		P = 0.661	P = 0.243
Subcutaneous Tissue: Fibrosarcoma			
Overall Rates (a)	12/50 (24%)	7/50 (14%)	5/50 (10%)
Adjusted Rates (b)	28.8%	16.7%	11.2%
Terminal Rates (c)	6/34 (18%)	0/33 (0%)	2/40 (5%)
Week of First Observation	81	71	73
Life Table Tests (d)	P = 0.043N	P = 0.221 N	P = 0.050 N
Incidental Tumor Tests (d)	P = 0.0451 P = 0.146N	P = 0.221 N P = 0.221 N	P = 0.030 N P = 0.114 N
	P = 0.038N	1 - 0.221	1 - 0.11411
Cochran-Armitage Trend Test (d) Fisher Exact Test (d)	r = 0.0381	P = 0.154 N	P = 0.054 N
A ISHEL EXACT TEST (U)		r - 0.1041N	r = 0.0041
Subcutaneous Tissue: Sarcoma or Fibros			
Overall Rates (a)	(e) 13/50 (26%)	7/50 (14%)	5/50 (10%)
Adjusted Rates (b)	31.3%	16.7%	11.2%
Terminal Rates (c)	7/34(21%)	0/33 (0%)	2/40 (5%)
Week of First Observation	81	71	73
Life Table Tests (d)	P = 0.026N	P = 0.164 N	P = 0.031 N
Incidental Tumor Tests (d)	P = 0.089 N	P = 0.156N	P = 0.070 N
Cochran-Armitage Trend Test (d)	P = 0.022N		
Fisher Exact Test (d)	1 -0.02211	P = 0.105 N	P = 0.033 N
Subcutaneous Tissue: Fibroma or Fibros			
Overall Rates (a)	14/50 (28%)	10/50 (20%)	11/50 (22%)
Adjusted Rates (b)	32.9%	24.3%	24.6%
Terminal Rates (c)	7/34 (21%)	3/33 (9%)	7/40 (18%)
Week of First Observation	81	71	73
Life Table Tests (d)	P = 0.236N	P = 0.323N	P = 0.259N
Incidental Tumor Tests (d)	P = 0.539	P = 0.364 N	P = 0.511N
Cochran-Armitage Trend Test (d)	P = 0.277 N		
Fisher Exact Test (d)		P = 0.241 N	P = 0.322N
Subcutaneous Tissue: Fibroma, Sarcoma,	or Fibrosproome		
Overall Rates (a)	(e) 15/50 (30%)	10/50 (20%)	11/50 (22%)
Adjusted Rates (b)	35.4%	24.3%	
			24.6%
Terminal Rates (c)	8/34 (24%)	3/33 (9%)	7/40 (18%)
Week of First Observation	81	71 D. 0.055N	73 D. 0.104N
Life Table Tests (d)	P = 0.175N	P = 0.255N	P = 0.194N
Incidental Tumor Tests (d)	P = 0.456N	P = 0.279N	P = 0.405N
Cochran-Armitage Trend Test (d)	P = 0.206 N		
Fisher Exact Test (d)		P = 0.178N	P = 0.247 N
.ung: Alveolar/Bronchiolar Adenoma			
Overall Rates (a)	4/50 (8%)	2/50 (4%)	4/50 (8%)
Adjusted Rates (b)	11.0%	6.1%	9.4%
Terminal Rates (c)	3/34 (9%)	2/33 (6%)	3/40 (7%)
Week of First Observation			
	97 D - 0 500N	104 D 0 250N	73 D. 0 5700
Life Table Tests (d)	P = 0.509N	P = 0.359N	P = 0.576N
Incidental Tumor Tests (d)	P = 0.570 N	P = 0.394 N	P = 0.632
Cochran-Armitage Trend Test (d)	P = 0.579		
Fisher Exact Test (d)	. 0.010	P=0.339N	P = 0.643

TABLE C3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

	Control	2,500 ppm	5,000 ppm
Lung: Alveolar/Bronchiolar Carcinoma	·····	<u>.</u>	<u></u> ,
Overall Rates (a)	2/50 (4%)	3/50 (6%)	0/50 (0%)
Adjusted Rates (b)	5.3%	9.1%	0.0%
Terminal Rates (c)	1/34 (3%)	3/33 (9%)	0/40 (0%)
Week of First Observation	95	104	0/40 (0 /0)
Life Table Tests (d)	P = 0.175N	P = 0.478	P = 0.224 N
Incidental Tumor Tests (d)	P = 0.248N	P = 0.437	P = 0.405N
Cochran-Armitage Trend Test (d)	P = 0.202N	1 -0.401	1 -0.40014
Fisher Exact Test (d)	1 = 0.2021	P = 0.500	P = 0.247 N
ung: Alveolar/Bronchiolar Adenoma or (Carcinoma		
Overall Rates (a)	6/50 (12%)	5/50 (10%)	4/50 (8%)
Adjusted Rates (b)	16.0%	15.2%	9.4%
Terminal Rates (c)	4/34 (12%)	5/33 (15%)	3/40 (7%)
Week of First Observation	95	104	73
Life Table Tests (d)	P = 0.242N	P = 0.533N	P = 0.307 N
Incidental Tumor Tests (d)	P = 0.337N	P = 0.590N	P = 0.476N
Cochran-Armitage Trend Test (d)	P = 0.337 N P = 0.309 N	1 - 0.05014	1 - 0.4/01N
Fisher Exact Test (d)	L - 0.9091	D-0 500N	D-0.270N
		P = 0.500N	P = 0.370 N
Hematopoietic System: Malignant Lympho	oma, Mixed Type		
Overall Rates (a)	6/50 (12%)	2/50 (4%)	4/50 (8%)
Adjusted Rates (b)	16.8%	6.1%	10.0%
Terminal Rates (c)	5/34 (15%)	2/33 (6%)	4/40 (10%)
Week of First Observation	97	104	104
Life Table Tests (d)	P = 0.221 N	P = 0.148N	P = 0.283N
Incidental Tumor Tests (d)	P = 0.278N	P = 0.167N	P = 0.374N
Cochran-Armitage Trend Test (d)	P = 0.290N		
Fisher Exact Test (d)	1 = 0.20010	P = 0.135N	P = 0.371 N
Hematopoietic System: Lymphoma, All M	alignant		
Overall Rates (a)		2/50 (691)	A (E D (0.0)
	8/50 (16%)	3/50 (6%)	4/50 (8%)
Adjusted Rates (b)	21.0%	8.1%	10.0%
Terminal Rates (c)	5/34 (15%)	2/33 (6%)	4/40 (10%)
Week of First Observation	95	71	104
Life Table Tests (d)	P = 0.091 N	P = 0.124N	P = 0.128N
Incidental Tumor Tests (d)	P = 0.181N	P = 0.165 N	P = 0.327 N
Cochran-Armitage Trend Test (d)	P = 0.122N		
Fisher Exact Test (d)		P = 0.100N	P = 0.179N
Circulatory System: Hemangiosarcoma			
Overall Rates (a)	3/50 (6%)	1/50 (2%)	3/50 (6%)
Adjusted Rates (b)	7.1%	2.9%	7.5%
Terminal Rates (c)	1/34 (3%)	0/33 (0%)	3/40 (7%)
Week of First Observation	73	100	104
Life Table Tests (d)	P = 0.552N	P = 0.329N	P = 0.614N
Incidental Tumor Tests (d)	P = 0.576	P = 0.310N	P = 0.560 N
Cochran-Armitage Trend Test (d)	P = 0.594		
Fisher Exact Test (d)		P = 0.309N	P = 0.661
Circulatory System: Hemangioma or Hem	angiosarcoma		
Overall Rates (a)	4/50 (8%)	2/50 (4%)	3/50 (6%)
Adjusted Rates (b)	9.2%	5.9%	7.5%
Terminal Rates (c)	1/34 (3%)	1/33 (3%)	3/40(7%)
Week of First Observation	73	100 (0 %)	104
Life Table Tests (d)	P = 0.379N	P = 0.370N	P = 0.458N
Incidental Tumor Tests (d)	P = 0.379 N P = 0.413 N	P = 0.370 N P = 0.301 N	P = 0.385N
		1 -0.0011	1 -0.0001
Cooknam Annitage Tread Test (1)			
Cochran-Armitage Trend Test (d) Fisher Exact Test (d)	P = 0.417N	P = 0.339 N	P = 0.500 N

TABLE C3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Control	2,500 ppm	5,000 ppm
Liver: Hepatocellular Adenoma			
Overall Rates (a)	8/50 (16%)	6/50 (12%)	7/50 (14%)
Adjusted Rates (b)	20.9%	18.2%	16.8%
Terminal Rates (c)	5/34 (15%)	6/33 (18%)	6/40 (15%)
Week of First Observation	88	104	80
Life Table Tests (d)	P = 0.342N	P = 0.426N	P = 0.405N
Incidental Tumor Tests (d)	P = 0.441N	P = 0.438N	P = 0.556N
Cochran-Armitage Trend Test (d)	P = 0.443N	1 - 0.40011	1 = 0.00011
Fisher Exact Test (d)		P = 0.387 N	P = 0.500 N
liver: Hepatocellular Carcinoma			
Overall Rates (a)	8/50 (16%)	3/50 (6%)	5/50 (10%)
Adjusted Rates (b)	19.3%	8.1%	11.3%
Terminal Rates (c)	3/34 (9%)	1/33 (3%)	2/40 (5%)
Week of First Observation	73	90	80
Life Table Tests (d)	P = 0.194N	P = 0.136N	P = 0.249N
Incidental Tumor Tests (d)	P = 0.340 N	P = 0.137N	P = 0.414N
Cochran-Armitage Trend Test (d)	P = 0.209N		
Fisher Exact Test (d)		P = 0.100 N	P = 0.277 N
Liver: Hepatocellular Adenoma or Carcir		0.00	
Overall Rates (a)	15/50 (30%)	8/50 (16%)	11/50 (22%)
Adjusted Rates (b)	35.5%	22.5%	25.3%
Terminal Rates (c)	8/34 (24%)	6/33 (18%)	8/40 (20%)
Week of First Observation	73	90	80
Life Table Tests (d)	P = 0.148N	P = 0.117 N	P = 0.184N
Incidental Tumor Tests (d)	P = 0.262N	P = 0.109N	P = 0.327 N
Cochran-Armitage Trend Test (d)	P = 0.202N		
Fisher Exact Test (d)		P = 0.077 N	P = 0.247 N
Adrenal Gland: Pheochromocytoma			
Overall Rates (a)	3/49 (6%)	1/48 (2%)	2/48 (4%)
Adjusted Rates (b)	8.4%	3.1%	5.0%
Terminal Rates (c)	2/34 (6%)	1/32 (3%)	2/40 (5%)
Week of First Observation	101	104	104
Life Table Tests (d)	P = 0.345N	P = 0.336N	P = 0.437 N
Incidental Tumor Tests (d)	P = 0.442N	P = 0.365 N	P = 0.588N
Cochran-Armitage Trend Test (d)	P = 0.408 N		
Fisher Exact Test (d)		P = 0.316N	P = 0.510N
Adrenal Gland: Pheochromocytoma or M	alignant Pheochromocy	rtoma	
Overall Rates (a)	4/49 (8%)	1/48 (2%)	2/48 (4%)
Adjusted Rates (b)	11.2%	3.1%	5.0%
Terminal Rates (c)	3/34 (9%)	1/32 (3%)	2/40 (5%)
Week of First Observation	101	104	104
Life Table Tests (d)	P = 0.195N	P = 0.205N	P = 0.274N
Incidental Tumor Tests (d)	P = 0.261 N	P = 0.225N	P = 0.390N
Cochran-Armitage Trend Test (d)	P = 0.246N		
Fisher Exact Test (d)		P = 0.187 N	P = 0.349 N
All Sites: Benign Tumors			
Overall Rates (a)	16/50 (32%)	15/50 (30%)	19/50 (38%)
Adjusted Rates (b)	40.2%	43.7%	42.9%
Terminal Rates (c)	40.2% 11/34 (32%)		42.9% 15/40 (38%)
		14/33 (42%) 72	
Week of First Observation	88 D=0.477	73 D = 0 FCON	73 D = 0.505
Life Table Test (d)	P = 0.477	P = 0.560N	P = 0.505
Incidental Tumor Test (d)	P = 0.298	P = 0.566	P = 0.233
Cochran-Armitage Trend Test (d)	P = 0.298		
Fisher Exact Test (d)		P = 0.500 N	P = 0.338

TABLE C3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Control	2,500 ppm	5,000 ppm
Il Sites: Malignant Tumors			
Overall Rates (a)	30/50 (60%)	15/50 (30%)	17/50 (34%)
Adjusted Rates (b)	63.8%	35.5%	36.7%
Terminal Rates (c)	17/34 (50%)	6/33 (18%)	11/40 (28%)
Week of First Observation	73	71	73
Life Table Test (d)	P = 0.008 N	P = 0.019 N	P = 0.009 N
Incidental Tumor Test (d)	P = 0.036N	P = 0.005 N	P = 0.032N
Cochran-Armitage Trend Test (d)	P = 0.006 N		
Fisher Exact Test (d)		P = 0.003 N	P = 0.008 N
All Sites: All Tumors			
Overall Rates (a)	37/50 (74%)	26/50 (52%)	29/50 (58%)
Adjusted Rates (b)	77.1%	60.3%	61.7%
Terminal Rates (c)	23/34 (68%)	16/33 (48%)	22/40 (55%)
Week of First Observation	73	71	73
Life Table Test (d)	P = 0.041 N	P = 0.096 N	P = 0.044N
Incidental Tumor Test (d)	P = 0.180N	P = 0.051 N	P = 0.178N
Cochran-Armitage Trend Test (d)	P = 0.062N		
Fisher Exact Test (d)		P = 0.019N	P = 0.070 N

TABLE C3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

(e) A neurofibrosarcoma was observed in an animal with a fibrosarcoma.

TABLE C4,	SUMMARY	OF THE INCIDENCE	E OF NONNEOPLASTIC	LESIONS IN MALE MICE IN THE
		TWO-YEAR FEED ST	TUDY OF ERYTHROMY	CIN STEARATE

U	ntreat	ed Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY	50	<u></u>	50	<u>_</u>	50	
ANIMALS NECROPSIED	50		50		50	
ANIMALS EXAMINED HISTOPATHOLOGICALLY	¥ 50		50		50	
NTEGUMENTARY SYSTEM				· · · · · · · · · · · · · · · · · · ·		
*Skin	(50)		(50)		(50)	
Ulcer, NOS	-	(2%)	1	(2%)	1	(2%)
Inflammation, acute Inflammation, chronic		(4%) (2%)	1	(2%)	1	(2%)
Ulcer, chronic	1	(270)		(2%)	1	(270)
Granuloma, foreign body			•	(4,0)	1	(2%)
Inflammation with fibrosis	1	(2%)				(2%)
Fibrosis	1	(2%)			3	(6%)
Exanthematous inflammation	1	(2%)				
Calcification, NOS			_			(2%)
Alopecia	•	(AGL)	2	(4%)	1	(2%)
Hyperkeratosis *Subcutaneous tissue	(50)	(4%)	(50)		(50)	
Congestion, NOS	(00)			(2%)	(80)	
Inflammation, chronic	1	(2%)	1	(2,0)	1	(2%)
RESPIRATORY SYSTEM						
#Trachea	(49)		(50)		(48)	
Inflammation, chronic focal				(2%)	(-9)	
#Tracheal gland	(49)		(50)		(48)	
Inflammation, acute		(2%)				
#Lung/bronchus	(50)		(50)		(50)	
Multiple cysts	-	(2%)	(50)		(50)	
#Lung Atelectasis	(50)		(50)		(50)	(2%)
Congestion, NOS	2	(4%)	5	(10%)		(2%)
Hemorrhage		(4%)	Ŭ	(10,0)	-	(4,0)
Inflammation, acute focal			1	(2%)		
Inflammation, acute/chronic				(2%)		
Inflammation, chronic	-		1	(2%)		
Inflammation, chronic focal	3	(6%)		(0.07)	1	(2%)
Fibrosis Perivascular cuffing	9	(6%)		(2%) (6%)	Q	(160)
Alveolar macrophages		(6%)		(8%)		(16%) (2%)
Hyperplasia, adenomatous		(4%)	-	(0,0)	•	(270)
IEMATOPOIETIC SYSTEM						
*Multiple organs	(50)		(50)		(50)	
Hyperplasia, lymphoid		(16%)		(6%)		(14%)
#Bone marrow	(50)		(50)		(50)	(001)
Atrophy, NOS Hyperplasia, NOS	e	(12%)	2	(4%)		(2%) (6%)
Angiectasis		(12%)	2	(T /V)		(0%) (2%)
Hyperplasia, granulocytic		(26%)	8	(16%)		(22%)
#Spleen	(50)		(49)		(50)	
Fibrosis, focal			1	(2%)		
Amyloidosis	-					(2%)
Atrophy, NOS	2	(4%)		(00)		(4%)
Angiectasis Hyperplasia, reticulum cell	1	(901)		(2%)	1	(2%)
Hyperplasia, reticulum cell Hyperplasia, lymphoid		(2%) (22%)		(2%) (41%)	91	(42%)
Hematopoiesis		(40%)		(41%) (12%)		(42%) (20%)
#Splenic red pulp	(50)		(49)	101	(50)	(2010)
			((00)	

	Untreat	ed Control	Low	Dose	High	Dose
HEMATOPOIETIC SYSTEM (Continued)						
#Mandibular lymph node	(48)		(48)		(42)	
Hemorrhage		(4%)	(40)			(2%)
Hemosiderosis		(2%)			-	(270)
Hyperplasia, lymphoid		(2%)				
#Renal lymph node	(48)	(= /0)	(48)		(42)	
Hemorrhage	(,			(2%)	(42)	
Plasmacytosis	1	(2%)	-			
Erythrophagocytosis	-	(=,0)			1	(2%)
Hyperplasia, lymphoid			1	(2%)	-	(2,0)
#Lung	(50)		(50)	(2,0)	(50)	
Leukocytosis, NOS		(6%)	4	(6%)		(6%)
Hyperplasia, lymphoid	2	(4%)		(6%)		(8%)
*Pericardium	(50)	(4))	(50)	(0707	(50)	(0/0)
Hyperplasia, lymphoid		(2%)	(00)		(00)	
#Salivary gland	(50)	(270)	(50)		(50)	
Hyperplasia, lymphoid		(16%)		(26%)		(900)
#Liver		(1070)	-	(20%)	-	(26%)
	(50)	(60)	(50)		(50)	(901)
Hematopoiesis		(6%)				(2%)
#Forestomach	(49)		(50)		(50)	
Mastocytosis		(2%)				
#Kidney	(50)		(50)		(50)	
Hyperplasia, lymphoid		(30%)		(26%)		(34%)
#Urinary bladder	(50)		(50)		(50)	
Hyperplasia, lymphoid	3	(6%)	4	(8%)	8	(16%)
#Prostate	(50)		(49)		(50)	
Hyperplasia, lymphoid	6	(12%)	4	(8%)	5	(10%)
#Thymus	(39)		(36)		(39)	
Cyst, NOS	7	(18%)	5	(14%)	4	(10%)
Multiple cysts	3	(8%)	1	(3%)	2	(5%)
Necrosis, NOS	1	(3%)				,
Atrophy, NOS	3	(8%)	3	(8%)		
Hyperplasia, epithelial				(3%)	2	(5%)
URCULATORY SYSTEM		<u></u>				
*Knee	(50)		(50)		(50)	
Perivasculitis	(00)			(2%)	(00)	
#Mandibular lymph node	(48)		(48)	(2.0)	(42)	
Lymphangiectasis	(40)			(2%)	(42)	
#Myocardium	(50)		(50)	(270)	(50)	
Fibrosis, focal	(00)		(30)			(2%)
Degeneration, NOS			1	(2%)		(2%)
#Pancreas	(49)		(49)	(270)	(49)	(470)
Perivasculitis	(43)		(43)			(2%)
	(50)		(40)			(270)
#Prostate		(90)	(49)		(50)	(90)
Perivasculitis	1	(2%)			1	(2%)
DIGESTIVE SYSTEM						
#Salivary gland	(50)		(50)		(50)	
Inflammation, acute/chronic				(2%)		
Atrophy, NOS				(8%)		(2%)
#Liver	(50)		(50)		(50)	
					1	(2%)
Multiple cysts				(2%)		
Inflammation, chronic focal		(100)	5	(10%)	4	(8%)
Inflammation, chronic focal Necrosis, focal		(12%)	0	· · · /		
Inflammation, chronic focal		(12%) (2%)	Ū	,		
Inflammation, chronic focal Necrosis, focal Infarct, NOS Metamorphosis, fatty				(2%)		
Inflammation, chronic focal Necrosis, focal Infarct, NOS			1	. ,		
Inflammation, chronic focal Necrosis, focal Infarct, NOS Metamorphosis, fatty	1		1	(2%)	1	(2%)
Inflammation, chronic focal Necrosis, focal Infarct, NOS Metamorphosis, fatty Pigmentation, NOS	1	(2%)	1	(2%)	1 (50)	(2%)

	Untreat	ed Control	Low	Dose	High	Dose
DIGESTIVE SYSTEM (Continued)			<u></u>			
*Gallbladder	(50)		(50)		(50)	
Inflammation, chronic focal			1	(2%)		
*Gallbladder/mucosa	(50)		(50)		(50)	
Cyst, NOS			1	(2%)	1	(2%)
Multiple cysts	2	(4%)			1	(2%)
Degeneration, hyaline					2	(4%)
*Gallbladder/mucous gland	(50)		(50)		(50)	
Fibrosis	1	(2%)				
#Bile duct	(50)		(50)		(50)	
Cyst, NOS					1	(2%)
Hyperplasia, NOS		(2%)				
#Pancreas	(49)		(49)		(49)	
Inflammation, chronic					1	(2%)
Fibrosis	1	(2%)	1	(2%)	4	
Lipoidosis		(0~)				(2%)
Atrophy, NOS		(2%)	(10)			(2%)
#Pancreatic acinus	(49)		(49)	(60)	(49)	(2%)
Cytoplasmic vacuolization				(6%) (4%)		
Hypertrophy, focal #Esophagoal submuses	(48)		(50)	(4170)		(2%)
#Esophageal submucosa Perivascular cuffing	(48)			(2%)	(48)	
#Stomach	(49)		(50)	(470)	(50)	
Granuloma, NOS	(49)		(00)			(2%)
#Glandular stomach	(49)		(50)		(50)	(270)
Mineralization	(43)			(2%)		(2%)
Cyst, NOS	3	(6%)		(8%)		(10%)
Multiple cysts	-	(2%)		(0,0)	0	(10,0)
Inflammation, acute/chronic	1	(270)	3	(6%)	1	(2%)
Inflammation, chronic focal	1	(2%)		(2%)		(10%)
Necrosis, focal	-	(2,0)		(2%)	Ũ	(10,0)
Calcification, NOS	2	(4%)	-	(= /*/		
Hyperplasia, epithelial	_	(1	(2%)
Dysplasia, NOS	1	(2%)			_	(=,
#Gastric serosa	(49)		(50)		(50)	
Inflammation, acute/chronic	()		,			(2%)
#Forestomach	(49)		(50)		(50)	(
Cyst, NOS				(2%)	1	(2%)
Inflammation, acute				(2%)		
Inflammation, chronic focal			1	(2%)		
Hyperplasia, epithelial			1	(2%)		
Hyperkeratosis					1	(2%)
Dysplasia, NOS						(4%)
#Duodenal mucosa	(48)		(45)		(48)	
Cyst, NOS		(2%)				
#Ileal submucosa	(48)		(45)		(48)	
Amyloidosis				(2%)		
*Rectum	(50)		(50)	(07)	(50)	
Prolapse	1	(2%)	1	(2%)	1	(2%)
RINARY SYSTEM		<u> </u>				
#Kidney	(50)		(50)		(50)	
Mineralization	8	(16%)		(14%)	3	(6%)
Hydronephrosis				(2%)		
Cyst, NOS	3	(6%)	2	(4%)		
Multiple cysts						(2%)
Congestion, NOS		.				(2%)
Glomerulonephritis, acute		(2%)	1	(2%)	1	(2%)
The law on builting a subtain	1	(2%)				
Pyelonephritis, acute						
Inflammation, acute		(2%)				
		(2%) (2%)	_	(2%)		

Erythromycin Stearate, NTP TR 338

	Untreat	ed Control	Low	Dose	High	Dose
JRINARY SYSTEM						
#Kidney (Continued)	(50)		(50)		(50)	
Fibrosis, focal	,			(2%)		
Perivascular cuffing			1	(2%)		
Nephropathy	11	(22%)	12	(24%)	11	(22%)
Atrophy, NOS		(6%)	3	(6%)	1	(2%)
Metaplasia, osseous		(2%)				
#Kidney/medulla	(50)		(50)		(50)	
Necrosis, focal				(2%)		
#Renal papilla	(50)		(50)		(50)	
Calcification, NOS	=	(2%)	(50)		(50)	
#Kidney/glomerulus	(50)		(50)	(90)	(50)	
Amyloidosis #Convoluted tubules	(50)			(2%)	(50)	
Degeneration, hyaline	(50)	(2%)	(50)		(50)	
Metamorphosis, fatty		(2%)				
#Kidney/pelvis	(50)	(210)	(50)		(50)	
Inflammation, suppurative		(2%)	(00)		(00)	
Inflammation, acute/chronic		(2%)				
*Ureter	(50)	(2,0)	(50)		(50)	
Inflammation, suppurative	(50)		(007			(2%)
#Urinary bladder	(50)		(50)		(50)	(-/-/
Calculus, gross observation only	1	(2%)				
Inflammation, acute	2	(4%)	1	(2%)		
Inflammation, acute/chronic	1	(2%)				
Inflammation, chronic focal	2	(4%)	1	(2%)	1	(2%)
#Urinary bladder/mucosa	(50)		(50)		(50)	
Ulcer, NOS		(2%)				
Degeneration, NOS		(2%)				
Degeneration, hyaline		(2%)				
Hyperplasia, epithelial	1	(2%)	1	(2%)		
NDOCRINE SYSTEM						
#Anterior pituitary	(50)		(50)		(50)	
Cyst, NOS	2	(4%)	1	(2%)	4	(8%)
Multiple cysts	1	(2%)	1	(2%)	1	(2%)
Focal cellular change	2	(4%)			2	(4%)
#Adrenal/capsule	(49)		(48)		(48)	
Hyperplasia, stromal	28	(57%)		(58%)	35	(73%)
#Adrenal cortex	(49)		(48)		(48)	
Ectopia		(4%)				(10%)
Degeneration, lipoid	3	(6%)				(4%)
Pigmentation, NOS					1	(2%)
Focal cellular change		(2%)				
Hypertrophy, focal		(22%)		(21%)		(38%)
Hyperplasia, focal		(6%)		(8%)		(4%)
#Adrenal medulla	(49)		(48)		(48)	
Hyperplasia, focal		(8%)		(15%)		
#Thyroid	(49)		(49)		(50)	
Follicular cyst, NOS	1	(2%)			-	
Inflammation, chronic focal		.0.0	-		1	(2%)
Degeneration, NOS		(2%)		(2%)		
#Thyroid follicle	(49)		(49)	(00)	(50)	
Corpora amylacea		(90)	1	(2%)		
Atrophy, NOS	1	(2%)				.00
Hyperplasia, cystic	(00)		195			(2%)
#Parathyroid	(32)	(20)	(35)		(31)	
Ectopia Cyst, NOS	1	(3%)	0	(G)		(201)
Cyst, NOS Multiple cysts	1	(3%)	2	(6%)	1	(3%)
multiple cysis	1	0701				

	Untreat	ed Control	Low	Dose	High	Dose
REPRODUCTIVE SYSTEM				·		
*Prepuce	(50)		(50)		(50)	
Impaction, NOS			(- 3)		1 · · · · ·	(2%)
Congestion, NOS			1	(2%)		
Ulcer, NOS			1	(2%)		
Inflammation, acute/chronic	1	(2%)				
Inflammation, chronic			1	(2%)	. 1	(2%)
Metaplasia, squamous		(2%)				
*Preputial gland	(50)		(50)		(50)	
Dilatation, NOS			1	(2%)	1	(2%)
Multiple cysts	2	(4%)				
Inflammation, NOS	13	(26%)	14	(28%)	9	(18%)
Metaplasia, squamous	16	(32%)	13	(26%)	12	(24%)
#Prostate	(50)		(49)		(50)	
Multiple cysts					1	(2%)
Hemorrhage				(2%)		
Inflammation, NOS		(16%)		(27%)		(16%)
*Seminal vesicle	(50)		(50)		(50)	
Dilatation, NOS		(2%)	4	(8%)		(6%)
Inflammation, suppurative	1	(2%)			1	(2%)
Inflammation, chronic	2	(4%)	1	(2%)		
#Testis	(50)		(48)		(50)	
Inflammation, chronic focal	1	(2%)				
Calcification, NOS	6	(12%)	1	(2%)	2	(4%)
Atrophy, NOS	3	(6%)	2	(4%)	2	(4%)
Hyperplasia, interstitial cell			1	(2%)	1	(2%)
Angiectasis	1	(2%)				
#Testis/tubule	(50)		(48)		(50)	
Cytomegaly					1	(2%)
NERVOUS SYSTEM						
#Brain	(50)		(50)		(50)	
Perivascular cuffing	1	(2%)				
#Brain/thalamus	(50)		(50)		(50)	
Calcification, NOS	25	(50%)	25	(50%)	21	(42%)
#Medulla oblongata	(50)		(50)		(50)	
Calcification, NOS					1	(2%)
*Sciatic nerve	(50)		(50)		(50)	
Inflammation, pyogranulomatous	,	(2%)	. ,			
SPECIAL SENSE ORGANS None						
MUSCULOSKELETAL SYSTEM		· · · · · · · · · · · · · · · · · · ·				
*Bone	(50)		(50)		(50)	
Atrophy, NOS				(2%)		
Osteosclerosis	3	(6%)		(8%)		
*Joint	(50)		(50)		(50)	
Dyschondroplasia				(2%)		
BODY CAVITIES				<u></u>		
*Peritoneum	(50)		(50)		(50)	
						(2%)

	Untreated Control	Low Dose	High Dose
ALL OTHER SYSTEMS			
Knee			
Dyschondroplasia	19	15	13
Adipose tissue			
Necrosis, fat	1	3	2

* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically. # Number of animals examined microscopically at this site

Erythromycin Stearate, NTP TR 338

124

APPENDIX D

SUMMARY OF LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

		PAGE
TABLE D1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	127
TABLE D2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	130
TABLE D3	ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	136
TABLE D4	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	139

125

Erythromycin Stearate, NTP TR 338

ŭ	Intrea	ted Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY	50		50		50	
ANIMALS NECROPSIED	50		49		50	
ANIMALS EXAMINED HISTOPATHOLOGICALLY	Y 50		49		50	
NTEGUMENTARY SYSTEM						
*Tail	(50)		(49)		(50)	
Fibrous histiocytoma				(2%)		
*Skin Adenoma, NOS	(50)		(49)	(0.21)	(50)	
*Subcutaneous tissue	(50)			(2%)	(50)	
Fibrosarcoma		(2%)	(49)		(50)	
Myxoma	1	(270)	1	(2%)		
Neurilemoma			•	(2 %)	1	(2%)
RESPIRATORY SYSTEM						
#Lung	(50)		(49)		(49)	
Alveolar/bronchiolar adenoma		(6%)		(6%)		(2%)
Alveolar/bronchiolar carcinoma	1	(2%)			1	(2%)
Teratoma, metastatic			1	(2%)		
HEMATOPOIETIC SYSTEM				· · · · · · · · · · · · · · · · · · ·		
*Multiple organs	(50)		(49)		(50)	
Malignant lymphoma, NOS	1	(2%)		(2%)		
Malignant lymphoma, undifferentiated type				(2%)		
Malignant lymphoma, histiocytic type	~ ~	(50.00)		(2%)		(2%)
Malignant lymphoma, mixed type	25	(50%)		(39%)	26	(52%)
Lymphocytic leukemia #Spleen	(50)			(2%)	(50)	
Malignant lymphoma, mixed type		(6%)	(49)		(50)	(9α)
#Renal lymph node	(45)	$(0, \mathbf{b})$	(44)		(48)	(2%)
Teratoma, metastatic	(10)		(, ,	(2%)
#Liver	(50)		(49)		(50)	(=,0)
Malignant lymphoma, histiocytic type			1	(2%)	1	(2%)
#Thymus	(41)		(46)		(41)	
Thymoma, benign	1	(2%)				
Malignant lymphoma, lymphocytic type			1	(2%)		
URCULATORY SYSTEM						
*Multiple organs	(50)		(49)	(2~)	(50)	
Hemangiosarcoma *Subcutaneous tissue				(2%)	(20)	
Hemangioma	(50)		(49)		(50)	(90)
#Spleen	(50)		(49)		(50)	(2%)
Hemangioma	(00)			(2%)	(50)	
Hemangiosarcoma				(2%)		
#Myocardium	(50)		(49)		(49)	
Hemangiosarcoma		(2%)				
#Uterus	(50)		(49)		(50)	
Hemangioma			1	(2%)		
DIGESTIVE SYSTEM				1		
#Liver	(50)		(49)		(50)	
Hepatocellular adenoma		(6%)		(10%)		(2%)
Hepatocellular carcinoma	1	(2%)	1	(2%)	1	(2%)

TABLE D1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEARFEED STUDY OF ERYTHROMYCIN STEARATE

	Untreat	ed Control	Low	Dose	High	Dose
URINARY SYSTEM						
#Kidney	(50)		(49)		(50)	
Teratoma, metastatic			1	(2%)		
ENDOCRINE SYSTEM						
#Anterior pituitary	(49)		(49)		(50)	
Carcinoma, NOS	1	(2%)	1	(2%)		
Adenoma, NOS		(37%)		(29%)	14	(28%)
#Adrenal/capsule	(50)		(48)		(50)	
Adenoma, NOS		(2%)				
#Adrenal medulla	(50)		(48)		(50)	
Pheochromocytoma						(2%)
#Thyroid	(50)		(48)		(48)	(07)
Follicular cell adenoma	(40)		1 4 17			(2%)
#Pancreatic islets	(49)	(90%)	(47)		(49)	
Islet cell adenoma	1	(2%)				
REPRODUCTIVE SYSTEM						
*Mammary gland	(50)		(49)		(50)	
Adenocarcinoma, NOS	1	(2%)				
Adenosquamous carcinoma						(2%)
#Uterus	(50)	(0.4)	(49)		(50)	
Leiomyoma		(2%)				
Endometrial stromal polyp		(2%)	(10)		(10)	
#Ovary	(48)	(0~)	(46)	(0~)	(48)	
Luteoma		(2%)		(2%)		(4%)
Granulosa cell tumor Teratoma, NOS		(2%) (2%)		(4%) (2%)	Z	(4%)
Teratoma, malignant	1	(270)		(2%) (2%)	1	(2%)
#Mesovarium	(48)		(46)	(270)	(48)	(270)
Alveolar/bronchiolar carcinoma, metastatic	(40)		(40)			(2%)
NERVOUS SYSTEM None	<u>.</u>					
SPECIAL SENSE ORGANS						
*Harderian gland	(50)		(49)		(50)	
Carcinoma, NOS			1	(2%)	1	(2%)
MUSCULOSKELETAL SYSTEM None						
BODY CAVITIES		· · · · · · · · · · · · · · · · · · ·				
*Mediastinum	(50)		(49)		(50)	
Alveolar/bronchiolar carcinoma, metastatic			· /			(2%)
ALL OTHER SYSTEMS		· · · · ·				
Tail						

TABLE D1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

TABLE D1.	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR
	FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Untreated Control	Low Dose	High Dose
ANIMAL DISPOSITION SUMMARY			
Animals initially in study	50	50	50
Natural death	5	5	2
Moribund sacrifice	7	10	8
Terminal sacrifice	38	34	40
Accidentally killed, NOS		1	
TUMOR SUMMARY Total animals with primary tumors** Total primary tumors Total animals with benign tumors Total benign tumors Total animals with malignant tumors Total animals with secondary tumors## Total animals with secondary tumors ## Total animals with tumors uncertain benign or malignant	44 67 24 30 31 35 2	41 63 24 28 27 32 1 2	39 58 22 22 31 34 2 3 3
	2	3.	2 2
Total uncertain tumors	2	3 ·	Z

* Number of animals receiving complete necropsy examinations; all gross lesions including masses examined microscopically. ** Primary tumors: all tumors except secondary tumors

.

Number of animals examined microscopically at this site
 ## Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ

ANIMAL NUMBER	1 3 2	1 0 6	1 0 9	1 5 0	1 4 8	1 3 9	$\frac{1}{2}$	1 4 0	1 3 6	1 0 8	1) 1) 4)	1 4 9	1 0 1	$\begin{array}{c} 1 \\ 0 \\ 2 \end{array}$	1 0 3	1 0 4	$ \begin{array}{c} 1 \\ 0 \\ 5 \end{array} $	1 0 7	1 1 0	$\begin{array}{c}1\\1\\1\end{array}$	$\frac{1}{2}$	$1\\1\\3$	1 1 5	1 1 6	1 1 7
WEEKS ON STUDY	0 7 6	0 8 0	0 9 1	0 9 1	0 9 3	0 9 5	0 9 6	0 9 7	0 9 9	1 0 0	1 0 0	1 0 3	1 0 4	$\begin{array}{c} 1\\ 0\\ 4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibrosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+
HEMATOPOIETIC SYSTEM Bone marrow Spieen Malignant lymphoma, mixed type Lymph nodes Thymus Thymoma, benign	++++++	++ + -	++++++	++++++	+ + + +	+ + + +	+ + +	+ + + -	+++-	+ + + +	+ + + -	+++++	++++	++++-	+ + + +	++ ++	+ + + +	+ + + +	+++++	+ + +	++++++	+ + + +	+++++	+ + + X + + +	+ + + + +
CIRCULATORY SYSTEM Heart Hemangiosarcoma	+	+	*	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Salivary gland Liver	+++	+++	+	++++	++++	+++	+++	+	++++	++++	++++	+	+++	+++	+++	+ + X	+++	+++	+ + +	+++	+++	+++	 + +	 + +	++++
Hepatocallular adenoma Hepatocellular carcinoma Bile duct Gallbladder & common bile duct Pancreas Esophagus Stomach Small intestine Large intestine	+ + + + + +	X + N - +	+ + + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + +	X + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + + +	++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +
URINARY SYSTEM Kidney Urinary bladder	++++	+++	+++	+++	+++	+	++++	+++	+++	+++	+++	++++	+++	++	+++	+++	+++	+++	+++	++++	+++	+++	++++	++++	++
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS Adenoma, NOS	+	+	+	+ x	-	+ X	+	+	+	+	+ X	+	+	+	+ X	+	+ X	+	+ X	+	+	+	+	+	+
Adrenal Adenoma, NOS Thyroid Parathyroid Pancreatic islets Islet cell adenoma	+++++++++++++++++++++++++++++++++++++++	+ - -	+ + +	+ + +	+ + +	+ + +	+ - +	+ + +	+ +	+ - +	+ + +	+ + + +	+++++	+ - +	+++++	+ + +	+ - +	+ + +	+ - + X	+ + +	+++++	+ +	+ +	+ - +	+ + +
REPRODUCTIVE SYSTEM Mammary gland Adenocarcinoma, NOS Uterus Leiomyoma	+	+ +	+ +	+ +	+ +	+++	++	+ +	N +	+ +	+	+ +	++	+ X +	+++	+ + X	++	++	+ +	+ +	+++	++	+ +	+	N +
Endometrial stromal polyp Ovary Luteoma Granulosa cell tumor Teratoma, NOS	+	+	+	+	+	* X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, NOS Malignant lymphoma, mixed type	N	N X	N	N X	N X	N	N X	N X			N	N	N	N	N	N	N		N X	N	N	N X	N X	N	N X

TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE IN THE TWO-YEAR FEEDSTUDY OF ERYTHROMYCIN STEARATE: UNTREATED CONTROL

+: Tissue examined microscopically
 -: Required tissue not examined microscopically
 X: Tumor incidence
 N: Necropsy, no autolysis, no microscopic examination
 S: Animal missexed

No tissue information submitted
 Necropsy, no histology due to protocol
 Autolysis
 Aninal missing
 B: No necropsy performed

											reu	.,														
ANIMAL NUMBER	1 1 8	1 1 9	$\begin{array}{c} 1 \\ 2 \\ 0 \end{array}$	$1 \\ 2 \\ 1$	$\frac{1}{2}$	$\frac{1}{2}$	$\frac{1}{2}$	$\frac{1}{5}$		$\frac{1}{2}$	$\frac{1}{2}$	1 3 0	$\begin{array}{c}1\\3\\1\end{array}$	1 3 3	$\frac{1}{3}$	$\frac{1}{3}{5}$	1 3 7	1 3 8	1 4 1	$1\\4\\2$	1 4 3	1 4 4	1 4 5	1 4 6	$\frac{1}{4}$	TOTAL:
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TISSUES TUMORS
INTEGUMENTARY SYSTEM Subcutaneous tissue Fibrosarcoma	+	+	*	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*50 1
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Trachea	+	+	+	+	+	+	+	+	+	+	+ X +	+	+	+	+	+	* x +	+	+	+	+ X +	+	+ X +	+	+	50 3 1 50
HEMATOPOIETIC SYSTEM Bone marrow Spleen Malignant lymphoma, mixed type Lymph nodes Thymus	+++++++++++++++++++++++++++++++++++++++	+++++++	+ + + +	+ + + +	+ + + +	++++++	+ + + +	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + X - +	+++++++	+ + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++++	++++++	++++++	+++++	++++-	++++-	+ + X +	+ + + +	+++++	50 50 3 45 41
Thymoma, benign CIRCULATORY SYSTEM Heart Hemangnosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	X +	+	+	+	+	+	+	+	+	1 50 1
DIGESTIVE SYSTEM Salvary gland Liver Hepatocellular adenoma Hepatocellular carcinoma	+ + X	++++	+++	+++	++++	+++++	++++	++++	+++	++++	++++	+++	+ + X	+++	++++	++++	+++	++++	+++	+++++	+ +	+++	++++	++++	++++	50 50 3 1
Bile duct Gallbladder & common bile duct Pancreas Esophagus Stomach Small intestine Large intestine	+++++	+++++++++++++++++++++++++++++++++++++++	++++++	+ + + + + + + +	++++++	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++	+ + + + + + +	+ + + + + + +	++++++	+++++++	+++++++	+ + + + + + +	+++++-+	+ + + + + + +	++++++	+++-++	+ + + + + + +	++++++	+ + + + + +	+++++++	++++++	+ + + + + + +	+ + + + + + + + + + + + + + + + + + + +	50 *50 49 48 49 47 49
URINARY SYSTEM Kidney Urinary bladder	++++	+++	+++	+++	+++	+ +	++++	+++	++	+++	+++	+++	+++	+ +	, + +		+++	+++		+++	+ +	+++	+++	+++	++++	50 50
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 1
Adenoma, NOS Adrenal Adenoma, NOS Thyroid Parathyroid Pancreatic islets Islet cell adenoma	+ + + + +	X + + + + +	+ + + +	X + + +	X + + + +	X + +++	+ + - +	X + + + + +	+ + - +	X + + + + +	X + -+ +	X + + + + +	X + + + +	X + + + +	+ + + +	+ + + +	x + + + +	+ +++	+ + + +	+ X + + +	++++	+ + + +	+ + - +	X + + + + +	X + + +	18 50 1 50 29 49 1
REPRODUCTIVE SYSTEM Mammary gland Adenocarcinoma, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*50
Uterus Leiomyoma Endometrial stromal polyp Ovary Luteoma Granulosa cell tumor Teratoma NOS	+	+	+ + X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	* X -	+	+	+ + X	+	+	+	÷	50 1 48 1 1 1
Teratoma, NOS NERVOUS SYSTEM Brain	+	+	л +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, NOS Malignant lymphoma, mixed type	N X	N X	N X	N	N	N X	N	N	N X	N X	N X	N	N	N	N X	N X	N X	N	N X	N X	N	N X	N	N	N X	*50 1 25

TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: UNTREATED CONTROL (Continued)

* Animals necropsied

TABLE D2.	INDIVIDUAL	ANIMAL TUM	OR PATHOLOG	Y OF FEMALE	MICE IN T	THE TWO-YEAR FEED
		STUDY OF EF	RYTHROMYCIN	STEARATE: L	OW DOSE	

ANIMAL NUMBER	0 1 0	0 2 9	0 0 7	0 1 5	0 4 6	0 0 3	0 0 9	0 3 2	0 2 8	0 4 0	0 0 1	0 4 7	0 0 4	0 1 8	0 3 6	0 3 1	$\begin{array}{c} 0\\ 0\\ 2\end{array}$	0 0 5	0 0 6	0 0 8	0 1 1	$\begin{array}{c} 0 \\ 1 \\ 2 \end{array}$	0 1 3	0 1 4	0 1 6
WEEKS ON STUDY	0 0 9	0 2 8	0 5 9	0 7 3	0 8 9	0 9 0	0 9 0	0 9 0	0 9 3	0 9 3	0 9 6	0 9 7	0 9 9	1 0 0	1 0 1	1 0 3	1 0 4	1 0 4	$\begin{array}{c}1\\0\\4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4
INTEGUMENTARY SYSTEM Skin	+	+	+	в	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma, NOS Subcutaneous tissue Myxoma	+	+	+	В	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Teratoma, metastatic Trachea	+ X +	+	+	B B	+	+ x +	+	++	+	+	+	+	++	+	+	+	+	+	+	+	* * +	+	+	+	+
HEMATOPOIETIC SYSTEM Bone marrow Spleen Hemangnoma	++++	+ +	+ +	B B	+ +	+++	+ +	+ + X	+ +	+++	+++	+ +	+ +	+ +	+ +	+ +	+ +	++++	++++	+ +	+ +	+ +	+ +	+ +	+ +
Hemangtosarcoma Lymph nodes Thymus Malignant lymphoma, lymphocytic type	+	+ +	+ +	B B	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ 	+ +	+ + X	+ -	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	+ +	- +
CIRCULATORY SYSTEM Heart	+	+	+	В	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DIGESTIVE SYSTEM Sahvary gland Liver Hepatocellular adenoma Hepatocellular carcinoma	+++	+ +	+ +	B B	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	++	+ +
Malignant lymphoma, histiocytic type Bile duct Gallbiadder & common bile duct Pancreas Esophagus Stomach Small intestine Large intestine	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	BBBBBBB	+ + + + + + + + + + + + + + + + + + + +	++++++	+ + + + + +	+ + + +	++++++	+ + + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + + + + + + + + + + + + + + + +	X + + + + + + + + +	+ + + + + +	+ N - + + - +	+ + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + + + +	+ + + + + + +	+ + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + +	+++++++
URINARY SYSTEM Kidney Teratoma, metastatic Urnary bladder	+ X +	+	+++	B B	+	+	+ +	++	++	+++	+	+++	+	+++	+++	+	+++	+	++	+++	+++	++	+	++	++
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS Adenoma, NOS Adrenal Thyroid	+	++++	+ + +	BBB	+++++	++++	++++	+ + +	++++	+ X + +	+ X + +	+ +	+ + + +	+++++	+++++	++++	+ + +	+++++	+ X + +	++++	+ X + +	+ X + +	++++	+++++	+ + +
Parathyroid REPRODUCTIVE SYSTEM	+	+		B	+	+	+		+	+	+	+			+	+		+	+	+	+	+	+	+	
Mammary gland Uterus Hemangioma Ovary Luteoma Granulosa cell tumor	+++	++	++	B B B	++	+ +	+ +	++	++	++	+ +	++	+ + +	+ + + X	+ + +	+ +	++	++	++	+ X +	++	++	+++	+ +	+ +
Teratoma, NOS Teratoma, mahgnant	x																								
NERVOUS SYSTEM Brain	+	+	+	в	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Harderian gland Carcinoma, NOS	N	N	N	В	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N
ALL OTHER SYSTEMS Multiple organs, NOS Hemangiosarcoma Malignant lymphoma, NOS Malignant lymphoma, undifferentiated type	N	N	N	В	N	N X	N	N	N	N	N	N X	N	N	N	N X	N	N	N	N	N	N	N	N	N
Malgnant lymphona, histocytic type Malgnant lymphona, histocytic type Lymphocytic leukemia Tail				в	x		x		x				x		x			x		x			x	x	

ANIMAL NUMBER	0	0	0	0	0	0	0	0	0	0	0	al	01	- or	of the	0	0		al	O.	OI.	0	0	0	0	1
	1 7	1 9	$\begin{array}{c} 2\\ 0 \end{array}$	$\frac{2}{1}$	$\overset{\circ}{2}$	$\frac{3}{3}$	2	$\frac{2}{5}$	2 6	$\frac{1}{2}$	0 3 0	0 3 3	0 3 4	0 3 5	3 7	3 8	3 9	4 1	4	4 3	4 4	4 5	4	4 9	0 5 0	TOTAL
WEEKS ON STUDY	1 0 4	1 0 4	$\begin{array}{c} 1 \\ 0 \\ 4 \end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	$1 \\ 0 \\ 4$	1 0 4	1 0 4	$1\\0\\4$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	$\begin{array}{c} 1\\0\\4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL TISSUES TUMORS
INTEGUMENTARY SYSTEM																					- <u>.</u>					***
Skin Adenoma, NOS Subcutaneous tissue Myxoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	* *	+ +	*49 1 *49 1
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Teratoma, metastatic Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	* x	49 3 1 49
HEMATOPOIETIC SYSTEM	·					<u> </u>											· · · ·								· ·	
Bone marrow Spleen Hemangtoma	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	49 49 1
Hemangiosarcoma Lymph nodes Thymus Malignant lymphoma, lymphocytic type	+++	+	+ +	+ +	X + +	+ +	+ +	+ +	+	+ +	+ +	+ +	- +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	1 44 46 1
CIRCULATORY SYSTEM Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
DIGESTIVE SYSTEM Salıvary gland Lıver Hepatocellular adenoma Hepatocellular carcınoma	+++++	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ + X	+ +	+ + X	+ +	+ +	+ +	49 49 5 1
Malignant lymphoma, histiocytic type Bile duct Gallbladder & common bile duct Pancreas Esophagus Stomach Small intestine Large intestine	+++++	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + +	+ + + + + +	++++++	+ + + + + + +	+ + + + + +	+ + + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + +	+ + + + + +	1 49 *49 47 49 49 49 47 48
URINARY SYSTEM Kıdney Teratoma, metastatıc Urınary biadder	+++	+++	+++	+++	+++	++++	+++	++	+++	+++	+	+++	++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	++	+++	49 1 47
ENDOCRINE SYSTEM Pituitary Carcinoma, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ x	+	+	+	+	+	+	+	+	+	+	49
Adenoma, NOS Adrenal Thyroid Parathyroid	X + + -	X + + +	+ +	X + + +	+ + +	X + +	+ + -	X + +	+ + +	++++	+++	+ + +	++++	+ + +	X + + +	X + +	+ + -	X + +	+ + +	++	+ + -	+ + +	+ + +	+ + +	X + -	14 48 48 31
REPRODUCTIVE SYSTEM Mammary gland Uterus Hemangnoma	+++++	+++	+ +	+ +	++	+ +	+++	+++	+ +	++++	++++	++++	++++	++++	+++	++++	+++	++++	+++	++++	++++	++++	+++	++	+ +	*49 49 1
Ovary Luteoma Granulosa cell tumor Teratoma, NOS Teratoma, malignant	+	-	x x	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+		+	+	+	+	+	+	$\begin{array}{c} 46\\1\\2\\1\\1\\1\end{array}$
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
SPECIAL SENSE ORGANS Harderian gland Carcinoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*49
ALL OTHER SYSTEMS Multiple organs, NOS Hemangiosarcoma Malignant lymphoma, NOS Mal. lymphoma, undifferentiated type Moliomet humphome betweets type	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*49 1 1 1
Malignant lymphoma, histiocytic type Malignant lymphoma, mixed type Lymphocytic leukemia	x	x		x	x		x	x	x		x		x	x	x				x					x		1 19 1
Tail Fibrous histiocytoma	1																									1

TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: LOW DOSE (Continued)

* Animals necropsied

SIUDI	OFL	n i	11	INU	<i>J</i> 191	IU	114	31	LA	117	111	L .	пр	un	D	ບອ	C.								
ANIMAL NUMBER	0 6 5	0 6 2	0 6 3	0 9 5	0 8 6	0 6 6	0 8 9	0 6 8	0 5 3	0 6 7	0 5 1	0 5 2	0 5 4	0 5 5	0 5 6	0 5 7	0 5 8	0 5 9	0 6 0	0 6 1	0 6 4	0 6 9	0 7 0	0 7 1	$\begin{array}{c} 0 \\ 7 \\ 2 \end{array}$
WEEKS ON STUDY	0 2 2	0 7 4	0 8 4	0 9 3	0 9 4	0 9 6	0 9 8	$1 \\ 0 \\ 2$	1 0 3	$1\\0\\3$	1 0 4	$\begin{array}{c}1\\0\\4\end{array}$	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4							
INTEGUMENTARY SYSTEM Subcutaneous tissue Hemangioma Neurilemoma	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+ X	+	+	+	+
RESPIRATORY SYSTEM Lungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Trachea	+	+	+	+	+	+	+	+ X +	+	+	+	+	+	+	++	+ X +	+	+	+++	+	+	+	++	+	++
HEMATOPOIETIC SYSTEM Bone marrow Spleen Malıgnant lymphoma, mıxed type Lymph nodes	+++++++++++++++++++++++++++++++++++++++	++++++	++++++	+++++	+++++	+++++	+ + +	+++++	++++++	+ + +	++++++	++++++	++++++	+ + +	++++++	+ + +	+ + +	+ + +	+ + +	+++++	+++++	+ + +	+ + +	+ + +	 + + +
Teratoma, metastatic Thymus CIRCULATORY SYSTEM		+	+	+	+	-	+		_	+	+	+	+	+		+	+	+	+	+	+	+	+	_	+
Heart DIGESTIVE SYSTEM Saivary gland	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver Hepatocellular adenoma Hepatocellular carcinoma Malig lymphoma, histocytic type	+	+	+ X	÷	÷	+	÷	+	÷	+ X	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+
Bile duct Gallbladder & common bile duct Pancreas Esophagus Stomach	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + + +	+ N + + +	+ + + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + - + +	+++++	+ + + + +	+ + + + +	++++++	+ + + + +	+ + + + +	+ + + + +	++++++	+ + + + +	+++++	++++++	+ + + + +	++++++	++++++	+++++	+ + + + +
Small intestine Large intestine	++	+++	++++	+++	++	++++	+++	++	++	+++	+++	+++	+++	+++	++	+++	++++	+++	+++	+++	++	+++	++	++	++
URINARY SYSTEM Kidney Urinary bladder	-	+ +	++	+ +	++	+ +	+ +	+ +	+ +	+ +	+ +	++	++++	+ +	+ +	+ +	++	+ +	+ +	+ +	+ +	+ +	++++	+ +	+ +
ENDOCRINE SYSTEM Pituitary Adenoma, NOS Adrenal Pheochromocytoma	++	+ +	+ +	* * +	+ X +	+ +	+ +	+ X +	+ X +	+ +	+ +	+ +	+ +	+ X +	+ X +	+ +	+ +	+ +	+ +	+ +	+ +	+ X +	+ +	+ +	+ X +
Thyroid Follicular cell adenoma Parathyroid	+ -	+	+	+	+	+	+	+	+	+	* * -	+	+ +	+ +	+ +	+ +	+ +	+	+	+	+	+	+	+ +	+ +
REPRODUCTIVE SYSTEM Mammary gland Adenosquamous carcinoma Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	* X +	+	+	+	+	+	+	+	+
Ovary Alveolar/bronchiolar carcinoma, metastatic Luteoma Granulosa cell tumor Teratoma, malignant	+ X	+	+	-	+	+	+	, X	- -	÷	+	+	÷	+	+	÷	+	+	+	+	+	+	÷	÷	÷
NERVOUS SYSTEM Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPECIAL SENSE ORGANS Harderian gland Carcinoma NOS	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	N
BODY CAVITIES Mediastinum Alveolar/bronchiolar carcinoma, metastat.c	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
ALL OTHER SYSTEMS Mult.ple organs, NOS Malignant lymphoma, histiocytic type Malignant lymphoma, mixed type	N	N	N	N	N X	N X	N X	N	N X	N X	N	N X	N X	N X	N	N X	N K	N	N	N X	N X	N X	N X	N	N
	·····																								

TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE IN THE TWO-YEAR FEEDSTUDY OF ERYTHROMYCIN STEARATE: HIGH DOSE

ANIMAL NUMBER	0 7 3	0 7 4	0 7 5	0 7 6	0 7 7	0 7 8	0 7 9	0 8 0	0 8 1	0 8 2	0 8 3	0 8 4	0 8 5	0 8 7	0 8 8	0 9 0	0 9 1	0 9 2	0 9 3	0 9 4	0 9 6	0 9 7	0 9 8	0 9 9	1 0 0	
WEEKS ON STUDY	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	1 0 4	TOTAL TISSUES TUMORS
NTEGUMENTARY SYSTEM ubcutaneous tissue Hemangioma Neurilemoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*50 1 1
ESPIRATORY SYSTEM ungs and bronchi Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma rachea	+ +	+	+	++	+	+	+	++	+	+	+	++	+		+	+	+	+	+	+	+++	+	++	+	++	49 1 1 49
IEMATOPOIETIC SYSTEM Jone marrow Spleen Malggnant lymphoma, mixed type Jymph nodes Teratoma, metastatic Chymus	++++	++++	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + +	+ + + +	+ + - +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + -	+ + + +	+ + X + +	+ + + +	+ + + +	+ + + +	 + + +	50 50 1 48 1 41
CIRCULATORY SYSTEM	+	+	+	+	+	+	+	+	+	+	+	+	+	_	+	+	+	+	+	+	+	+	+	+	+	49
DIGESTIVE SYSTEM Salivary gland Liver Hepatocellular adenoma Hepatocellular carcinoma Malignant lymphoma, histiocytic type Bile duct Gallbladder & common bile duct Pancreas Esophagus Stomach Small intestine Large intestine URINARY SYSTEM Kidney Urinary bladder ENDOCRINE SYSTEM Pituitary Adenoma, NOS	+++++++++++++++++++++++++++++++++++++++	++ ++++++ ++ ++	+++++++++++++++++++++++++++++++++++++++	++ ++++++++++++++++++++++++++++++++++++	+++++++++++++++*	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++ ++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + X	+++++++++++++++++++++++++++++++++++++++	++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + X	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + X + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + +	++ +++++ ++ ++ ++	+ + + + + + + + + + + + X	+++++++++++++++++++++++++++++++++++++++	+++ ++++++ ++ ++	50 50 1 1 50 *50 49 49 49 50 50 50 50 48 50 48
Adrenal Pheochromocytoma Thyroid Follicular cell adenoma Parathyroid	++++++	+ X + +	+ + +	+ + +	++	+ + +	+ + +	+ + +	+ + +	+ + +	++	+ + +	+ + +	+	+ + +	+ + +	+ + +	+ + -	+ + -	+ + +	+ + +	+ + +	+ + +	+ + +	+ - -	50 1 48 1 34
REPRODUCTIVE SYSTEM Mammary gland Adenosquamous carcinoma Uterus Ovary Alveolar/bronchiolar carcinoma, meta Luteoma Granulosa cell tumor Teratoma, malignant	+ + + +	+ + +	+ + +	+ + +	N + +	+++++	+ + +	+ + +	+ + +	+ + +	+ + +	++++	+ + +	++++	+ + + X	+ + + X	+ + +	+ + +	+ + +	+ + + X	+ + + X	+ + +	+ + +	++++	+ + +	*50 1 50 48 1 2 2 1
NERVOUS SYSTEM	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
PECIAL SENSE ORGANS Hardeman gland Carcinoma, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 1
BODY CAVITIES Mediastinum Alveolar/bronchiolar carcinoma, meta	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50 1
ALL OTHER SYSTEMS Multiple organs, NOS Malignant lymphoma, histiocytic type Malignant lymphoma, mixed type	N	N	N	N	N	N X	N	N	N X	N	N X	N X	N X	N X	N X	N X	N	N X	N	N X	N	N X	N X	N X	N	*50 1 26

TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: HIGH DOSE (Continued)

* Animals necropsied

	Control	2,500 ppm	5,000 ppm
Lung: Alveolar/Bronchiolar Adenoma			
Overall Rates (a)	3/50 (6%)	3/49 (6%)	1/49 (2%)
Adjusted Rates (b)	7.9%	8.0%	2.6%
Terminal Rates (c)	3/38 (8%)	2/34 (6%)	1/39 (3%)
Week of First Observation	104	90	104
Life Table Tests (d)	P = 0.237N	P = 0.614	P = 0.296N
Incidental Tumor Tests (d)	P = 0.267 N	P = 0.642	P = 0.296N
Cochran-Armitage Trend Test (d)	P = 0.246N		1 0120011
Fisher Exact Test (d)		P = 0.651	P = 0.316N
Lung: Alveolar/Bronchiolar Adenoma or (Carcinoma		
Overall Rates (a)	4/50 (8%)	3/49 (6%)	2/49 (4%)
Adjusted Rates (b)	10.5%	8.0%	4.8%
Terminal Rates (c)	4/38 (11%)	2/34 (6%)	1/39 (3%)
Week of First Observation	104	90	102
Life Table Tests (d)	P = 0.258N	P = 0.557N	P = 0.321 N
Incidental Tumor Tests (d)	P = 0.297N	P = 0.530N	P = 0.338N
Cochran-Armitage Trend Test (d)	P = 0.273N	1 0100011	1 - 0.00011
Fisher Exact Test (d)	1 0.41011	P = 0.511 N	P = 0.349N
Hematopoietic System: Malignant Lympho	oma. Mixed Type		
Overall Rates (a)	28/50 (56%)	19/49 (39%)	27/50 (54%)
Adjusted Rates (b)	63.3%	48.0%	61.3%
Terminal Rates (c)	22/38 (58%)	14/34 (41%)	23/40 (58%)
Week of First Observation	91	89	94
Life Table Tests (d)	P = 0.378N	P = 0.154N	P = 0.404N
Incidental Tumor Tests (d)	P = 0.477N	P = 0.097N	P = 0.496N
Cochran-Armitage Trend Test (d)	P = 0.460N	1 -0.00111	1 - 0.40011
Fisher Exact Test (d)	1 = 0.40011	P = 0.065 N	P = 0.500 N
Hematopoietic System: Lymphoma, All Ma	alignant		
Overall Rates (a)	29/50 (58%)	23/49 (47%)	29/50 (58%)
Adjusted Rates (b)	64.1%	54.5%	63.0%
Terminal Rates (c)	22/38 (58%)		23/40 (58%)
Week of First Observation	80	15/34 (44%)	
		89 D-0.047N	84 D - 0 477D
Life Table Tests (d)	P = 0.447N	P = 0.347N	P = 0.477N
Incidental Tumor Tests (d)	P = 0.469	P = 0.236N	P = 0.499
Cochran-Armitage Trend Test (d) Fisher Exact Test (d)	P = 0.540	D-0.194N	P = 0.580N
		P = 0.184N	P=0.5001
Hematopoietic System: Lymphoma or Leu Overall Rates (a)	kemia 29/50 (58%)	24/49 (49%)	29/50 (58%)
Adjusted Rates (b)	64.1%	56.9%	63.0%
Terminal Rates (c)	22/38 (58%)	16/34 (47%)	23/40 (58%)
Week of First Observation	80	89	23/40 (38%) 84
Life Table Tests (d)	P = 0.446N	P = 0.417N	P = 0.477N
Incidental Tumor Tests (d)	P = 0.440 N P = 0.471	P = 0.417 N P = 0.307 N	P = 0.477 N P = 0.499
Cochran-Armitage Trend Test (d)	P = 0.540	x = 0.00 (11	1 - 0.400
Fisher Exact Test (d)	x 0.040	P = 0.243N	P = 0.580 N
ribher Bhaet rest (a)			
	anginsarcoma		
Circulatory System: Hemangioma or Hem		4/49 (8%)	1/50 (2%)
Circulatory System: Hemangioma or Hem Overall Rates (a)	1/50 (2%)	4/49 (8%) 10 1%	1/50 (2%) 2 5%
Circulatory System: Hemangioma or Hem Overall Rates (a) Adjusted Rates (b)	1/50 (2%) 2.1%	10.1%	2.5%
Circulatory System: Hemangioma or Hem Overall Rates (a) Adjusted Rates (b) Terminal Rates (c)	1/50 (2%) 2.1% 0/38 (0%)	10.1% 2/34 (6%)	2.5% 1/40 (3%)
Circulatory System: Hemangioma or Hem Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation	1/50 (2%) 2.1% 0/38 (0%) 91	10.1% 2/34 (6%) 90	2.5% 1/40 (3%) 104
Circulatory System: Hemangioma or Hem Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation Life Table Tests (d)	1/50 (2%) 2.1% 0/38 (0%) 91 P = 0.591 N	10.1% 2/34(6%) 90 P=0.156	$2.5\% \\ 1/40 (3\%) \\ 104 \\ P = 0.757 N$
Circulatory System: Hemangioma or Hem Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation	1/50 (2%) 2.1% 0/38 (0%) 91	10.1% 2/34 (6%) 90	2.5% 1/40 (3%) 104

TABLE D3. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

	Control	2,500 ppm	5,000 ppm
Liver: Hepatocellular Adenoma			***************
Overall Rates (a)	3/50 (6%)	5/49 (10%)	1/50 (2%)
Adjusted Rates (b)	7.9%	14.0%	2.5%
Terminal Rates (c)	3/38 (8%)	4/34 (12%)	1/40 (3%)
Week of First Observation	104	97	104
Life Table Tests (d)	P = 0.249N	P = 0.298	P = 0.287N
Incidental Tumor Tests (d)	P = 0.255N	P = 0.305	P = 0.287N
		F = 0.305	F = 0.2071N
Cochran-Armitage Trend Test (d) Fisher Exact Test (d)	P = 0.264 N	P = 0.346	P = 0.309 N
Liver: Hepatocellular Adenoma or Carc	inoma		
Overall Rates (a)	4/50 (8%)	6/49 (12%)	2/50 (4%)
Adjusted Rates (b)	9.8%	16.9%	4.8%
Terminal Rates (c)	3/38 (8%)	5/34(15%)	1/40 (3%)
Week of First Observation	80	97	103
Life Table Tests (d)	P = 0.274N	P = 0.307	P = 0.320N
Incidental Tumor Tests (d)	P = 0.314N	P = 0.334	P = 0.410N
Cochran-Armitage Trend Test (d)	P = 0.291 N		
Fisher Exact Test (d)		P = 0.357	P = 0.339N
Anterior Pituitary Gland: Adenoma		1.1.10	1.4 (#000.00)
Overall Rates (a)	18/49 (37%)	14/49 (29%)	14/50 (28%)
Adjusted Rates (b)	44.8%	38.4%	31.5%
Terminal Rates (c)	16/38 (42%)	12/34 (35%)	10/40(25%)
Week of First Observation	95	93	93
Life Table Tests (d)	P = 0.186N	P = 0.393 N	P = 0.216N
Incidental Tumor Tests (d)	P = 0.181 N	P = 0.352N	P = 0.213N
Cochran-Armitage Trend Test (d)	P = 0.204 N		
Fisher Exact Test (d)		P = 0.259 N	P = 0.238N
Anterior Pituitary Gland: Adenoma or (Carcinoma		
Overall Rates (a)	19/49 (39%)	14/49 (29%)	14/50 (28%)
Adjusted Rates (b)	45.9%	38.4%	31.5%
Terminal Rates (c)	16/38 (42%)	12/34 (35%)	10/40 (25%)
Week of First Observation	91	93	93
Life Table Tests (d)	P = 0.139N	P = 0.322N	P = 0.166N
Incidental Tumor Tests (d)	P = 0.144N	P = 0.269N	P = 0.187N
Cochran-Armitage Trend Test (d)	P = 0.149N	1 = 0.20010	1 = 0.10110
Fisher Exact Test (d)	1 -0.1451	P = 0.196N	P = 0.178N
Overall Rates (a)	or 2/48 (4%)	2/46 (4%)	4/48 (8%)
Adjusted Rates (b)	4.9%	5.8%	10.0%
		5.8% 1/31 (3%)	
Terminal Rates (c)	1/36 (3%)		4/40(10%)
Week of First Observation	95 D0.905	100 D=0.645	104 D=0.270
Life Table Tests (d)	P = 0.295	P = 0.645	P = 0.379
Incidental Tumor Tests (d)	P = 0.247	P = 0.668	P = 0.342
	P = 0.253	D	•
Cochran-Armitage Trend Test (d)		P = 0.675	P = 0.339
Cochran-Armitage Trend Test (d) Fisher Exact Test (d)			
Fisher Exact Test (d)			
	24/50 (48%)	24/49 (49%)	22/50 (44%)
Fisher Exact Test (d) All Sites: Benign Tumors	24/50 (48%) 59.8%	24/49 (49%) 60.9%	22/50 (44%) 49.8%
Fisher Exact Test (d) All Sites: Benign Tumors Overall Rates (a)			
Fisher Exact Test (d) All Sites: Benign Tumors Overall Rates (a) Adjusted Rates (b)	59.8%	60.9%	49.8%
Fisher Exact Test (d) All Sites: Benign Tumors Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation	59.8% 22/38 (58%) 95	60.9% 19/34 (56%)	49.8% 18/40 (45%)
Fisher Exact Test (d) All Sites: Benign Tumors Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation Life Table Test (d)	59.8% 22/38 (58%) 95 P=0.305N	60.9% 19/34 (56%) 90 P = 0.374	49.8% 18/40 (45%) 93 P=0.335N
Fisher Exact Test (d) All Sites: Benign Tumors Overall Rates (a) Adjusted Rates (b) Terminal Rates (c) Week of First Observation	59.8% 22/38 (58%) 95	60.9% 19/34 (56%) 90	49.8% 18/40 (45%) 93

TABLE D3. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDYOF ERYTHROMYCIN STEARATE (Continued)

	Control	2,500 ppm	5,000 ppm
All Sites: Malignant Tumors	· · · · · · · · · · · · · · · · · · ·	<u></u>	• · · • • • • • • • • • • • • • • • • •
Overall Rates (a)	31/50 (62%)	27/49 (55%)	31/50 (62%)
Adjusted Rates (b)	67.0%	61.0%	64.5%
Terminal Rates (c)	23/38 (61%)	17/34 (50%)	23/40 (58%)
Week of First Observation	80	9	22
Life Table Test (d)	P = 0.445 N	P = 0.500 N	P = 0.474N
Incidental Tumor Test (d)	P = 0.484	P = 0.290N	P = 0.538
Cochran-Armitage Trend Test (d)	P = 0.541		
Fisher Exact Test (d)		P = 0.311N	P = 0.582N
All Sites: All Tumors			
Overall Rates (a)	44/50 (88%)	41/49 (84%)	39/50 (78%)
Adjusted Rates (b)	91.6%	87.2%	79.6%
Terminal Rates (c)	34/38 (89%)	28/34 (82%)	30/40 (75%)
Week of First Observation	80	9	22
Life Table Test (d)	P = 0.134N	P = 0.467	P = 0.143N
Incidental Tumor Test (d)	P = 0.137 N	P = 0.429N	P = 0.148N
Cochran-Armitage Trend Test (d)	P = 0.114N		
Fisher Exact Test (d)		P = 0.371 N	P = 0.144N

TABLE D3. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

	Untreat	ed Control	Low	Dose	High	Dose
ANIMALS INITIALLY IN STUDY	50		50		50	
ANIMALS NECROPSIED	50		49		50	
ANIMALS EXAMINED HISTOPATHOLOGIC	ALLY 50		49		50	
NTEGUMENTARY SYSTEM		<u> </u>				
*Skin	(50)		(49)		(50)	
Ulcer, acute	1	(2%)		(2%)		
Hyperkeratosis			1	(2%)		
RESPIRATORY SYSTEM						
#Tracheal gland	(50)		(49)		(49)	
Cyst, NOS					1	(2%)
Multiple cysts					1	(2%)
#Lung	(50)		(49)		(49)	
Atelectasis			1	(2%)		(2%)
Congestion, NOS		(4%)		(0.27)		(2%)
Hemorrhage		(2%)	4	(8%)		(4%)
Lymphocytic inflammatory infiltrate		(2%)			2	(4%)
Inflammation, chronic		(2%)	~	(19)		
Inflammation, chronic focal	1	(2%)	2	(4%)	-	(0) (7)
Perivascular cuffing		(90)			1	(2%)
Alveolar macrophages		(2%)				
Osteophyte Hyperplasia, adenomatous		(2%) (2%)	3	(6%)		
	·····				<u>.</u>	
IEMATOPOIETIC SYSTEM						
*Multiple organs	(50)	(4.4.4)	(49)	(1.0 %)	(50)	(
Hyperplasia, lymphoid		(14%)		(12%)		(12%)
*Subcutaneous tissue	(50)	(90)	(49)		(50)	
Mastocytosis #Bone marrow		(2%)	(40)		(50)	
Cyst, NOS	(50)		(49)		(50)	(901)
Fibrosis, focal	9	(4%)				(2%)
Lipoidosis		(2%)			1	(2%)
Atrophy, NOS		(2%) (2%)	2	(6%)	1	(901)
Hyperplasia, NOS		(6%)		(6%)	1	(2%)
Angiectasis		(0%) (2%)		(2%)		
Hyperplasia, granulocytic		(26%)		(12%)	5	(10%)
#Spleen	(50)	~~~~~	(49)		(50)	(10/0)
Inflammation, acute/chronic	(····/			(2%)
Amyloidosis	1	(2%)				
Hemosiderosis	1	(2%)	1	(2%)	1	(2%)
Leukemoid reaction	1	(2%)				
Hyperplasia, reticulum cell				(6%)		(4%)
Hyperplasia, lymphoid		(22%)		(35%)		(22%)
Hematopoiesis		(18%)		(14%)		(12%)
#Mandibular lymph node	(45)		(44)		(48)	
Hemorrhage				(2%)	1	(2%)
Angiectasis		(2%)	1	(2%)		
Hyperplasia, lymphoid Mastocytosis	1	(2%)	1	(2%)	2	(4%)
#Renal lymph node	(45)		(44)	(270)	(48)	
Plasmacytosis		(2%)	(44)		(40)	
#Lung	(50)	(2.70)	(49)		(49)	
Leukocytosis, NOS	(00)			(2%)	(=3)	
Hyperplasia, lymphoid	2	(4%)		(6%)		
#Salivary gland	(50)		(49)		(50)	

	Untreat	ted Control	Low	Dose	High	Dose
HEMATOPOIETIC SYSTEM (Continued)						
#Liver	(50)		(49)		(50)	
Hematopoiesis		(4%)	((
#Pancreas	(49)		(47)		(49)	
Hyperplasia, lymphoid	(,			(2%)	x	
#Kidney	(50)		(49)		(50)	
Hyperplasia, lymphoid	9	(18%)	7	(14%)	8	(16%)
#Urinary bladder	(50)		(47)		(48)	
Hyperplasia, lymphoid	1	(2%)	9	(19%)	7	(15%)
#Mesovarium	(48)		(46)		(48)	
Hyperplasia, lymphoid	1	(2%)				
#Anterior pituitary	(49)		(49)		(50)	
Hyperplasia, eosinophilic				(2%)		
#Adrenal cortex	(50)		(48)		(50)	
Hematopoiesis		(4%)				
#Thymus	(41)		(46)		(41)	
Cyst, NOS		(7%)		(11%)		(5%)
Multiple cysts		(15%)		(11%)	-	(20%)
Atrophy, NOS	2	(5%)		(2%)		(5%)
Hyperplasia, epithelial				(4%)		(2%)
Hyperplasia, lymphoid	4	(10%)	6	(13%)	1	(2%)
CIRCULATORY SYSTEM						
*Multiple organs	(50)		(49)		(50)	
Perivasculitis	1	(2%)				
#Lung/bronchus	(50)		(49)		(49)	
Thrombosis, NOS	1	(2%)				
#Myocardium	(50)		(49)		(49)	
Fibrosis, focal			1	(2%)		
Perivascular cuffing			1	(2%)		
#Ovary	(48)		(46)		(48)	
Thrombosis, NOS	2	(4%)			1	(2%)
#Thyroid	(50)		(48)		(48)	
Perivasculitis	1	(2%)				
DIGESTIVE SYSTEM						
#Salivary gland	(50)		(49)		(50)	
Ectopia						(2%)
Mineralization				(2%)		
Dilatation/ducts			1	(2%)		
Multiple cysts					1	(2%)
Necrosis, focal	1	(2%)				
Atrophy, focal						(2%)
#Liver	(50)		(49)		(50)	
Ectopia		(2%)				
Lymphocytic inflammatory infiltrate	1	(2%)	1	(2%)		
Inflammation, acute focal					1	(2%)
Degeneration, NOS		(2%)		(2%)		
Necrosis, focal	9	(18%)		(10%)	8	(16%)
Necrosis, coagulative				(2%)		
Metamorphosis, fatty			1	(2%)	1	(2%)
Pigmentation, NOS	1	(2%)				
Basophilic cyto change						(2%)
Focal cellular change	1	(2%)				(2%)
Clear cell change				(2%)	1	(2%)
Hepatocytomegaly		(2%)		(2%)		
*Gallbladder	(50)		(49)		(50)	
Cyst, NOS	1	(2%)	9	(4%)	1	(2%)
Hemosiderosis	L	(270)	4	(10)		(2%)

	Untreat	ed Control	Low	Dose	High	Dose
DIGESTIVE SYSTEM (Continued)					, , , , , , , , , , , , , , , , , , , 	
#Bile duct	(50)		(49)		(50)	
Cyst, NOS		(2%)	(40)		4 · · · · ·	(2%)
Degeneration, hyaline	-	(2,0)	1	(2%)	•	(2,0)
#Pancreas	(49)		(47)	(2,0)	(49)	
Lymphocytic inflammatory infiltrate	(40)		(41)			(2%)
Inflammation, chronic						(2%)
Atrophy, NOS	3	(6%)	9	(4%)		(2%)
#Pancreatic acinus	(49)	(0%)	(47)	(470)	(49)	(270)
Cytoplasmic vacuolization	(43)			(2%)	(45)	
Hypertrophy, focal	1	(2%)		(2%) (2%)		
#Stomach	(49)	(270)	(49)	(276)	(50)	
Lymphocytic inflammatory infiltrate		(2%)	(45)		(50)	
Inflammation, chronic focal	1	(270)	1	(2%)		
#Glandular stomach	(49)		(49)	(2%)	(50)	
Mineralization	(49)			(901)	(50)	
	0	(6%)		(2%)	-	(100)
Cyst, NOS Multiple gyste		(- · · ·)		(8%)		(10%)
Multiple cysts Inflammation, acute/chronic		(6%)		(6%)	1	(2%)
,		(2%)	-	(6%)		
Inflammation, chronic	2	(4%)	1	(2%)	-	
Degeneration, hyaline		(0~)	-			(2%)
Calcification, NOS		(2%)	3	(6%)		(4%)
Dysplasia, NOS		(2%)				(2%)
#Forestomach	(49)		(49)		(50)	
Cyst, NOS		(2%)				
Multiple cysts		(4%)				
Inflammation, acute	1	(2%)				
Inflammation, acute/chronic				(2%)		
Inflammation, chronic focal			1	(2%)		
Erosion		(2%)				
Crystals, NOS	1	(2%)				
JRINARY SYSTEM			·		<u> </u>	<u> </u>
#Kidney	(50)		(49)		(50)	
Cyst, NOS		(2%)		(2%)		(2%)
Multiple cysts		(2%)	1	(2 %)	+	(270)
Hemorrhage		(2%)				
Lymphocytic inflammatory infiltrate		(2%)			1	(2%)
Glomerulonephritis, acute		(2%)	1	(901)	1	(270)
		(2%) (2%)	1	(2%)		
Pyelonephritis, acute						
Glomerulonephritis, subacute	1	(2%)	0	(40)		
Glomerulonephritis, chronic	4	(0,0)		(4%)	•	(00)
Nephropathy	4	(8%)	3	(6%)		(6%)
Nephrosis, NOS				(0~)	1	(2%)
Nephrosis, hemoglobinuric			1	(2%)		
Calcification, NOS					1	(2%)
Metaplasia, osseous		(4%)		(4%)		
#Renal papilla	(50)		(49)		(50)	
Necrosis, NOS		(2%)				
#Perirenal tissue	(50)		(49)		(50)	
Inflammation, acute/chronic					1	(2%)
Necrosis, fat						(2%)
#Kidney/glomerulus	(50)		(49)		(50)	
Amyloidosis		(2%)	/			(2%)
#Convoluted tubules	(50)		(49)		(50)	
Degeneration, hyaline	(00)		()			(8%)
#Kidnev/pelvis	(50)		(49)		(50)	
Amyloidosis		(2%)	(10)		(00)	
#Urinary bladder	(50)	(=)	(47)		(48)	
		(2%)	(=)		(40)	
Perivascular cuffing	1	(2%)				

	Untreat	ed Control	Low	Dose	High	Dose
ENDOCRINE SYSTEM			<u> </u>			
#Pituitary	(49)		(49)		(50)	
Angiectasis		(6%)		(2%)		(4%)
#Pituitary intermedia	(49)		(49)		(50)	
Hyperplasia, focal		(2%)				
#Anterior pituitary	(49)		(49)		(50)	
Cyst, NOS		(4%)		(2%)		
Focal cellular change	2	(4%)	_	(4%)		(4%)
Hypertrophy, focal		((2%)		(2%)
Hyperplasia, focal		(31%)		(29%)		(24%)
#Pituitary acidophil cell	(49)		(49)		(50)	(99)
Hyperplasia, NOS	(40)		(10)			(2%)
#Pituitary posterior	(49)	(2%)	(49)		(50)	
Gliosis #Adrenal/capsule	(50)	(270)	(48)		(50)	
Cyst, NOS		(2%)	(40)		(00)	
Hyperplasia, stromal		(98%)	44	(92%)	50	(100%)
#Adrenal cortex	(50)	(20.0)	(48)		(50)	(=== 0,0)
Ectopia		(12%)		(10%)		(4%)
Cyst, NOS		(2%)	-		-	
Degeneration, lipoid	2	(4%)	2	(4%)	1	(2%)
Amyloidosis						(2%)
Hypertrophy, focal	3	(6%)		(6%)		(2%)
Hyperplasia, focal				(2%)		(2%)
#Adrenal medulla	(50)		(48)		(50)	
Focal cellular change				(27)	1	(2%)
Hyperplasia, focal				(2%)	(10)	
#Thyroid	(50)		(48)		(48)	(90)
Follicular cyst, NOS						(2%)
Inflammation, acute focal	1	(2%)			1	(2%)
Inflammation, acute/chronic Inflammation, chronic focal		(2%)			1	(2%)
Hyperplasia, follicular cell	1	(4, 10)				(2%)
#Thyroid follicle	(50)		(48)		(48)	
Multiple cysts		(2%)	()		(10)	
Inflammation, acute		(2%)				
Degeneration, NOS		-			1	(2%)
Hyperplasia, papillary	9	(18%)		(13%)		(17%)
Hyperplasia, cystic			2	(4%)		(2%)
#Parathyroid	(29)		(31)		(34)	
Ectopia				(3%)	-	(0 ~)
Cyst, NOS		(0.01)	1	(3%)		(3%)
Multiple cysts		(3%)	/ A 17 \			(3%)
#Pancreatic islets	(49)		(47)	(2%)	(49)	
Hyperplasia, NOS			1	(4 /0)		
EPRODUCTIVE SYSTEM						
*Mammary gland	(50)		(49)		(50)	
Dilatation/ducts		(10%)	7	(14%)	8	(16%)
Cyst, NOS	1	(2%)		(0.4)		
Fibrosis				(2%)		
Hyperplasia, NOS				(2%)	(50)	
*Mammary duct	(50)		(49)	(90)	(50)	
Dilatation, NOS	(=0)			(2%)	(50)	
#Uterus	(50)	(4%)	(49) G	(18%)		(2%)
Dilatation, NOS Cyst, NOS	Z	(+±-70)		(18%) (2%)	I	(270)
v ,			1	(2,0)	1	(2%)
Pyometra #Uterus/endometrium	(50)		(49)		1501	
#Uterus/endometrium	(50) 3	(6%)	(49) 3	(6%)	(50) 2	(4%)
		(6%)		(6%)	2	(4%) (2%)

	Untreat	ed Control	Low	Dose	High	Dose
REPRODUCTIVE SYSTEM		<u></u>		- <u></u>		,
#Uterus/endometrium (Continued)	(50)		(49)		(50)	
Inflammation, acute		(2%)	(40)		(00)	
Hyperplasia, cystic		(88%)	38	(78%)	45	(90%)
Hyperplasia, stromal		(2%)		(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		(00,00)
Angiectasis		(6%)	2	(4%)	5	(10%)
#Fallopian tube	(50)		(49)		(50)	
Cyst, NOS	1	(2%)				
Multiple cysts	1	(2%)				
#Ovary/parovarian	(48)		(46)		(48)	
Inflammation, acute/chronic						(2%)
#Ovary	(48)		(46)		(48)	
Cyst, NOS	6	(13%)	10	(22%)		(21%)
Multiple cysts	2	(4%)	3	(7%)		(8%)
Hematoma, NOS	5	(10%)	7	(15%)		(10%)
Abscess, NOS	3	(6%)			-	
Calcification, NOS					2	(4%)
Angiectasis	3	(6%)	2	(4%)	2	(4%)
#Mesovarium	(48)		(46)		(48)	
Multiple cysts					1	(2%)
Necrosis, fat					1	(2%)
NERVOUS SYSTEM					·····	
#Brain	(50)		(49)		(50)	
Congestion, NOS	1	(2%)				
Hemorrhage			2	(4%)	1	(2%)
Lymphocytic inflammatory infiltrate	1	(2%)			-	/
Perivascular cuffing		(2%)				
#Brain/thalamus	(50)	,	(49)		(50)	
Calcification, NOS		(32%)		(24%)	(-+)	(36%)
#Cerebellum	(50)		(49)	((50)	(
Perivascular cuffing				(2%)	(10)	
PECIAL SENSE ORGANS		······································			·····	
*Eye/cornea	(50)		(49)		(50)	
Inflammation, acute	(20)			(2%)	(23)	
*Ear	(50)		(49)		(50)	
Hemorrhage		(2%)	· · · ·			
MUSCULOSKELETAL SYSTEM				· · · · · · · · · · · · · · · · · · ·	<u></u>	
*Bone	(50)		(49)		(50)	
Fibrous osteodystrophy	1	(2%)				
Osteosclerosis	17	(34%)	17	(35%)	17	(34%)
*Skeletal muscle	(50)		(49)		(50)	
Necrosis, NOS			1	(2%)		
BODY CAVITIES						<u> </u>
*Pleura	(50)		(49)		(50)	
Inflammation, suppurative	1	(2%)				
*Mesentery	(50)		(49)		(50)	
Inflammation, acute					1	(2%)
Inflammation, acute/chronic					1	(2%)
Necrosis, fat						(2%)

TABLE D4. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE
TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

	Untreated Control	Low Dose	High Dose
LL OTHER SYSTEMS			
*Multiple organs	(50)	(49)	(50)
Amyloidosis	1 (2%)	1 (2%)	
Tail			
Osteosclerosis			1
Knee			
Dyschondroplasia	4	3	7
Adipose tissue			
Necrosis, fat	3	1	3

TABLE D4. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THETWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE (Continued)

* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically. # Number of animals examined microscopically at this site

APPENDIX E

GENETIC TOXICOLOGY OF

ERYTHROMYCIN STEARATE

		PAGE
TABLE E1	MUTAGENICITY OF ERYTHROMYCIN STEARATE IN <i>SALMONELLA</i> <i>TYPHIMURIUM</i>	146
TABLE E2	MUTAGENICITY OF ERYTHROMYCIN STEARATE IN MOUSE L5178Y LYMPHOMA CELLS	147
TABLE E3	INDUCTION OF SISTER CHROMATID EXCHANGES IN CHINESE HAMSTER OVARY CELLS BY ERYTHROMYCIN STEARATE	149
TABLE E4	INDUCTION OF CHROMOSOMAL ABERRATIONS IN CHINESE HAMSTER OVARY CELLS BY ERYTHROMYCIN STEARATE	150

Strain	Dose		20		nts/plate (b) amster)	+ 90	(rat)
Strain	(µg/plate)	Trial 1	Trial 2	Trial 1	Trial 2	Trial 1	Trial 2
 TA100	0	108 ± 3.2	104 ± 4.6	134 ± 8.3	117 ± 5.3	116 ± 7.8	133 ± 10.4
	0.3		117 ± 2.8		140 ± 1.9		140 ± 6.1
	1	168 ± 10.3	101 ± 6.8	114 ± 12.4	120 ± 14.9	120 ± 9.3	136 ± 8.5
	3	129 ± 4.8	103 ± 7.2	90 ± 6.5	128 ± 7.1	142 ± 18.3	125 ± 12.6
	10	95 ± 13.6	72 ± 7.4	63 ± 7.2	114 ± 5.8	116 ± 9.7	114 ± 6.8
	33	Toxic	13 ± 1.8	(c) 0 ± 0.0	(c) 24 ± 24.0	$(c) 0 \pm 0.0$	57 ± 5.5
	100	Toxic		(c) 0 ± 0.0		Toxic	
Trial Posit		Negative	Negative	Negative	Negative	Negative	Negative
	rol(d)	467 ± 18.0	419 ± 12.6	$2,355 \pm 34.5$	778 ± 10.2	846 ± 26.4	495 ± 23.2
TA1535	0	31 ± 0.7	32 ± 1.8	42 ± 3.6	35 ± 4.3	41 ± 5.5	24 ± 1.3
	0.3		20 ± 3.9		22 ± 3.9		32 ± 2.0
	1	39 ± 3.2	27 ± 3.8	31 ± 3.3	20 ± 3.3	43 ± 5.3	29 ± 2.3
	3	31 ± 5.7	25 ± 2.6	26 ± 1.9	18 ± 1.5	35 ± 4.2	27 ± 0.6
	10	23 ± 3.5	24 ± 2.6	32 ± 3.2	15 ± 1.9	42 ± 5.2	19 ± 1.2
	33	21 ± 3.0	16 ± 2.1	$(c) 6 \pm 6.0$	14 ± 2.6	27 ± 0.9	23 ± 4.9
	100	(c) 0 ± 0.0		(c) 0 ± 0.0		11 ± 1.9	
Trial Posit	summary ive	Negative	Negative	Negative	Negative	Negative	Negative
cont	rol (d)	443 ± 29.1	379 ± 22.3	645 ± 25.2	356 ± 53.3	331 ± 13.7	120 ± 13.2
TA1537		11 ± 1.8	6 ± 0.6	19 ± 4.7	7 ± 0.7	14 ± 1.2	15 ± 1.2
	0.3		6 ± 0.3		11 ± 3.3		13 ± 0.7
	1	9 ± 2.5	5 ± 1.3	14 ± 0.3	7 ± 0.9	11 ± 1.5	13 ± 3.2
	3	16 ± 1.5	4 ± 0.9	10 ± 2.2	5 ± 1.2	$10 \pm 1.2 \\ 11 \pm 4.0$	9 ± 0.3 11 ± 2.7
	10	14 ± 3.5	7 ± 1.7 3 ± 1.0	15 ± 1.7	$9 \pm 2.6 \\ 7 \pm 2.3$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	11 ± 2.7 6 ± 1.5
	33	7 ± 1.2	3 ± 1.0	$(c) 2 \pm 2.0$	1 ± 2.3	$(c) 1 \pm 1.0$	0 <u>-</u> 1.5
	100	Toxic		(c) 0 ± 0.0		(0) 1 \pm 1.0	
Tria. Posit	l summary tive	Negative	Negative	Negative	Negative	Negative	Negative
cont	trol(d)	388 ± 33.5	277 ± 25.1	591 ± 16.8	454 ± 17.6	266 ± 9.8	204 ± 14.8
TA98	0	28 ± 2.2	18 ± 3.8	48 ± 5.8	26 ± 2.9	37 ± 2.3	33 ± 4.0
	0.3		22 ± 1.7		31 ± 4.4		31 ± 5.2
	1	29 ± 2.0	17 ± 0.3	27 ± 3.8	27 ± 3.6	48 ± 7.9	40 ± 6.7
	3	25 ± 0.6	19 ± 5.2	29 ± 0.3	28 ± 0.9	43 ± 1.2	35 ± 5.0
	10	25 ± 2.3	10 ± 1.2	22 ± 3.0	24 ± 4.2	34 ± 6.6	24 ± 1.5
	33	20 ± 2.6	8 ± 2.2	9 ± 4.4	22 ± 1.5	35 ± 7.1	29 ± 2.2
	100	Toxic		(c) 0 ± 0.0		-22 ± 4.0	
Tria Posit	l summary tive	Negative	Negative	Negative	Negative	ų.	Negative
	trol(d)	758 ± 14.2	730 ± 18.6	$1,856 \pm 19.6$	477 ± 29.8	436 ± 5.1	401 ± 33.1

TABLE E1. MUTAGENICITY OF ERYTHROMYCIN STEARATE IN SALMONELLA TYPHIMURIUM (a)

(a) Study performed at SRI International. The detailed protocol is presented by Haworth et al. (1983). Cells and study compound or solvent (95% ethanol) were incubated in the absence of exogenous metabolic activation (-S9) or with Aroclor 1254-induced S9 from male Syrian hamster liver or male Sprague Dawley rat liver. High dose was limited by toxicity or solubility but did not exceed 10 mg/plate; 0 µg/plate dose is the solvent control.

(b) Revertants are presented as mean \pm standard error from three plates.

⁽e) Slight toxicity

⁽d) Positive control; 2-aminoanthracene was used on all strains in the presence of S9. In the absence of metabolic activation, 4-nitro-o-phenylenediamine was used with TA98, sodium azide was used with TA100 and TA1535, and 9-aminoacridine was used with TA1537.

Compound	Concentration (µg/ml)	Cloning Efficiency (percent)	Relative Total Growth (percent)	Mutant Count	Mutant Fraction (c)
- S9					<u> </u>
Trial 1					
Ethanol (d)		82.5 ± 3.9	100.0 ± 2.7	175.3 ± 17.3	70.5 ± 3.3
Erythromycin stearate	6.25 12.5 25 50 100 (e) 150 200	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{rrrrr} 190.3 \pm & 8.3 \\ 222.7 \pm & 8.2 \\ 213.3 \pm & 12.3 \\ 210.0 \pm & 3.5 \\ 265.3 \pm & 19.7 \\ 352.0 \pm & 55.6 \\ \end{array}$	$70.7 \pm 5.584.3 \pm 4.973.7 \pm 4.986.7 \pm 2.0(f) 118.0 \pm 3.8(f) 154.7 \pm 17.6$
Ethyl methanesulfonat	e 250	69.3 ± 0.9	47.0 ± 3.6	1,096.7 ± 85.0	(f) 527.7 ± 38.8
Trial 2					
Ethanol (d)		71.3 ± 9.2	100.0 ± 10.4	98.5 ± 7.2	47.8 ± 4.8
Erythromycin stearate	25 50 75 100 125 (e) 150	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$
Ethyl methanesulfonat	e 250	50.0 ± 6.7	59.0 ± 7.5	772.7 ± 19.2	(f) 532.3 ± 63.8
Trial 3					
Ethanol (d)		100.0 ± 5.8	100.3 ± 2.7	75.3 ± 8.3	25.0 ± 2.2
Erythromycin stearate	40 60 80 100 (g) 120 (e,g) 140	$\begin{array}{rrrrr} 71.0 \pm 12.0 \\ 76.0 \pm 6.6 \\ 63.0 \pm 1.5 \\ 54.3 \pm 2.2 \\ 50.0 \pm 13.0 \\ 55.5 \pm 3.5 \end{array}$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$55.0 \pm 6.0 \\ 68.3 \pm 16.2 \\ 78.0 \pm 17.9 \\ 79.7 \pm 5.2 \\ 57.5 \pm 7.5 \\ 75.0 \pm 1.0 \\ \end{array}$	$\begin{array}{rrrr} 26.0 \pm & 2.0\\ 29.7 \pm & 5.8\\ (f) 41.0 \pm & 9.1\\ (f) 49.3 \pm & 2.9\\ 40.0 \pm & 5.0\\ (f) 45.5 \pm & 3.5 \end{array}$
Methyl methanesulfons	ate 5	76.0 ± 9.2	60.7 ± 10.8	453.0 ± 93.9	(f) 196.3 ± 26.8
+ S9 (h)					
Trial 1					
Ethanol (d)		86.8 ± 4.2	99.8 ± 12.4	265.3 ± 23.4	102.0 ± 6.6
Erythromycin stearate	31.3 62.5 125 (e) 250 500 (i) 750 1,000	$\begin{array}{rrrr} 49.3 \pm & 4.5 \\ 71.0 \pm & 7.0 \\ 69.0 \pm & 5.0 \\ 80.3 \pm & 11.8 \\ 65.0 \pm & 6.5 \\ 42 \\ & & \\$	$58.0 \pm 7.0 \\72.7 \pm 2.9 \\71.7 \pm 5.0 \\59.3 \pm 6.2 \\39.0 \pm 4.5 \\8 \\-$	$\begin{array}{r} 243.0 \pm 10.3 \\ 228.0 \pm 4.4 \\ 245.0 \pm 14.6 \\ 339.0 \pm 44.8 \\ 380.7 \pm 15.2 \\ 416 \end{array}$	(f) 166.3 ± 7.6 109.7 ± 12.9 119.3 ± 10.5 142.0 ± 12.1 (f) 197.7 ± 15.0 329
Methylcholanthrene	2.5	71.7 ± 2.6	49.0 ± 10.7	712.7 ± 4.3	(f) 334.3 ± 13.0

TABLE E2. MUTAGENICITY OF ERYTHROMYCIN STEARATE IN MOUSE L5178Y LYMPHOMA CELLS (a,b)

Compound	Cloning Relative Concentration Efficiency Total Growth (µg/ml) (percent) (percent)		Total Growth	Mutant Count	Mutant Fraction (c)		
- S9 (Continued)							
Trial 2							
Ethanol (d)		72.0 ± 4.8	100.0 ± 5.7	140.5 ± 4.2	66.3 ± 5.6		
Erythromycin stearate	100 (e) 200 400 500 600 700 800	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{c} 86.3 \pm 3.5 \\ 127.0 \pm 16.6 \\ 117.7 \pm 24.7 \\ 193.0 \pm 15.9 \\ 211.3 \pm 18.6 \\ 182.7 \pm 19.1 \\ \end{array}$	$\begin{array}{rrrr} 42.7 \pm & 5.8 \\ 57.7 \pm & 11.1 \\ 75.0 \pm & 32.1 \\ (f) & 148.0 \pm & 23.3 \\ (f) & 174.7 \pm & 42.8 \\ (f) & 102.3 \pm & 22.1 \\ \end{array}$		
Methylcholanthrene	2.5	70.7 ± 5.2	71.0 ± 5.5	580.7 ± 46.3	(f) 275.0 ± 25.9		

TABLE E2. MUTAGENICITY OF ERYTHROMYCIN STEARATE IN MOUSE L5178Y LYMPHOMA CELLS (Continued)

(a) Study performed at Litton Bionetics, Inc. The experimental protocol is presented in detail by Myhr et al. (1985) and follows the basic format of Clive et al. (1979). The highest dose of study compound is determined by solubility or toxicity and may not exceed 5 mg/ml. All doses are tested in triplicate unless otherwise specified; the average for the three tests is presented in the table. Cells (6×10^{5} /ml) were treated for 4 hours at 37° C in medium, washed, resuspended in medium, and incubated for 48 hours at 37° C. After expression, 3×10^{6} cells were plated in medium and soft agar supplemented with trifluorothymidine for selection of cells that were mutant at the thymidine kinase (TK) locus, and 600 cells were plated in nonselective medium and soft agar to determine the cloning efficiency.

(b) Mean \pm standard error of replicate trials for approximately (3×10^6) cells each. All data are evaluated statistically for both trend and peak response (P < 0.05 for at least one of the three highest dose sets). Both responses must be significantly (P < 0.05) positive for a chemical to be considered mutagenic. If only one of these responses is significant, the call is "questionable"; the absence of both trend and peak response results in a "negative" call.

(c) Mutant fraction (frequency) is a ratio of the mutant count to the cloning efficiency, divided by 3 (to arrive at MF per 1×10^6 cells treated); MF = mutant fraction.

(d) Data presented are the results of four tests.

(e) Precipitate present at this and all higher doses.

(f) Significant positive response; occurs when the relative mutant fraction (average MF of treated culture/average MF of solvent control) is greater than or equal to 1.6.

(g) Data presented are the results of two tests; doses were lethal in one test.

(h) Tests conducted with metabolic activation were performed as described in (a) except that S9, prepared from the liver of Aroclor 1254-induced F344 rats, was added at the same time as the study chemical and/or solvent.

(i) Value given is for one test only; doses in two tests were lethal.

Compound	Dose (µg/ml)	Total Cells	No. of Chromo- somes	No. of SCEs	SCEs/ Chromo- some	SCEs/ Cell	Hours in BrdU	Relative SCEs/Cell (percent) (b)
- S9 (c)					<u> </u>			
Trial 1Summary: Negative								
Dimethyl sulfoxide		50 50	1,0 4 6 1,052	476 463	0.46 0.44	9.5 9.3	26.0 26.0	
Erythromycin stearate	5 16 50 160	50 31 50 50	1,050 650 1,046 1,047	462 278 483 472	0.44 0.43 0.46 0.45	9.2 9.0 9.7 9.4	26.0 26.0 26.0 26.0	98.9 96.8 104.3 101.1
Mitomycin C	0.001 0.010	50 10	1,0 49 209	853 619	0.81 2.96	17.1 61.9	26.0 26.0	183.9 665.6
Trial 2Summary: Negative								
Dimethyl sulfoxide		50	1,041	425	0.41	8.5	26.5	
Erythromycin stearate	25 50 100 160	50 50 50 0	1,029 1,027 1,016	377 425 396	0.37 0.41 0.39	7.5 8.5 7.9	26.5 26.5 26.5 (d) 31.5	88.2 100.0 92.9
Mitomycin C	0.001 0.010	50 10	1,044 210	557 490	0.53 2.33	11.1 49 .0	26.5 26.5	130.6 576.5
+ S9 (e)								
Trial 1Summary: Negative								
Dimethyl sulfoxide		50 50	1,052 1,050	417 418	0.40 0.40	8.3 8.4	$\begin{array}{c} 27.0\\ 27.0\end{array}$	
Erythromycin stearate	50 160 500	50 50 50	1,050 1,050 1,051	374 426 449	0.36 0.41 0.43	7.5 8.5 9.0	27.0 27.0 27.0	89.3 101.2 107.1
Cyclophosphamide	0.3 2	50 10	1,052 210	765 493	$\begin{array}{c} 0.73 \\ 2.35 \end{array}$	15.3 49.3	27.0 27.0	182.1 586.9
Trial 2Summary: Negative								
Dimethyl sulfoxide		50	1,042	467	0.45	9.3	26.0	
Erythromycin stearate	300 400 500	50 50 50	1,049 1,050 1,050	450 440 475	0.43 0.42 0.45	9.0 8.8 9.5	26.0 26.0 26.0	96.8 94.6 102.2
Cyclophosphamide	$\begin{array}{c} 0.3\\2\end{array}$	50 10	1,048 210	643 356	0.61 1.70	12.9 35.6	26.0 26.0	138.7 382.8

TABLE E3. INDUCTION OF SISTER CHROMATID EXCHANGES IN CHINESE HAMSTER OVARY CELLS BY ERYTHROMYCIN STEARATE (a)

(a) Study performed at Environmental Health Research and Testing Laboratory. SCE = sister chromatid exchange; BrdU = bromodeoxyuridine. A detailed description of the SCE protocol is presented by Galloway et al. (1985). Briefly, Chinese hamster ovary cells were incubated with study compound or solvent (dimethyl sulfoxide) as described in (c) or (e) below and cultured for sufficient time to reach second metaphase division. Cells were then collected by mitotic shake-off, fixed, air-dried, and stained. (b) SCEs/cell in treated culture expressed as a percent of the SCEs/cell in the control culture

(c) In the absence of S9, Chinese hamster ovary cells were incubated with study compound or solvent for 2 hours at 37° C. Then BrdU was added, and incubation was continued for 24 hours. Cells were washed, fresh medium containing BrdU and colcemid was added, and incubation was continued for 2-3 hours.

(d) Because some chemicals induce a delay in the cell division cycle, harvest times are occasionally extended to maximize the proportion of second division cells available for analysis.

(e) In the presence of S9, cells were incubated with study compound or solvent for 2 hours at 37° C. Then cells were washed, and medium containing BrdU was added. Cells were incubated for a further 26 hours, with colcemid present for the final 2-3 hours. S9 was from the liver of Aroclor 1254-induced male Sprague Dawley rats.

		Trial 1			Trial 2					
Dose (µg/ml)	Total Cells	No. of Abs	Abs/ Cell	Percent Cells with Abs	Dose (µg/ml)	Total Cells	No. of Abs	Abs/ Cell	Percent Cells with Abs	
– S9 (b)Harv	vest time 🛛	12.5 h			– S9 (b)H	arvest tir	ne 12.0 h			
Dimethyl sulfo	xide				Dimethyl su	lfoxide				
•	100	1	0.01	1		100	2	0.02	2	
	100	0	0.00	0						
Erythromycin	stearate				Erythromyc	in steara	te			
16	100	0	0.00	0	160	100	4	0.04	3	
50	100	2	0.02	2	300	100	3	0.03	3	
160	100	3	0.03	3	400	100	3	0.03	3	
500	100	0	0.00	0	500	100	1	0.01	1	
Summary	: Negativ	e			Summary: Negative					
Mitomycin C					Mitomycin (C				
0.250	100	36	0.36	28	0.150	100	7	0.07	6	
1	50	27	0.54	40	0.250	100	26	0.26	20	
+ S9 (c)Harv	vest time	12.0 h								
Dimethyl sulfo	xide									
Ū	100	0	0.00	0						
	100	1	0.01	1						
Erythromycin	stearate									
50	100	0	0.00	0						
160	100	0	0.00	0						
500	100	1	0.01	1						
Summary	7: Negativ	e .								
Cyclophosphai	mide									
15	100	10	0.10	9						
50	50	27	0.54	38						

TABLE E4. INDUCTION OF CHROMOSOMAL ABERRATIONS IN CHINESE HAMSTER OVARY CELLS BY ERYTHROMYCIN STEARATE (a)

(a) Study performed at Environmental Health Research and Testing Laboratory. Abs = aberrations. A detailed presentation of the technique for detecting chromosomal aberrations is presented by Galloway et al. (1985). Briefly, Chinese hamster ovary cells were incubated with study compound or solvent (dimethyl sulfoxide) as indicated in (b) or (c). Cells were arrested in first metaphase by addition of colcemid and harvested by mitotic shake-off, fixed, and stained in 6% Giemsa.

(b) In the absence of S9, Chinese hamster ovary cells were incubated with study compound or solvent (dimethyl sulfoxide) for 8-10 hours at 37° C. Cells were then washed, and fresh medium containing colcemid was added for an additional 2-3 hours followed by harvest.

(c) In the presence of S9, cells were incubated with study compound or solvent (dimethyl sulfoxide) for 2 hours at 37°C. Cells were then washed, medium was added, and incubation was continued for 8-10 hours. Colcemid was added for the last 2-3 hours of incubation before harvest. S9 was from the liver of Aroclor 1254-induced male Sprague Dawley rats.

APPENDIX F

.

SENTINEL ANIMAL PROGRAM

.

I. Methods

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via viral serology on sera from extra (sentinel) animals in the study rooms. These animals are untreated, and these animals and the study animals are both subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Fifteen $B6C3F_1$ mice and 15 F344/N rats of each sex are selected at the time of randomization and allocation of the animals to the various study groups. Five animals of each designated sentinel group are killed at 6, 12, and 18 months on study. Data from animals surviving 24 months are collected from 5/50 randomly selected control animals of each sex and species. The blood from each animal is collected and clotted, and the serum is separated. The serum is cooled on ice and shipped to Microbiological Associates' Comprehensive Animal Diagnostic Service for determination of the viral antibody titers. The following tests are performed:

Hemagglutination
Inhibition

MicePVM (pneumonia virus of mice)
Reo 3 (reovirus type 3)
GDVII (Theiler's
encephalomyelitis virus)
Poly (polyoma virus)
MVM (minute virus of mice)
Ectro (infectious ectromelia)
Sendai (6, 12, 24 mo)RatsPVM

tats PVM KRV (Kilham rat virus) H-1 (Toolan's H-1 virus) Sendai (6, 12, 24 mo)

II. Results

No positive results were obtained.

Complement <u>Fixation</u>

M. Ad. (mouse adenovirus) LCM (lymphocytic choriomeningitis virus) Sendai (18 mo) MHV (mouse hepatitis virus)

RCV (rat coronavirus)

Sendai (18 mo)

APPENDIX G

FEED AND COMPOUND CONSUMPTION BY RATS AND MICE IN THE TWO-YEAR FEED STUDIES OF ERYTHROMYCIN STEARATE

TABLE	G1	FEED AND COMPOUND CONSUMPTION BY MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	154
TABLE	G2	FEED AND COMPOUND CONSUMPTION BY FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	155
TABLE	G3	FEED AND COMPOUND CONSUMPTION BY MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	156
TABLE	G4	FEED AND COMPOUND CONSUMPTION BY FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE	157

PAGE

TABLE G1. FEED AND COMPOUND CONSUMPTION BY MALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

	Cor	itrol		5,00	0 ppm			10,000 ppm				
Week	Grams Feed/ Day (a)	Body Weight (grams)	Grams Feed/ Day (a)	Body Weight (grams)	Low/ Control (b)	Dose/ Day (c)	Grams Feed/ Day (a)	Body Weight (grams)	High/ Control (b)	Dose/ Day (c)		
1	16	168	16	167	1.0	479	15	164	0.9	915		
6	14	293	15	292	1.1	257	14	278	1.0	504		
10	15	335	15	336	1.0	223	14	316	0.9	443		
13	16	369	16	369	1.0	217	15	350	0.9	429		
17	16	396	15	393	0.9	191	16	375	1.0	427		
21	15	407	16	406	1.1	197	15	390	1.0	385		
27	16	432	16	426	1.0	188	16	410	1.0	390		
31	16	442	15	439	0.9	171	15	424	0.9	354		
35	15	445	15	445	1.0	169	15	430	1.0	349		
40	15	458	15	458	1.0	164	15	443	1.0	339		
44	14	457	14	451	1.0	155	13	438	0.9	2 9 7		
48	15	468	15	462	1.0	162	15	453	1.0	331		
52	15	469	15	469	1.0	160	15	455	1.0	330		
57	14	467	14	471	1.0	149	14	455	1.0	308		
61	14	470	15	472	1.1	159	15	457	1.1	328		
65	14	464	14	466	1.0	150	14	454	1.0	308		
70	14	467	14	452	1.0	155	13	449	0.9	290		
75	15	466	14	464	0.9	151	14	448	0.9	313		
79	14	461	13	452	0.9	144	14	440	1.0	318		
83	15	465	15	453	1.0	166	14	445	0.9	315		
87	15	462	13	449	0.9	145	13	436	0.9	298		
91	12	444	12	445	1.0	135	12	425	1.0	282		
96	13	438	14	460	1.1	152	13	421	1.0	309		
100	13	437	13	427	1.0	152	13	416	1.0	313		
 Mean	14.6	424	14.5	422	1.0	183	14.3	407	1.0	370		
SD (d)	1.1		1.1		0.06	69	1.0		0.06	129		
CV(e)	7.5		7.6		6.0	37.7	7.0		6.0	34.9		

(a) Grams of feed removed from feeder per animal per day. Not corrected for scatter.

(b) Grams of feed per day for the dosed group divided by that for the controls(c) Milligrams of erythromycin stearate consumed per day per kilogram of body weight

(d) Standard deviation

(e) Coefficient of variation = (standard deviation/mean) \times 100

TABLE G2. FEED AND COMPOUND CONSUMPTION BY FEMALE RATS IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

	Cor	ntrol		5,00	0 ppm			10,0	00 ppm	
Week	Grams Feed/ Day (a)	Body Weight (grams)	Grams Feed/ Day (a)	Body	Low/ Control (b)	Dose/ Day (c)	Grams Feed/ Day (a)	Body Weight (grams)	High/ Control (b)	Dose/ Day (c)
1	10	126	10	127	1.0	394	10	124	1.0	806
6	10	179	10	181	1.0	276	10	172	1.0	581
10	10	196	10	198	1.0	253	9	187	0.9	481
13	10	205	10	208	1.0	240	10	196	1.0	510
17	10	219	10	222	1.0	225	11	209	1.1	526
21	10	220	10	227	1.0	220	10	212	1.0	472
27	10	233	11	238	1.1	231	10	222	1.0	450
31	10	238	9	245	0.9	184	10	229	1.0	437
35	10	255	11	247	1.1	223	10	230	1.0	435
40	10	249	11	256	1.1	215	10	234	1.0	427
44	10	256	10	261	1.0	192	10	241	1.0	415
48	11	263	12	273	1.1	220	11	250	1.0	440
52	11	273	11	283	1.0	194	11	257	1.0	428
57	11	289	11	292	1.0	188	10	266	0.9	376
61	11	293	12	304	1.1	197	11	275	1.0	400
65	11	302	11	313	1.0	176	11	283	1.0	389
70	11	313	12	322	1.1	186	11	292	1.0	377
75	11	317	12	326	1.1	184	11	295	1.0	373
79	11	321	11	327	1.0	168	11	294	1.0	374
83	11	323	11	328	1.0	168	11	297	1.0	370
87	11	326	13	330	1.2	197	10	296	0.9	338
91	11	316	10	328	0.9	152	9	290	0.8	310
96	11	330	11	336	1.0	164	11	299	1.0	368
100	10	329	11	328	1.1	168	11	300	1.1	367
Mean	10.5	265	10.8	271	1.0	209	10.4	248	1.0	435
SD(d)	0.5		0.9		0.1	50	0.6		0.1	101
CV (e)	4.8		8.3		10.0	23.9	5.8		10.0	23.2

(a) Grams of feed removed from feeder per animal per day. Not corrected for scatter.

(b) Grams of feed per day for the dosed group divided by that for the controls(c) Milligrams of erythromycin stearate consumed per day per kilogram of body weight

(d) Standard deviation

(e) Coefficient of variation = (standard deviation/mean) \times 100

TABLE G3. FEED AND COMPOUND CONSUMPTION BY MALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

	Control		2,500 ppm			5,000 ppm				
Week	Grams Feed/ Day (a)	Body Weight (grams)	Grams Feed/ Day (a)	Body	Low/ Control (b)	Dose/ Day (c)	Grams Feed/ Day (a)	Body Weight (grams)	High/ Control (b)	Dose/ Day (c)
2	3	26.2	3	25.3	1.0	296	3	25.3	1.0	593
8	4	30.9	4	30.5	1.0	328	4	29.6	1.0	676
9	4	31.3	4	31.2	1.0	321	3	30.1	0.8	498
13	4	33.0	4	32.9	1.0	304	4	32.3	1.0	619
16	4	33.4	4	35.1	1.0	285	4	33.5	1.0	5 9 7
20	4	35.4	4	35.8	1.0	27 9	4	34.5	1.0	580
26	4	35.1	4	37.0	1.0	270	4	35.1	1.0	570
30	4	36.3	4	36.4	1.0	275	4	35.4	1.0	565
34	4	37.2	4	37.5	1.0	267	4	36.6	1.0	546
38	4	36.9	4	38.0	1.0	263	4	36.8	1.0	543
42	4	38.4	4	39.0	1.0	256	4	38.8	1.0	515
46	4	39.5	4	39.6	1.0	253	4	39.0	1.0	513
50	4	39.7	4	40.0	1.0	250	4	39.1	1.0	512
55	4	39.7	4	39.5	1.0	253	4	39.0	1.0	513
58	4	39.4	4	39.3	1.0	254	4	39.0	1.0	513
63	4	40.2	4	40.2	1.0	2 49	4	39.7	1.0	504
68	4	39.5	4	40.0	1.0	250	4	39.0	1.0	513
72	4	39.1	4	39.3	1.0	254	4	38.5	1.0	519
77	4	39.1	4	38.4	1.0	260	4	38.0	1.0	526
81	4	39.2	4	38.6	1.0	25 9	4	37.7	1.0	531
85	4	38.0	4	37.8	1.0	265	4	37.8	1.0	529
8 9	3	37.8	4	39.3	1.3	254	4	38.3	1.3	522
94	4	37.5	4	38.3	1.0	261	4	37.2	1.0	538
98	4	37.4	4	39.5	1.0	253	4	37.7	1.0	531
Mean	3.9	36.7	4.0	37.0	1.0	269	3.9	36.2	1.0	544
SD (d)	0.3		0.2		0.1	22	0.3		0.1	43
CV (e)	7.7		5.0		10.0	8.2	7.7		10.0	7.9

(a) Grams of feed removed from feeder per animal per day. Not corrected for scatter.
(b) Grams of feed per day for the dosed group divided by that for the controls
(c) Milligrams of erythromycin stearate consumed per day per kilogram of body weight

(d) Standard deviation (e) Coefficient of variation = (standard deviation/mean) \times 100

TABLE G4. FEED AND COMPOUND CONSUMPTION BY FEMALE MICE IN THE TWO-YEAR FEED STUDY OF ERYTHROMYCIN STEARATE

Control		2,500 ppm			5,000 ppm					
Week	Grams Feed/ Day (a)	Body Weight (grams)	Grams Feed/ Day (a)	Body	Low/ Control (b)	Dose/ Day (c)	Grams Feed/ Day (a)	Body	High/ Control (b)	Dose/ Day (c)
2	3	20.7	3	20.5	1.0	366	3	20.5	1.0	732
8	3	23.9	3	23.5	1.0	319	3	23.5	1.0	638
9	3	23.9	3	23.9	1.0	314	3	24.1	1.0	622
13	3	26.3	3	26.5	1.0	283	3	26.2	1.0	573
16	3	27.2	3	27.8	1.0	270	3	27.1	1.0	554
20	4	29.5	3	28.9	0.8	260	3	28.7	0.8	52 3
26	3	30.4	3	30.3	1.0	248	3	29.2	1.0	514
30	3	31.8	3	32.0	1.0	234	4	30.9	1.3	647
34	4	34.3	3	34.0	0.8	221	3	33.2	0.8	452
38	3	34.8	3	35.0	1.0	214	3	33.4	1.0	449
42	3	35.2	3	36.2	1.0	207	3	35.2	1.0	426
46	4	37.4	3	37.4	0.8	201	4	36.7	1.0	545
50	4	38.1	4	38.3	1.0	261	4	37.9	1.0	528
55	4	37.7	3	37.8	0.8	198	4	37.6	1.0	532
58	4	38.6	4	37.0	1.0	270	4	37.4	1.0	535
63	4	39.7	3	38.5	0.8	195	3	39.1	0.8	384
68	4	40.1	4	38.9	1.0	257	4	39.6	1.0	505
72	4	39.7	4	38.6	1.0	259	4	40.2	1.0	498
77	4	39.1	4	38.5	1.0	260	3	39.1	0.8	384
81	4	39.9	3	38.9	0.8	193	4	39.8	1.0	503
85	4	39.9	3	39.5	0.8	190	3	40.3	0.8	372
89	3	39.3	3	39.0	1.0	192	3	39.9	1.0	376
94	4	39.5	4	39.2	1.0	255	3	40.2	0.8	373
98	4	39.5	4	39.9	1.0	251	3	40.9	0.8	367
Mean	3.6	34.4	3.3	34.2	0.9	247	3.3	34.2	0.9	501
SD(d)	0.5		0.5		0.1	45	0.5		0.1	99
CV (e)	13.9		15.2		11.1	18.2	15.2		11.1	19.8

(a) Grams of feed removed from feeder per animal per day. Not corrected for scatter.

(b) Grams of feed per day for the dosed group divided by that for the controls(c) Milligrams of erythromycin stearate consumed per day per kilogram of body weight

(d) Standard deviation

(e) Coefficient of variation = (standard deviation/mean) \times 100

Erythromycin Stearate, NTP TR 338 158

APPENDIX H

INGREDIENTS, NUTRIENT COMPOSITION, AND CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION

Meal Diet: September 1980 to October 1982

(Manufactured by Zeigler Bros., Inc., Gardners, PA)

		PAGE
TABLE H1	INGREDIENTS OF NIH 07 RAT AND MOUSE RATION	160
TABLE H2	VITAMINS AND MINERALS IN NIH 07 RAT AND MOUSE RATION	160
TABLE H3	NUTRIENT COMPOSITION OF NIH 07 RAT AND MOUSE RATION	161
TABLE H4	CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION	162

Ingredients (b)	Percent by Weight		
Ground #2 yellow shelled corn	24.50		
Fround hard winter wheat	23.00		
oybean meal (49% protein)	12.00		
ish meal (60% protein)	10.00		
Vheat middlings	10.00		
ried skim milk	5.00		
lfalfa meal (dehydrated, 17% protein)	4.00		
orn gluten meal (60% protein)	3.00		
y oil	2.50		
ried brewer's yeast	2.00		
ry molasses	1.50		
icalcium phosphate	1.25		
round limestone	0.50		
alt	0.50		
remixes (vitamin and mineral)	0.25		

TABLE H1. INGREDIENTS OF NIH 07 RAT AND MOUSE RATION (a)

(a) NIH, 1978; NCI, 1976
(b) Ingredients ground to pass through a U.S. Standard Screen No. 16 before being mixed

	Amount	Source		
Vitamins				
Α	5,500,000 IU	Stabilized vitamin A palmitate or acetate		
D_3	4,600,000 IU	D-activated animal sterol		
К ₃	2.8 g	Menadione		
d-a-Tocopheryl acetate	20,000 IŪ			
Choline	560.0 g	Choline chloride		
Folic acid	2.2 g			
Niacin	30.0 g			
d-Pantothenic acid	18.0 g	d-Calcium pantothenate		
Riboflavin	3.4 g	·		
Thiamine	10.0 g	Thiamine mononitrate		
B ₁₂	4,000 µg			
Pyridoxine	1.7 g	Pyridoxine hydrochloride		
Biotin	140.0 mg	d-Biotin		
Minerals				
Iron	120.0 g	Iron sulfate		
Manganese	60.0 g	Manganous oxide		
Zinc	16.0 g	Zinc oxide		
Copper	4.0 g	Copper sulfate		
Iodine	1.4 g	Calcium iodate		
Cobalt	0.4 g	Cobalt carbonate		

TABLE H2. VITAMINS AND MINERALS IN NIH 07 RAT AND MOUSE RATION (a)

(a) Per ton (2,000 lb) of finished product

Nutrients	Mean ± Standard Deviation	Range	Number of Samples	
Crude protein (percent by weight)	24.22 ± 1.07	22.6-26.3	24	
Crude fat (percent by weight)	5.09 ± 0.46	4.2-6.0	24	
Crude fiber (percent by weight)	3.42 ± 0.39	2.4-4.2	24	
Ash (percent by weight)	6.63 ± 0.38	5.97-7.42	24	
Amino Acids (percent of total die	et)			
Arginine	1.260	1.21-1.31	2	
Cystine	0.395	0.39-0.40	2	
Glycine	1.175	1.15-1.20	2	
Histidine	0.553	0.530-0.576	2	
Isoleucine	0.908	0.881-0.934	2	
Leucine	1.905	1.85-1.96	2	
Lysine	1.250	1.20-1.30	2	
Methionine	0.310	0.306-0.314	2	
Phenylalanine Threonine	0.967	0.960-0.974	2	
Tryptophan	0.834 0.175	0.827-0.840	2 2	
Typosine	0.175	0.171 - 0.178 0.566 - 0.607	2 2	
Valine	1.085	1.05-1.12	2	
Essential Fatty Acids (percent of	f total diet)			
Linoleic	2.37		1	
Linolenic	0.308		1	
Arachidonic	0.008		1	
Vitamins				
Vitamin A (IU/kg)	$11,108 \pm 1,093$	9,100-14,000	24	
Vitamin D (IU/kg)	6,300		1	
a-Tocopherol (ppm)	37.6	31.1-44.0	2	
Thiamine (ppm)	19.0 ± 2.73	16.0-26.0	(b) 23	
Riboflavin (ppm)	6.9	6.1-7.4	2	
Niacin (ppm)	75	65-85	2	
Pantothenic acid (ppm)	30.2 7.2	29.8-30.5	2	
Pyridoxine (ppm) Falia acid (ppm)	2.1	5.6-8.8	2	
Folic acid (ppm) Biotin (ppm)	0.24	1.8-2.4 0.21-0.27	2 2	
Vitamin B_{12} (ppb)	12.8	10.6-15.0	$\frac{2}{2}$	
Choline (ppm)	3,315	3,200-3,430	2	
Minerals				
Calcium (percent)	1.25 ± 0.15	1.10-1.53	24	
Phosphorus (percent)	0.99 ± 0.08	0.84-1.10	24	
Potassium (percent)	0.809	$0.772 \cdot 0.846$	2	
Chloride (percent)	0.557	0.479-0.635	2	
Sodium (percent)	0.304	0.258-0.349	2	
Magnesium (percent)	0.172	0.166-0.177	2	
Sulfur (percent)	0.278	0.270-0.285	2	
Iron (ppm)	418	409-426	2	
Manganese (ppm)	90.8	86.0-95.5	2	
Zinc (ppm)	55.1	54.2-56.0	2	
Copper (ppm) Iodine (ppm)	$12.68 \\ 2.58$	9.65-15.70 1.52-3.64	$2 \\ 2$	
	2.00	1.02-0.04	Z	
Chromium (ppm)	1.86	1.79-1.93	2	

TABLE H3. NUTRIENT COMPOSITION OF NIH 07 RAT AND MOUSE RATION (a)

(a) One or two batches of feed analyzed for nutrients reported in this table were manufactured in January and/or April 1983.

(b) One batch (7/22/81) not analyzed for thiamine

Contaminants	Mean ± Standard Deviation	Range	Number of Samples
Arsenic (ppm)	0.41 ± 0.15	0.13-0.93	24
Cadmium (ppm) (a)	< 0.10		24
Lead (ppm)	1.07 ± 0.73	0.27-2.93	24
Mercury (ppm) (a)	< 0.05		24
Selenium (ppm)	0.29 ± 0.07	0.16-0.48	24
Aflatoxins(ppb)(a,b)	<10	<5.0-10.0	24
Nitrate nitrogen (ppm) (c)	9.18 ± 4.33	0.6-18.0	24
Nitrite nitrogen (ppm) (c)	1.99 ± 1.30	0.4-5.3	24
3HA (ppm) (d,e)	5.10 ± 4.19	< 0.4-15.0	24
3HT (ppm) (d)	3.05 ± 1.52	1.2-6.0	24
Aerobic plate count (CFU/g)	$80,604 \pm 48,850$	7,000-210,000	24
Coliform (MPN/g) (f)	883 ± 908	<3-2,400	24
E. coli (MPN/g) (f,g)	8.0 ± 7.91	<3-23	23
E. coli (MPN/g) (f,h)	13.88 ± 30.00	<3-150	24
fotal nitrosamines (ppb) (i, j)	6.69 ± 5.60	<1.2-18.8	22
Total nitrosamines (ppb) (i,k)	14.55 ± 27.15	<1.2-101.6	24
V-Nitrosodimethylamine (ppb) (i,l)	5.25 ± 5.33	0.6-16.8	22
V-Nitrosodimethylamine (ppb) (i,m)	13.02 ± 26.80	0.6-99	24
V-Nitrosopyrrolidine (ppb)	1.21 ± 0.66	<0.3-2.4	24
Pesticides (ppm)			
a-BHC (a,n)	< 0.01		24
β -BHC (a)	< 0.02		24
y-BHC-Lindane (a)	< 0.01		24
δ-BHC (a)	< 0.01		24
Heptachlor (a)	< 0.01		24
Aldrin (a)	< 0.01		24
Heptachlor epoxide (a)	< 0.01		24
DDE (0)	< 0.01	0.05 (7/14/81)	24
DDD (a)	< 0.01		24
DDT (a)	< 0.01		24
HCB (a)	< 0.01		24
Mirex (a)	< 0.01		24
Methoxychlor (p)	< 0.05	0.13 (8/25/81); 0.6 (6/29/82)	24
Dieldrin (a)	< 0.01		24
Endrin (a) Telodrin (a)	< 0.01		24
Chlordane (a)	<0.01 <0.05		24 24
Toxaphene (a)	< 0.05		24 24
Estimated PCBs (a)	< 0.1		24 24
Ronnel (a)	< 0.2		24
Ethion (a)	< 0.01		24
Trithion (a)	< 0.02		24
Diazinon (a)	< 0.1		24
Methyl parathion (a)	< 0.02		24
Ethyl parathion (a)	< 0.02		24
Malathion (q)	0.08 ± 0.05	< 0.05-0.25	24
Endosulfan I (a)	< 0.01		24
Endosulfan II (a)	< 0.01		24
Endosulfan sulfate (a)	< 0.03		24

TABLE H4. CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION

TABLE H4. CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION (Continued)

(g) Mean, standard deviation, and range exclude one high value of 150 obtained for the batch produced on 8/26/82.

(h) Mean, standard deviation, and range include the high value listed in footnote (g). (i) All values were corrected for percent recovery.

(j) Mean, standard deviation, and range exclude one very high value of 101.6 ppb obtained for the batch produced on 1/26/81 and one very high value of 100.3 ppb obtained for the batch produced on 4/27/81.

(k) Mean, standard deviation, and range include the high values listed in footnote (j).

(1) Mean, standard deviation, and range exclude one very high values fisted in foothote (1). (1) Mean, standard deviation, and range exclude one very high value of 97.9 ppb obtained for the batch produced on 1/26/81 and one very high value of 99 ppb obtained for the batch produced on 4/27/81.

(m) Mean, standard deviation, and range include the very high values given in footnote (l).

(n) BHC = hexachlorocyclohexane or benzene hexachloride

(o) There was one observation above the detection limit; the value and date it was obtained are given under the range.

(p) There were two observations above the detection limit; the values and dates they were obtained are given under the range. (q) Ten batches contained more than 0.05 ppm.

⁽a) All values were less than the detection limit, given in the table as the mean.

⁽b) The detection limit was reduced from 10 ppb to 5 ppb after 7/81.

⁽c) Source of contamination: Alfalfa, grains, and fish meal

⁽d) Source of contamination: Soy oil and fish meal

⁽e) One batch produced on 4/27/81 contained less than 0.5 ppm; the value was <0.04.

⁽f) MPN = most probable number

Erythromycin Stearate, NTP TR 338

164

APPENDIX I

AUDIT SUMMARY

165

The experimental data, documents, and pathology materials for the 2-year toxicology and carcinogenesis studies of erythromycin stearate in rats and mice were audited for accuracy, consistency, completeness, and compliance with Good Laboratory Practice (GLP) regulations of the Food and Drug Administration (fully implemented by the NTP on October 1, 1981). The studies were conducted for the NTP by Physiological Research Laboratories, Minneapolis, Minnesota, under a subcontract with Tracor Jitco, Inc., until February 28, 1983, and then under contract with the National Institute of Environmental Health Sciences (NIEHS). Animal dosing with erythromycin stearate in feed began on December 9, 1980, for rats and on December 23, 1980, for mice. The retrospective audit was conducted at the NTP Archives, Research Triangle Park, North Carolina, in January 1987 by Argus Research Laboratories, Paul A. Wennerberg, D.V.M., M.S., Principal Investigator. Other individuals involved in the conduct of the audit are listed in the full audit report, which is on file at the NIEHS. The audit included a review of:

- (1) All records concerning animal receipt, quarantine, randomization, and disposition prior to study start.
- (2) Body weight, clinical observation, and feed consumption data for a random 10% sample of study animals.
- (3) All inlife records involving protocol, correspondence, environmental conditions, mortality, animal identification, and correlation of final inlife observation of masses, date of death, and disposition with necropsy records.
- (4) All postmortem records for individual animals concerning identification, disposition codes, condition codes, correlation between gross observations and microscopic diagnoses, and tissue accountability.
- (5) All chemistry records.
- (6) All wet tissue bags for inventory and wet tissues from a random 10% sample of the study animals plus other relevant cases to verify animal identification and to examine for untrimmed lesions.
- (7) Blocks and slides of tissues from all control and high dose animals to examine for proper match and inventory.
- (8) Tabulated pathology diagnoses for a random 10% of study animals to verify computer data entry.
- (9) Data and results pertaining to the 2-year studies of erythromycin stearate in the Preliminary Draft (3/87) of the NTP Technical Report.

The audit showed that the studies were conducted following the prescribed statement of work. Inlife procedures and events were documented adequately by the archival records with the exception that information on procedural details for randomization and the disposition of surplus animals was incomplete. Audit findings from review of the inlife records were few in number and minor in nature and involved only the clinical records. For example, 4 rats and 1 mouse had masses during their last month of survival which lacked corresponding necropsy observation, and 10 rats had observations involving eyes (pale, red crust, or opaque) which were not recorded either in the inlife or necropsy records. Also, the date and mode of death entered into separate records maintained for animal census and clinical observations were either not internally consistent or sometimes not listed in both records for five rats and five mice; however, one of the two records was always in agreement with the disposition code listed on the ncropsy record form. Analytical chemistry records were present with only minor exceptions and documented study conduct and data adequately.

Animals were identified individually by toe clip (numbers 1-99) or a combination of toe clip and ear punch (numbers 100-150) per sex and species. Neither toes nor ears were saved for animals that died early in the study, and only toes were saved for animals killed at the end of the studies. Accordingly, inspection of wet tissues could only partly confirm animal identification; none of the 89 rats and 64 mice examined was incorrectly identified or could possibly have been involved in an animal mixup. The audit identified 19 untrimmed potential lesions (4 in target organs) in the wet tissues of 19/89 rats examined, and 3 untrimmed potential lesions in 3/64 mice examined. As a result, NTP staff initiated a complete review of wet tissues for untrimmed lesions. The complete review of wet tissues of rats from these studies identified 164 potential untrimmed lesions in 108 rats (male and female); these diagnoses have been incorporated in the tables of the Technical Report. Analysis of the lesions in mice indicated that further review was not required. There were a variety of gross observations without a corresponding microscopic correlate (22 in rats with 7 involving target organs, and 9 in mice), which were distributed across study groups. Full details about these and other audit findings are presented in the audit report.

In conclusion, the study records at the NTP Archives support the data and results presented in this NTP Technical Report.

NATIONAL TOXICOLOGY PROGRAM TECHNICAL REPORTS **PRINTED AS OF OCTOBER 1988**

TR No	. CHEMICAL
201	2,3,7,8-Tetrachlorodibenzo-p-dioxin (Dermal)
206	Dibromochloropropane
207	Cytembena
208	FD & C Yellow No. 6
209	2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin (Gavage)
210	1,2-Dibromoethane (Inhalation)
211	C.I. Acid Orange 10 Di(2 atbulbevul)adinate
212	Di(2-ethylhexyl)adipate Butylbenzyl Phthalate
$\begin{array}{c} 213 \\ 214 \end{array}$	Caprolactam
	Bisphenol A
215 216	11-Aminoundecanoic Acid
210	Di(2-ethylhexyl)phthalate
217	2,6-Dichloro- <i>p</i> -phenylenediamine
219	C.I. Acid Red 14
221	Locust Bean Gum
222	C.I. Disperse Yellow 3
223	Eugenol
224	Tara Gum
225	D & C Red No. 9
226	C.I. Solvent Yellow 14
227	Gum Arabic
229	Guar Gum
230	Agar
231	Stannous Chloride
233	2-Biphenylamine Hydrochloride
234	Allyl Isothiocyanate
235	Zearalenone
236	D-Mannitol
238	Ziram
239	Bis(2-chloro-1-methylethyl)ether
240	Propyl Gallate
242	Diallyl Phthalate (Mice)
244	Polybrominated Biphenyl Mixture
245	Melamine
247	L-Ascorbic Acid
248 249	4,4'-Methylenedianiline Dihydrochloride
249	Amosite Asbestos Benzyl Acetate
250	Toluene Diisocyanate
252	Geranyl Acetate
253	Allyl Isovalerate
255	1,2-Dichlorobenzene
257	Diglycidyl Resorcinol Ether
259	Ethyl Acrylate
261	Chlorobenzene
263	1,2-Dichloropropane
266	Monuron
267	Propylene Oxide
269	Telone II®
271	HC Blue No. 1
272	Propylene
273	Trichloroethylene (Four strains of rats)

- 273 Trichloroethylene (Four strains of rats)
- Tris(2-ethylhexyl)phosphate 274

- TR No. CHEMICAL
- 275 2-Chloroethanol
- 8-Hydroxyquinoline 276
- H.C. Red No. 3 281 282
- Chlorodibromomethane Diallylphthalate (Rats) 284
- C.I. Basic Red 9 Monohydrochloride 285
 - Dimethyl Hydrogen Phosphite 287
 - 288 1,3-Butadiene
 - 289 Benzene
 - 291 Isophorone
 - 293 HC Blue No. 2
 - Chlorinated Trisodium Phosphate 294
 - Chrysotile Asbestos (Rats) 295
 - Tetrakis(hydroxymethy)phosphonium Sulfate and 296 Tetrakis(hydroxymethy)phosphonium Chloride
 - Dimethyl Morpholinophosphoramidate 298
 - C.I. Disperse Blue 1 299
 - 3-Chloro-2-methylpropene 300
 - o-Phenylphenol 301
 - 303 4-Vinylcyclohexene
 - 304 Chlorendic Acid
 - Chlorinated Paraffins (C_{23} , 43% chlorine) 305
 - 306 Dichloromethane
 - Ephedrine Sulfate 307
 - Chlorinated Paraffins (C_{12} , 60% chlorine) Decabromodiphenyl Oxide 308
 - 309
 - Marine Diesel Fuel and JP-5 Navy Fuel 310
 - Tetrachloroethylene (Inhalation) 311
 - 312 n-Butyl Chloride
 - Methyl Methacrylate 314
 - Oxytetracycline Hydrochloride 315
 - 1-Chloro-2-methylpropene 316
 - Chlorpheniramine Maleate 317
 - Ampicillin Trihydrate 318
 - 319 1.4-Dichlorobenzene
 - 320 Rotenone
 - 321 Bromodichloromethane
 - Phenylephrine Hydrochloride 322
 - 323 Dimethyl Methylphosphonate
 - 324 Boric Acid
 - Pentachloronitrobenzene 325
 - 326 Ethylene Oxide
 - 327 Xylenes (Mixed)
 - Methyl Carbamate 328
 - 329 1,2-Epoxybutane
 - 4-Hexylresorcinol 330
 - Malonaldehyde, Sodium Salt 331
 - 332 Mercaptobenzothiazole
 - N-Phenyl-2-naphthylamine 333
 - 2-Amino-5-nitrophenol 334
 - 336 Penicillin VK
 - Nitrofurazone 337
 - 2-Amino-4-nitrophenol 339

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709.